CA2753061C - Novel hetero pyrrole analogs acting on cannabinoid receptors - Google Patents
Novel hetero pyrrole analogs acting on cannabinoid receptors Download PDFInfo
- Publication number
- CA2753061C CA2753061C CA2753061A CA2753061A CA2753061C CA 2753061 C CA2753061 C CA 2753061C CA 2753061 A CA2753061 A CA 2753061A CA 2753061 A CA2753061 A CA 2753061A CA 2753061 C CA2753061 C CA 2753061C
- Authority
- CA
- Canada
- Prior art keywords
- ring
- alkyl
- members
- group
- integer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- -1 hetero pyrrole analogs Chemical class 0.000 title claims abstract description 239
- 102000018208 Cannabinoid Receptor Human genes 0.000 title claims description 15
- 108050007331 Cannabinoid receptor Proteins 0.000 title claims description 15
- 102000009132 CB1 Cannabinoid Receptor Human genes 0.000 claims abstract description 11
- 108010073366 CB1 Cannabinoid Receptor Proteins 0.000 claims abstract description 11
- 125000000217 alkyl group Chemical group 0.000 claims description 495
- 125000006413 ring segment Chemical group 0.000 claims description 226
- 125000000623 heterocyclic group Chemical group 0.000 claims description 205
- 125000002837 carbocyclic group Chemical group 0.000 claims description 180
- 125000003118 aryl group Chemical group 0.000 claims description 173
- 125000001072 heteroaryl group Chemical group 0.000 claims description 161
- 125000005842 heteroatom Chemical group 0.000 claims description 159
- 229910052757 nitrogen Inorganic materials 0.000 claims description 144
- 229910052736 halogen Inorganic materials 0.000 claims description 143
- 150000002367 halogens Chemical class 0.000 claims description 143
- 125000004432 carbon atom Chemical group C* 0.000 claims description 139
- 229910006069 SO3H Inorganic materials 0.000 claims description 90
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 claims description 90
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 88
- 125000002619 bicyclic group Chemical group 0.000 claims description 83
- 125000003367 polycyclic group Chemical group 0.000 claims description 83
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims description 82
- 150000001875 compounds Chemical class 0.000 claims description 82
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 82
- 125000004585 polycyclic heterocycle group Chemical group 0.000 claims description 82
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 claims description 80
- 229910052799 carbon Inorganic materials 0.000 claims description 80
- 229910052717 sulfur Inorganic materials 0.000 claims description 80
- 125000000169 tricyclic heterocycle group Chemical group 0.000 claims description 79
- 125000006307 alkoxy benzyl group Chemical group 0.000 claims description 76
- RAHZWNYVWXNFOC-UHFFFAOYSA-N sulfur dioxide Inorganic materials O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 claims description 62
- 229910052760 oxygen Inorganic materials 0.000 claims description 60
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 58
- 125000003282 alkyl amino group Chemical group 0.000 claims description 47
- 125000004414 alkyl thio group Chemical group 0.000 claims description 47
- 125000003545 alkoxy group Chemical group 0.000 claims description 46
- 101100006377 Arabidopsis thaliana CHX8 gene Proteins 0.000 claims description 45
- 102100039259 Cytochrome c oxidase subunit 8A, mitochondrial Human genes 0.000 claims description 45
- 101000745956 Homo sapiens Cytochrome c oxidase subunit 8A, mitochondrial Proteins 0.000 claims description 45
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 45
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims description 44
- 101000854931 Homo sapiens Visual system homeobox 2 Proteins 0.000 claims description 43
- 102100020676 Visual system homeobox 2 Human genes 0.000 claims description 43
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 34
- 229910002091 carbon monoxide Inorganic materials 0.000 claims description 26
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 18
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 claims description 18
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 18
- 125000004312 morpholin-2-yl group Chemical group [H]N1C([H])([H])C([H])([H])OC([H])(*)C1([H])[H] 0.000 claims description 18
- 125000004572 morpholin-3-yl group Chemical group N1C(COCC1)* 0.000 claims description 18
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 18
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 claims description 18
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims description 18
- 150000003839 salts Chemical class 0.000 claims description 18
- 241001465754 Metazoa Species 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- 125000004429 atom Chemical group 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 4
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims description 3
- 229960002715 nicotine Drugs 0.000 claims description 3
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims description 3
- 208000007848 Alcoholism Diseases 0.000 claims description 2
- 208000027559 Appetite disease Diseases 0.000 claims description 2
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims description 2
- 208000022497 Cocaine-Related disease Diseases 0.000 claims description 2
- 208000019454 Feeding and Eating disease Diseases 0.000 claims description 2
- 108090001061 Insulin Proteins 0.000 claims description 2
- 208000003863 Marijuana Abuse Diseases 0.000 claims description 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 206010057852 Nicotine dependence Diseases 0.000 claims description 2
- 208000008589 Obesity Diseases 0.000 claims description 2
- 208000026251 Opioid-Related disease Diseases 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims description 2
- 208000025569 Tobacco Use disease Diseases 0.000 claims description 2
- 125000002252 acyl group Chemical group 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 201000009322 cannabis abuse Diseases 0.000 claims description 2
- 201000001843 cannabis dependence Diseases 0.000 claims description 2
- 238000002512 chemotherapy Methods 0.000 claims description 2
- 201000006145 cocaine dependence Diseases 0.000 claims description 2
- 230000007812 deficiency Effects 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 206010013663 drug dependence Diseases 0.000 claims description 2
- 229940125396 insulin Drugs 0.000 claims description 2
- 150000002632 lipids Chemical class 0.000 claims description 2
- 208000019423 liver disease Diseases 0.000 claims description 2
- 208000030159 metabolic disease Diseases 0.000 claims description 2
- 235000020824 obesity Nutrition 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 201000000980 schizophrenia Diseases 0.000 claims description 2
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 2
- XSXHWVKGUXMUQE-UHFFFAOYSA-N osmium dioxide Inorganic materials O=[Os]=O XSXHWVKGUXMUQE-UHFFFAOYSA-N 0.000 claims 29
- 125000005462 imide group Chemical group 0.000 claims 28
- 229910004679 ONO2 Inorganic materials 0.000 claims 2
- 125000001893 nitrooxy group Chemical group [O-][N+](=O)O* 0.000 claims 2
- DUVIPVWOYAEPOY-UHFFFAOYSA-N 1-(2,4-dichlorophenyl)-N-(1,1-dioxo-1,4-thiazinan-4-yl)-4-ethyl-5-(4-iodophenyl)pyrazole-3-carboxamide Chemical compound CCC=1C(C(=O)NN2CCS(=O)(=O)CC2)=NN(C=2C(=CC(Cl)=CC=2)Cl)C=1C1=CC=C(I)C=C1 DUVIPVWOYAEPOY-UHFFFAOYSA-N 0.000 claims 1
- SUIXEXMGNGHSIY-UHFFFAOYSA-N 1-(2,4-dichlorophenyl)-n-(1,1-dioxo-1,4-thiazinan-4-yl)-5-(4-iodophenyl)-4-methylpyrazole-3-carboxamide Chemical compound CC=1C(C(=O)NN2CCS(=O)(=O)CC2)=NN(C=2C(=CC(Cl)=CC=2)Cl)C=1C1=CC=C(I)C=C1 SUIXEXMGNGHSIY-UHFFFAOYSA-N 0.000 claims 1
- CXHDARAKZUYDRF-UHFFFAOYSA-N 1-(2-chloro-4-fluorophenyl)-5-(4-chlorophenyl)-N-(1,1-dioxo-1,4-thiazinan-4-yl)-4-ethylpyrazole-3-carboxamide Chemical compound CCC=1C(C(=O)NN2CCS(=O)(=O)CC2)=NN(C=2C(=CC(F)=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 CXHDARAKZUYDRF-UHFFFAOYSA-N 0.000 claims 1
- BOQZYEORFGDCPF-UHFFFAOYSA-N 1-(2-chloro-4-fluorophenyl)-5-[4-(4-cyanobut-1-ynyl)phenyl]-N-(1,1-dioxo-1,4-thiazinan-4-yl)-4-ethylpyrazole-3-carboxamide Chemical compound CCC=1C(C(=O)NN2CCS(=O)(=O)CC2)=NN(C=2C(=CC(F)=CC=2)Cl)C=1C1=CC=C(C#CCCC#N)C=C1 BOQZYEORFGDCPF-UHFFFAOYSA-N 0.000 claims 1
- MIAFODQDXFCWNZ-UHFFFAOYSA-N 1-(2-chloro-4-fluorophenyl)-N-(1,1-dioxo-1,4-thiazinan-4-yl)-4-ethyl-5-(4-iodophenyl)pyrazole-3-carboxamide Chemical compound CCC=1C(C(=O)NN2CCS(=O)(=O)CC2)=NN(C=2C(=CC(F)=CC=2)Cl)C=1C1=CC=C(I)C=C1 MIAFODQDXFCWNZ-UHFFFAOYSA-N 0.000 claims 1
- POBLTYTXPIMLEP-UHFFFAOYSA-N 4-[4-[2-(2,4-dichlorophenyl)-5-[(1,1-dioxo-1,4-thiazinan-4-yl)carbamoyl]-4-methylpyrazol-3-yl]phenyl]but-3-ynyl nitrate Chemical compound Cc1c(nn(c1-c1ccc(cc1)C#CCCO[N+]([O-])=O)-c1ccc(Cl)cc1Cl)C(=O)NN1CCS(=O)(=O)CC1 POBLTYTXPIMLEP-UHFFFAOYSA-N 0.000 claims 1
- PLOBJNIMCIRHAA-UHFFFAOYSA-N 5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-N-(1,1-dioxo-1,4-thiazinan-4-yl)-4-ethylpyrazole-3-carboxamide Chemical compound CCC=1C(C(=O)NN2CCS(=O)(=O)CC2)=NN(C=2C(=CC(Cl)=CC=2)Cl)C=1C1=CC=C(Br)C=C1 PLOBJNIMCIRHAA-UHFFFAOYSA-N 0.000 claims 1
- VCYYRVPLINRWIH-UHFFFAOYSA-N 5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-N-(1,1-dioxo-1,4-thiazinan-4-yl)-4-methylpyrazole-3-carboxamide Chemical compound CC=1C(C(=O)NN2CCS(=O)(=O)CC2)=NN(C=2C(=CC(Cl)=CC=2)Cl)C=1C1=CC=C(Br)C=C1 VCYYRVPLINRWIH-UHFFFAOYSA-N 0.000 claims 1
- BBBAEROPTWPVLO-UHFFFAOYSA-N 5-(4-bromophenyl)-1-(2-chloro-4-fluorophenyl)-N-(1,1-dioxo-1,4-thiazinan-4-yl)-4-ethylpyrazole-3-carboxamide Chemical compound CCC=1C(C(=O)NN2CCS(=O)(=O)CC2)=NN(C=2C(=CC(F)=CC=2)Cl)C=1C1=CC=C(Br)C=C1 BBBAEROPTWPVLO-UHFFFAOYSA-N 0.000 claims 1
- TZDRPXKDMNGORA-UHFFFAOYSA-N 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-N-(1,1-dioxo-1,4-thiazinan-4-yl)-4-ethylpyrazole-3-carboxamide Chemical compound CCC=1C(C(=O)NN2CCS(=O)(=O)CC2)=NN(C=2C(=CC(Cl)=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 TZDRPXKDMNGORA-UHFFFAOYSA-N 0.000 claims 1
- YHNZGJXKEQOFFU-UHFFFAOYSA-N 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-N-(1,1-dioxo-1,4-thiazinan-4-yl)-4-methylpyrazole-3-carboxamide Chemical compound CC=1C(C(=O)NN2CCS(=O)(=O)CC2)=NN(C=2C(=CC(Cl)=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 YHNZGJXKEQOFFU-UHFFFAOYSA-N 0.000 claims 1
- XBHQLFVDGLPBCK-UHFFFAOYSA-N 5-[4-(4-cyanobut-1-ynyl)phenyl]-1-(2,4-dichlorophenyl)-n-(1,1-dioxo-1,4-thiazinan-4-yl)-4-methylpyrazole-3-carboxamide Chemical compound CC=1C(C(=O)NN2CCS(=O)(=O)CC2)=NN(C=2C(=CC(Cl)=CC=2)Cl)C=1C1=CC=C(C#CCCC#N)C=C1 XBHQLFVDGLPBCK-UHFFFAOYSA-N 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 239000005557 antagonist Substances 0.000 abstract description 21
- 102000005962 receptors Human genes 0.000 abstract description 17
- 108020003175 receptors Proteins 0.000 abstract description 17
- 238000000034 method Methods 0.000 abstract description 14
- 230000007935 neutral effect Effects 0.000 abstract description 10
- 108010073376 CB2 Cannabinoid Receptor Proteins 0.000 abstract description 9
- 102000009135 CB2 Cannabinoid Receptor Human genes 0.000 abstract description 9
- 150000002460 imidazoles Chemical class 0.000 abstract description 5
- 230000001766 physiological effect Effects 0.000 abstract description 3
- 239000002840 nitric oxide donor Substances 0.000 abstract description 2
- 150000002916 oxazoles Chemical class 0.000 abstract description 2
- 239000000825 pharmaceutical preparation Substances 0.000 abstract description 2
- 150000003217 pyrazoles Chemical class 0.000 abstract description 2
- 229940044551 receptor antagonist Drugs 0.000 abstract description 2
- 239000002464 receptor antagonist Substances 0.000 abstract description 2
- 150000003557 thiazoles Chemical class 0.000 abstract description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical class O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 abstract 1
- 210000001428 peripheral nervous system Anatomy 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 30
- 238000005160 1H NMR spectroscopy Methods 0.000 description 28
- 125000004093 cyano group Chemical group *C#N 0.000 description 25
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 25
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 24
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 20
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 19
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 19
- 125000001424 substituent group Chemical group 0.000 description 19
- 150000003949 imides Chemical group 0.000 description 18
- 229910052698 phosphorus Inorganic materials 0.000 description 17
- 230000027455 binding Effects 0.000 description 16
- 150000001721 carbon Chemical group 0.000 description 16
- 239000000203 mixture Substances 0.000 description 16
- 230000000694 effects Effects 0.000 description 15
- 239000007787 solid Substances 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- 150000002148 esters Chemical class 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 12
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 12
- 229920006395 saturated elastomer Polymers 0.000 description 12
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 11
- 239000011541 reaction mixture Substances 0.000 description 11
- JZCPYUJPEARBJL-UHFFFAOYSA-N rimonabant Chemical compound CC=1C(C(=O)NN2CCCCC2)=NN(C=2C(=CC(Cl)=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 JZCPYUJPEARBJL-UHFFFAOYSA-N 0.000 description 11
- 229960003015 rimonabant Drugs 0.000 description 11
- 239000000556 agonist Substances 0.000 description 10
- 239000000460 chlorine Substances 0.000 description 10
- 229940093499 ethyl acetate Drugs 0.000 description 10
- 235000019439 ethyl acetate Nutrition 0.000 description 10
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 9
- 239000012044 organic layer Substances 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 8
- 229930003827 cannabinoid Natural products 0.000 description 8
- 239000003557 cannabinoid Substances 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 238000003384 imaging method Methods 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 102100033868 Cannabinoid receptor 1 Human genes 0.000 description 6
- 101710187010 Cannabinoid receptor 1 Proteins 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 229940125782 compound 2 Drugs 0.000 description 6
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 6
- 235000019341 magnesium sulphate Nutrition 0.000 description 6
- 239000000651 prodrug Substances 0.000 description 6
- 229940002612 prodrug Drugs 0.000 description 6
- 239000012217 radiopharmaceutical Substances 0.000 description 6
- 229940121896 radiopharmaceutical Drugs 0.000 description 6
- 230000002799 radiopharmaceutical effect Effects 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 5
- 150000001204 N-oxides Chemical class 0.000 description 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 230000003375 cannabimimetic effect Effects 0.000 description 5
- 229940125758 compound 15 Drugs 0.000 description 5
- 238000003818 flash chromatography Methods 0.000 description 5
- 150000004677 hydrates Chemical class 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 239000002207 metabolite Substances 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 239000004031 partial agonist Substances 0.000 description 5
- 239000012453 solvate Substances 0.000 description 5
- 239000011593 sulfur Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 4
- 102100036214 Cannabinoid receptor 2 Human genes 0.000 description 4
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 150000001408 amides Chemical class 0.000 description 4
- 239000012267 brine Substances 0.000 description 4
- 229940065144 cannabinoids Drugs 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 125000005843 halogen group Chemical group 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
- 239000003208 petroleum Substances 0.000 description 4
- 230000006461 physiological response Effects 0.000 description 4
- 238000000159 protein binding assay Methods 0.000 description 4
- 230000002285 radioactive effect Effects 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 229910052938 sodium sulfate Inorganic materials 0.000 description 4
- 235000011152 sodium sulphate Nutrition 0.000 description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
- FJTCRHXSVHRKBR-UHFFFAOYSA-N 1-(4-iodophenyl)propan-1-one Chemical compound CCC(=O)C1=CC=C(I)C=C1 FJTCRHXSVHRKBR-UHFFFAOYSA-N 0.000 description 3
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- WKBOTKDWSSQWDR-OIOBTWANSA-N Bromine-77 Chemical compound [77Br] WKBOTKDWSSQWDR-OIOBTWANSA-N 0.000 description 3
- 101710187022 Cannabinoid receptor 2 Proteins 0.000 description 3
- 244000025254 Cannabis sativa Species 0.000 description 3
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 230000001593 cAMP accumulation Effects 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 125000001153 fluoro group Chemical group F* 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 125000001624 naphthyl group Chemical group 0.000 description 3
- 230000000737 periodic effect Effects 0.000 description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000002603 single-photon emission computed tomography Methods 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 125000005034 trifluormethylthio group Chemical group FC(S*)(F)F 0.000 description 3
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 2
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- PVFOHMXILQEIHX-UHFFFAOYSA-N 8-[(6-bromo-1,3-benzodioxol-5-yl)sulfanyl]-9-[2-(2-bromophenyl)ethyl]purin-6-amine Chemical compound C=1C=2OCOC=2C=C(Br)C=1SC1=NC=2C(N)=NC=NC=2N1CCC1=CC=CC=C1Br PVFOHMXILQEIHX-UHFFFAOYSA-N 0.000 description 2
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 229940124802 CB1 antagonist Drugs 0.000 description 2
- 235000008697 Cannabis sativa Nutrition 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 208000019695 Migraine disease Diseases 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- YZCKVEUIGOORGS-IGMARMGPSA-N Protium Chemical compound [1H] YZCKVEUIGOORGS-IGMARMGPSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 102000000070 Sodium-Glucose Transport Proteins Human genes 0.000 description 2
- 108010080361 Sodium-Glucose Transport Proteins Proteins 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 150000001447 alkali salts Chemical class 0.000 description 2
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 2
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 2
- 239000000164 antipsychotic agent Substances 0.000 description 2
- 239000002948 appetite stimulant Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000013262 cAMP assay Methods 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 229940125797 compound 12 Drugs 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- 125000006165 cyclic alkyl group Chemical group 0.000 description 2
- MGNZXYYWBUKAII-UHFFFAOYSA-N cyclohexa-1,3-diene Chemical compound C1CC=CC=C1 MGNZXYYWBUKAII-UHFFFAOYSA-N 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- NLUNLVTVUDIHFE-UHFFFAOYSA-N cyclooctylcyclooctane Chemical compound C1CCCCCCC1C1CCCCCCC1 NLUNLVTVUDIHFE-UHFFFAOYSA-N 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 229910052805 deuterium Inorganic materials 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 229960004242 dronabinol Drugs 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229940079865 intestinal antiinfectives imidazole derivative Drugs 0.000 description 2
- 230000000155 isotopic effect Effects 0.000 description 2
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 206010027599 migraine Diseases 0.000 description 2
- YKVJZSZZQKQJMO-UHFFFAOYSA-N n-methoxy-n-methylpropanamide Chemical compound CCC(=O)N(C)OC YKVJZSZZQKQJMO-UHFFFAOYSA-N 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 238000009206 nuclear medicine Methods 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000002600 positron emission tomography Methods 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- RZWZRACFZGVKFM-UHFFFAOYSA-N propanoyl chloride Chemical compound CCC(Cl)=O RZWZRACFZGVKFM-UHFFFAOYSA-N 0.000 description 2
- 229940121649 protein inhibitor Drugs 0.000 description 2
- 239000012268 protein inhibitor Substances 0.000 description 2
- 230000000506 psychotropic effect Effects 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000002098 pyridazinyl group Chemical group 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 210000003568 synaptosome Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- 125000004306 triazinyl group Chemical group 0.000 description 2
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 description 2
- 229910052722 tritium Inorganic materials 0.000 description 2
- 229910052727 yttrium Inorganic materials 0.000 description 2
- XLYOFNOQVPJJNP-NJFSPNSNSA-N ((18)O)water Chemical compound [18OH2] XLYOFNOQVPJJNP-NJFSPNSNSA-N 0.000 description 1
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 1
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- ITOFPJRDSCGOSA-KZLRUDJFSA-N (2s)-2-[[(4r)-4-[(3r,5r,8r,9s,10s,13r,14s,17r)-3-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H](CC[C@]13C)[C@@H]2[C@@H]3CC[C@@H]1[C@H](C)CCC(=O)N[C@H](C(O)=O)CC1=CNC2=CC=CC=C12 ITOFPJRDSCGOSA-KZLRUDJFSA-N 0.000 description 1
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- AXJQVVLKUYCICH-OAQYLSRUSA-N (4s)-5-(4-chlorophenyl)-n-(4-chlorophenyl)sulfonyl-n'-methyl-4-phenyl-3,4-dihydropyrazole-2-carboximidamide Chemical compound C=1C=C(Cl)C=CC=1C([C@H](C1)C=2C=CC=CC=2)=NN1C(=NC)NS(=O)(=O)C1=CC=C(Cl)C=C1 AXJQVVLKUYCICH-OAQYLSRUSA-N 0.000 description 1
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 description 1
- 125000004845 (C1-C6) alkylsulfonylamino group Chemical group 0.000 description 1
- 125000006528 (C2-C6) alkyl group Chemical group 0.000 description 1
- YDKNASMIEZGJEJ-UHFFFAOYSA-N 1,1-dioxo-1,4-thiazinan-4-amine Chemical compound NN1CCS(=O)(=O)CC1 YDKNASMIEZGJEJ-UHFFFAOYSA-N 0.000 description 1
- NDOVLWQBFFJETK-UHFFFAOYSA-N 1,4-thiazinane 1,1-dioxide Chemical compound O=S1(=O)CCNCC1 NDOVLWQBFFJETK-UHFFFAOYSA-N 0.000 description 1
- AKAOMSFPCWJXKK-UHFFFAOYSA-N 1-(5-iodothiophen-2-yl)propan-1-one Chemical compound CCC(=O)C1=CC=C(I)S1 AKAOMSFPCWJXKK-UHFFFAOYSA-N 0.000 description 1
- KFNNPQDSPLWLCX-UHFFFAOYSA-N 1-[1-(4-chlorophenyl)cyclobutyl]-n,n,3-trimethylbutan-1-amine;hydron;chloride;hydrate Chemical compound O.Cl.C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 KFNNPQDSPLWLCX-UHFFFAOYSA-N 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical compound [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 description 1
- VEPOHXYIFQMVHW-XOZOLZJESA-N 2,3-dihydroxybutanedioic acid (2S,3S)-3,4-dimethyl-2-phenylmorpholine Chemical compound OC(C(O)C(O)=O)C(O)=O.C[C@H]1[C@@H](OCCN1C)c1ccccc1 VEPOHXYIFQMVHW-XOZOLZJESA-N 0.000 description 1
- OVSKIKFHRZPJSS-UHFFFAOYSA-N 2,4-D Chemical compound OC(=O)COC1=CC=C(Cl)C=C1Cl OVSKIKFHRZPJSS-UHFFFAOYSA-N 0.000 description 1
- GRUHREVRSOOQJG-UHFFFAOYSA-N 2,4-dichlorobenzonitrile Chemical compound ClC1=CC=C(C#N)C(Cl)=C1 GRUHREVRSOOQJG-UHFFFAOYSA-N 0.000 description 1
- PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 1
- UXGVMFHEKMGWMA-UHFFFAOYSA-N 2-benzofuran Chemical compound C1=CC=CC2=COC=C21 UXGVMFHEKMGWMA-UHFFFAOYSA-N 0.000 description 1
- ROIMNSWDOJCBFR-UHFFFAOYSA-N 2-iodothiophene Chemical compound IC1=CC=CS1 ROIMNSWDOJCBFR-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- VUIDKQHXAUDXKD-UHFFFAOYSA-N 281-32-3 Chemical compound C1C(O2)CC3CC1OC2O3 VUIDKQHXAUDXKD-UHFFFAOYSA-N 0.000 description 1
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 1
- GPIUUMROPXDNRH-UHFFFAOYSA-N 3647-74-3 Chemical compound C1C2C3C(=O)NC(=O)C3C1C=C2 GPIUUMROPXDNRH-UHFFFAOYSA-N 0.000 description 1
- SVJKMLBXJJZCHN-UHFFFAOYSA-N 4-(aminomethyl)benzenesulfonamide;propanoic acid Chemical group CCC(O)=O.NCC1=CC=C(S(N)(=O)=O)C=C1 SVJKMLBXJJZCHN-UHFFFAOYSA-N 0.000 description 1
- MINMDCMSHDBHKG-UHFFFAOYSA-N 4-[4-[[6-methoxy-2-(2-methoxyimidazo[2,1-b][1,3,4]thiadiazol-6-yl)-1-benzofuran-4-yl]oxymethyl]-5-methyl-1,3-thiazol-2-yl]morpholine Chemical compound N1=C2SC(OC)=NN2C=C1C(OC1=CC(OC)=C2)=CC1=C2OCC(=C(S1)C)N=C1N1CCOCC1 MINMDCMSHDBHKG-UHFFFAOYSA-N 0.000 description 1
- WDFQBORIUYODSI-UHFFFAOYSA-N 4-bromoaniline Chemical compound NC1=CC=C(Br)C=C1 WDFQBORIUYODSI-UHFFFAOYSA-N 0.000 description 1
- HMXDWDSNPRNUKI-UHFFFAOYSA-N 5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(1-piperidinyl)-3-pyrazolecarboxamide Chemical compound CCC=1C(C(=O)NN2CCCCC2)=NN(C=2C(=CC(Cl)=CC=2)Cl)C=1C1=CC=C(Br)C=C1 HMXDWDSNPRNUKI-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- OZAIFHULBGXAKX-VAWYXSNFSA-N AIBN Substances N#CC(C)(C)\N=N\C(C)(C)C#N OZAIFHULBGXAKX-VAWYXSNFSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- QGZKDVFQNNGYKY-OUBTZVSYSA-N Ammonia-15N Chemical compound [15NH3] QGZKDVFQNNGYKY-OUBTZVSYSA-N 0.000 description 1
- 101100453274 Arabidopsis thaliana JOX3 gene Proteins 0.000 description 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- PWDLDBWXTVILPC-WGAVTJJLSA-N CC(C)(N)CC1=CC=CC=C1.C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 Chemical compound CC(C)(N)CC1=CC=CC=C1.C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 PWDLDBWXTVILPC-WGAVTJJLSA-N 0.000 description 1
- KCBAMQOKOLXLOX-BSZYMOERSA-N CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O Chemical compound CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O KCBAMQOKOLXLOX-BSZYMOERSA-N 0.000 description 1
- BQXUPNKLZNSUMC-YUQWMIPFSA-N CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 Chemical compound CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 BQXUPNKLZNSUMC-YUQWMIPFSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 1
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- OKTJSMMVPCPJKN-OUBTZVSYSA-N Carbon-13 Chemical compound [13C] OKTJSMMVPCPJKN-OUBTZVSYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 102100025597 Caspase-4 Human genes 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 229940093444 Cyclooxygenase 2 inhibitor Drugs 0.000 description 1
- 229940127193 DGAT1 inhibitor Drugs 0.000 description 1
- 206010012218 Delirium Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 229940124213 Dipeptidyl peptidase 4 (DPP IV) inhibitor Drugs 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 229940122746 Fatty acid amide hydrolase inhibitor Drugs 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 101800001586 Ghrelin Proteins 0.000 description 1
- 102400000442 Ghrelin-28 Human genes 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 101100273284 Homo sapiens CASP4 gene Proteins 0.000 description 1
- 101000875075 Homo sapiens Cannabinoid receptor 2 Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 102100023915 Insulin Human genes 0.000 description 1
- ZCYVEMRRCGMTRW-AHCXROLUSA-N Iodine-123 Chemical compound [123I] ZCYVEMRRCGMTRW-AHCXROLUSA-N 0.000 description 1
- 229940086609 Lipase inhibitor Drugs 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 229940122023 Melanin concentrating hormone receptor antagonist Drugs 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 102100031545 Microsomal triglyceride transfer protein large subunit Human genes 0.000 description 1
- 102000010909 Monoamine Oxidase Human genes 0.000 description 1
- 108010062431 Monoamine oxidase Proteins 0.000 description 1
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101100314144 Mus musculus Tnip1 gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- QJGQUHMNIGDVPM-BJUDXGSMSA-N Nitrogen-13 Chemical compound [13N] QJGQUHMNIGDVPM-BJUDXGSMSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 102000016979 Other receptors Human genes 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 241000282520 Papio Species 0.000 description 1
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 1
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000720974 Protium Species 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical class C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 238000003477 Sonogashira cross-coupling reaction Methods 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- NINIDFKCEFEMDL-AKLPVKDBSA-N Sulfur-35 Chemical compound [35S] NINIDFKCEFEMDL-AKLPVKDBSA-N 0.000 description 1
- 239000012317 TBTU Substances 0.000 description 1
- QLYKJCMUNUWAGO-GAJHUEQPSA-N Taranabant Chemical compound N([C@@H](C)[C@@H](CC=1C=CC(Cl)=CC=1)C=1C=C(C=CC=1)C#N)C(=O)C(C)(C)OC1=CC=C(C(F)(F)F)C=N1 QLYKJCMUNUWAGO-GAJHUEQPSA-N 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- HQVHOQAKMCMIIM-HXUWFJFHSA-N WIN 55212-2 Chemical compound C([C@@H]1COC=2C=CC=C3C(C(=O)C=4C5=CC=CC=C5C=CC=4)=C(N1C3=2)C)N1CCOCC1 HQVHOQAKMCMIIM-HXUWFJFHSA-N 0.000 description 1
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- PNDPGZBMCMUPRI-XXSWNUTMSA-N [125I][125I] Chemical compound [125I][125I] PNDPGZBMCMUPRI-XXSWNUTMSA-N 0.000 description 1
- XAKBSHICSHRJCL-UHFFFAOYSA-N [CH2]C(=O)C1=CC=CC=C1 Chemical group [CH2]C(=O)C1=CC=CC=C1 XAKBSHICSHRJCL-UHFFFAOYSA-N 0.000 description 1
- KPCZJLGGXRGYIE-UHFFFAOYSA-N [C]1=CC=CN=C1 Chemical group [C]1=CC=CN=C1 KPCZJLGGXRGYIE-UHFFFAOYSA-N 0.000 description 1
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 1
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- CPELXLSAUQHCOX-AHCXROLUSA-N ac1l4zwb Chemical compound [76BrH] CPELXLSAUQHCOX-AHCXROLUSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 1
- 229910001573 adamantine Inorganic materials 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 239000000048 adrenergic agonist Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 239000000883 anti-obesity agent Substances 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229940125710 antiobesity agent Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 125000003435 aroyl group Chemical group 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-FTXFMUIASA-N bromine-75 Chemical compound [75BrH] CPELXLSAUQHCOX-FTXFMUIASA-N 0.000 description 1
- CPELXLSAUQHCOX-NJFSPNSNSA-N bromine-82 Chemical compound [82BrH] CPELXLSAUQHCOX-NJFSPNSNSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- APJYYFNGGGLDJF-UHFFFAOYSA-N but-3-ynyl methanesulfonate Chemical compound CS(=O)(=O)OCCC#C APJYYFNGGGLDJF-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000003556 cannabinoid 2 receptor agonist Substances 0.000 description 1
- RBHJBMIOOPYDBQ-UHFFFAOYSA-N carbon dioxide;propan-2-one Chemical compound O=C=O.CC(C)=O RBHJBMIOOPYDBQ-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-BJUDXGSMSA-N carbon-11 Chemical compound [11C] OKTJSMMVPCPJKN-BJUDXGSMSA-N 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- ZAMOUSCENKQFHK-OUBTZVSYSA-N chlorine-36 Chemical compound [36Cl] ZAMOUSCENKQFHK-OUBTZVSYSA-N 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 239000003354 cholesterol ester transfer protein inhibitor Substances 0.000 description 1
- 229940125881 cholesteryl ester transfer protein inhibitor Drugs 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 208000014797 chronic intestinal pseudoobstruction Diseases 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 229940126208 compound 22 Drugs 0.000 description 1
- 229940125833 compound 23 Drugs 0.000 description 1
- 229940125961 compound 24 Drugs 0.000 description 1
- 229940125846 compound 25 Drugs 0.000 description 1
- 229940127204 compound 29 Drugs 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 229940124558 contraceptive agent Drugs 0.000 description 1
- 229940012193 contrave Drugs 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- WYACBZDAHNBPPB-UHFFFAOYSA-N diethyl oxalate Chemical compound CCOC(=O)C(=O)OCC WYACBZDAHNBPPB-UHFFFAOYSA-N 0.000 description 1
- 239000003603 dipeptidyl peptidase IV inhibitor Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- IQQBRKLVEALROM-UHFFFAOYSA-N drinabant Chemical compound C=1C(F)=CC(F)=CC=1N(S(=O)(=O)C)C(C1)CN1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 IQQBRKLVEALROM-UHFFFAOYSA-N 0.000 description 1
- 239000006274 endogenous ligand Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- SIOIQIWIQSMQAG-UHFFFAOYSA-N ethyl 3-bromo-2-oxobutanoate Chemical compound CCOC(=O)C(=O)C(C)Br SIOIQIWIQSMQAG-UHFFFAOYSA-N 0.000 description 1
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
- LFRXBSFJOBAAMC-UHFFFAOYSA-N ethylbenzene;heptane;oxolane Chemical compound C1CCOC1.CCCCCCC.CCC1=CC=CC=C1 LFRXBSFJOBAAMC-UHFFFAOYSA-N 0.000 description 1
- 239000003940 fatty acid amidase inhibitor Substances 0.000 description 1
- RMBPEFMHABBEKP-UHFFFAOYSA-N fluorene Chemical compound C1=CC=C2C3=C[CH]C=CC3=CC2=C1 RMBPEFMHABBEKP-UHFFFAOYSA-N 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- YCKRFDGAMUMZLT-BJUDXGSMSA-N fluorine-18 atom Chemical compound [18F] YCKRFDGAMUMZLT-BJUDXGSMSA-N 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 230000005251 gamma ray Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- GNKDKYIHGQKHHM-RJKLHVOGSA-N ghrelin Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CN)COC(=O)CCCCCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CC=CC=C1 GNKDKYIHGQKHHM-RJKLHVOGSA-N 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000003877 glucagon like peptide 1 receptor agonist Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 150000002431 hydrogen Chemical group 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- XMBWDFGMSWQBCA-OIOBTWANSA-N iodane Chemical compound [124IH] XMBWDFGMSWQBCA-OIOBTWANSA-N 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 229940044173 iodine-125 Drugs 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 229960005060 lorcaserin Drugs 0.000 description 1
- XTTZERNUQAFMOF-QMMMGPOBSA-N lorcaserin Chemical compound C[C@H]1CNCCC2=CC=C(Cl)C=C12 XTTZERNUQAFMOF-QMMMGPOBSA-N 0.000 description 1
- FRIJBUGBVQZNTB-UHFFFAOYSA-M magnesium;ethane;bromide Chemical compound [Mg+2].[Br-].[CH2-]C FRIJBUGBVQZNTB-UHFFFAOYSA-M 0.000 description 1
- 210000005171 mammalian brain Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229940045623 meridia Drugs 0.000 description 1
- SPAKMVQVTSVXES-UHFFFAOYSA-N methanol;oxolane;hydrate Chemical compound O.OC.C1CCOC1 SPAKMVQVTSVXES-UHFFFAOYSA-N 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 108010038232 microsomal triglyceride transfer protein Proteins 0.000 description 1
- 238000010852 mitochondrial transfer Methods 0.000 description 1
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- MKQLBNJQQZRQJU-UHFFFAOYSA-N morpholin-4-amine Chemical compound NN1CCOCC1 MKQLBNJQQZRQJU-UHFFFAOYSA-N 0.000 description 1
- KRKPYFLIYNGWTE-UHFFFAOYSA-N n,o-dimethylhydroxylamine Chemical compound CNOC KRKPYFLIYNGWTE-UHFFFAOYSA-N 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- UMRZSTCPUPJPOJ-KNVOCYPGSA-N norbornane Chemical compound C1C[C@H]2CC[C@@H]1C2 UMRZSTCPUPJPOJ-KNVOCYPGSA-N 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- NIHNNTQXNPWCJQ-UHFFFAOYSA-N o-biphenylenemethane Natural products C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 1
- UNAZAADNBYXMIV-UHFFFAOYSA-N otenabant Chemical compound C1CC(NCC)(C(N)=O)CCN1C1=NC=NC2=C1N=C(C=1C(=CC=CC=1)Cl)N2C1=CC=C(Cl)C=C1 UNAZAADNBYXMIV-UHFFFAOYSA-N 0.000 description 1
- 229950005009 otenabant Drugs 0.000 description 1
- QVGXLLKOCUKJST-BJUDXGSMSA-N oxygen-15 atom Chemical compound [15O] QVGXLLKOCUKJST-BJUDXGSMSA-N 0.000 description 1
- VMUWIDHKAIGONP-UHFFFAOYSA-N pent-4-ynenitrile Chemical compound C#CCCC#N VMUWIDHKAIGONP-UHFFFAOYSA-N 0.000 description 1
- 229960003562 phentermine Drugs 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- 239000007856 photoaffinity label Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000004036 potassium channel stimulating agent Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000004129 prosencephalon Anatomy 0.000 description 1
- ILVXOBCQQYKLDS-UHFFFAOYSA-N pyridine N-oxide Chemical compound [O-][N+]1=CC=CC=C1 ILVXOBCQQYKLDS-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 239000002461 renin inhibitor Substances 0.000 description 1
- 229940086526 renin-inhibitors Drugs 0.000 description 1
- WMMMJGKFKKBRQR-UHFFFAOYSA-N rosonabant Chemical compound C1=CC(Cl)=CC=C1C1N(C=2C(=CC(Cl)=CC=2)Cl)N=C(C(=O)NN2CCCCC2)C1 WMMMJGKFKKBRQR-UHFFFAOYSA-N 0.000 description 1
- 229950007834 rosonabant Drugs 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 229960004425 sibutramine Drugs 0.000 description 1
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 230000005586 smoking cessation Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 229950003174 surinabant Drugs 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 229950005022 taranabant Drugs 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005309 thioalkoxy group Chemical group 0.000 description 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
- 230000002992 thymic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- 239000003174 triple reuptake inhibitor Substances 0.000 description 1
- XLRPYZSEQKXZAA-OCAPTIKFSA-N tropane Chemical compound C1CC[C@H]2CC[C@@H]1N2C XLRPYZSEQKXZAA-OCAPTIKFSA-N 0.000 description 1
- 229930004006 tropane Natural products 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- XLYOFNOQVPJJNP-OUBTZVSYSA-N water-17o Chemical compound [17OH2] XLYOFNOQVPJJNP-OUBTZVSYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 229940002552 xenical Drugs 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Abstract
Disclosed are biologically active hetero pyrrole analogs such as imidazoles, thiazoles, oxazoles and pyrazoles capable of interacting with the CB1 and/or CB2 cannabinoid receptors. Aspects disclose hetero pyrrole analogs acting as CB1 and/or CB 1 receptor antagonists, having selectivity for the CB 1 or CB2 receptor, acting as neutral antagonists, acting preferentially on CB 1 receptors located in the peripheral nervous system, and/or acting as nitric oxide donors. Pharmaceutical preparations employing the disclosed analogs and methods of administering therapeutically effective amounts of the disclosed analogs to provide a physiological effect are also disclosed.
Description
NOVEL HETERO PYRROLE ANALOGS ACTING ON
CANNABINOID RECEPTORS
Field of the Invention The present invention relates generally to biologically active hetero pyrrole analogs such as imidazoles, thiazoles, oxazoles and pyrazoles capable of interacting with the CBI and/or the CB2 cannabinoid receptors, including neutral antagonists, inverse-agonists and partial agonists. Another aspect of the invention is concerned with such compounds having a range of useful applications including use of certain neutral antagonists, inverse-agonists and partial agonists to treat medical conditions with no or substantially reduced incidence of side-effects. Other aspects of the invention are concerned with new and improved hetero pyrrole analogs acting as neutral antagonists, inverse-agonists and partial agonists selective for the and/or the CB2 receptors and use of these new and improved hetero pyrrole analogs as peripherally acting or centrally acting compounds. Also, aspects of the invention are concerned with all isotopic variations of these compounds, combination therapy and pharmaceutical preparations and compositions employing the inventive analogs and methods of administering therapeutically effective amounts of the inventive analogs to provide a physiological effect.
Background of the Invention Marijuana (Cannabis sativa) and derivatives have been used for medicinal and recreational purposes. The major active constituent extracted from Cannabis sativa is the classical cannabinoid A9-Tetrahydrocannabinol (A9-THC). The effects of such cannabinoids are due to an interaction with specific high-affinity receptors.
Presently, two cannabinoid receptors have been characterized: CB1, a central receptor found in the mammalian brain and a number of other sites in peripheral tissues; and CB2, a peripheral receptor found principally in cells related to the immune system.
The CB1 receptor is believed to mediate the psychoactive properties associated with classical cannabinoids. Characterization of these receptors has been made possible by the development of specific synthetic ligands such as the agonists WIN 55212-2 and CP
55,940.
In addition to acting at the cannabinoid receptors, cannabinoids such as A9-THC also affect cellular membranes, thereby producing undesirable side effects such as drowsiness, impairment of monoamine oxidase function and impairment of non-receptor mediated brain function. The addictive and psychotropic properties of some cannabinoids also limit their therapeutic value.
International Publication number WO 03/007887 A2 to Finke et al describes imidazole derivatives alleged to have binding affinity for the central cannabinoid receptor. International Publication number WO 03/027076 A2 to Kruse et al also describes some imidazole derivatives alleged to have binding affinity for cannabinoid receptors.
Brief Description of the Drawings Figures 1A-1B are graphs showing cAMP accumulation with hCB1-HEK292 cells (Compound 2 and 15); and Figures 2A-2C are graphs showing food intake, weigh change and body weight following administration of Compound 15 to rats.
Summary of the Invention Briefly stated, one embodiment of the invention is concerned with new and improved cannabimimetic (cannabinoid like) imidazole analogs. The inventive cannabimimetic imidazole ligands of this embodiment can be represented by general formula I and their enantiomers, diastereomers, geometric isomers, racemates, tautomers, rotamers, atropisomers, metabolites, in vivo hydrolysable esters, N-oxides, salts, solvates, hydrates, polymorphic forms( crystalline or amorphous) or pro-drugs:
R4 ______________________________ ( I R3 Ny1 2)N 0
CANNABINOID RECEPTORS
Field of the Invention The present invention relates generally to biologically active hetero pyrrole analogs such as imidazoles, thiazoles, oxazoles and pyrazoles capable of interacting with the CBI and/or the CB2 cannabinoid receptors, including neutral antagonists, inverse-agonists and partial agonists. Another aspect of the invention is concerned with such compounds having a range of useful applications including use of certain neutral antagonists, inverse-agonists and partial agonists to treat medical conditions with no or substantially reduced incidence of side-effects. Other aspects of the invention are concerned with new and improved hetero pyrrole analogs acting as neutral antagonists, inverse-agonists and partial agonists selective for the and/or the CB2 receptors and use of these new and improved hetero pyrrole analogs as peripherally acting or centrally acting compounds. Also, aspects of the invention are concerned with all isotopic variations of these compounds, combination therapy and pharmaceutical preparations and compositions employing the inventive analogs and methods of administering therapeutically effective amounts of the inventive analogs to provide a physiological effect.
Background of the Invention Marijuana (Cannabis sativa) and derivatives have been used for medicinal and recreational purposes. The major active constituent extracted from Cannabis sativa is the classical cannabinoid A9-Tetrahydrocannabinol (A9-THC). The effects of such cannabinoids are due to an interaction with specific high-affinity receptors.
Presently, two cannabinoid receptors have been characterized: CB1, a central receptor found in the mammalian brain and a number of other sites in peripheral tissues; and CB2, a peripheral receptor found principally in cells related to the immune system.
The CB1 receptor is believed to mediate the psychoactive properties associated with classical cannabinoids. Characterization of these receptors has been made possible by the development of specific synthetic ligands such as the agonists WIN 55212-2 and CP
55,940.
In addition to acting at the cannabinoid receptors, cannabinoids such as A9-THC also affect cellular membranes, thereby producing undesirable side effects such as drowsiness, impairment of monoamine oxidase function and impairment of non-receptor mediated brain function. The addictive and psychotropic properties of some cannabinoids also limit their therapeutic value.
International Publication number WO 03/007887 A2 to Finke et al describes imidazole derivatives alleged to have binding affinity for the central cannabinoid receptor. International Publication number WO 03/027076 A2 to Kruse et al also describes some imidazole derivatives alleged to have binding affinity for cannabinoid receptors.
Brief Description of the Drawings Figures 1A-1B are graphs showing cAMP accumulation with hCB1-HEK292 cells (Compound 2 and 15); and Figures 2A-2C are graphs showing food intake, weigh change and body weight following administration of Compound 15 to rats.
Summary of the Invention Briefly stated, one embodiment of the invention is concerned with new and improved cannabimimetic (cannabinoid like) imidazole analogs. The inventive cannabimimetic imidazole ligands of this embodiment can be represented by general formula I and their enantiomers, diastereomers, geometric isomers, racemates, tautomers, rotamers, atropisomers, metabolites, in vivo hydrolysable esters, N-oxides, salts, solvates, hydrates, polymorphic forms( crystalline or amorphous) or pro-drugs:
R4 ______________________________ ( I R3 Ny1 2)N 0
2 A comprises a direct bond, 0, or -(CH2)1N(R5) B comprises a direct bond, 0, N(R5), - (CH2)1 - or -NH-S02 -R5 is hydrogen, OH, alkyl or substituted alkyl and 1 is an integer from 0 to 3.
In a variation of formula 1, R1 and R2 each independently comprise -(CH2)n-Z.
n is an integer from 0 to about 7.
Z comprises H, halogen, CF3, CF2H, N3, NCS, CN, NO2, NX1X2, OX3, SX3, OAc, OSO2X3, 0-acyl, S-acyl, S02-alkyl, SO-alkyl, SC(CH3)2C00X8, OC(CH3)2C00X8 , C(CH3)2C00X8, Si(alkyl)3, 0-aroyl, 0(CH2)10X3, 0(CH2)JNX1X2, alkyl-CN, NH-acyl, NH-aroyl, CHO, C(halogen)3, COOX3, SO3H, SO2NX1X2, CONX1X2, NHC(0)0-alkyl, NHS02-alkyl, alkoxy, alkyl, alcohol, alkylmercapto, alkylamino, di-alkylamino, alkylsulfinyl or alkylsulfonyl, CX4X8X8, -CH=CHX8 , X1 and X2 each independently comprise H or alkyl, or X1 and X2 together comprise part of a heterocyclic ring having about 4 to about 7 ring members and optionally one additional heteroatom selected from 0, N or S, or X1 and X2 together comprise part of an imide ring having about 5 to about 6 members, X3 comprises H, alkyl, aryl, NO2, NO, (CH2)mCN, hydroxyloweralkyl, or alkyl-NX1X2, X4, X5, and X6 each independently comprise H, alkyl, carbocyclic ring, hydroxyloweralkyl, alkyl-OH, halogen, CN, SNO, S(S02)alkyl, NX1X2, COOX3, CONX3, OX7, or 0-alkyl-X7 wherein X7 comprises H, alkyl, NO2, NO, P(0)(0X8)2, PH(0)(0X8), S(0)kN(alky1)2, S(0)kX8, S(0)k0X8, COOX8, CONX8, SO3H, COX8, wherein X5 comprises H, alkyl, carbocyclic ring, heterocyclic ring, aromatic ring, heteroaromatic ring, or -CX9=CHX10 wherein
In a variation of formula 1, R1 and R2 each independently comprise -(CH2)n-Z.
n is an integer from 0 to about 7.
Z comprises H, halogen, CF3, CF2H, N3, NCS, CN, NO2, NX1X2, OX3, SX3, OAc, OSO2X3, 0-acyl, S-acyl, S02-alkyl, SO-alkyl, SC(CH3)2C00X8, OC(CH3)2C00X8 , C(CH3)2C00X8, Si(alkyl)3, 0-aroyl, 0(CH2)10X3, 0(CH2)JNX1X2, alkyl-CN, NH-acyl, NH-aroyl, CHO, C(halogen)3, COOX3, SO3H, SO2NX1X2, CONX1X2, NHC(0)0-alkyl, NHS02-alkyl, alkoxy, alkyl, alcohol, alkylmercapto, alkylamino, di-alkylamino, alkylsulfinyl or alkylsulfonyl, CX4X8X8, -CH=CHX8 , X1 and X2 each independently comprise H or alkyl, or X1 and X2 together comprise part of a heterocyclic ring having about 4 to about 7 ring members and optionally one additional heteroatom selected from 0, N or S, or X1 and X2 together comprise part of an imide ring having about 5 to about 6 members, X3 comprises H, alkyl, aryl, NO2, NO, (CH2)mCN, hydroxyloweralkyl, or alkyl-NX1X2, X4, X5, and X6 each independently comprise H, alkyl, carbocyclic ring, hydroxyloweralkyl, alkyl-OH, halogen, CN, SNO, S(S02)alkyl, NX1X2, COOX3, CONX3, OX7, or 0-alkyl-X7 wherein X7 comprises H, alkyl, NO2, NO, P(0)(0X8)2, PH(0)(0X8), S(0)kN(alky1)2, S(0)kX8, S(0)k0X8, COOX8, CONX8, SO3H, COX8, wherein X5 comprises H, alkyl, carbocyclic ring, heterocyclic ring, aromatic ring, heteroaromatic ring, or -CX9=CHX10 wherein
3 X9 and X10 each independently comprise H or alkyl Wherein m is an integer from 0 to 7 j is an integer from 0 to about 6, or k is an integer from 0 to about 2 In a variation of formula I, R1 and R2 each independently comprise -(CH2)n-Z.
n is an integer from 0 to about 7.
Z comprises a carbocyclic ring having about 4 to about 7 ring members, a heterocyclic ring having about 4 to about 7 ring members, an aromatic ring having about 5 to about 7 ring members, a heteroaromatic ring having about 5 to about ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring, a heteropolycyclic ring; or any above group substituted on at least one available ring atom by an alkyl group; or any above group substituted on at least one available ring nitrogen atom by a benzyl group, a substituted benzyl group, an alkoxybenzyl group, a substituted alkoxybenzyl group, a benzhydryl group or a substituted benzhydryl group; and wherein the connecting point between the -(CH2)n-group and the Z group can be any available ring carbon atom or any available ring nitrogen atom.
In a variation of formula I, R1 and R2 each independently comprise -(CH2)n-Z.
n is an integer from 0 to about 7.
Z comprises a 5 member unsaturated ring having 0 to 4 independently selected heteroatoms as ring members, a substituted 5 member unsaturated ring having 0 to 4 independently selected heteroatoms as ring members, a 6 member aromatic ring having 0 to 5 independently selected heteroatoms as ring members or a substituted 6 member aromatic ring having 0 to 5 independently selected heteroatoms; and wherein the connecting point between the -(CH2)n- group and the Z
group can be any available ring carbon atom or any available ring nitrogen atom.
n is an integer from 0 to about 7.
Z comprises a carbocyclic ring having about 4 to about 7 ring members, a heterocyclic ring having about 4 to about 7 ring members, an aromatic ring having about 5 to about 7 ring members, a heteroaromatic ring having about 5 to about ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring, a heteropolycyclic ring; or any above group substituted on at least one available ring atom by an alkyl group; or any above group substituted on at least one available ring nitrogen atom by a benzyl group, a substituted benzyl group, an alkoxybenzyl group, a substituted alkoxybenzyl group, a benzhydryl group or a substituted benzhydryl group; and wherein the connecting point between the -(CH2)n-group and the Z group can be any available ring carbon atom or any available ring nitrogen atom.
In a variation of formula I, R1 and R2 each independently comprise -(CH2)n-Z.
n is an integer from 0 to about 7.
Z comprises a 5 member unsaturated ring having 0 to 4 independently selected heteroatoms as ring members, a substituted 5 member unsaturated ring having 0 to 4 independently selected heteroatoms as ring members, a 6 member aromatic ring having 0 to 5 independently selected heteroatoms as ring members or a substituted 6 member aromatic ring having 0 to 5 independently selected heteroatoms; and wherein the connecting point between the -(CH2)n- group and the Z
group can be any available ring carbon atom or any available ring nitrogen atom.
4 In a variation of formula I, R1 and R2 each independently comprise -(C H2)-Z.
n is an integer from 0 to about 7.
Z comprises 1-, 2- or 3-pyrrolidinyl, 1-, 2-, 3- or 4-piperidinyl, 2-, 3- or 4-morpholinyl, 2-, 3- or 4-thiomorpholinyl, 1-, 2- or 3-azetidinyl, 1- or 2-piperazinyl, 2- or 3-tetrahydrofuranyl; or any above group substituted on at least one available ring atom by an alkyl group; or any above group substituted on at least one available ring nitrogen atom by a benzyl group, a substituted benzyl group, an alkoxybenzyl group, a substituted alkoxybenzyl group, a benzhydryl group or a substituted benzhydryl group; and wherein the connecting point between the -(CH2)n- group and the Z
group can be any available ring carbon atom or any available ring nitrogen atom.
In a variation of formula I, R1 and R2 each independently comprise -(CH2)n-Z.
n is an integer from 0 to about 7.
Z comprises )i_xy ry y ' mx N X
( NNYJX
\ ______ N , __ X X y N Y N
N \ X
Ny N N N y 0 \ 7-1 Y 01 X
Y N Or *ex N
\N \N
N N N nrw )6Nr1/ )(\- N' y X
wherein X and Y each independently comprise, H, halogen, CF3, CFA N3, NOS, ON, NO2, NX1X2, OX3, SX3, OAc, 0S02X3, 0-acyl, S-acyl, S02-alkyl, SO-alkyl, SC(CH3)2000X8, OC(CH3)2C00X8 , C(CH3)2000X8, Si(alkyl)3, alkyl-ON, 0-aroyl, 0(CH2)i0X3, 0(CH2)JNX1X2, NH-acyl, NH-aroyl, CHO, C(halogen)3, COOX3, SO3H, SO2NX1X2, CONX1X2, NHC(0)0-alkyl, NHS02-alkyl, alkoxy, alkyl, alcohol, alkylmercapto, alkylamino, di-alkylamino, alkylsulfinyl or alkylsulfonyl, CX4X5X6, -CH=CHX8 , -CCX8 ;
X1 and X2 each independently comprise H or alkyl, or X1 and X2 together comprise part of a heterocyclic ring having about 4 to about 7 ring members and optionally one additional heteroatom selected from 0, N or S, or X1 and X2 together comprise part of an imide ring having about 5 to about 6 members, X3 comprises H, alkyl, aryl, NO2, (0H2)mCN, hydroxyloweralkyl, or alkyl-NX1X2, X4, X5, and X8 each independently comprise H, alkyl, carbocyclic ring, hydroxyloweralkyl, alkyl-OH, halogen, ON, SNO, S(S02)alkyl, NX1X2, 000X3, CONX3, OX7, or 0-alkyl-X7 wherein X7 comprises H, alkyl, NO2, NO, P(0)(0X8)2, PH(0)(0X8), S(0)kN(alkyl)2, S(0)kX8, S(0)k0X8, 000X8, CONX8, SO3H, COX8, wherein X8 comprises H, alkyl, carbocyclic ring, heterocyclic ring, aromatic ring, heteroaromatic ring, or -0X0=CHX10 wherein X9 and X10 each independently comprise H or alkyl Wherein m is an integer from 0 to 7 j is an integer from 0 to about 6, or W comprises H or alkyl k is an integer from 0 to about 2 In a variation of formula I, R1 and R2 each independently -(CH2)n-Z.
n is an integer from 0 to about 7.
Z comprises a carbocyclic ring having 6 ring atoms fused to a heterocyclic ring having from 5 to 7 ring atoms, a carbocyclic ring having 6 ring atoms fused to a heteroaromatic ring having from 5 to 7 ring atoms, a heterocyclic ring having 6 ring atoms fused to a heterocyclic ring having from 5 to 7 ring atoms, an heterocyclic ring having 6 ring atoms fused to a heteroaromatic ring having from 5 to 7 ring atoms, an aromatic ring having 6 ring atoms fused to a heterocyclic ring having from 5 to 7 ring atoms, an aromatic ring having 6 ring atoms fused to a heteroaromatic ring having from 5 to 7 ring atoms, a heteroaromatic ring having 6 ring atoms fused to a heterocyclic ring having from 5 to 7 ring atoms or a heteroaromatic ring having 6 ring atoms fused to a heteroaromatic ring having from 5 to 7 ring atoms.
In a variation of formula I, R1 and R2 each independently comprise -(CH2)n-Z;
n comprises an integer from 0 to about 7;
Z comprises an unsaturated ring having 5 ring atoms and 0 to 2 independently selected heteroatoms as ring members fused to an unsaturated ring having 5 ring atoms and 0 to 4 independently selected heteroatoms as ring members, an unsaturated ring having 5 ring atoms and 0 to 2 independently selected heteroatoms as ring members fused to an unsaturated ring having 6 or 7 ring atoms and 0 to independently selected heteroatoms as ring members or an unsaturated ring having 6 ring atoms and 0 to 4 independently selected heteroatoms as ring members fused to an unsaturated ring having 6 or 7 ring atoms and 0 to 4 independently selected heteroatoms as ring members.
In a variation of formula I, R1 and R2 each independently comprise -(CH2)m -Qi-(CH2)n-Z;
Q1 comprises NH, 0, S,-CH=CH-, -CO, SO2 or 0S02;
m is an integer from 1 to about 7;
n is an integer from 0 to about 7;
Z comprises H, halogen, CF3, CF2H, N3, NCS, CN, NO2, NX1X2, OX3, SX3, OAc, 0S02X3, 0-acyl, S-acyl, S02-alkyl, SO-alkyl, SC(CH3)2C00X8, OC(CH3)2C00X8 , C(CH3)2C00X8, Si(alkyl)3, 0-aroyl, 0(CH2)i0X3, 0(CH2)iNX1X2, alkyl-CN, NH-acyl, NH-aroyl, CHO, C(halogen)3, COOX3, SO3H, SO2NX1X2, CONX1X2, NHC(0)0-alkyl, NHS02-alkyl, alkoxy, alkyl, alcohol, alkylmercapto, alkylamino, di-alkylamino, alkylsulfinyl or alkylsulfonyl, CX4X5X8, -CH=CHX8 , -CmCX8 ;
X1 and X2 each independently comprise H or alkyl:or X1 and X2 together comprise part of a heterocyclic ring having about 4 to about 7 ring members and optionally one additional heteroatom selected from 0, N or S, or X1 and X2 together comprise part of an imide ring having about 5 to about 6 members;
X3 comprises H, alkyl, NO2, NO, (CH2)mCN, hydroxyloweralkyl, or alkyl-NX1X2;
X4, X5, and X6 each independently comprise H, alkyl, 'carbocyclic ring, hydroxyloweralkyl, alkyl-OH, halogen, CN, SNO, S(S02)alkyl, NX1X2, COOX3, CONX3, OX7, or 0-alkyl-X7, wherein X7 comprises H, alkyl, NO2, NO, P(0)(0X8)2, PH(0)(0X8), S(0)kN(alky1)2, S(0)kX8, S(0)k0X8, COOX8, CONX8, SO3H, COX8, wherein X8 comprises H, alkyl, carbocyclic ring, heterocyclic ring, aromatic ring, heteroaromatic ring, or -CX0=CHX10, wherein X9 and X10 each independently comprise H or alkyl;
m is an integer from 0 to 7;
j is an integer from 0 to about 6, and k is an integer from 0 to about 2.
In a variation of formula I, R1 and R2 each independently comprise -Q2-(CH2)n-Z, Q2 is optionally present and if present comprises -CH2-NH, -CH2-0, -CH2-S, -CH2-S02 or -CH2-0S02;
n is an integer from 0 to about 7;
Z comprises H, halogen, CF3, CF2H, N3, NCS, CN, NO2, NX1X2, OX3, SX3, OAc, 0S02X3, 0-acyl, S-acyl, S02-alkyl, SO-alkyl, SC(CH3)2C00X8, OC(CH3)2000X8 , C(CH3)2C00X8, Si(alkyl)3, 0-aroyl, 0(CH2)j0X3, 0(CH2)iNX1X2, alkyl-CN, NH-acyl, NH-aroyl, CHO, C(halogen)3, COOX3, SO3H, SO2NX1X2, CONX1X2, NHC(0)0-alkyl, NHS02-alkyl, alkoxy, alkyl, alcohol, alkylmercapto, alkylamino, di-alkylamino, alkylsulfinyl or alkylsulfonyl, CX4X5X6, -CH=CHX8 , -C-7=-CX8 X1 and X2 each independently comprise H or alkyl, or X1 and X2 together comprise part of a heterocyclic ring having about 4 to about 7 ring members and optionally one additional heteroatom selected from 0, N or S, or X1 and X2 together comprise part of an imide ring having about 5 to about 6 members, X3 comprises H, alkyl, NO2, NO, (CH2)mCN, hydroxyloweralkyl, or alkyl-NX1X2, X4, X5, and X6 each independently comprise H, alkyl, carbocyclic ring, hydroxyloweralkyl, alkyl-OH, halogen, CN, SNO, S(S02)alkyl, NX1X2, COOX3, CONX3, OX7, or 0-alkyl-X7, wherein X7 comprises H, alkyl, NO2, NO, P(0)(0X8)2, PH(0)(0X8), S(0)kN(alky1)2, S(0)kX8, S(0)k0X8, COOX8, CONX8, SO3H, COX8, wherein X8 comprises H, alkyl, carbocyclic ring, heterocyclic ring, aromatic ring, heteroaromatic ring, or -CX0=CHX10, wherein X9 and X10 each independently comprise H or alkyl;
m is an integer from 0 to 7;
j is an integer from 0 to about 6; and k is an integer from 0 to about 2.
In a variation of formula I, R1 and R2 each independently comprise -(CH2)m - 01 -(CH2)n-Z;
Qi comprises NH, 0, S, CH=CH, CC, CO, SO2 or 0S02;
m is an integer from 1 to about 7;
n is an integer from 0 to about 7; and Z comprises a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring.
In a variation of formula I, R1 and R2 each independently comprise -(CH2)m - Q1 -(CH2)n-Z;
Qi comprises NH, 0, S, CH=CH, CC, CO, SO2 or 0S02;
m is an integer from 1 to about 7;
n is an integer from 0 to about 7;
Z comprises a carbocyclic ring having about 4 to about 7 ring members, a heterocyclic ring having about 4 to about 7 ring members, an aromatic ring having about 5 to about 7 ring members, a heteroaromatic ring having about 5 to about ring members; a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring, a heteropolycyclic ring or any above group substituted on at least one available ring atom by an alkyl group or any above group substituted on at least one available ring nitrogen atom by a benzyl group, a substituted benzyl group, an alkoxybenzyl group, a substituted alkoxybenzyl group, a benzhydryl group or a substituted benzhydryl group; and wherein the connecting point between the -(CH2)n-group and the Z group can be any available ring carbon atom or any available ring nitrogen atom.
In a variation of formula I, R1 and R2 each independently comprise -(CH2)m - Qi -(CH2)n-Z;
Qi comprises N, 0, S, CH=CH, CC, CO, SO2 or 0S02;
m is an integer from 1 to about 7;
n is an integer from 0 to about 7; and Z comprises a 5 member unsaturated ring having 0 to 4 independently selected heteroatoms as. ring members, a substituted 5 member unsaturated ring having 0 to 4 independently selected heteroatoms as ring members, a 6 member aromatic ring having 0 to 5 independently selected heteroatoms as ring members or a substituted 6 member aromatic ring having 0 to 5 independently selected heteroatoms; and wherein the connecting point between the -(CH2)n- group and the Z
group can be any available ring carbon atom or any available ring nitrogen atom.
In a variation of formula I R1 and R2 each independently comprise -(CH2)m- Qi -(CH2)n-Z;
Qi comprises NH, 0, S, CH=CH, Cm-C, CO, SO2 or OS02;
m is an integer from 1 to about 7;
n is an integer from 0 to about 7; and Z comprises 1-, 2- or 3-pyrrolidinyl, 1-, 2-, 3- or 4-piperidinyl, 2-, 3- or 4-morpholinyl, 2-, 3- or 4-thiomorpholinyl, 1-, 2- or 3-azetidinyl, 1- or 2-piperazinyl, 2- or 3-tetrahydrofuranyl; or any above group substituted on at least one available ring atom by an alkyl group; or any above group substituted on at least one available ring nitrogen atom by a benzyl group, a substituted benzyl group, an alkoxybenzyl group, a substituted alkoxybenzyl group, a benzhydryl group or a substituted benzhydryl group; and wherein the connecting point between the -(CH2),- group and the Z
group can be any available ring carbon atom or any available ring nitrogen atom.
In a variation of formula I R1 and R2 each independently comprise -(CH2)m- Qi -(CH2)n-Z;
Qi comprises N, 0, S, CH=CH, CC, CO, SO2 or OS02;
m is an integer from 1 to about 7;
n is an integer from 0 to about 7;
Z comprises x <.Ns , y =
X __________________________________ 11¨>-NX
W
x _____________________ N x y y Xy N N\
Y I N Yor Y
N
\N,.
N
N-W N r x\\-1, N Y -1CY
X
wherein X and Y each independently comprise, H, halogen, CF3, CF2H, N3, NCS, CN, NO2, NX1X2, OX3, SX3, OAc, 0S02X3, 0-acyl, S-acyl, S02-alkyl, SO-alkyl, SC(CH3)2C00X8, OC(CH3)2000X8 , C(CH3)2C00X8, Si(alkyl)3, alkyl-CN, 0-aroyl, 0(CH2)10X3, 0(CH2)iNX1X2, NH-acyl, NH-aroyl, CHO, C(halogen)3, COOX3, SO3H, SO2NX1X2, CONX1X2, NHC(0)0-alkyl, NHS02-alkyl, alkoxy, alkyl, alcohol, alkylmercapto, alkylamino, di-alkylamino, alkylsulfinyl or alkylsulfonyl, CX4X5X6, -CH=CHX8 , -CmCX8 ;
X1 and X2 each independently comprise H or alkyl, or X1 and X2 together comprise part of a heterocyclic ring having about 4 to about 7 ring members and optionally one additional heteroatom selected from 0, N or S, or X1 and X2 together comprise part of an imide ring having about 5 to about 6 members, X3 comprises H, alkyl, NO2, (CH2)mCN, hydroxyloweralkyl, or alkyl-NX1X2, X4, X5, and X6 each independently comprise H, alkyl, carbocyclic ring, hydroxyloweralkyl, alkyl-OH, halogen, CN, SNO, S(S02)alkyl, NX1X2, COOX3, CONX3, OX7, or 0-alkyl-X7, wherein X7 comprises H, alkyl, NO2, NO, P(0)(OX8)2, PH(0)(0X8), S(0)kN(alky1)2, S(0)kX8, S(0)k0X8, COOX8, CONX8, SO3H, COX8, wherein X8 comprises H, alkyl, carbocyclic ring, heterocyclic ring, aromatic ring, heteroaromatic ring, or -CX9=CHX113, wherein X9 and X10 each independently comprise H or alkyl;
m is an integer from 0 to 7;
j is an integer from 0 to about 6;
k is an integer from 0 to about 2; and W comprises H or alkyl In a variation of formula I R1 and R2 each independently comprise.
-(CH2)m - Qi -(CH2)n-Z;
Qi comprises NH, 0, S, CH=CH, CC, CO, SO2 or 0S02;
m is an integer from 1 to about 7;
n is an integer from 0 to about 7; and Z comprises an unsaturated ring having 5 ring atoms and 0 to 2 independently selected heteroatoms as ring members fused to an unsaturated ring having 5 ring atoms and 0 to 4 independently selected heteroatoms as ring members, an unsaturated ring having 5 ring atoms and 0 to 2 independently selected heteroatoms as ring members fused to an unsaturated ring having 6 or 7 ring atoms and 0 to independently selected heteroatoms as ring members or an unsaturated ring having 6 ring atoms and 0 to 4 independently selected heteroatoms as ring members fused to an unsaturated ring having 6 or 7 ring atoms and 0 to 4 independently selected heteroatoms as ring members.
In a variation of formula I R1 and R2 each independently comprise -(CH2)rn - Qi -(CH2)n-Z;
Q1 comprises NH, 0, S, CH=C1-1, CC, CO, SO2 or 0S02;
m is an integer from 1 to about 7;
n is an integer from 0 to about 7; and Z comprises QFJ
Nv ,\\H
or In a variation of formula I R1 and R2 each independently comprise -T-(C H2)-Z;
n comprises an integer from 0 to about 7;
T comprises a carbocyclic ring having 3 to about 8 ring members, an unsaturated ring having 3 to about 8 carbon atoms as ring members, an aromatic ring having 5 to about 8 carbon atoms as ring members, a heterocyclic ring having 3 to about 8 ring members, a heteroaromatic ring having 5 to about 8 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring;
Z comprises H, halogen, CF3, CF2H, N3, NCS, CN, NO2, NX1X2, OX3, SX3, OAc, 0S02X3, 0-acyl, S-acyl, S02-alkyl, SO-alkyl, SC(CH3)2C00X8, OC(CH3)2C00X8 , C(CH3)2000X8, Si(alkyl)3, 0-aroyl, 0(CH2)j0X3, 0(CH2)\IX1X2, alkyl-CN, NH-acyl, NH-aroyl, CHO, C(halogen)3, COOX3, SO3H, SO2NX1X2, CONX1X2, NHC(0)0-alkyl, NHS02-alkyl, alkoxy, alkyl, alcohol, alkylmercapto, alkylamino, di-alkylamino, alkylsulfinyl or alkylsulfonyl, CX4X5X8, -CH=CHX8 , X1 and X2 each independently comprise H or alkyl, or X1 and X2 together comprise part of a heterocyclic ring having about 4 to about 7 ring members and optionally one additional heteroatom selected from 0, N or S, or X1 and X2 together comprise part of an imide ring having about 5 to about 6 members, X3 comprises H, alkyl, NO2, NO, (CH2)mCN, hydroxyloweralkyl, or alkyl-NX1X2, X4, X6, and X6 each independently comprise H, alkyl, carbocyclic ring, hydroxyloweralkyl, alkyl-OH, halogen, CN, SNO, S(S02)alkyl, NX1X2, COOX3, CONX3, OX7, or 0-alkyl-X7, wherein X7 comprises H, alkyl, NO2, NO, P(0)(0X8)2, PH(0)(0X8), S(0)kN(alky1)2, S(0)kX8, S(0)k0X8, COOX8, CONX8, SO3H, COX8, wherein X8 comprises H, alkyl, carbocyclic ring, heterocyclic ring, aromatic ring, heteroaromatic ring, or -CX0=CHX10, wherein X9 and X10 each independently comprise H or alkyl;
m is an integer from 0 to 7;
j is an integer from 0 to about 6; and k is an integer from 0 to about 2 In a variation of formula I R1 and R2 each independently comprise -T-(C H2)-Z;
n comprises an integer from 0 to about 7;
T comprises a carbocyclic ring having 3 to about 8 ring members, an unsaturated ring having 3 to about 8 carbon atoms as ring members, an aromatic ring having 5 to about 8 carbon atoms as ring members, a heterocyclic ring having 3 to about 8 ring members, a heteroaromatic ring having 5 to about 8 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring; and Z comprises a carbocyclic ring having about 4 to about 7 ring members, a heterocyclic ring having about 4 to about 7 ring members, an aromatic ring having about 5 to about 7 ring members, a heteroaromatic ring having about 5 to about ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring, a heteropolycyclic ring; or any above group substituted on at least one available ring atom by an alkyl group; or any above group substituted on at least one available ring nitrogen atom by a benzyl group, a substituted benzyl group, an alkoxybenzyl group, a substituted alkoxybenzyl group, a benzhydryl group or a substituted benzhydryl group; and wherein the connecting point between the -(CH2)n-group and the Z group can be any available ring carbon atom or any available ring nitrogen atom.
In a variation of formula I R1 and R2 each independently comprise -T-(C H2)-Z;
n comprises an integer from 0 to about 7;
T comprises a carbocyclic ring having 3 to about 8 ring members, an unsaturated ring having 3 to about 8 carbon atoms as ring members, an aromatic ring having 5 to about 8 carbon atoms as ring members, a heterocyclic ring having 3 to about 8 ring members, a heteroaromatic ring having 5 to about 8 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring; and Z comprises 1-, 2- or 3-pyrrolidinyl, 1-, 2-, 3- or 4-piperidinyl, 2-, 3- or 4-morpholinyl, 2-, 3- or 4-thiomorpholinyl, 1-, 2- or 3-azetidinyl, 1- or 2-piperazinyl, 2- or 3-tetrahydrofuranyl; or any above group substituted on at least one available ring atom by an alkyl group; or any above group substituted on at least one available ring nitrogen atom by a benzyl group, a substituted benzyl group, an alkoxybenzyl group, a substituted alkoxybenzyl group, a benzhydryl group or a substituted benzhydryl group; and wherein the connecting point between the -(CH2)n- group and the Z
group can be any available ring carbon atom or any available ring nitrogen atom.
In a variation of formula I R1 and R2 each independently comprise -T-(CH2)n-Z;
n comprises an integer from 0 to about 7;
T comprises a carbocyclic ring having 3 to about 8 ring members, an unsaturated ring having 3 to about 8 carbon atoms as ring members, an aromatic ring having 5 to about 8 carbon atoms as ring members, a heterocyclic ring having 3 to about 8 ring members, a heteroaromatic ring having 5 to about 8 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring;
Z comprises at X
N\'SX \yµ14--N x y , W Y
rµY-4_y S Y el Y N
01 Yor ee Xy y \ N \ N
N N N
N'r X\\-- 1 / )(\\ N Y y X
wherein X and Y each independently comprise, H, halogen, CF3, CF2H, N3, NCS, CN, NO2, NX1X2, OX3, SX3, OAc, 0S02X3, 0-acyl, S-acyl, S02-alkyl, SO-alkyl, SC(CH3)2C00X8, OC(CH3)2C00X8 , C(CH3)2C00X8, Si(alkyl)3, alkyl-CN, 0-aroyl, 0(CH2)i0X3, 0(CH2)JNX1X2, NH-acyl, NH-aroyl, CHO, C(halogen)3, COOX3, SO3H, SO2NX1X2, CONX1X2, NHC(0)0-alkyl, NHS02-alkyl, alkoxy, alkyl, alcohol, alkylmercapto, alkylamino, di-alkylamino, alkylsulfinyl or alkylsulfonyl, CX4X5X6, -CH=CHX8 , ;
X1 and X2 each independently comprise H or alkyl, or X1 and X2 together comprise part of a heterocyclic ring having about 4 to about 7 ring members and optionally one additional heteroatom selected from 0, N or S, or X1 and X2 together comprise part of an imide ring having about 5 to about 6 members, X3 comprises H, alkyl, NO2, (CH2)mCN, hydroxyloweralkyl, or alkyl-NX1X2, X4, X5, and X6 each independently comprise H, alkyl, carbocyclic ring, hydroxyloweralkyl, alkyl-OH, halogen, CN, SNO, S(S02)alkyl, NX1X2, COOX3, CONX3, OX7, or 0-alkyl-X7 wherein X7 comprises H, alkyl, NO2, NO, P(0)(0X8)2, PH(0)(0X8), S(0)kN(alky1)2, S(0)kX8, S(0)k0X8, 000X8, CONX8, SO3H, COX8, wherein X8 comprises H, alkyl, carbocyclic ring, heterocyclic ring, aromatic ring, heteroaromatic ring, or -CX9=CHX10 wherein X9 and X10 each independently comprise H or alkyl;
m is an integer from 0 to 7;
j is an integer from 0 to about 6;
k is an integer from 0 to about 2; and W comprises H or alkyl.
In a variation of formula I R1 and R2 each independently comprise -T-(CH2)n-Z;
n comprises an integer from 0 to about 7;
T comprises a carbocyclic ring having 3 to about 8 ring members, an unsaturated ring having 3 to about 8 carbon atoms as ring members, an aromatic ring having 5 to about 8 carbon atoms as ring members, a heterocyclic ring having 3 to about 8 ring members, a heteroaromatic ring having 5 to about 8 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring;
Z comprises an unsaturated ring having 5 ring atoms and 0 to 2 independently selected heteroatoms as ring members fused to an unsaturated ring having 5 ring atoms and 0 to 4 independently selected heteroatoms as ring members, an unsaturated ring having 5 ring atoms and 0 to 2 independently selected heteroatoms as ring members fused to an unsaturated ring having 6 or 7 ring atoms and 0 to independently selected heteroatoms as ring members or an unsaturated ring having 6 ring atoms and 0 to 3 independently selected heteroatoms as ring members fused to an unsaturated ring having 6 or 7 ring atoms and 0 to 4 independently selected heteroatoms as ring members.
In a variation of formula I R1 and R2 each independently comprise -T-(CH2)n-Qi -(CH2)n-Z;
each n independently comprises an integer from 0 to about 7;
T comprises a carbocyclic ring having 3 to about 8 ring members, an unsaturated ring having 3 to about 8 carbon atoms as ring members, an aromatic ring having 5 to about 8 carbon atoms as ring members, a heterocyclic ring having 3 to about 8 ring members, a heteroaromatic ring having 5 to about 8 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring;
Qi comprises NH, 0, S, CH=CH, CC, CO, SO2 or 0S02;
Z comprises H, halogen, CF3, CF2H, N3, NCS, CN, NO2, NX1X2, OX3, SX3, OAc, 0S02X3, 0-acyl, S-acyl, S02-alkyl, SO-alkyl, SC(CH3)2C00X8, OC(CH3)2C00X8 , C(CH3)2C00X8, Si(alkyl)3, 0-aroyl, 0(CH2)i0X3, 0(CH2)iNX1X2, alkyl-CN, NH-acyl, NH-aroyl, CHO, C(halogen)3, COOX3, SO3H, SO2NX1X2, CONX1X2, NHC(0)0-alkyl, NHS02-alkyl, alkoxy, alkyl, alcohol, alkylmercapto, alkylamino, di-alkylamino, alkylsulfinyl or alkylsulfonyl, CX4X5X6, -CH=CHX8 , X1 and X2 each independently comprise H or alkyl, or X1 and X2 together comprise part of a heterocyclic ring having about 4 to about 7 ring members and optionally one additional heteroatom selected from 0, N or S, or X1 and X2 together comprise part of an imide ring having about 5 to about 6 members, X3 comprises H, alkyl, NO2, NO, (CH2)mCN, hydroxyloweralkyl, or alkyl-NX1X2, X4, X5, and X8 each independently comprise H, alkyl, carbocyclic ring, hydroxyloweralkyl, alkyl-OH, halogen, CN, SNO, S(S02)alkyl, NX1X2, COOX3, CONX3, OX7, or 0-alkyl-X7, wherein X7 comprises H, alkyl, NO2, NO, P(0)(0X8)2, PH(0)(0X8), S(0)kN(alky1)2, S(0)kX8, S(0)k0X8, COOX8, CONX8, SO3H, COX8, wherein X8 comprises H, alkyl, carbocyclic ring, heterocyclic ring, aromatic ring, heteroaromatic ring, or -CX9=CHX10, wherein X9 and X10 each independently comprise H or alkyl;
m is an integer from 0 to 7;
j is an integer from 0 to about 6; and k is an integer from 0 to about 2 In a variation of formula I R1 and R2 each independently comprise -T-(CH2)n-Qi -(CH-Z;
each n independently comprises an integer from 0 to about 7;
T comprises a carbocyclic ring having 3 to about 8 ring members, an unsaturated ring having 3 to about 8 carbon atoms as ring members, an aromatic ring having 5 to about 8 carbon atoms as ring members, a heterocyclic ring having 3 to about 8 ring members, a heteroaromatic ring having 5 to about 8 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring;
Qi comprises NH, 0, S, CH=CH, CC, CO, SO2 or 0S02;
Z comprises a carbocyclic ring having about 4 to about 7 ring members, a heterocyclic ring having about 4 to about 7 ring members, an aromatic ring having about 5 to about 7 ring members, a heteroaromatic ring having about 5 to about ring members, a bicyclic ring, a heterobicyclic ring, a polycyclic ring, a heteropolycyclic ring; or any above group substituted on at least one available ring atom by an alkyl group; or any above group substituted on at least one available ring nitrogen atom by a benzyl group, a substituted benzyl group, an alkoxybenzyl group, a substituted alkoxybenzyl group, a benzhydryl group or a substituted benzhydryl group; and wherein the connecting point between the -(CH2)n- group and the Z
group can be any available ring carbon atom or any available ring nitrogen atom.
In a variation of formula I R1 and R2 each independently comprise -T-(CH2)n-Qi -(CH-Z;
each n independently comprises an integer from 0 to about 7;
T comprises a carbocyclic ring having 3 to about 8 ring members, an unsaturated ring having 3 to about 8 carbon atoms as ring members, an aromatic ring having 5 to about 8 carbon atoms as ring members, a heterocyclic ring having 3 to about 8 ring members, a heteroaromatic ring having 5 to about 8 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring;
Qi comprises NH, 0, S, CH=CH, CC, CO, SO2 or 0S02;
Z comprises 1-, 2- or 3-pyrrolidinyl, 1-, 2-, 3- or 4-piperidinyl, 2-, 3- or 4-morpholinyl, 2-, 3- or 4-thiomorpholinyl, 1-, 2- or 3-azetidinyl, 1- or 2-piperazinyl, 2- or 3-tetrahydrofuranyl; or any above group substituted on at least one available ring atom by an alkyl group; or any above group substituted on at least one available ring nitrogen atom by a benzyl group, a substituted benzyl group, an alkoxybenzyl group, a substituted alkoxybenzyl group, a benzhydryl group or a substituted benzhydryl group; and wherein the connecting point between the -(CH2)n- group and the Z
group can be any available ring carbon atom or any available ring nitrogen atom.
In a variation of formula I R1 and R2 each independently comprise -T-(CH2)n-Qi -(CH-Z;
each n independently comprises an integer from 0 to about 7;
T comprises a carbocyclic ring having 3 to about 8 ring members, an unsaturated ring having 3 to about 8 carbon atoms as ring members, an aromatic ring having 5 to about 8 carbon atoms as ring members, a heterocyclic ring having 3 to about 8 ring members, a heteroaromatic ring having 5 to about 8 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring;
Q1 comprises NH, 0, S, CH=CH, CC, CO, SO2 or 0S02;
Z comprises ?,NO KNs , W X _ii\i- -NX
\
X X Y _____________ N N
X X X
X X
el N Yor 0.
N
\N. \ N
N N N N-W
\\- 1 / xY x wherein X and Y each independently comprise, H, halogen, CF3, CF2H, N3, NCS, CN, NO2, NX1X2, OX3, SX3, OAc, 0S02X3, 0-acyl, S-acyl, S02-alkyl, SO-alkyl, SC(CH3)2C00X8, OC(CH3)2000X8 , C(CH3)2C00X8, Si(alkyl)3, alkyl-CN, 0-aroyl, 0(CH2)i0X3, 0(CH2)JNX1X2, NH-acyl, NH-aroyl, CHO, C(halogen)3, COOX3, SO3H, SO2NX1X2, CONX1X2, NHC(0)0-alkyl, NHS02-alkyl, alkoxy, alkyl, alcohol, alkylmercapto, alkylamino, di-alkylamino, alkylsulfinyl or alkylsulfonyl, CX4X5X6, -CH=CHX8 , -CCX8 ;
Xi and X2 each independently comprise H or alkyl, or X1 and X2 together comprise part of a heterocyclic ring having about 4 to about 7 ring members and optionally one additional heteroatom selected from 0, N or S, or X1 and X2 together comprise part of an imide ring having about 5 to about 6 members, X3 comprises H, alkyl, NO2, (CH2)mCN, hydroxyloweralkyl, or alkyl-NX1X2, X4, X6, and X6 each independently comprise H, alkyl, carbocyclic ring, hydroxyloweralkyl, alkyl-OH, halogen, CN, SNO, S(S02)alkyl, Nk1X2, COOX3, CONX3, 0)(7, or 0-alkyl-X7, wherein X7 comprises H, alkyl, NO2, NO, P(0)(0)(02, PI-1(0)(0M, S(0)kN(alkyl)2, S(0)kX8, S(0)k0X8, COOX8, CONX8, SO3H, COX8, wherein X8 comprises H, alkyl, carbocyclic ring, heterocyclic ring, aromatic ring, heteroaromatic ring, or ¨CX9=CHX10, wherein X9 and X10 each independently comprise H or alkyl;
m is an integer from 0 to 7;
j is an integer from 0 to about 6;
k is an integer from 0 to about 2; and W comprises H or alkyl.
In a variation of formula I R1 and R2 each independently comprise ¨T¨(CH2)n¨
Qi ¨(CH2)n¨Z;
each n independently comprises an integer from 0 to about 7;
T comprises a carbocyclic ring having 3 to about 8 ring members, an unsaturated ring having 3 to about 8 carbon atoms as ring members, an aromatic ring having 5 to about 8 carbon atoms as ring members, a heterocyclic ring having 3 to about 8 ring members, a heteroaromatic ring having 5 to about 8 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring;
Qi comprises NH, 0, S, CH=CH, CC, CO, SO2 or OS02; and Z comprises an unsaturated ring having 5 ring atoms and 0 to 2 independently selected heteroatoms as ring members fused to an unsaturated ring having 5 ring atoms and 0 to 2 independently selected heteroatoms as ring members, an unsaturated ring having 5 ring atoms and 0 to 2 independently selected heteroatoms as ring members fused to an unsaturated ring having 6 or 7 ring atoms and 0 to independently selected heteroatoms as ring members or an unsaturated ring having 6 ring atoms and 0 to 3 independently selected heteroatoms as ring members fused to an unsaturated ring having 6 or 7 ring atoms and 0 to 4 independently selected heteroatoms as ring members.
In a variation of formula I, R1 and R2 each independently comprise -T-(CI-12)n- Q1 -(CH-Z;
T comprises a carbocyclic ring having 3 to about 8 ring members, an unsaturated ring having 3 to about 8 carbon atoms as ring members, an aromatic ring having 5 to about 8 carbon atoms as ring members, a heterocyclic ring having 3 to about 8 ring members, a heteroaromatic ring having 5 to about 8 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring;
each n independently comprises an integer from 0 to about 7;
Qi comprises NH, 0, S, CH=CH, CC, CO, SO2 or 0S02;
Z comprises:
-N/ )--E or -N N-E
wherein E comprises a C1 to about C4, linear or branched alkyl group, a phenyl group, a substituted phenyl group, a benzyl group or a substituted benzyl group.
In a variation of formula I, R1 and R2 each independently comprise -T-(C1-12)n- Q1 -(CH-Z;
T comprises a carbocyclic ring having 3 to about 8 ring members, an unsaturated ring having 3 to about 8 carbon atoms as ring members, an aromatic ring having 5 to about 8 carbon atoms as ring members, a heterocyclic ring having 3 to about 8 ring members, a heteroaromatic ring having 5 to about 8 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring;
each n independently comprises an integer from 0 to about 7;
Q1 comprises NH, 0, S, CH=CH, CC, CO, SO2 or 0S02;
Z comprises ___________________________________ 0 0 ¨
H
¨NO ¨NI _______________ \(CH2)k <(CH2)k <(CH2)k N \ or wherein k is an integer from 1 to about 5. A1 and A2 each independently comprise a Cl to about C4 alkyl group, a phenyl group or a substituted phenyl group.
In a variation of formula I, R3 comprises a carbocyclic ring having about 4 to about 7 members, a heterocyclic ring having about 4 to about 7 members, an aromatic ring having about 5 to about 7 ring members, a heteroaromatic ring having about 5 to about 7 members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring.
J¨K
In a variation of formula I, R3 comprises wherein G comprises CH, C(CH3), C(CN) or N;
L, K and J each independently comprise (CH2)n, (CH3)2, C=0, 0, -CHOH, C(CH3)0M1, C(CH2)n(X)Y, NMi, SO2 SO or S;
n is an integer from 0 to about 7;
M1 is H, alkyl, C(0)M2, wherein M2 is H, alkyl, NM3M4, 0M5 and M3, M4 and M5 are independently H, OH or alkyl,and X and Y each independently comprise, H, halogen, CF3, CF2H, N3, NCS, CN, NO2, NX1X2, OX3, SX3, OAc, OSO2X3, 0-acyl, S-acyl, S02-alkyl, SO-alkyl, SC(CH3)2C00X8, OC(CH3)2COOX8 C(CH3)2C00X8, Si(alkyl)3, alkyl-CN, 0-aroyl, 0(CH2)i0X3, 0(CH2)iNX1X2, NH-acyl, NH-aroyl, CHO, C(halogen)3, COOX3, SOH, SO2NX1X2, CONX1X2, NHC(0)0-alkyl, NHS02-alkyl, alkoxy, alkyl, alcohol, alkylmercapto, alkylamino, di-alkylamino, alkylsulfinyl or alkylsulfonyl, CX4X5X6, -CH=CHX8 , ;
X1 and X2 each independently comprise H or alkyl, or X1 and X2 together comprise part of a heterocyclic ring having about 4 to about 7 ring members and optionally one additional heteroatom selected from 0, N or S, or X1 and X2 together comprise part of an imide ring having about 5 to about 6 members, X3 comprises H, alkyl, NO2, (CH2)mCN, hydroxyloweralkyl, or alkyl-NX1X2, X4, X8, and X8 each independently comprise H, alkyl, carbocyclic ring, hydroxyloweralkyl, alkyl-OH, halogen, CN, SNO, S(S02)alkyl, NX1X2, COOX3, CONX3, OX7, or 0-alkyl-X7, wherein X7 comprises H, alkyl, NO2, NO, P(0)(0X8)2, PH(0)(0X8), S(0)kN(alkyl)2, S(0)kX8, S(0)k0X8, COOX8, CONX8, SO3H, COX8, wherein X8 comprises H, alkyl, carbocyclic ring, heterocyclic ring, aromatic ring, heteroaromatic ring, or -CX9=CHX10, wherein X9 and X10 each independently comprise H or alkyl;
m is an integer from 0 to 7;
j is an integer from 0 to about 6; and k is an integer from 0 to about 2.
In a variation of formula I, R3 comprises e wherein G, L and J each independently comprise CH or N.
In a variation of formula I, R3 comprises 1:Ti( o 26 r X
N y W
X; N X X =X \)ç/;( y ___ y Ny , y ''or N
\fµl \N
N N N
XN\-- I / N Y __ X
wherein X and Y each independently comprise, H, halogen, CF3, CF2H, N3, NCS, CN, NO2, NX1X2, OX3, SX3, OAc, 0S02X3, 0-acyl, S-acyl, S02-alkyl, SO-alkyl, SC(CH3)2C00X8, OC(CH3)2C00X8 , C(CH3)2C00X8, Si(alkyl)3, alkyl-CN, 0-aroyl, 0(CH2),OX3, 0(CH2)JNX1X2, NH-acyl, NH-aroyl, CHO, C(halogen)3, COOX3, SO3H, SO2NX1X2, CONX1X2, NHC(0)0-alkyl, NHS02-alkyl, alkoxy, alkyl, alcohol, alkylmercapto, alkylamino, di-alkylamino, alkylsulfinyl or alkylsulfonyl, CX4X5X6, -CH=CHX8 , -CCX8 ;
X1 and X2 each independently comprise H or alkyl, or X1 and X2 together comprise part of a heterocyclic ring having about 4 to about 7 ring members and optionally one additional heteroatom selected from 0, N or S, or X1 and X2 together comkrise part of an imide ring having about 5 to about 6 members, X3 comprises H, alkyl, NO2, (CH2)mCN, hydroxyloweralkyl, or alkyl-NX1X2, X4, X5, and X6 each independently comprise H, alkyl, carbocyclic ring, hydroxyloweralkyl, alkyl-OH, halogen, CN, SNO, S(S02)alkyl, NX1X2, COOX3, CONX3, OX7, or 0-alkyl-X7, wherein X7 comprises H, alkyl, NO2, NO, P(0)(0X8)2, PH(0)(0X8), S(0)kN(alkyl)2, S(0)kX8, S(0)k0X8, COOX8, CONX8, SO3H, COX8, wherein X8 comprises H, alkyl, carbocyclic ring, heterocyclic ring, aromatic ring, heteroaromatic ring, or -CX9=CHX10, wherein X9 and X10 each independently comprise H or alkyl;
m is an integer from 0 to 7;
j is an integer from 0 to about 6;
k is an integer from 0 to about 2; and W comprises H or alkyl.
In a variation of formula I, R3 comprises a carbocyclic ring having 6 ring atoms fused to a heterocyclic ring having from 5 to 7 ring atoms, a carbocyclic ring having 6 ring atoms fused to a heteroaromatic ring having from 5 to 7 ring atoms, a heterocyclic ring having 6 ring atoms fused to a heterocyclic ring having from
n is an integer from 0 to about 7.
Z comprises 1-, 2- or 3-pyrrolidinyl, 1-, 2-, 3- or 4-piperidinyl, 2-, 3- or 4-morpholinyl, 2-, 3- or 4-thiomorpholinyl, 1-, 2- or 3-azetidinyl, 1- or 2-piperazinyl, 2- or 3-tetrahydrofuranyl; or any above group substituted on at least one available ring atom by an alkyl group; or any above group substituted on at least one available ring nitrogen atom by a benzyl group, a substituted benzyl group, an alkoxybenzyl group, a substituted alkoxybenzyl group, a benzhydryl group or a substituted benzhydryl group; and wherein the connecting point between the -(CH2)n- group and the Z
group can be any available ring carbon atom or any available ring nitrogen atom.
In a variation of formula I, R1 and R2 each independently comprise -(CH2)n-Z.
n is an integer from 0 to about 7.
Z comprises )i_xy ry y ' mx N X
( NNYJX
\ ______ N , __ X X y N Y N
N \ X
Ny N N N y 0 \ 7-1 Y 01 X
Y N Or *ex N
\N \N
N N N nrw )6Nr1/ )(\- N' y X
wherein X and Y each independently comprise, H, halogen, CF3, CFA N3, NOS, ON, NO2, NX1X2, OX3, SX3, OAc, 0S02X3, 0-acyl, S-acyl, S02-alkyl, SO-alkyl, SC(CH3)2000X8, OC(CH3)2C00X8 , C(CH3)2000X8, Si(alkyl)3, alkyl-ON, 0-aroyl, 0(CH2)i0X3, 0(CH2)JNX1X2, NH-acyl, NH-aroyl, CHO, C(halogen)3, COOX3, SO3H, SO2NX1X2, CONX1X2, NHC(0)0-alkyl, NHS02-alkyl, alkoxy, alkyl, alcohol, alkylmercapto, alkylamino, di-alkylamino, alkylsulfinyl or alkylsulfonyl, CX4X5X6, -CH=CHX8 , -CCX8 ;
X1 and X2 each independently comprise H or alkyl, or X1 and X2 together comprise part of a heterocyclic ring having about 4 to about 7 ring members and optionally one additional heteroatom selected from 0, N or S, or X1 and X2 together comprise part of an imide ring having about 5 to about 6 members, X3 comprises H, alkyl, aryl, NO2, (0H2)mCN, hydroxyloweralkyl, or alkyl-NX1X2, X4, X5, and X8 each independently comprise H, alkyl, carbocyclic ring, hydroxyloweralkyl, alkyl-OH, halogen, ON, SNO, S(S02)alkyl, NX1X2, 000X3, CONX3, OX7, or 0-alkyl-X7 wherein X7 comprises H, alkyl, NO2, NO, P(0)(0X8)2, PH(0)(0X8), S(0)kN(alkyl)2, S(0)kX8, S(0)k0X8, 000X8, CONX8, SO3H, COX8, wherein X8 comprises H, alkyl, carbocyclic ring, heterocyclic ring, aromatic ring, heteroaromatic ring, or -0X0=CHX10 wherein X9 and X10 each independently comprise H or alkyl Wherein m is an integer from 0 to 7 j is an integer from 0 to about 6, or W comprises H or alkyl k is an integer from 0 to about 2 In a variation of formula I, R1 and R2 each independently -(CH2)n-Z.
n is an integer from 0 to about 7.
Z comprises a carbocyclic ring having 6 ring atoms fused to a heterocyclic ring having from 5 to 7 ring atoms, a carbocyclic ring having 6 ring atoms fused to a heteroaromatic ring having from 5 to 7 ring atoms, a heterocyclic ring having 6 ring atoms fused to a heterocyclic ring having from 5 to 7 ring atoms, an heterocyclic ring having 6 ring atoms fused to a heteroaromatic ring having from 5 to 7 ring atoms, an aromatic ring having 6 ring atoms fused to a heterocyclic ring having from 5 to 7 ring atoms, an aromatic ring having 6 ring atoms fused to a heteroaromatic ring having from 5 to 7 ring atoms, a heteroaromatic ring having 6 ring atoms fused to a heterocyclic ring having from 5 to 7 ring atoms or a heteroaromatic ring having 6 ring atoms fused to a heteroaromatic ring having from 5 to 7 ring atoms.
In a variation of formula I, R1 and R2 each independently comprise -(CH2)n-Z;
n comprises an integer from 0 to about 7;
Z comprises an unsaturated ring having 5 ring atoms and 0 to 2 independently selected heteroatoms as ring members fused to an unsaturated ring having 5 ring atoms and 0 to 4 independently selected heteroatoms as ring members, an unsaturated ring having 5 ring atoms and 0 to 2 independently selected heteroatoms as ring members fused to an unsaturated ring having 6 or 7 ring atoms and 0 to independently selected heteroatoms as ring members or an unsaturated ring having 6 ring atoms and 0 to 4 independently selected heteroatoms as ring members fused to an unsaturated ring having 6 or 7 ring atoms and 0 to 4 independently selected heteroatoms as ring members.
In a variation of formula I, R1 and R2 each independently comprise -(CH2)m -Qi-(CH2)n-Z;
Q1 comprises NH, 0, S,-CH=CH-, -CO, SO2 or 0S02;
m is an integer from 1 to about 7;
n is an integer from 0 to about 7;
Z comprises H, halogen, CF3, CF2H, N3, NCS, CN, NO2, NX1X2, OX3, SX3, OAc, 0S02X3, 0-acyl, S-acyl, S02-alkyl, SO-alkyl, SC(CH3)2C00X8, OC(CH3)2C00X8 , C(CH3)2C00X8, Si(alkyl)3, 0-aroyl, 0(CH2)i0X3, 0(CH2)iNX1X2, alkyl-CN, NH-acyl, NH-aroyl, CHO, C(halogen)3, COOX3, SO3H, SO2NX1X2, CONX1X2, NHC(0)0-alkyl, NHS02-alkyl, alkoxy, alkyl, alcohol, alkylmercapto, alkylamino, di-alkylamino, alkylsulfinyl or alkylsulfonyl, CX4X5X8, -CH=CHX8 , -CmCX8 ;
X1 and X2 each independently comprise H or alkyl:or X1 and X2 together comprise part of a heterocyclic ring having about 4 to about 7 ring members and optionally one additional heteroatom selected from 0, N or S, or X1 and X2 together comprise part of an imide ring having about 5 to about 6 members;
X3 comprises H, alkyl, NO2, NO, (CH2)mCN, hydroxyloweralkyl, or alkyl-NX1X2;
X4, X5, and X6 each independently comprise H, alkyl, 'carbocyclic ring, hydroxyloweralkyl, alkyl-OH, halogen, CN, SNO, S(S02)alkyl, NX1X2, COOX3, CONX3, OX7, or 0-alkyl-X7, wherein X7 comprises H, alkyl, NO2, NO, P(0)(0X8)2, PH(0)(0X8), S(0)kN(alky1)2, S(0)kX8, S(0)k0X8, COOX8, CONX8, SO3H, COX8, wherein X8 comprises H, alkyl, carbocyclic ring, heterocyclic ring, aromatic ring, heteroaromatic ring, or -CX0=CHX10, wherein X9 and X10 each independently comprise H or alkyl;
m is an integer from 0 to 7;
j is an integer from 0 to about 6, and k is an integer from 0 to about 2.
In a variation of formula I, R1 and R2 each independently comprise -Q2-(CH2)n-Z, Q2 is optionally present and if present comprises -CH2-NH, -CH2-0, -CH2-S, -CH2-S02 or -CH2-0S02;
n is an integer from 0 to about 7;
Z comprises H, halogen, CF3, CF2H, N3, NCS, CN, NO2, NX1X2, OX3, SX3, OAc, 0S02X3, 0-acyl, S-acyl, S02-alkyl, SO-alkyl, SC(CH3)2C00X8, OC(CH3)2000X8 , C(CH3)2C00X8, Si(alkyl)3, 0-aroyl, 0(CH2)j0X3, 0(CH2)iNX1X2, alkyl-CN, NH-acyl, NH-aroyl, CHO, C(halogen)3, COOX3, SO3H, SO2NX1X2, CONX1X2, NHC(0)0-alkyl, NHS02-alkyl, alkoxy, alkyl, alcohol, alkylmercapto, alkylamino, di-alkylamino, alkylsulfinyl or alkylsulfonyl, CX4X5X6, -CH=CHX8 , -C-7=-CX8 X1 and X2 each independently comprise H or alkyl, or X1 and X2 together comprise part of a heterocyclic ring having about 4 to about 7 ring members and optionally one additional heteroatom selected from 0, N or S, or X1 and X2 together comprise part of an imide ring having about 5 to about 6 members, X3 comprises H, alkyl, NO2, NO, (CH2)mCN, hydroxyloweralkyl, or alkyl-NX1X2, X4, X5, and X6 each independently comprise H, alkyl, carbocyclic ring, hydroxyloweralkyl, alkyl-OH, halogen, CN, SNO, S(S02)alkyl, NX1X2, COOX3, CONX3, OX7, or 0-alkyl-X7, wherein X7 comprises H, alkyl, NO2, NO, P(0)(0X8)2, PH(0)(0X8), S(0)kN(alky1)2, S(0)kX8, S(0)k0X8, COOX8, CONX8, SO3H, COX8, wherein X8 comprises H, alkyl, carbocyclic ring, heterocyclic ring, aromatic ring, heteroaromatic ring, or -CX0=CHX10, wherein X9 and X10 each independently comprise H or alkyl;
m is an integer from 0 to 7;
j is an integer from 0 to about 6; and k is an integer from 0 to about 2.
In a variation of formula I, R1 and R2 each independently comprise -(CH2)m - 01 -(CH2)n-Z;
Qi comprises NH, 0, S, CH=CH, CC, CO, SO2 or 0S02;
m is an integer from 1 to about 7;
n is an integer from 0 to about 7; and Z comprises a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring.
In a variation of formula I, R1 and R2 each independently comprise -(CH2)m - Q1 -(CH2)n-Z;
Qi comprises NH, 0, S, CH=CH, CC, CO, SO2 or 0S02;
m is an integer from 1 to about 7;
n is an integer from 0 to about 7;
Z comprises a carbocyclic ring having about 4 to about 7 ring members, a heterocyclic ring having about 4 to about 7 ring members, an aromatic ring having about 5 to about 7 ring members, a heteroaromatic ring having about 5 to about ring members; a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring, a heteropolycyclic ring or any above group substituted on at least one available ring atom by an alkyl group or any above group substituted on at least one available ring nitrogen atom by a benzyl group, a substituted benzyl group, an alkoxybenzyl group, a substituted alkoxybenzyl group, a benzhydryl group or a substituted benzhydryl group; and wherein the connecting point between the -(CH2)n-group and the Z group can be any available ring carbon atom or any available ring nitrogen atom.
In a variation of formula I, R1 and R2 each independently comprise -(CH2)m - Qi -(CH2)n-Z;
Qi comprises N, 0, S, CH=CH, CC, CO, SO2 or 0S02;
m is an integer from 1 to about 7;
n is an integer from 0 to about 7; and Z comprises a 5 member unsaturated ring having 0 to 4 independently selected heteroatoms as. ring members, a substituted 5 member unsaturated ring having 0 to 4 independently selected heteroatoms as ring members, a 6 member aromatic ring having 0 to 5 independently selected heteroatoms as ring members or a substituted 6 member aromatic ring having 0 to 5 independently selected heteroatoms; and wherein the connecting point between the -(CH2)n- group and the Z
group can be any available ring carbon atom or any available ring nitrogen atom.
In a variation of formula I R1 and R2 each independently comprise -(CH2)m- Qi -(CH2)n-Z;
Qi comprises NH, 0, S, CH=CH, Cm-C, CO, SO2 or OS02;
m is an integer from 1 to about 7;
n is an integer from 0 to about 7; and Z comprises 1-, 2- or 3-pyrrolidinyl, 1-, 2-, 3- or 4-piperidinyl, 2-, 3- or 4-morpholinyl, 2-, 3- or 4-thiomorpholinyl, 1-, 2- or 3-azetidinyl, 1- or 2-piperazinyl, 2- or 3-tetrahydrofuranyl; or any above group substituted on at least one available ring atom by an alkyl group; or any above group substituted on at least one available ring nitrogen atom by a benzyl group, a substituted benzyl group, an alkoxybenzyl group, a substituted alkoxybenzyl group, a benzhydryl group or a substituted benzhydryl group; and wherein the connecting point between the -(CH2),- group and the Z
group can be any available ring carbon atom or any available ring nitrogen atom.
In a variation of formula I R1 and R2 each independently comprise -(CH2)m- Qi -(CH2)n-Z;
Qi comprises N, 0, S, CH=CH, CC, CO, SO2 or OS02;
m is an integer from 1 to about 7;
n is an integer from 0 to about 7;
Z comprises x <.Ns , y =
X __________________________________ 11¨>-NX
W
x _____________________ N x y y Xy N N\
Y I N Yor Y
N
\N,.
N
N-W N r x\\-1, N Y -1CY
X
wherein X and Y each independently comprise, H, halogen, CF3, CF2H, N3, NCS, CN, NO2, NX1X2, OX3, SX3, OAc, 0S02X3, 0-acyl, S-acyl, S02-alkyl, SO-alkyl, SC(CH3)2C00X8, OC(CH3)2000X8 , C(CH3)2C00X8, Si(alkyl)3, alkyl-CN, 0-aroyl, 0(CH2)10X3, 0(CH2)iNX1X2, NH-acyl, NH-aroyl, CHO, C(halogen)3, COOX3, SO3H, SO2NX1X2, CONX1X2, NHC(0)0-alkyl, NHS02-alkyl, alkoxy, alkyl, alcohol, alkylmercapto, alkylamino, di-alkylamino, alkylsulfinyl or alkylsulfonyl, CX4X5X6, -CH=CHX8 , -CmCX8 ;
X1 and X2 each independently comprise H or alkyl, or X1 and X2 together comprise part of a heterocyclic ring having about 4 to about 7 ring members and optionally one additional heteroatom selected from 0, N or S, or X1 and X2 together comprise part of an imide ring having about 5 to about 6 members, X3 comprises H, alkyl, NO2, (CH2)mCN, hydroxyloweralkyl, or alkyl-NX1X2, X4, X5, and X6 each independently comprise H, alkyl, carbocyclic ring, hydroxyloweralkyl, alkyl-OH, halogen, CN, SNO, S(S02)alkyl, NX1X2, COOX3, CONX3, OX7, or 0-alkyl-X7, wherein X7 comprises H, alkyl, NO2, NO, P(0)(OX8)2, PH(0)(0X8), S(0)kN(alky1)2, S(0)kX8, S(0)k0X8, COOX8, CONX8, SO3H, COX8, wherein X8 comprises H, alkyl, carbocyclic ring, heterocyclic ring, aromatic ring, heteroaromatic ring, or -CX9=CHX113, wherein X9 and X10 each independently comprise H or alkyl;
m is an integer from 0 to 7;
j is an integer from 0 to about 6;
k is an integer from 0 to about 2; and W comprises H or alkyl In a variation of formula I R1 and R2 each independently comprise.
-(CH2)m - Qi -(CH2)n-Z;
Qi comprises NH, 0, S, CH=CH, CC, CO, SO2 or 0S02;
m is an integer from 1 to about 7;
n is an integer from 0 to about 7; and Z comprises an unsaturated ring having 5 ring atoms and 0 to 2 independently selected heteroatoms as ring members fused to an unsaturated ring having 5 ring atoms and 0 to 4 independently selected heteroatoms as ring members, an unsaturated ring having 5 ring atoms and 0 to 2 independently selected heteroatoms as ring members fused to an unsaturated ring having 6 or 7 ring atoms and 0 to independently selected heteroatoms as ring members or an unsaturated ring having 6 ring atoms and 0 to 4 independently selected heteroatoms as ring members fused to an unsaturated ring having 6 or 7 ring atoms and 0 to 4 independently selected heteroatoms as ring members.
In a variation of formula I R1 and R2 each independently comprise -(CH2)rn - Qi -(CH2)n-Z;
Q1 comprises NH, 0, S, CH=C1-1, CC, CO, SO2 or 0S02;
m is an integer from 1 to about 7;
n is an integer from 0 to about 7; and Z comprises QFJ
Nv ,\\H
or In a variation of formula I R1 and R2 each independently comprise -T-(C H2)-Z;
n comprises an integer from 0 to about 7;
T comprises a carbocyclic ring having 3 to about 8 ring members, an unsaturated ring having 3 to about 8 carbon atoms as ring members, an aromatic ring having 5 to about 8 carbon atoms as ring members, a heterocyclic ring having 3 to about 8 ring members, a heteroaromatic ring having 5 to about 8 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring;
Z comprises H, halogen, CF3, CF2H, N3, NCS, CN, NO2, NX1X2, OX3, SX3, OAc, 0S02X3, 0-acyl, S-acyl, S02-alkyl, SO-alkyl, SC(CH3)2C00X8, OC(CH3)2C00X8 , C(CH3)2000X8, Si(alkyl)3, 0-aroyl, 0(CH2)j0X3, 0(CH2)\IX1X2, alkyl-CN, NH-acyl, NH-aroyl, CHO, C(halogen)3, COOX3, SO3H, SO2NX1X2, CONX1X2, NHC(0)0-alkyl, NHS02-alkyl, alkoxy, alkyl, alcohol, alkylmercapto, alkylamino, di-alkylamino, alkylsulfinyl or alkylsulfonyl, CX4X5X8, -CH=CHX8 , X1 and X2 each independently comprise H or alkyl, or X1 and X2 together comprise part of a heterocyclic ring having about 4 to about 7 ring members and optionally one additional heteroatom selected from 0, N or S, or X1 and X2 together comprise part of an imide ring having about 5 to about 6 members, X3 comprises H, alkyl, NO2, NO, (CH2)mCN, hydroxyloweralkyl, or alkyl-NX1X2, X4, X6, and X6 each independently comprise H, alkyl, carbocyclic ring, hydroxyloweralkyl, alkyl-OH, halogen, CN, SNO, S(S02)alkyl, NX1X2, COOX3, CONX3, OX7, or 0-alkyl-X7, wherein X7 comprises H, alkyl, NO2, NO, P(0)(0X8)2, PH(0)(0X8), S(0)kN(alky1)2, S(0)kX8, S(0)k0X8, COOX8, CONX8, SO3H, COX8, wherein X8 comprises H, alkyl, carbocyclic ring, heterocyclic ring, aromatic ring, heteroaromatic ring, or -CX0=CHX10, wherein X9 and X10 each independently comprise H or alkyl;
m is an integer from 0 to 7;
j is an integer from 0 to about 6; and k is an integer from 0 to about 2 In a variation of formula I R1 and R2 each independently comprise -T-(C H2)-Z;
n comprises an integer from 0 to about 7;
T comprises a carbocyclic ring having 3 to about 8 ring members, an unsaturated ring having 3 to about 8 carbon atoms as ring members, an aromatic ring having 5 to about 8 carbon atoms as ring members, a heterocyclic ring having 3 to about 8 ring members, a heteroaromatic ring having 5 to about 8 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring; and Z comprises a carbocyclic ring having about 4 to about 7 ring members, a heterocyclic ring having about 4 to about 7 ring members, an aromatic ring having about 5 to about 7 ring members, a heteroaromatic ring having about 5 to about ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring, a heteropolycyclic ring; or any above group substituted on at least one available ring atom by an alkyl group; or any above group substituted on at least one available ring nitrogen atom by a benzyl group, a substituted benzyl group, an alkoxybenzyl group, a substituted alkoxybenzyl group, a benzhydryl group or a substituted benzhydryl group; and wherein the connecting point between the -(CH2)n-group and the Z group can be any available ring carbon atom or any available ring nitrogen atom.
In a variation of formula I R1 and R2 each independently comprise -T-(C H2)-Z;
n comprises an integer from 0 to about 7;
T comprises a carbocyclic ring having 3 to about 8 ring members, an unsaturated ring having 3 to about 8 carbon atoms as ring members, an aromatic ring having 5 to about 8 carbon atoms as ring members, a heterocyclic ring having 3 to about 8 ring members, a heteroaromatic ring having 5 to about 8 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring; and Z comprises 1-, 2- or 3-pyrrolidinyl, 1-, 2-, 3- or 4-piperidinyl, 2-, 3- or 4-morpholinyl, 2-, 3- or 4-thiomorpholinyl, 1-, 2- or 3-azetidinyl, 1- or 2-piperazinyl, 2- or 3-tetrahydrofuranyl; or any above group substituted on at least one available ring atom by an alkyl group; or any above group substituted on at least one available ring nitrogen atom by a benzyl group, a substituted benzyl group, an alkoxybenzyl group, a substituted alkoxybenzyl group, a benzhydryl group or a substituted benzhydryl group; and wherein the connecting point between the -(CH2)n- group and the Z
group can be any available ring carbon atom or any available ring nitrogen atom.
In a variation of formula I R1 and R2 each independently comprise -T-(CH2)n-Z;
n comprises an integer from 0 to about 7;
T comprises a carbocyclic ring having 3 to about 8 ring members, an unsaturated ring having 3 to about 8 carbon atoms as ring members, an aromatic ring having 5 to about 8 carbon atoms as ring members, a heterocyclic ring having 3 to about 8 ring members, a heteroaromatic ring having 5 to about 8 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring;
Z comprises at X
N\'SX \yµ14--N x y , W Y
rµY-4_y S Y el Y N
01 Yor ee Xy y \ N \ N
N N N
N'r X\\-- 1 / )(\\ N Y y X
wherein X and Y each independently comprise, H, halogen, CF3, CF2H, N3, NCS, CN, NO2, NX1X2, OX3, SX3, OAc, 0S02X3, 0-acyl, S-acyl, S02-alkyl, SO-alkyl, SC(CH3)2C00X8, OC(CH3)2C00X8 , C(CH3)2C00X8, Si(alkyl)3, alkyl-CN, 0-aroyl, 0(CH2)i0X3, 0(CH2)JNX1X2, NH-acyl, NH-aroyl, CHO, C(halogen)3, COOX3, SO3H, SO2NX1X2, CONX1X2, NHC(0)0-alkyl, NHS02-alkyl, alkoxy, alkyl, alcohol, alkylmercapto, alkylamino, di-alkylamino, alkylsulfinyl or alkylsulfonyl, CX4X5X6, -CH=CHX8 , ;
X1 and X2 each independently comprise H or alkyl, or X1 and X2 together comprise part of a heterocyclic ring having about 4 to about 7 ring members and optionally one additional heteroatom selected from 0, N or S, or X1 and X2 together comprise part of an imide ring having about 5 to about 6 members, X3 comprises H, alkyl, NO2, (CH2)mCN, hydroxyloweralkyl, or alkyl-NX1X2, X4, X5, and X6 each independently comprise H, alkyl, carbocyclic ring, hydroxyloweralkyl, alkyl-OH, halogen, CN, SNO, S(S02)alkyl, NX1X2, COOX3, CONX3, OX7, or 0-alkyl-X7 wherein X7 comprises H, alkyl, NO2, NO, P(0)(0X8)2, PH(0)(0X8), S(0)kN(alky1)2, S(0)kX8, S(0)k0X8, 000X8, CONX8, SO3H, COX8, wherein X8 comprises H, alkyl, carbocyclic ring, heterocyclic ring, aromatic ring, heteroaromatic ring, or -CX9=CHX10 wherein X9 and X10 each independently comprise H or alkyl;
m is an integer from 0 to 7;
j is an integer from 0 to about 6;
k is an integer from 0 to about 2; and W comprises H or alkyl.
In a variation of formula I R1 and R2 each independently comprise -T-(CH2)n-Z;
n comprises an integer from 0 to about 7;
T comprises a carbocyclic ring having 3 to about 8 ring members, an unsaturated ring having 3 to about 8 carbon atoms as ring members, an aromatic ring having 5 to about 8 carbon atoms as ring members, a heterocyclic ring having 3 to about 8 ring members, a heteroaromatic ring having 5 to about 8 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring;
Z comprises an unsaturated ring having 5 ring atoms and 0 to 2 independently selected heteroatoms as ring members fused to an unsaturated ring having 5 ring atoms and 0 to 4 independently selected heteroatoms as ring members, an unsaturated ring having 5 ring atoms and 0 to 2 independently selected heteroatoms as ring members fused to an unsaturated ring having 6 or 7 ring atoms and 0 to independently selected heteroatoms as ring members or an unsaturated ring having 6 ring atoms and 0 to 3 independently selected heteroatoms as ring members fused to an unsaturated ring having 6 or 7 ring atoms and 0 to 4 independently selected heteroatoms as ring members.
In a variation of formula I R1 and R2 each independently comprise -T-(CH2)n-Qi -(CH2)n-Z;
each n independently comprises an integer from 0 to about 7;
T comprises a carbocyclic ring having 3 to about 8 ring members, an unsaturated ring having 3 to about 8 carbon atoms as ring members, an aromatic ring having 5 to about 8 carbon atoms as ring members, a heterocyclic ring having 3 to about 8 ring members, a heteroaromatic ring having 5 to about 8 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring;
Qi comprises NH, 0, S, CH=CH, CC, CO, SO2 or 0S02;
Z comprises H, halogen, CF3, CF2H, N3, NCS, CN, NO2, NX1X2, OX3, SX3, OAc, 0S02X3, 0-acyl, S-acyl, S02-alkyl, SO-alkyl, SC(CH3)2C00X8, OC(CH3)2C00X8 , C(CH3)2C00X8, Si(alkyl)3, 0-aroyl, 0(CH2)i0X3, 0(CH2)iNX1X2, alkyl-CN, NH-acyl, NH-aroyl, CHO, C(halogen)3, COOX3, SO3H, SO2NX1X2, CONX1X2, NHC(0)0-alkyl, NHS02-alkyl, alkoxy, alkyl, alcohol, alkylmercapto, alkylamino, di-alkylamino, alkylsulfinyl or alkylsulfonyl, CX4X5X6, -CH=CHX8 , X1 and X2 each independently comprise H or alkyl, or X1 and X2 together comprise part of a heterocyclic ring having about 4 to about 7 ring members and optionally one additional heteroatom selected from 0, N or S, or X1 and X2 together comprise part of an imide ring having about 5 to about 6 members, X3 comprises H, alkyl, NO2, NO, (CH2)mCN, hydroxyloweralkyl, or alkyl-NX1X2, X4, X5, and X8 each independently comprise H, alkyl, carbocyclic ring, hydroxyloweralkyl, alkyl-OH, halogen, CN, SNO, S(S02)alkyl, NX1X2, COOX3, CONX3, OX7, or 0-alkyl-X7, wherein X7 comprises H, alkyl, NO2, NO, P(0)(0X8)2, PH(0)(0X8), S(0)kN(alky1)2, S(0)kX8, S(0)k0X8, COOX8, CONX8, SO3H, COX8, wherein X8 comprises H, alkyl, carbocyclic ring, heterocyclic ring, aromatic ring, heteroaromatic ring, or -CX9=CHX10, wherein X9 and X10 each independently comprise H or alkyl;
m is an integer from 0 to 7;
j is an integer from 0 to about 6; and k is an integer from 0 to about 2 In a variation of formula I R1 and R2 each independently comprise -T-(CH2)n-Qi -(CH-Z;
each n independently comprises an integer from 0 to about 7;
T comprises a carbocyclic ring having 3 to about 8 ring members, an unsaturated ring having 3 to about 8 carbon atoms as ring members, an aromatic ring having 5 to about 8 carbon atoms as ring members, a heterocyclic ring having 3 to about 8 ring members, a heteroaromatic ring having 5 to about 8 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring;
Qi comprises NH, 0, S, CH=CH, CC, CO, SO2 or 0S02;
Z comprises a carbocyclic ring having about 4 to about 7 ring members, a heterocyclic ring having about 4 to about 7 ring members, an aromatic ring having about 5 to about 7 ring members, a heteroaromatic ring having about 5 to about ring members, a bicyclic ring, a heterobicyclic ring, a polycyclic ring, a heteropolycyclic ring; or any above group substituted on at least one available ring atom by an alkyl group; or any above group substituted on at least one available ring nitrogen atom by a benzyl group, a substituted benzyl group, an alkoxybenzyl group, a substituted alkoxybenzyl group, a benzhydryl group or a substituted benzhydryl group; and wherein the connecting point between the -(CH2)n- group and the Z
group can be any available ring carbon atom or any available ring nitrogen atom.
In a variation of formula I R1 and R2 each independently comprise -T-(CH2)n-Qi -(CH-Z;
each n independently comprises an integer from 0 to about 7;
T comprises a carbocyclic ring having 3 to about 8 ring members, an unsaturated ring having 3 to about 8 carbon atoms as ring members, an aromatic ring having 5 to about 8 carbon atoms as ring members, a heterocyclic ring having 3 to about 8 ring members, a heteroaromatic ring having 5 to about 8 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring;
Qi comprises NH, 0, S, CH=CH, CC, CO, SO2 or 0S02;
Z comprises 1-, 2- or 3-pyrrolidinyl, 1-, 2-, 3- or 4-piperidinyl, 2-, 3- or 4-morpholinyl, 2-, 3- or 4-thiomorpholinyl, 1-, 2- or 3-azetidinyl, 1- or 2-piperazinyl, 2- or 3-tetrahydrofuranyl; or any above group substituted on at least one available ring atom by an alkyl group; or any above group substituted on at least one available ring nitrogen atom by a benzyl group, a substituted benzyl group, an alkoxybenzyl group, a substituted alkoxybenzyl group, a benzhydryl group or a substituted benzhydryl group; and wherein the connecting point between the -(CH2)n- group and the Z
group can be any available ring carbon atom or any available ring nitrogen atom.
In a variation of formula I R1 and R2 each independently comprise -T-(CH2)n-Qi -(CH-Z;
each n independently comprises an integer from 0 to about 7;
T comprises a carbocyclic ring having 3 to about 8 ring members, an unsaturated ring having 3 to about 8 carbon atoms as ring members, an aromatic ring having 5 to about 8 carbon atoms as ring members, a heterocyclic ring having 3 to about 8 ring members, a heteroaromatic ring having 5 to about 8 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring;
Q1 comprises NH, 0, S, CH=CH, CC, CO, SO2 or 0S02;
Z comprises ?,NO KNs , W X _ii\i- -NX
\
X X Y _____________ N N
X X X
X X
el N Yor 0.
N
\N. \ N
N N N N-W
\\- 1 / xY x wherein X and Y each independently comprise, H, halogen, CF3, CF2H, N3, NCS, CN, NO2, NX1X2, OX3, SX3, OAc, 0S02X3, 0-acyl, S-acyl, S02-alkyl, SO-alkyl, SC(CH3)2C00X8, OC(CH3)2000X8 , C(CH3)2C00X8, Si(alkyl)3, alkyl-CN, 0-aroyl, 0(CH2)i0X3, 0(CH2)JNX1X2, NH-acyl, NH-aroyl, CHO, C(halogen)3, COOX3, SO3H, SO2NX1X2, CONX1X2, NHC(0)0-alkyl, NHS02-alkyl, alkoxy, alkyl, alcohol, alkylmercapto, alkylamino, di-alkylamino, alkylsulfinyl or alkylsulfonyl, CX4X5X6, -CH=CHX8 , -CCX8 ;
Xi and X2 each independently comprise H or alkyl, or X1 and X2 together comprise part of a heterocyclic ring having about 4 to about 7 ring members and optionally one additional heteroatom selected from 0, N or S, or X1 and X2 together comprise part of an imide ring having about 5 to about 6 members, X3 comprises H, alkyl, NO2, (CH2)mCN, hydroxyloweralkyl, or alkyl-NX1X2, X4, X6, and X6 each independently comprise H, alkyl, carbocyclic ring, hydroxyloweralkyl, alkyl-OH, halogen, CN, SNO, S(S02)alkyl, Nk1X2, COOX3, CONX3, 0)(7, or 0-alkyl-X7, wherein X7 comprises H, alkyl, NO2, NO, P(0)(0)(02, PI-1(0)(0M, S(0)kN(alkyl)2, S(0)kX8, S(0)k0X8, COOX8, CONX8, SO3H, COX8, wherein X8 comprises H, alkyl, carbocyclic ring, heterocyclic ring, aromatic ring, heteroaromatic ring, or ¨CX9=CHX10, wherein X9 and X10 each independently comprise H or alkyl;
m is an integer from 0 to 7;
j is an integer from 0 to about 6;
k is an integer from 0 to about 2; and W comprises H or alkyl.
In a variation of formula I R1 and R2 each independently comprise ¨T¨(CH2)n¨
Qi ¨(CH2)n¨Z;
each n independently comprises an integer from 0 to about 7;
T comprises a carbocyclic ring having 3 to about 8 ring members, an unsaturated ring having 3 to about 8 carbon atoms as ring members, an aromatic ring having 5 to about 8 carbon atoms as ring members, a heterocyclic ring having 3 to about 8 ring members, a heteroaromatic ring having 5 to about 8 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring;
Qi comprises NH, 0, S, CH=CH, CC, CO, SO2 or OS02; and Z comprises an unsaturated ring having 5 ring atoms and 0 to 2 independently selected heteroatoms as ring members fused to an unsaturated ring having 5 ring atoms and 0 to 2 independently selected heteroatoms as ring members, an unsaturated ring having 5 ring atoms and 0 to 2 independently selected heteroatoms as ring members fused to an unsaturated ring having 6 or 7 ring atoms and 0 to independently selected heteroatoms as ring members or an unsaturated ring having 6 ring atoms and 0 to 3 independently selected heteroatoms as ring members fused to an unsaturated ring having 6 or 7 ring atoms and 0 to 4 independently selected heteroatoms as ring members.
In a variation of formula I, R1 and R2 each independently comprise -T-(CI-12)n- Q1 -(CH-Z;
T comprises a carbocyclic ring having 3 to about 8 ring members, an unsaturated ring having 3 to about 8 carbon atoms as ring members, an aromatic ring having 5 to about 8 carbon atoms as ring members, a heterocyclic ring having 3 to about 8 ring members, a heteroaromatic ring having 5 to about 8 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring;
each n independently comprises an integer from 0 to about 7;
Qi comprises NH, 0, S, CH=CH, CC, CO, SO2 or 0S02;
Z comprises:
-N/ )--E or -N N-E
wherein E comprises a C1 to about C4, linear or branched alkyl group, a phenyl group, a substituted phenyl group, a benzyl group or a substituted benzyl group.
In a variation of formula I, R1 and R2 each independently comprise -T-(C1-12)n- Q1 -(CH-Z;
T comprises a carbocyclic ring having 3 to about 8 ring members, an unsaturated ring having 3 to about 8 carbon atoms as ring members, an aromatic ring having 5 to about 8 carbon atoms as ring members, a heterocyclic ring having 3 to about 8 ring members, a heteroaromatic ring having 5 to about 8 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring;
each n independently comprises an integer from 0 to about 7;
Q1 comprises NH, 0, S, CH=CH, CC, CO, SO2 or 0S02;
Z comprises ___________________________________ 0 0 ¨
H
¨NO ¨NI _______________ \(CH2)k <(CH2)k <(CH2)k N \ or wherein k is an integer from 1 to about 5. A1 and A2 each independently comprise a Cl to about C4 alkyl group, a phenyl group or a substituted phenyl group.
In a variation of formula I, R3 comprises a carbocyclic ring having about 4 to about 7 members, a heterocyclic ring having about 4 to about 7 members, an aromatic ring having about 5 to about 7 ring members, a heteroaromatic ring having about 5 to about 7 members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring.
J¨K
In a variation of formula I, R3 comprises wherein G comprises CH, C(CH3), C(CN) or N;
L, K and J each independently comprise (CH2)n, (CH3)2, C=0, 0, -CHOH, C(CH3)0M1, C(CH2)n(X)Y, NMi, SO2 SO or S;
n is an integer from 0 to about 7;
M1 is H, alkyl, C(0)M2, wherein M2 is H, alkyl, NM3M4, 0M5 and M3, M4 and M5 are independently H, OH or alkyl,and X and Y each independently comprise, H, halogen, CF3, CF2H, N3, NCS, CN, NO2, NX1X2, OX3, SX3, OAc, OSO2X3, 0-acyl, S-acyl, S02-alkyl, SO-alkyl, SC(CH3)2C00X8, OC(CH3)2COOX8 C(CH3)2C00X8, Si(alkyl)3, alkyl-CN, 0-aroyl, 0(CH2)i0X3, 0(CH2)iNX1X2, NH-acyl, NH-aroyl, CHO, C(halogen)3, COOX3, SOH, SO2NX1X2, CONX1X2, NHC(0)0-alkyl, NHS02-alkyl, alkoxy, alkyl, alcohol, alkylmercapto, alkylamino, di-alkylamino, alkylsulfinyl or alkylsulfonyl, CX4X5X6, -CH=CHX8 , ;
X1 and X2 each independently comprise H or alkyl, or X1 and X2 together comprise part of a heterocyclic ring having about 4 to about 7 ring members and optionally one additional heteroatom selected from 0, N or S, or X1 and X2 together comprise part of an imide ring having about 5 to about 6 members, X3 comprises H, alkyl, NO2, (CH2)mCN, hydroxyloweralkyl, or alkyl-NX1X2, X4, X8, and X8 each independently comprise H, alkyl, carbocyclic ring, hydroxyloweralkyl, alkyl-OH, halogen, CN, SNO, S(S02)alkyl, NX1X2, COOX3, CONX3, OX7, or 0-alkyl-X7, wherein X7 comprises H, alkyl, NO2, NO, P(0)(0X8)2, PH(0)(0X8), S(0)kN(alkyl)2, S(0)kX8, S(0)k0X8, COOX8, CONX8, SO3H, COX8, wherein X8 comprises H, alkyl, carbocyclic ring, heterocyclic ring, aromatic ring, heteroaromatic ring, or -CX9=CHX10, wherein X9 and X10 each independently comprise H or alkyl;
m is an integer from 0 to 7;
j is an integer from 0 to about 6; and k is an integer from 0 to about 2.
In a variation of formula I, R3 comprises e wherein G, L and J each independently comprise CH or N.
In a variation of formula I, R3 comprises 1:Ti( o 26 r X
N y W
X; N X X =X \)ç/;( y ___ y Ny , y ''or N
\fµl \N
N N N
XN\-- I / N Y __ X
wherein X and Y each independently comprise, H, halogen, CF3, CF2H, N3, NCS, CN, NO2, NX1X2, OX3, SX3, OAc, 0S02X3, 0-acyl, S-acyl, S02-alkyl, SO-alkyl, SC(CH3)2C00X8, OC(CH3)2C00X8 , C(CH3)2C00X8, Si(alkyl)3, alkyl-CN, 0-aroyl, 0(CH2),OX3, 0(CH2)JNX1X2, NH-acyl, NH-aroyl, CHO, C(halogen)3, COOX3, SO3H, SO2NX1X2, CONX1X2, NHC(0)0-alkyl, NHS02-alkyl, alkoxy, alkyl, alcohol, alkylmercapto, alkylamino, di-alkylamino, alkylsulfinyl or alkylsulfonyl, CX4X5X6, -CH=CHX8 , -CCX8 ;
X1 and X2 each independently comprise H or alkyl, or X1 and X2 together comprise part of a heterocyclic ring having about 4 to about 7 ring members and optionally one additional heteroatom selected from 0, N or S, or X1 and X2 together comkrise part of an imide ring having about 5 to about 6 members, X3 comprises H, alkyl, NO2, (CH2)mCN, hydroxyloweralkyl, or alkyl-NX1X2, X4, X5, and X6 each independently comprise H, alkyl, carbocyclic ring, hydroxyloweralkyl, alkyl-OH, halogen, CN, SNO, S(S02)alkyl, NX1X2, COOX3, CONX3, OX7, or 0-alkyl-X7, wherein X7 comprises H, alkyl, NO2, NO, P(0)(0X8)2, PH(0)(0X8), S(0)kN(alkyl)2, S(0)kX8, S(0)k0X8, COOX8, CONX8, SO3H, COX8, wherein X8 comprises H, alkyl, carbocyclic ring, heterocyclic ring, aromatic ring, heteroaromatic ring, or -CX9=CHX10, wherein X9 and X10 each independently comprise H or alkyl;
m is an integer from 0 to 7;
j is an integer from 0 to about 6;
k is an integer from 0 to about 2; and W comprises H or alkyl.
In a variation of formula I, R3 comprises a carbocyclic ring having 6 ring atoms fused to a heterocyclic ring having from 5 to 7 ring atoms, a carbocyclic ring having 6 ring atoms fused to a heteroaromatic ring having from 5 to 7 ring atoms, a heterocyclic ring having 6 ring atoms fused to a heterocyclic ring having from
5 to 7 ring atoms, a heterocyclic ring having 6 ring atoms fused to a heteroaromatic ring having from 5 to 7 ring atoms, an aromatic ring having 6 ring atoms fused to a heterocyclic ring having from 5 to 7 ring atoms, an aromatic ring having 6 ring atoms fused to a heteroaromatic ring having from 5 to 7 ring atoms, a heteroaromatic ring having 6 ring atoms fused to a heterocyclic ring having from 5 to 7 ring atoms or a heteroaromatic ring having 6 ring atoms fused to a heteroaromatic ring having from 5 to 7 ring atoms.
In a variation of formula I, R4 comprises H, halogen, CF3, CF2H, N3, NCS, CN, NO2, phenyl, NX1X2, OX3, SX3, OAc, 0S02X3, 0-acyl, S-acyl, S02-alkyl, SO-alkyl, SC(CH3)2C00X8, OC(CH3)2C00X8 , C(CH3)2C00X8, Si(alkyl)3, alkyl-CN, 0-aroyl, 0(CH2)j0X3, 0(CH2)iNX1X2, NH-acyl, NH-aroyl, CHO, C(halogen)3, COOX3, SO3H, SO2NX1X2, CONX1X2, NHC(0)0-alkyl, NHS02-alkyl, alkoxy, alkyl, alcohol, alkylmercapto, alkylamino, di-alkylamino, alkylsulfinyl or alkylsulfonyl, CX4X5X8, -CH=CHX8 , X1 and X2 each independently comprise H or alkyl, or X1 and X2 together comprise part of a heterocyclic ring having about 4 to about 7 ring members and optionally one additional heteroatom selected from 0, N or S, or X1 and X2 together comprise part of an imide ring having about 5 to about 6 members, X3 comprises H, alkyl, NO2, (CH2)mCN, hydroxyloweralkyl, or alkyl-NX1X2, X4, X5, and X6 each independently comprise H, alkyl, carbocyclic ring, hydroxyloweralkyl, alkyl-OH, halogen, CN, SNO, S(S02)alkyl, NX1X2, COOX3, CONX3, OX7, or 0-alkyl-X7, wherein X7 comprises H, alkyl, NO2, NO, P(0)(0X8)2, PH(0)(0X8), S(0)kN(alky1)2, S(0)kX8, S(0)k0X8õ COOX8, CONX8, SO3H, COX8, wherein X8 comprises H, alkyl, carbocyclic ring, heterocyclic ring, aromatic ring, heteroaromatic ring, or ¨CX0=CHX10, wherein X9 and X10 each independently comprise H or alkyl;
m is an integer from 0 to 7;
j is an integer from 0 to about 6; and k is an integer from 0 to about 2.
In a variation of formula I, R4 comprises a carbocyclic ring having about 4 to about 7 ring members, a heterocyclic ring having about 4 to about 7 ring members, an aromatic ring having about 5 to about 7 ring members, a heteroaromatic ring having about 5 to about 7 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring.
In an advantageous variation of formula I, R4 comprises , H N 0 or In a variation of formula I, R4 comprises ¨(CH2)d¨Z;
d is an integer from 1 to about 6;
comprises H, halogen, CF3, CF2H, N3, NCS, CN, NO2, phenyl, NX1X2, OX3, SX3, OAc, 0S02X3, 0-acyl, S-acyl, S02-alkyl, SO-alkyl, SC(CH3)2C00X8, OC(CH3)2C00X8 , C(CH3)2C00X8, Si(alkyl)3, alkyl-CN, 0-aroyl, 0(CH2)JOX3, 0(CH2)1r1X1X2, NH-acyl, NH-aroyl, CHO, C(halogen)3, COOX3, SO3H, SO2NX1X2, CONX1X2, NHC(0)0-alkyl, NHS02-alkyl, alkoxy, alkyl, alcohol, alkylmercapto, alkylamino, di-alkylamino, alkylsulfinyl or alkylsulfonyl, CX4X8X8, -CH=CHX8 , X1 and X2 each independently comprise H or alkyl, or X1 and X2 together comprise part of a heterocyclic ring having about 4 to about 7 ring members and optionally one additional heteroatom selected from 0, N or S, or X1 and X2 together comprise part of an imide ring having about 5 to about 6 members, X3 comprises H, alkyl, NO2, (CH2)mCN, hydroxyloweralkyl, or alkyl-NX1X2, X4, X6, and X6 each independently comprise H, alkyl, carbocyclic ring, hydroxyloweralkyl, alkyl-OH, halogen, CN, SNO, S(S02)alkyl, NX1X2, COOX3, CONX3, OX7, or 0-alkyl-X7, wherein X7 comprises H, alkyl, NO2, NO, P(0)(0X8)2, PH(0)(0X8), S(0)kN(alkyl)2, S(0)kX8, S(0)k0X8, COOX8, CONX8, SO3H, COX8, wherein X8 comprises H, alkyl, carbocyclic ring, heterocyclic ring, aromatic ring, heteroaromatic ring, or -CX0=CHX10, wherein X9 and X10 each independently comprise H or alkyl;
m is an integer from 0 to 7;
j is an integer from 0 to about 6; and k is an integer from 0 to about 2.
In a variation of formula I, R4 comprises -CH2OH or -CH2Oalkyl.
In a variation of formula I, R4 comprises -(CH2)d-Z;
d is an integer from 1 to about 6; and Z comprises a carbocyclic ring having about 4 to about 7 ring members, a heterocyclic ring having about 4 to about 7 ring members, an aromatic ring having about 5 to about 7 ring members, a heteroaromatic ring having about 5 to about ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring, a heteropolycyclic ring; or any above group substituted on at least one available ring atom by an alkyl group; or any above group substituted on at least one available ring nitrogen atom by a benzyl group, a substituted benzyl group, an alkoxybenzyl group, a substituted alkoxybenzyl group, a benzhydryl group or a substituted benzhydryl group; and wherein the connecting point between the -(CH2)d-group and the Z group can be any available ring carbon atom or any available ring nitrogen atom.
In a variation of formula I, R4 comprises -(CH2)d-Z;
d is an integer from 1 to about 6; and Z comprises 1-, 2- or 3-pyrrolidinyl, 1-, 2-, 3- or 4-piperidinyl, 2-, 3- or 4-morpholinyl, 2-, 3- or 4-thiomorpholinyl, 1-, 2- or 3-azetidinyl, 1- or 2-piperazinyl, 2- or 3-tetrahydrofuranyl; or any above group substituted on at least one ring atom by an alkyl group; or any above group substituted on at least one available ring nitrogen atom by a benzyl group, a substituted benzyl group, an alkoxybenzyl group, a substituted alkoxybenzyl group, a benzhydryl group or a substituted benzhydryl group; and wherein the connecting point between the -(CH2)d- group and the Z
group can be any available ring carbon atom or any available ring nitrogen atom.
In a variation of formula I, R4 comprises -(CH2 )m - Q1 -(CH2)n-Z;
Qi comprises NH, 0, S, CH=CH, C1=-C, CO, SO2 or 0S02;
m is an integer from 1 to about 7;
n is an integer from 0 to about 7;
Z comprises H, halogen, CF3, CF2H, N3, NCS, CN, NO2, phenyl, NX1X2, OX3, SX3, OAc, 0S02X3, 0-acyl, S-acyl, S02-alkyl, SO-alkyl, SC(CH3)2C00X8, OC(CH3)2C00X8 , C(CH3)2C00X8, Si(alkyl)3, alkyl-CN, 0-aroyl, 0(CH2)10X3, 0(CH2)1NX1X2, NH-acyl, NH-aroyl, CHO, C(halogen)3, COOX3, SO3H, SO2NX1X2, CONX1X2, NHC(0)0-alkyl, NHS02-alkyl, alkoxy, alkyl, alcohol, alkylmercapto, alkylamino, di-alkylamino, alkylsulfinyl or alkylsulfonyl, CX4X5X6, -CH=CHX8 , X1 and X2 each independently comprise H or alkyl, or X1 and X2 together comprise part of a heterocyclic ring having about 4 to about 7 ring members and optionally one additional heteroatom selected from 0, N or S, or X1 and X2 together comprise part of an imide ring having about 5 to about 6 members, X3 comprises H, alkyl, NO2, (CH2)mCN, hydroxyloweralkyl, or alkyl-NX1X2, X4, X5, and X6 each independently comprise H, alkyl, carbocyclic ring, hydroxyloweralkyl, alkyl-OH, halogen, CN, SNO, S(S02)alkyl, NX1X2, COOX3, CONX3, OX7, or 0-alkyl-X7, wherein X7 comprises H, alkyl, NO2, NO, P(0)(0X8)2, PH(0)(0X8), S(0)kN(alky1)2, S(0)kX8, S(0)k0X8, COOX8, CONX8, SO3H, COX8, wherein X8 comprises H, alkyl, carbocyclic ring, heterocyclic ring, aromatic ring, heteroaromatic ring, or -CX9=CHX10, wherein X9 and X10 each independently comprise H or alkyl;
m is an integer from 0 to 7;
j is an integer from 0 to about 6; and k is an integer from 0 to about 2.
In a variation of formula I, R4 comprises -(CH2)m - Q1 -(CH2)n-Z;
Qi comprises NH, 0, S, CH=CH, CC, CO, SO2 or OS02;
m is an integer from 1 to about 7;
n is an integer from 0 to about 7; and Z comprises a carbocyclic ring having about 4 to about 7 ring members, a heterocyclic ring having about 4 to about 7 ring members, an aromatic ring having about 5 to about 7 ring members, a heteroaromatic ring having about 5 to about ring members; a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring, a heteropolycyclic ring; or any above group substituted on at least one available ring atom by an alkyl group; or any above group substituted on at least one available ring nitrogen atom by a benzyl group, a substituted benzyl group, an alkoxybenzyl group, a substituted alkoxybenzyl group, a benzhydryl group or a substituted benzhydryl group; and wherein the connecting point between the -(CH2)n-group and the Z group can be any available ring carbon atom or any available ring nitrogen atom.
In a variation of formula I R4 comprises ¨(CH2)m ¨ Q1 ¨(CH2)n¨Z.
Qi comprises NH, 0, S, CH=CH, CC, CO, SO2 or 0S02.
m is an integer from 1 to about 7.
n is an integer from 0 to about 7.
Z comprises 1-, 2- or 3-pyrrolidinyl, 1-, 2-, 3- or 4-piperidinyl, 2-, 3- or 4-morpholinyl, 2-, 3- or 4-thiomorpholinyl, 1-, 2- or 3-azetidinyl, 1- or 2-piperazinyl, 2- or 3-tetrahydrofuranyl; or any above group substituted on at least one available ring atom by an alkyl; or any above group substituted on at least one available ring nitrogen atom by a benzyl group, a substituted benzyl group, an alkoxybenzyl group, a substituted alkoxybenzyl group, a benzhydryl group or a substituted benzhydryl group; and wherein the connecting point between the -(CH2)n- group and the Z
group can be any available ring carbon atom or any available ring nitrogen atom.
In a variation of formula I R4 comprises ¨(CH2)m ¨ Q1 ¨(CH2)n¨Z.
Qi comprises NH, 0, S, CH=CH, CC, CO, SO2 or 0S02. =
m is an integer from 1 to about 7.
n is an integer from 0 to about 7.
Z comprises kX p Ks \-N jax Wy, N- Y, N
N; ,X __ y X Ny ___ y 0\_;111 Y el Y el N N Yor ee Y
N NN N
X\\-- I / )(\=\ N Y \ky X
wherein X and Y each independently comprise, H, halogen, CF3, CF2H, N3, NCS, CN, NO2, NX1X2, OX3, SX3, OAc, 0S02X3, 0-acyl, S-acyl, S02-alkyl, SO-alkyl, SC(CH3)2C00X8, OC(CH3)2C00X8 , C(CH3)2C00X8, Si(alkyl)3, alkyl-CN, 0-aroyl, 0(CH2)i0X3, 0(CH2)iNX1X2, NH-acyl, NH-aroyl, CHO, C(halogen)3, COOX3, SO3H, SO2NX1X2, CONX1X2, NHC(0)0-alkyl, NHS02-alkyl alkoxy, alkyl, alcohol, alkylmercapto, alkylamino, di-alkylamino, alkylsulfinyl or alkylsulfonyl, CX4X5X6, -CH=CHX8 , -CCX8 ;
X1 and X2 each independently comprise H or alkyl, or X1 and X2 together comprise part of a heterocyclic ring having about 4 to about 7 ring members and optionally one additional heteroatom selected from 0, N or S, or X1 and X2 together comprise part of an imide ring having about 5 to about 6 members, X3 comprises H, alkyl, NO2, (CH2)mCN, hydroxyloweralkyl, or alkyl-NX1X2, X4, X6, and X6 each independently comprise H, alkyl, carbocyclic ring, hydroxyloweralkyl, alkyl-OH, halogen, CN, SNO, S(S02)alkyl, NX1X2, COOX3, CONX3, OX7, or 0-alkyl-X7, wherein X7 comprises H, alkyl, NO2, NO, P(0)(0X8)2, PH(0)(0X8), S(0)kN(alkyl)2, S(0)kX8, S(0)k0X8, COOX8, CONX8, SO3H, COX8, wherein X8 comprises H, alkyl, carbocyclic ring, heterocyclic ring, aromatic ring, heteroaromatic ring, or -CX9=CHX10, wherein X9 and X10 each independently comprise H or alkyl;
m is an integer from 0 to 7;
j is an integer from 0 to about 6;
k is an integer from 0 to about 2;
W comprises H or alkyl.
In any variation of formula I, when A is a direct bond; and B is N(R5); and either of R1 and R2 is phenyl [optionally substituted with one more halogen atoms, (C1-C6) alkyl, (C1-C6) alkoxy, trifluoromethyl, cyano, nitro, (C1-C6) alkyl sulfonyl, (C1-C6) alkyl sulfonyl amino, (C1-C6) alkyl carbonyl-amino, (C1-C6) alkyl amino-carbonyl-amino or phenyl], (C2-C6) alkyl, cyclohexyl [optionally substituted with (C1-C6) alkyl, (C1-C6) alkoxy, trifluoromethyl, cyano or one or more fluorine atoms], 1-napthyl or 2-napthyl [optionally substituted with one or more halogen atoms, (C1-C6) alkyl, (C1-C6) alkoxy, trifluoromethyl or cyano], benzyl [optionally substituted on the phenyl ring with one or more halogen atoms, (Ci-C6) alkyl, (C1-C6) alkoxy, trifluoromethyl or cyano], a 5- to 10-membered saturated or unsaturated heterocyclic radical [optionally substituted with one or more fluorine atoms, (C1-C6) alkyl, (C1-C6) alkoxy, trifluoromethyl or cyano] and a 5- to 10- membered aromatic monocyclic or bicyclic heterocyclic radical [optionally substituted with one more halogen atoms, (C1-C6) alkyl, (C1-C6) alkoxy, trifloromethyl, cyano, nitro or phenyl] and R3 is any above described variation; then R4 can not be H, (C1-C6) alkyl, benzyl, chloro, or bromo.
In any variation of formula I, when A is a direct bond; and B is N(R5); and either R1 or R2 is phenyl, thienyl, 2-pyridinyl, 3-pyridinyl, 4-pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl or any above group substituted with 1, 2, 3 or 4 substituents which can be the same or different, selected from C1_3 alkyl, C1_3 alkoxy, hydroxy, halogen, trifluoromethyl, trifluoromethylthio, trifluoromethoxy, nitro, amino, mono- or dialkyl (C1_2)-amino, mono- or dialkyl (C1_2)-amido, (C1_3)-alkoxycarbonyl, carboxyl, cyano, carbomyl, acetyl and naphthyl; and R3 is any above described variation; then R4 can not be H, halogen, CN, carbomyl, formyl, acetyl, trifluoroacetyl, fluoroacetyl, propionyl, sulfamoyl, methanesulfonyl, methylsulfanyl, branched or unbranched C1-4 alkyl group, which C1_4 alkyl group may be substituted with 1 to 3 fluoro atoms or with a single bromo, chloro, iodo, cyano or hydroxy group.
Another embodiment of the invention comprises cannabimimetic thiazole and oxazole ligands represented by formula II and their enantiomers, diastereomers, geometric isomers, racemates, tautomers, rotamers, atropisomers, metabolites, in vivo hydrolysable esters, N-oxides, salts, solvates, hydrates, polymorphic forms( crystalline or amorphous) or pro-drugs:
WNvy N
A
yR3 wherein A, B, R1, R2 and R3 are as defined above for compounds of formula W comprises S or 0.
In any variation of formula II, when A is a direct bond; B is NR5 as defined above; R1 and R3 are any above described variation; and W is S; then R2 cannot be a phenyl group with one or more substituents selected from branched or unbranched C1_3-alkyl, branched or unbranched C1_3-alkoxy, hydroxy, halogen, CF3, trifluoromethylthio, trifluoromethoxy, nitro, amino, mono-or dialkyl(C1_2)-amino, mono-or dialkyl(C1_2)-amido, branched or unbranched (C1_3)-alkoxycarbonyl, trifluoromethylsulfonyl, sulfamoyl, branched or unbranched (C1_3)-sulfonyl, carboxyl, cyano, carbamoyl, branched or unbranched dialkyl(C1_3)-aminosulfonyl, branched or unbranched monoalkyl(C1_3)-aminosulfonyl and acetyl.
Another embodiment of the invention comprises cannabimimetic triazole ligands represented by formula III and their enantiomers, diastereomers, geometric isomers, racemates, tautomers, rotamers, atropisomers, metabolites, in vivo hydrolysable esters, N-oxides, salts, solvates, hydrates, polymorphic forms( crystalline or amorphous) or pro-drugs:
R1 \ R2 N N
III
wherein A, B, R1, R2 and R3 are as defined above for compounds of formula In any variation of formula III, when A is a direct bond; B is NR5; R3 is any above described variation; then either or both of R1 and R2 cannot be a phenyl, naphthyl, thienyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, or triazinyl group, or any above group substituted with 1-4 substituents, which can be same or different, selected from branched or unbranched (C1_3)alkyl or alkoxy, hydroxy, halogen, trifluoromethyl, trifluoromethylthio, trifluoromethoxy, nitro, amino, mono- or dialkyl (C1-2)-amino, mono- or dialkyl (C1_2)-amido, (Ci_3)-alkoxycarbonyl, trifluoromethylsulfonyl, sulfomyl, (Ci_3)-alkylsulfonyl, carboxyl, cyano, carbomyl, (C1_3)-dialkylaminosulfonyl, (C1_3)-monoalkylamino-sulfonyl and acetyl.
Another embodiment of the invention comprises cannabimimetic pyrazole ligands represented by formula IV and their enantiomers, diastereomers, geometric isomers, racemates, tautomers, rotamers, atropisomers, metabolites, in vivo hydrolysable esters, N-oxides, salts, solvates, hydrates, polymorphic forms( crystalline or amorphous) or pro-drugs:
R4\ zA13 Ri , Iv wherein A, 13, R2 and R3 are as defined above for compounds of formula I.
In a variation of formula IV, R1 comprises -T-(CH2)n-Q-(CH2)n-Z.
each n independently comprises an integer from 0 to about 7.
T comprises a carbocyclic ring having 3 to about 8 ring members, an unsaturated ring having 3 to about 8 carbon atoms as ring members, an aromatic ring having 5 to about 8 carbon atoms as ring members, a heterocyclic ring having 3 to about 8 ring members, a heteroaromatic ring having 5 to about 8 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring.
Q comprises CH=CH, Z comprises H, halogen, CF3, CF2H, N3, NCS, CN, NO2, NX1X2, OX3, SX3, OAc, 0S02X3, 0-acyl, S-acyl, S02-alkyl, SO-alkyl, SC(CH3)2C00X8, OC(CH3)2C00X8 , C(CH3)2C00X8, Si(alkyl)3, 0-aroyl, 0(CH2)10X3, 0(CH2)1NX1X2, alkyl-CN, NH-acyl, NH-aroyl, CHO, C(halogen)3, COOX3, SO3H, SO2NX1X2, CONX1X2, NHC(0)0-alkyl, NHS02-alkyl alkoxy, alkyl, alcohol, alkylmercapto, alkylamino, di-alkylamino, alkylsuffinyl or alkylsulfonyl, CX4X5X8, -CH=CHX8 , -Cm-CX8 X1 and X2 each independently comprise H or alkyl, or X1 and X2 together comprise part of a heterocyclic ring having about 4 to about 7 ring members and optionally one additional heteroatom selected from 0, N or S, or X1 and X2 together comprise part of an imide ring having about 5 to about 6 members, X3 comprises H, alkyl, NO2, NO, (CH2)mCN, hydroxyloweralkyl, or alkyl-NX1X2, X4, X5, and X6 each independently comprise H, alkyl, carbocyclic ring, hydroxyloweralkyl, alkyl-OH, halogen, ON, SNO, S(S02)alkyl, NX1X2, COOX3, CONX3, OX7, or 0-alkyl-X7, wherein X7 comprises H, alkyl, NO2, NO, P(0)(0)(8)2, PH(0)(OX8), S(0)kN(alky1)2, S(0)kX8, S(0)k0X8, COOX8, CONX8, SO3H, COX8, wherein X8 comprises H, alkyl, carbocyclic ring, heterocyclic ring, aromatic ring, heteroaromatic ring, or -CX9=CHX10, wherein X9 and X10 each independently comprise H or alkyl;
m is an integer from 0 to 7;
j is an integer from 0 to about 6; and k is an integer from 0 to about 2.
In a variation of formula IV R1 comprises -T-(CH2)n-Q-(CH2)n-Z.
each n independently comprises an integer from 0 to about 7.
T comprises a carbocyclic ring having 3 to about 8 ring members, an unsaturated ring having 3 to about 8 carbon atoms as ring members, an aromatic ring having 5 to about 8 carbon atoms as ring members, a heterocyclic ring having 3 to about 8 ring members, a heteroaromatic ring having 5 to about 8 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring.
Q comprises CH=CH, Z comprises a carbocyclic ring having about 4 to about 7 ring members, a heterocyclic ring having about 4 to about 7 ring members, an aromatic ring having about 5 to about 7 ring members, a heteroaromatic ring having about 5 to about ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring, a heteropolycyclic ring; or any above group substituted on at least one available ring atom by an alkyl group; or any above group substituted on at least one available ring nitrogen atom by a benzyl group, a substituted benzyl group, an alkoxybenzyl group, a substituted alkoxybenzyl group, a benzhydryl group or a substituted benzhydryl group; and wherein the connecting point between the -(CH2)n-group and the Z group can be any available ring carbon atom or any available ring nitrogen atom.
In a variation of formula IV, R1 comprises -T-(CH2)n-Q-(CH2)n-Z.
each n independently comprises an integer from 0 to about 7.
T comprises a carbocyclic ring having 3 to about 8 ring members, an unsaturated ring having 3 to about 8 carbon atoms as ring members, an aromatic ring having 5 to about 8 carbon atoms as ring members, a heterocyclic ring having 3 to about 8 ring members, a heteroaromatic ring having 5 to about 8 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring.
Q comprises CH=CH, Z comprises 1-, 2- or 3-pyrrolidinyl, 1-, 2-, 3- or 4-piperidinyl, 2-, 3- or 4-morpholinyl, 2-, 3- or 4-thiomorpholinyl, 1-, 2- or 3-azetidinyl, 1- or 2-piperazinyl, 2- or 3-tetrahydrofuranyl; or any above group substituted on at least one available ring atom by an alkyl group; or any above group substituted on at least one available ring nitrogen atom by a benzyl group, a substituted benzyl group, an alkoxybenzyl group, a substituted alkoxybenzyl group, a benzhydryl group or a substituted benzhydryl group; and wherein the connecting point between the -(CH2)n- group and the Z
group can be any available ring carbon atom or any available ring nitrogen atom.
In a variation of formula IV, R1 comprises -T-(CH2)n-Q-(CH2)n-Z.
each n independently comprises an integer from 0 to about 7.
T comprises a carbocyclic ring having 3 to about 8 ring members, an unsaturated ring having 3 to about 8 carbon atoms as ring members, an aromatic ring having 5 to about 8 carbon atoms as ring members, a heterocyclic ring having 3 to about 8 ring members, a heteroaromatic ring having 5 to about 8 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring.
Q comprises CH=CH, Z comprises )-(`( _____________________________ ja X
N N L\Lx N x x Y, W y N-j N'N
N _1( N Yor Y
\1=1 \N
N N NNW
X\\i- I / x)LN \-11`), X
wherein X and Y each independently comprise, H, halogen, CF3, CF2H, N3, NCS, CN, NO2, NX1X2, OX3, SX3, OAc, 0S02X3, 0-acyl, S-acyl, S02-alkyl, SO-alkyl, SC(CH3)2000X8, OC(CH3)2C00X8 , C(CH3)2C00X8, Si(alkyl)3, alkyl-CN, 0-aroyl, 0(CH2)i0X3, 0(CH2)iNX1X2, NH-acyl, NH-aroyl, CHO, C(halogen)3, COOX3, SO3H, SO2NX1X2, CONX1X2, NHC(0)0-alkyl, NHS02-alkyl alkoxy, alkyl, alcohol, alkylmercapto, alkylamino, di-alkylamino, alkylsulfinyl or alkylsulfonyl, CX4X8X8, -CH=CHX8 , -CCX8 ;
X1 and X2 each independently comprise H or alkyl, or X1 and X2 together comprise part of a heterocyclic ring having about 4 to about 7 ring members and optionally one additional heteroatom selected from 0, N or S, or X1 and X2 together comprise part of an imide ring having about 5 to about 6 members, X3 comprises H, alkyl, NO2, (CH2)mCN, hydroxyloweralkyl, or alkyl-NX1X2, X4, X5, and X6 each independently comprise H, alkyl, carbocyclic ring, hydroxyloweralkyl, alkyl-OH, halogen, CN, SNO, S(S02)alkyl, NX1X2, COOX3, CONX3, OX7, or 0-alkyl-X7, wherein X7 comprises H, alkyl, NO2, NO, P(0)(0X8)2, PH(0)(0X8), S(0)kN(alky1)2, S(0)kX8, S(0)k0X8, COOX8, CONX8, SO3H, COX8, wherein X8 comprises H, alkyl, carbocyclic ring, heterocyclic ring, aromatic ring, heteroaromatic ring, or -CX9=CHX10, wherein X9 and X10 each independently comprise H or alkyl;
m is an integer from 0 to 7;
j is an integer from 0 to about 6;
k is an integer from 0 to about 2; and W comprises H or alkyl.
In a variation of formula IV, R1 comprises -T-(CH2)n-Q-(CH2)n-Z.
each n independently comprises an integer from 0 to about 7.
T comprises a carbocyclic ring having 3 to about 8 ring members, an unsaturated ring having 3 to about 8 carbon atoms as ring members, an aromatic ring having 5 to about 8 carbon atoms as ring members, a heterocyclic ring having 3 to about 8 ring members, a heteroaromatic ring having 5 to about 8 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring.
Q comprises CH=CH, Z comprises an unsaturated ring having 5 ring atoms and 0 to 2 independently selected heteroatoms as ring members fused to an unsaturated ring having 5 ring atoms and 0 to 4 independently selected heteroatoms as ring members, an unsaturated ring having 5 ring atoms and 0 to 2 independently ,selected heteroatoms as ring members fused to an unsaturated ring having 6 or 7 ring atoms and 0 to independently selected heteroatoms as ring members or an unsaturated ring having
In a variation of formula I, R4 comprises H, halogen, CF3, CF2H, N3, NCS, CN, NO2, phenyl, NX1X2, OX3, SX3, OAc, 0S02X3, 0-acyl, S-acyl, S02-alkyl, SO-alkyl, SC(CH3)2C00X8, OC(CH3)2C00X8 , C(CH3)2C00X8, Si(alkyl)3, alkyl-CN, 0-aroyl, 0(CH2)j0X3, 0(CH2)iNX1X2, NH-acyl, NH-aroyl, CHO, C(halogen)3, COOX3, SO3H, SO2NX1X2, CONX1X2, NHC(0)0-alkyl, NHS02-alkyl, alkoxy, alkyl, alcohol, alkylmercapto, alkylamino, di-alkylamino, alkylsulfinyl or alkylsulfonyl, CX4X5X8, -CH=CHX8 , X1 and X2 each independently comprise H or alkyl, or X1 and X2 together comprise part of a heterocyclic ring having about 4 to about 7 ring members and optionally one additional heteroatom selected from 0, N or S, or X1 and X2 together comprise part of an imide ring having about 5 to about 6 members, X3 comprises H, alkyl, NO2, (CH2)mCN, hydroxyloweralkyl, or alkyl-NX1X2, X4, X5, and X6 each independently comprise H, alkyl, carbocyclic ring, hydroxyloweralkyl, alkyl-OH, halogen, CN, SNO, S(S02)alkyl, NX1X2, COOX3, CONX3, OX7, or 0-alkyl-X7, wherein X7 comprises H, alkyl, NO2, NO, P(0)(0X8)2, PH(0)(0X8), S(0)kN(alky1)2, S(0)kX8, S(0)k0X8õ COOX8, CONX8, SO3H, COX8, wherein X8 comprises H, alkyl, carbocyclic ring, heterocyclic ring, aromatic ring, heteroaromatic ring, or ¨CX0=CHX10, wherein X9 and X10 each independently comprise H or alkyl;
m is an integer from 0 to 7;
j is an integer from 0 to about 6; and k is an integer from 0 to about 2.
In a variation of formula I, R4 comprises a carbocyclic ring having about 4 to about 7 ring members, a heterocyclic ring having about 4 to about 7 ring members, an aromatic ring having about 5 to about 7 ring members, a heteroaromatic ring having about 5 to about 7 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring.
In an advantageous variation of formula I, R4 comprises , H N 0 or In a variation of formula I, R4 comprises ¨(CH2)d¨Z;
d is an integer from 1 to about 6;
comprises H, halogen, CF3, CF2H, N3, NCS, CN, NO2, phenyl, NX1X2, OX3, SX3, OAc, 0S02X3, 0-acyl, S-acyl, S02-alkyl, SO-alkyl, SC(CH3)2C00X8, OC(CH3)2C00X8 , C(CH3)2C00X8, Si(alkyl)3, alkyl-CN, 0-aroyl, 0(CH2)JOX3, 0(CH2)1r1X1X2, NH-acyl, NH-aroyl, CHO, C(halogen)3, COOX3, SO3H, SO2NX1X2, CONX1X2, NHC(0)0-alkyl, NHS02-alkyl, alkoxy, alkyl, alcohol, alkylmercapto, alkylamino, di-alkylamino, alkylsulfinyl or alkylsulfonyl, CX4X8X8, -CH=CHX8 , X1 and X2 each independently comprise H or alkyl, or X1 and X2 together comprise part of a heterocyclic ring having about 4 to about 7 ring members and optionally one additional heteroatom selected from 0, N or S, or X1 and X2 together comprise part of an imide ring having about 5 to about 6 members, X3 comprises H, alkyl, NO2, (CH2)mCN, hydroxyloweralkyl, or alkyl-NX1X2, X4, X6, and X6 each independently comprise H, alkyl, carbocyclic ring, hydroxyloweralkyl, alkyl-OH, halogen, CN, SNO, S(S02)alkyl, NX1X2, COOX3, CONX3, OX7, or 0-alkyl-X7, wherein X7 comprises H, alkyl, NO2, NO, P(0)(0X8)2, PH(0)(0X8), S(0)kN(alkyl)2, S(0)kX8, S(0)k0X8, COOX8, CONX8, SO3H, COX8, wherein X8 comprises H, alkyl, carbocyclic ring, heterocyclic ring, aromatic ring, heteroaromatic ring, or -CX0=CHX10, wherein X9 and X10 each independently comprise H or alkyl;
m is an integer from 0 to 7;
j is an integer from 0 to about 6; and k is an integer from 0 to about 2.
In a variation of formula I, R4 comprises -CH2OH or -CH2Oalkyl.
In a variation of formula I, R4 comprises -(CH2)d-Z;
d is an integer from 1 to about 6; and Z comprises a carbocyclic ring having about 4 to about 7 ring members, a heterocyclic ring having about 4 to about 7 ring members, an aromatic ring having about 5 to about 7 ring members, a heteroaromatic ring having about 5 to about ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring, a heteropolycyclic ring; or any above group substituted on at least one available ring atom by an alkyl group; or any above group substituted on at least one available ring nitrogen atom by a benzyl group, a substituted benzyl group, an alkoxybenzyl group, a substituted alkoxybenzyl group, a benzhydryl group or a substituted benzhydryl group; and wherein the connecting point between the -(CH2)d-group and the Z group can be any available ring carbon atom or any available ring nitrogen atom.
In a variation of formula I, R4 comprises -(CH2)d-Z;
d is an integer from 1 to about 6; and Z comprises 1-, 2- or 3-pyrrolidinyl, 1-, 2-, 3- or 4-piperidinyl, 2-, 3- or 4-morpholinyl, 2-, 3- or 4-thiomorpholinyl, 1-, 2- or 3-azetidinyl, 1- or 2-piperazinyl, 2- or 3-tetrahydrofuranyl; or any above group substituted on at least one ring atom by an alkyl group; or any above group substituted on at least one available ring nitrogen atom by a benzyl group, a substituted benzyl group, an alkoxybenzyl group, a substituted alkoxybenzyl group, a benzhydryl group or a substituted benzhydryl group; and wherein the connecting point between the -(CH2)d- group and the Z
group can be any available ring carbon atom or any available ring nitrogen atom.
In a variation of formula I, R4 comprises -(CH2 )m - Q1 -(CH2)n-Z;
Qi comprises NH, 0, S, CH=CH, C1=-C, CO, SO2 or 0S02;
m is an integer from 1 to about 7;
n is an integer from 0 to about 7;
Z comprises H, halogen, CF3, CF2H, N3, NCS, CN, NO2, phenyl, NX1X2, OX3, SX3, OAc, 0S02X3, 0-acyl, S-acyl, S02-alkyl, SO-alkyl, SC(CH3)2C00X8, OC(CH3)2C00X8 , C(CH3)2C00X8, Si(alkyl)3, alkyl-CN, 0-aroyl, 0(CH2)10X3, 0(CH2)1NX1X2, NH-acyl, NH-aroyl, CHO, C(halogen)3, COOX3, SO3H, SO2NX1X2, CONX1X2, NHC(0)0-alkyl, NHS02-alkyl, alkoxy, alkyl, alcohol, alkylmercapto, alkylamino, di-alkylamino, alkylsulfinyl or alkylsulfonyl, CX4X5X6, -CH=CHX8 , X1 and X2 each independently comprise H or alkyl, or X1 and X2 together comprise part of a heterocyclic ring having about 4 to about 7 ring members and optionally one additional heteroatom selected from 0, N or S, or X1 and X2 together comprise part of an imide ring having about 5 to about 6 members, X3 comprises H, alkyl, NO2, (CH2)mCN, hydroxyloweralkyl, or alkyl-NX1X2, X4, X5, and X6 each independently comprise H, alkyl, carbocyclic ring, hydroxyloweralkyl, alkyl-OH, halogen, CN, SNO, S(S02)alkyl, NX1X2, COOX3, CONX3, OX7, or 0-alkyl-X7, wherein X7 comprises H, alkyl, NO2, NO, P(0)(0X8)2, PH(0)(0X8), S(0)kN(alky1)2, S(0)kX8, S(0)k0X8, COOX8, CONX8, SO3H, COX8, wherein X8 comprises H, alkyl, carbocyclic ring, heterocyclic ring, aromatic ring, heteroaromatic ring, or -CX9=CHX10, wherein X9 and X10 each independently comprise H or alkyl;
m is an integer from 0 to 7;
j is an integer from 0 to about 6; and k is an integer from 0 to about 2.
In a variation of formula I, R4 comprises -(CH2)m - Q1 -(CH2)n-Z;
Qi comprises NH, 0, S, CH=CH, CC, CO, SO2 or OS02;
m is an integer from 1 to about 7;
n is an integer from 0 to about 7; and Z comprises a carbocyclic ring having about 4 to about 7 ring members, a heterocyclic ring having about 4 to about 7 ring members, an aromatic ring having about 5 to about 7 ring members, a heteroaromatic ring having about 5 to about ring members; a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring, a heteropolycyclic ring; or any above group substituted on at least one available ring atom by an alkyl group; or any above group substituted on at least one available ring nitrogen atom by a benzyl group, a substituted benzyl group, an alkoxybenzyl group, a substituted alkoxybenzyl group, a benzhydryl group or a substituted benzhydryl group; and wherein the connecting point between the -(CH2)n-group and the Z group can be any available ring carbon atom or any available ring nitrogen atom.
In a variation of formula I R4 comprises ¨(CH2)m ¨ Q1 ¨(CH2)n¨Z.
Qi comprises NH, 0, S, CH=CH, CC, CO, SO2 or 0S02.
m is an integer from 1 to about 7.
n is an integer from 0 to about 7.
Z comprises 1-, 2- or 3-pyrrolidinyl, 1-, 2-, 3- or 4-piperidinyl, 2-, 3- or 4-morpholinyl, 2-, 3- or 4-thiomorpholinyl, 1-, 2- or 3-azetidinyl, 1- or 2-piperazinyl, 2- or 3-tetrahydrofuranyl; or any above group substituted on at least one available ring atom by an alkyl; or any above group substituted on at least one available ring nitrogen atom by a benzyl group, a substituted benzyl group, an alkoxybenzyl group, a substituted alkoxybenzyl group, a benzhydryl group or a substituted benzhydryl group; and wherein the connecting point between the -(CH2)n- group and the Z
group can be any available ring carbon atom or any available ring nitrogen atom.
In a variation of formula I R4 comprises ¨(CH2)m ¨ Q1 ¨(CH2)n¨Z.
Qi comprises NH, 0, S, CH=CH, CC, CO, SO2 or 0S02. =
m is an integer from 1 to about 7.
n is an integer from 0 to about 7.
Z comprises kX p Ks \-N jax Wy, N- Y, N
N; ,X __ y X Ny ___ y 0\_;111 Y el Y el N N Yor ee Y
N NN N
X\\-- I / )(\=\ N Y \ky X
wherein X and Y each independently comprise, H, halogen, CF3, CF2H, N3, NCS, CN, NO2, NX1X2, OX3, SX3, OAc, 0S02X3, 0-acyl, S-acyl, S02-alkyl, SO-alkyl, SC(CH3)2C00X8, OC(CH3)2C00X8 , C(CH3)2C00X8, Si(alkyl)3, alkyl-CN, 0-aroyl, 0(CH2)i0X3, 0(CH2)iNX1X2, NH-acyl, NH-aroyl, CHO, C(halogen)3, COOX3, SO3H, SO2NX1X2, CONX1X2, NHC(0)0-alkyl, NHS02-alkyl alkoxy, alkyl, alcohol, alkylmercapto, alkylamino, di-alkylamino, alkylsulfinyl or alkylsulfonyl, CX4X5X6, -CH=CHX8 , -CCX8 ;
X1 and X2 each independently comprise H or alkyl, or X1 and X2 together comprise part of a heterocyclic ring having about 4 to about 7 ring members and optionally one additional heteroatom selected from 0, N or S, or X1 and X2 together comprise part of an imide ring having about 5 to about 6 members, X3 comprises H, alkyl, NO2, (CH2)mCN, hydroxyloweralkyl, or alkyl-NX1X2, X4, X6, and X6 each independently comprise H, alkyl, carbocyclic ring, hydroxyloweralkyl, alkyl-OH, halogen, CN, SNO, S(S02)alkyl, NX1X2, COOX3, CONX3, OX7, or 0-alkyl-X7, wherein X7 comprises H, alkyl, NO2, NO, P(0)(0X8)2, PH(0)(0X8), S(0)kN(alkyl)2, S(0)kX8, S(0)k0X8, COOX8, CONX8, SO3H, COX8, wherein X8 comprises H, alkyl, carbocyclic ring, heterocyclic ring, aromatic ring, heteroaromatic ring, or -CX9=CHX10, wherein X9 and X10 each independently comprise H or alkyl;
m is an integer from 0 to 7;
j is an integer from 0 to about 6;
k is an integer from 0 to about 2;
W comprises H or alkyl.
In any variation of formula I, when A is a direct bond; and B is N(R5); and either of R1 and R2 is phenyl [optionally substituted with one more halogen atoms, (C1-C6) alkyl, (C1-C6) alkoxy, trifluoromethyl, cyano, nitro, (C1-C6) alkyl sulfonyl, (C1-C6) alkyl sulfonyl amino, (C1-C6) alkyl carbonyl-amino, (C1-C6) alkyl amino-carbonyl-amino or phenyl], (C2-C6) alkyl, cyclohexyl [optionally substituted with (C1-C6) alkyl, (C1-C6) alkoxy, trifluoromethyl, cyano or one or more fluorine atoms], 1-napthyl or 2-napthyl [optionally substituted with one or more halogen atoms, (C1-C6) alkyl, (C1-C6) alkoxy, trifluoromethyl or cyano], benzyl [optionally substituted on the phenyl ring with one or more halogen atoms, (Ci-C6) alkyl, (C1-C6) alkoxy, trifluoromethyl or cyano], a 5- to 10-membered saturated or unsaturated heterocyclic radical [optionally substituted with one or more fluorine atoms, (C1-C6) alkyl, (C1-C6) alkoxy, trifluoromethyl or cyano] and a 5- to 10- membered aromatic monocyclic or bicyclic heterocyclic radical [optionally substituted with one more halogen atoms, (C1-C6) alkyl, (C1-C6) alkoxy, trifloromethyl, cyano, nitro or phenyl] and R3 is any above described variation; then R4 can not be H, (C1-C6) alkyl, benzyl, chloro, or bromo.
In any variation of formula I, when A is a direct bond; and B is N(R5); and either R1 or R2 is phenyl, thienyl, 2-pyridinyl, 3-pyridinyl, 4-pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl or any above group substituted with 1, 2, 3 or 4 substituents which can be the same or different, selected from C1_3 alkyl, C1_3 alkoxy, hydroxy, halogen, trifluoromethyl, trifluoromethylthio, trifluoromethoxy, nitro, amino, mono- or dialkyl (C1_2)-amino, mono- or dialkyl (C1_2)-amido, (C1_3)-alkoxycarbonyl, carboxyl, cyano, carbomyl, acetyl and naphthyl; and R3 is any above described variation; then R4 can not be H, halogen, CN, carbomyl, formyl, acetyl, trifluoroacetyl, fluoroacetyl, propionyl, sulfamoyl, methanesulfonyl, methylsulfanyl, branched or unbranched C1-4 alkyl group, which C1_4 alkyl group may be substituted with 1 to 3 fluoro atoms or with a single bromo, chloro, iodo, cyano or hydroxy group.
Another embodiment of the invention comprises cannabimimetic thiazole and oxazole ligands represented by formula II and their enantiomers, diastereomers, geometric isomers, racemates, tautomers, rotamers, atropisomers, metabolites, in vivo hydrolysable esters, N-oxides, salts, solvates, hydrates, polymorphic forms( crystalline or amorphous) or pro-drugs:
WNvy N
A
yR3 wherein A, B, R1, R2 and R3 are as defined above for compounds of formula W comprises S or 0.
In any variation of formula II, when A is a direct bond; B is NR5 as defined above; R1 and R3 are any above described variation; and W is S; then R2 cannot be a phenyl group with one or more substituents selected from branched or unbranched C1_3-alkyl, branched or unbranched C1_3-alkoxy, hydroxy, halogen, CF3, trifluoromethylthio, trifluoromethoxy, nitro, amino, mono-or dialkyl(C1_2)-amino, mono-or dialkyl(C1_2)-amido, branched or unbranched (C1_3)-alkoxycarbonyl, trifluoromethylsulfonyl, sulfamoyl, branched or unbranched (C1_3)-sulfonyl, carboxyl, cyano, carbamoyl, branched or unbranched dialkyl(C1_3)-aminosulfonyl, branched or unbranched monoalkyl(C1_3)-aminosulfonyl and acetyl.
Another embodiment of the invention comprises cannabimimetic triazole ligands represented by formula III and their enantiomers, diastereomers, geometric isomers, racemates, tautomers, rotamers, atropisomers, metabolites, in vivo hydrolysable esters, N-oxides, salts, solvates, hydrates, polymorphic forms( crystalline or amorphous) or pro-drugs:
R1 \ R2 N N
III
wherein A, B, R1, R2 and R3 are as defined above for compounds of formula In any variation of formula III, when A is a direct bond; B is NR5; R3 is any above described variation; then either or both of R1 and R2 cannot be a phenyl, naphthyl, thienyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, or triazinyl group, or any above group substituted with 1-4 substituents, which can be same or different, selected from branched or unbranched (C1_3)alkyl or alkoxy, hydroxy, halogen, trifluoromethyl, trifluoromethylthio, trifluoromethoxy, nitro, amino, mono- or dialkyl (C1-2)-amino, mono- or dialkyl (C1_2)-amido, (Ci_3)-alkoxycarbonyl, trifluoromethylsulfonyl, sulfomyl, (Ci_3)-alkylsulfonyl, carboxyl, cyano, carbomyl, (C1_3)-dialkylaminosulfonyl, (C1_3)-monoalkylamino-sulfonyl and acetyl.
Another embodiment of the invention comprises cannabimimetic pyrazole ligands represented by formula IV and their enantiomers, diastereomers, geometric isomers, racemates, tautomers, rotamers, atropisomers, metabolites, in vivo hydrolysable esters, N-oxides, salts, solvates, hydrates, polymorphic forms( crystalline or amorphous) or pro-drugs:
R4\ zA13 Ri , Iv wherein A, 13, R2 and R3 are as defined above for compounds of formula I.
In a variation of formula IV, R1 comprises -T-(CH2)n-Q-(CH2)n-Z.
each n independently comprises an integer from 0 to about 7.
T comprises a carbocyclic ring having 3 to about 8 ring members, an unsaturated ring having 3 to about 8 carbon atoms as ring members, an aromatic ring having 5 to about 8 carbon atoms as ring members, a heterocyclic ring having 3 to about 8 ring members, a heteroaromatic ring having 5 to about 8 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring.
Q comprises CH=CH, Z comprises H, halogen, CF3, CF2H, N3, NCS, CN, NO2, NX1X2, OX3, SX3, OAc, 0S02X3, 0-acyl, S-acyl, S02-alkyl, SO-alkyl, SC(CH3)2C00X8, OC(CH3)2C00X8 , C(CH3)2C00X8, Si(alkyl)3, 0-aroyl, 0(CH2)10X3, 0(CH2)1NX1X2, alkyl-CN, NH-acyl, NH-aroyl, CHO, C(halogen)3, COOX3, SO3H, SO2NX1X2, CONX1X2, NHC(0)0-alkyl, NHS02-alkyl alkoxy, alkyl, alcohol, alkylmercapto, alkylamino, di-alkylamino, alkylsuffinyl or alkylsulfonyl, CX4X5X8, -CH=CHX8 , -Cm-CX8 X1 and X2 each independently comprise H or alkyl, or X1 and X2 together comprise part of a heterocyclic ring having about 4 to about 7 ring members and optionally one additional heteroatom selected from 0, N or S, or X1 and X2 together comprise part of an imide ring having about 5 to about 6 members, X3 comprises H, alkyl, NO2, NO, (CH2)mCN, hydroxyloweralkyl, or alkyl-NX1X2, X4, X5, and X6 each independently comprise H, alkyl, carbocyclic ring, hydroxyloweralkyl, alkyl-OH, halogen, ON, SNO, S(S02)alkyl, NX1X2, COOX3, CONX3, OX7, or 0-alkyl-X7, wherein X7 comprises H, alkyl, NO2, NO, P(0)(0)(8)2, PH(0)(OX8), S(0)kN(alky1)2, S(0)kX8, S(0)k0X8, COOX8, CONX8, SO3H, COX8, wherein X8 comprises H, alkyl, carbocyclic ring, heterocyclic ring, aromatic ring, heteroaromatic ring, or -CX9=CHX10, wherein X9 and X10 each independently comprise H or alkyl;
m is an integer from 0 to 7;
j is an integer from 0 to about 6; and k is an integer from 0 to about 2.
In a variation of formula IV R1 comprises -T-(CH2)n-Q-(CH2)n-Z.
each n independently comprises an integer from 0 to about 7.
T comprises a carbocyclic ring having 3 to about 8 ring members, an unsaturated ring having 3 to about 8 carbon atoms as ring members, an aromatic ring having 5 to about 8 carbon atoms as ring members, a heterocyclic ring having 3 to about 8 ring members, a heteroaromatic ring having 5 to about 8 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring.
Q comprises CH=CH, Z comprises a carbocyclic ring having about 4 to about 7 ring members, a heterocyclic ring having about 4 to about 7 ring members, an aromatic ring having about 5 to about 7 ring members, a heteroaromatic ring having about 5 to about ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring, a heteropolycyclic ring; or any above group substituted on at least one available ring atom by an alkyl group; or any above group substituted on at least one available ring nitrogen atom by a benzyl group, a substituted benzyl group, an alkoxybenzyl group, a substituted alkoxybenzyl group, a benzhydryl group or a substituted benzhydryl group; and wherein the connecting point between the -(CH2)n-group and the Z group can be any available ring carbon atom or any available ring nitrogen atom.
In a variation of formula IV, R1 comprises -T-(CH2)n-Q-(CH2)n-Z.
each n independently comprises an integer from 0 to about 7.
T comprises a carbocyclic ring having 3 to about 8 ring members, an unsaturated ring having 3 to about 8 carbon atoms as ring members, an aromatic ring having 5 to about 8 carbon atoms as ring members, a heterocyclic ring having 3 to about 8 ring members, a heteroaromatic ring having 5 to about 8 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring.
Q comprises CH=CH, Z comprises 1-, 2- or 3-pyrrolidinyl, 1-, 2-, 3- or 4-piperidinyl, 2-, 3- or 4-morpholinyl, 2-, 3- or 4-thiomorpholinyl, 1-, 2- or 3-azetidinyl, 1- or 2-piperazinyl, 2- or 3-tetrahydrofuranyl; or any above group substituted on at least one available ring atom by an alkyl group; or any above group substituted on at least one available ring nitrogen atom by a benzyl group, a substituted benzyl group, an alkoxybenzyl group, a substituted alkoxybenzyl group, a benzhydryl group or a substituted benzhydryl group; and wherein the connecting point between the -(CH2)n- group and the Z
group can be any available ring carbon atom or any available ring nitrogen atom.
In a variation of formula IV, R1 comprises -T-(CH2)n-Q-(CH2)n-Z.
each n independently comprises an integer from 0 to about 7.
T comprises a carbocyclic ring having 3 to about 8 ring members, an unsaturated ring having 3 to about 8 carbon atoms as ring members, an aromatic ring having 5 to about 8 carbon atoms as ring members, a heterocyclic ring having 3 to about 8 ring members, a heteroaromatic ring having 5 to about 8 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring.
Q comprises CH=CH, Z comprises )-(`( _____________________________ ja X
N N L\Lx N x x Y, W y N-j N'N
N _1( N Yor Y
\1=1 \N
N N NNW
X\\i- I / x)LN \-11`), X
wherein X and Y each independently comprise, H, halogen, CF3, CF2H, N3, NCS, CN, NO2, NX1X2, OX3, SX3, OAc, 0S02X3, 0-acyl, S-acyl, S02-alkyl, SO-alkyl, SC(CH3)2000X8, OC(CH3)2C00X8 , C(CH3)2C00X8, Si(alkyl)3, alkyl-CN, 0-aroyl, 0(CH2)i0X3, 0(CH2)iNX1X2, NH-acyl, NH-aroyl, CHO, C(halogen)3, COOX3, SO3H, SO2NX1X2, CONX1X2, NHC(0)0-alkyl, NHS02-alkyl alkoxy, alkyl, alcohol, alkylmercapto, alkylamino, di-alkylamino, alkylsulfinyl or alkylsulfonyl, CX4X8X8, -CH=CHX8 , -CCX8 ;
X1 and X2 each independently comprise H or alkyl, or X1 and X2 together comprise part of a heterocyclic ring having about 4 to about 7 ring members and optionally one additional heteroatom selected from 0, N or S, or X1 and X2 together comprise part of an imide ring having about 5 to about 6 members, X3 comprises H, alkyl, NO2, (CH2)mCN, hydroxyloweralkyl, or alkyl-NX1X2, X4, X5, and X6 each independently comprise H, alkyl, carbocyclic ring, hydroxyloweralkyl, alkyl-OH, halogen, CN, SNO, S(S02)alkyl, NX1X2, COOX3, CONX3, OX7, or 0-alkyl-X7, wherein X7 comprises H, alkyl, NO2, NO, P(0)(0X8)2, PH(0)(0X8), S(0)kN(alky1)2, S(0)kX8, S(0)k0X8, COOX8, CONX8, SO3H, COX8, wherein X8 comprises H, alkyl, carbocyclic ring, heterocyclic ring, aromatic ring, heteroaromatic ring, or -CX9=CHX10, wherein X9 and X10 each independently comprise H or alkyl;
m is an integer from 0 to 7;
j is an integer from 0 to about 6;
k is an integer from 0 to about 2; and W comprises H or alkyl.
In a variation of formula IV, R1 comprises -T-(CH2)n-Q-(CH2)n-Z.
each n independently comprises an integer from 0 to about 7.
T comprises a carbocyclic ring having 3 to about 8 ring members, an unsaturated ring having 3 to about 8 carbon atoms as ring members, an aromatic ring having 5 to about 8 carbon atoms as ring members, a heterocyclic ring having 3 to about 8 ring members, a heteroaromatic ring having 5 to about 8 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring.
Q comprises CH=CH, Z comprises an unsaturated ring having 5 ring atoms and 0 to 2 independently selected heteroatoms as ring members fused to an unsaturated ring having 5 ring atoms and 0 to 4 independently selected heteroatoms as ring members, an unsaturated ring having 5 ring atoms and 0 to 2 independently ,selected heteroatoms as ring members fused to an unsaturated ring having 6 or 7 ring atoms and 0 to independently selected heteroatoms as ring members or an unsaturated ring having
6 ring atoms and 0 to 3 independently selected heteroatoms as ring members fused to an unsaturated ring having 6 or 7 ring atoms and 0 to 4 independently selected heteroatoms as ring members In a variation of formula IV, R1 comprises -T-(CH2)n- Q-(CH2)n-Z.
T comprises a carbocyclic ring having 3 to about 8 ring members, an unsaturated ring having 3 to about 8 carbon atoms as ring members, an aromatic ring having 5 to about 8 carbon atoms as ring members, a heterocyclic ring having 3 to about 8 ring members, a heteroaromatic ring having 5 to about 8 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring.
each n independently comprises an integer from 0 to about 7.
Q comprises CH=CH, Z comprises )¨E or E comprises a Cl to about 04, linear or branched alkyl group, a phenyl group, a substituted phenyl group, a benzyl group or a substituted benzyl group.
In a variation of formula IV, R1 comprises -TACH2)n- Q-(CH2),-Z.
T comprises a carbocyclic ring having 3 to about 8 ring members, an unsaturated ring having 3 to about 8 carbon atoms as ring members, an aromatic ring having 5 to about 8 carbon atoms as ring members, a heterocyclic ring having 3 to about 8 ring members, a heteroaromatic ring having 5 to about 8 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring.
each n independently comprises an integer from 0 to about 7.
Q comprises CH=CH, CC.
Z comprises ______________________________________ 0 H ,A1 0 -NO ¨N1 ____________________ CH2)k <(ICH2 )k ¨Nx or N(CH2)k <(I 2 k is an integer from 1 to about 5. A1 and A2 each independently comprise a Cl to about C4 alkyl group, a phenyl group or a substituted phenyl group.
The inventive compounds in any formula, embodiment or variation include any and all possible isomers and steroisomers. In general, the compositions of the invention may be alternately formulated to comprise, consist of, or consist essentially of, any appropriate components herein disclosed. The compositions of the invention may additionally, or alternatively, be formulated so as to be devoid, or substantially free, of any components, materials, ingredients, adjuvants or species used in the prior art compositions or that are otherwise not necessary to the achievement of the function and/or objectives of the present invention.
Unless otherwise specifically defined, "acyl" refers to the general formula -C(0)alkyl.
Unless otherwise specifically defined, "acyloxy" refers to the general formula -0-acyl.
Unless otherwise specifically defined, "alcohol" refers to the general formula alkyl-OH and includes primary, secondary and tertiary variations.
Unless otherwise specifically defined, "alkyl" or "lower alkyl" refers to a linear, branched or cyclic alkyl group having from 1 to about 10 carbon atoms, and advantageously 1 to about 7 carbon atoms including, for example, methyl, ethyl, propyl, butyl, hexyl, octyl, isopropyl, isobutyl, tert-butyl, cyclopropyl, cyclohexyl, cyclooctyl, vinyl and allyl. The alkyl group can be saturated or unsaturated.
The alkyl group can be unsubstituted, singly substituted or, if possible, multiply substituted, with substituent groups in any possible position. Unless otherwise specifically limited, a cyclic alkyl group includes monocyclic, bicyclic, tricyclic, tetracyclic and polycyclic rings, for example norbornyl, adamantyl and related terpenes.
Unless otherwise specifically defined, "alkoxy" refers to the general formula -0-alkyl.
Unless otherwise specifically defined, "alkylmercapto" refers to the general formula -S-alkyl.
Unless otherwise specifically defined, "alkylamino" refers to the general formula -(NH)-alkyl.
Unless otherwise specifically defined, "di-alkylamino" refers to the general formula -N-(alkyl)2. Unless otherwise specifically limited di-alkylamino includes cyclic amine compounds such as piperidine and morpholine.
Unless otherwise specifically defined, an aromatic ring is an unsaturated ring structure having about 5 to about 7 ring members and including only carbon as ring atoms. The aromatic ring structure can be unsubstituted, singly substituted or, if possible, multiply substituted, with substituent groups in any possible position.
Unless otherwise specifically defined, "aryl" refers to an aromatic ring system that includes only carbon as ring atoms, for example phenyl, biphenyl or naphthyl.
The aryl group can be unsubstituted, singly substituted or, if possible, multiply substituted, with substituent groups in any possible position.
Unless otherwise specifically defined, "aroyl" refers to the general formula -C(=0)-aryl.
Unless otherwise specifically defined, a bicyclic ring structure comprises 2 fused or bridged rings that include only carbon as ring atoms. The bicyclic ring structure can be saturated or unsaturated. The bicyclic ring structure can be unsubstituted, singly substituted or, if possible, multiply substituted, with substituent groups in any possible position. The individual rings may or may not be of the same type. Examples of bicyclic ring structures include naphthalene and bicyclooctane.
Unless otherwise specifically defined, a carbocyclic ring is a non-aromatic ring structure, saturated or unsaturated, having about 3 to about 8 ring members that includes only carbon as ring atoms, for example, cyclohexadiene or cyclohexane.
The carbocyclic ring can be unsubstituted, singly substituted or, if possible, multiply substituted, with substituent groups in any possible position.
Unless otherwise specifically defined, "halogen" refers to an atom selected from fluorine, chlorine, bromine and iodine.
Unless otherwise specifically defined, a heteroaromatic ring is an unsaturated ring structure having about 5 to about 8 ring members independently selected from carbon atoms and one or more heteroatoms, including oxygen, nitrogen and/or sulfur, for example, pyridine, furan, quinoline, and their derivatives. The heteroaromatic ring can be unsubstituted, singly substituted or, if possible, multiply substituted, with substituent groups in any possible position.
Unless otherwise specifically defined, a heterobicyclic ring structure comprises 2 fused or bridged rings having ring members independently selected from carbon and one or more heteroatoms, including oxygen, nitrogen and/or sulfur. The heterobicyclic ring structure can be saturated or unsaturated. The heterobicyclic ring can be unsubstituted, singly substituted or, if possible, multiply substituted, with substituent groups in any possible position. The individual rings may or may not be of the same type. Examples of heterobicyclic ring structures include isobenzofuran and indole.
Unless otherwise specifically defined, a heterocyclic ring is a saturated or unsaturated ring structure having about 3 to about 8 ring members independently selected from carbon atoms and one or more heteroatoms, including oxygen, nitrogen and/or sulfur; for example, piperidine, morpholine, piperazine, pyrrolidine, thiomorpholine, 1,1-dioxothiomorpholine and their derivatives. The heterocyclic ring can be unsubstituted, singly substituted or, if possible, multiply substituted, with substituent groups in any possible position.
Unless otherwise specifically defined, a heterotricyclic ring structure comprises 3 fused, bridged, or both fused and bridged rings having ring members independently selected from carbon and one or more heteroatoms, including oxygen, nitrogen and/or sulfur. The heterotricyclic ring structure may be saturated or unsaturated.
The heterotricyclic ring structure can be unsubstituted, singly substituted or, if possible, multiply substituted, with substituent groups in any possible position. The individual rings may or may not be of the same type. Examples of heterotricyclic ring structures include carbazole, phenanthroline, phenazine, 2,4,10-trioxaadamantane and tetradecahydro-phenanthroline.
Unless otherwise specifically defined, a heteropolycyclic ring structure comprises more than 3 rings that may be fused, bridged or both fused and bridged and that have ring members independently selected from carbon and one or more heteroatoms, including oxygen, nitrogen and/or sulfur. The heteropolycyclic ring structure can be saturated or unsaturated. The heteropolycyclic ring structure can be unsubstituted, singly substituted or, if possible, multiply substituted, with substituent groups in any possible position. The individual rings may or may not be of the same type. Examples of heteropolycyclic ring structures include azaadamantine, tropane, homotropane and 5-norbornene-2,3-dicarboximide.
Unless otherwise specifically defined, the term "phenacyl" refers to the general formula ¨phenyl¨acyl.
Unless otherwise specifically defined, a polycyclic ring structure comprises more than 3 rings that may be fused, bridged or both fused and bridged, and that includes carbon as ring atoms. The polycyclic ring structure can be saturated or unsaturated. The polycyclic ring structure can be unsubstituted, singly substituted or, if possible, multiply substituted, with substituent groups in any possible position. The individual rings may or may not be of the same type. Examples of polycyclic ring structures include adamantine, bicyclooctane, norbornane and bicyclononanes.
Unless otherwise specifically defined, a spirocycle refers to a ring system wherein a single atom is the only common member of two rings. A spirocycle can comprise a saturated carbocyclic ring comprising about 3 to about 8 ring members, a heterocyclic ring comprising about 3 to about 8 ring atoms wherein up to about 3 ring atoms may be N, S, or 0 or a combination thereof.
Unless otherwise specifically defined, a tricyclic ring structure comprises 3 rings that may be fused, bridged or both fused and bridged, and that includes carbon as ring atoms. The tricyclic ring structure can be saturated or unsaturated.
The tricyclic ring structure can be unsubstituted, singly substituted or, if possible, multiply substituted, with substituent groups in any possible position. and may be substituted or unsubstituted. The individual rings may or may not be of the same type.
Examples of tricyclic ring structures include fluorene and anthracene.
Unless otherwise specifically limited the term substituted means substituted by a below-described substituent group in any possible position. Substituent groups for the above moieties useful in the invention are those groups that do not significantly diminish the biological activity of the inventive compound. Substituent groups that do not significantly diminish the biological activity of the inventive compound include, for example, H, halogen, N3, NCS, CN, NO2, NX1X2, OX3, C(X3)3, OAc, 0-acyl, 0-aroyl, NH-acyl, NH-aroyl, NHCOalkyl, CHO, C(halogen)3, COOX3, SO3H, P03H2, SO2NX1X2, CONX1X2, alkyl, alcohol, alkoxy, alkylmercapto, alkylamino, di-alkylamino, sulfonamide, thioalkoxy or methylene dioxy when the substituted structure has two adjacent carbon atoms, wherein X1 and X2 each independently comprise H or alkyl, or X1 and X2 together comprise part of a heterocyclic ring having about 4 to about 7 ring members and optionally one additional heteroatom selected from 0, N or S, or X1 and X2 together comprise part of an imide ring having about 5 to about 6 members and X3 comprises H, alkyl, hydroxyloweralkyl, or alkyl-NX1X2.
Unless otherwise specifically limited a substituent group may be in any possible position.
Some of the inventive compounds show a high affinity for at least one of the cannabinoid receptors. Thus, another aspect of the invention is use of at least one of the inventive compounds to interact with a cannabinoid receptor.
Some of the novel heteropyrrole derivatives show selectivity for the CB1 cannabinoid receptor. These inventive CB1 selective analogs are able to interact with the CB1 cannabinoid receptors present in the CNS as well as the periphery without affecting the CB2 receptors to the same degree. Therefore, still another aspect of the invention is use of at least one of the inventive compounds to preferentially interact with a CBI cannabinoid receptors present either in the CNS or the periphery.
The inventive heteropyrrole analogs described herein, and physiologically acceptable salts thereof, have pharmacological properties when administered in therapeutically effective amounts for providing a physiological response.
Thus, another aspect of the invention is the administration of a therapeutically effective amount of at least one of the inventive compounds, or a physiologically acceptable salt thereof, to an individual or animal to provide a physiological response.
A better understanding of the invention will be obtained from the following detailed description of the article and the desired features, properties, characteristics, and the relation of the elements as well as the process steps, one with respect to each of the others, as set forth and exemplified in the description and illustrative embodiments.
Detailed Description As used herein a "therapeutically effective amount" of a compound, is the quantity of a compound which, when administered to an individual or animal, results in a sufficiently high level of that compound in the individual or animal to cause a physiological response, for example a discernible increase or decrease in stimulation of cannabinoid receptors. The inventive compounds described herein, and physiologically acceptable salts thereof, have pharmacological properties when administered in therapeutically effective amounts individually or in combination for providing a physiological response useful to treat marijuana abuse, obesity, lifestyle choices such as a desire to lose weight, other metabolic disorders including improvement in lipid profiles and insulin related deficiencies, hepatic disease, cardiometabolic diseases, congestive obstructive pulmonary disorders, inflammatory bowel disease, smoking cessation, bone defects, arthritis, inflammation, benign prostatic hypertrophy, asthma, migraine, chronic-intestinal pseudo obstruction, constipation, schizophrenia, epilepsy, stress, memory disorders, migraine, vomiting, thymic disorders, dyskinesia, kinetic disorder, anxiety disorders, psychotic disorders, cognitive disorders, appetite disorders, mood disorders, delirious disorders, neuropathies, Parkinson's disease, Alzheimers disease, depression, psychosomatic-induced disease, diabetes, sexual dysfunctions, as well as for alcohol, opioid, nicotine and cocaine addiction, etc. Additionally, these analogs can be useful in cancer chemotherapy. Typically, a "therapeutically effective amount" of an inventive compound is believed to range from about 0.01 mg/day to about 1,000 mg/day.
As used herein, an "individual" refers to a human. An "animal" refers to, for example nonhuman-primates such as monkeys and baboons, veterinary animals, such as rodents, dogs, cats, horses and the like, and farm animals, such as cows, pigs and the like In a certain embodiments, the compound disclosed in the invention can be used in combination with other acceptable pharmaceutical substances.
In embodiments in which compounds of the disclosure is used in combination with Rimonabant (Accomplia, Sanofi-Aventis) or other CBI antagonists, it will be possible to reduce or even eliminate one or more of these side-effects, particularly nausea. That is, it is possible to reduce the amount of Rimonabant or other antagonists administered to the individual who has had, is receiving or is about to receive a therapeutically effective amount of the compound of the disclosure.
In one embodiment, the amount of Rimonabant administered to the individual is reduced by 1.5 to 5-fold compared to the accepted therapeutic amount. The individual is then dosed with a therapeutically effective amount of at least one of the compounds of the disclosure. Of course, it is also possible to increase the length of time between doses of Rimonabant with the same or similar effect.
Accordingly, one embodiment provides for a method for reducing unwanted side-effects (one or more of nausea, dizziness, diarrhea, and anxiety) typically associated with administration of SR141716A (AccompliaTm/Rimonabant) or other CBI antagonists to certain individuals. A particular method involves administering a therapeutically effective amount of at least one of the compounds of the disclosure so as to reduce the side-effects in that individual. As discussed, the method can involve reducing the amount of SR141716A (AccompliaTm/Rimonabant) or other CB1 antagonists administered to the individual.
As will be apparent, the compounds of the invention can be used alone or in combination with other CBI receptor antagonists or anti-obesity agents known to the field. Examples of such agents include SR141716A or AccompliaTm/rimonabant(Sanofi-Aventis), Xenical (Roche), Meridia (Abbott, Sibutramine), surinabant (Sanofi-Aventis), AVE1625(Sanofi-Aventis), CP-946,598 or otenabant (Pfizer), rosonabant(Esteve), taranabant (Merck), SLV-319 (Solvay Pharmaceuticals/BMS), V24343 (Vernalis), Qnexa(Vivus), Contrave(Orexigen), Empatic(Orexigen), lorcaserin(Arena), Phentermine.
Compounds of the invention can also be used in combination with a a potassium channel opener, opiod antagonist, anticonvulsant agent, contraceptive agent, antipsychotic agent, anticonstipation agent, nicotine receptor agonist or partial agonist, CB2 agonist, melanin-concentrating hormone receptor antagonist, anti-psychotic agents, peroxisome proliferator-activated receptors agonists, ghrelin antagonists, GLP-1 agonist, fatty acid amide hydrolase inhibitor, an intestinal-acting microsomal triglyceride transfer protein inhibitor, a dipeptidyl-peptidase IV
inhibitor, a statin, a sterol absorption inhibitor (f3-lactam), Beta-3 adrenergic agonist, a biguanide, Sodium glucose transport (SGLT2) antagonist, cyclooxygenase-2 inhibitor, renin inhibitor, monoamine oxidase inhibitor, CETP inhibitor, ACAT
inhibitor, DGAT-1 inhibitor, Mitochondrial Transfer Protein inhibitor, noradrenalin-serotonin-dopamine reuptake inhibitor or a lipase inhibitor.
In one embodiment, less than five compounds of the disclosure, preferably one or two of same is used in combination with less than five of the known CB1 antagonists, preferably one or two of same.
In one embodiment, the compound disclosed in the invention could in itself act as a drug with a combination effect. For example compounds disclosed in the invention could dually act as a CBI antagonist as well as 118-hydroxy steroid dehydrogenase-1 inhibitor. In certain embodiments, the compound could act dually as a CBI antagonist as well as a nitric oxide donor.
By "physiologically acceptable salts" is meant, salts typically useful for pharmaceutical applications including acid addition salts and basic salts.
Examples of acid addition salts are hydrochloride salts, hydrobromide salts, methane sulfonate salts etc. Examples of basic salts are salts where the cation is selected from alkali metals, such as sodium and potassium, alkaline earth metals, such as calcium, and ammonium ions. Other examples of physiologically acceptable salts can be found in "Remington's Pharmaceutical Sciences" 17. Ed. Alfonso R. Gennaro (Ed.), Mark Publishing Company, Easton, Pa., U.S.A., 1985 and more recent editions, and in Encyclopedia of Pharmaceutical Technology.
Polymorphic forms show improved physiochemical properties and stability for formulation purposes. In one embodiment, the compounds disclosed in the invention could exist in various solid forms. The solid forms can be crystalline and amorphous forms, but not limited to, solvates, hydrates, hydrolyzable esters and N-oxides of the compounds defined in the specification. These solid forms can be obtained by treating either the free base or their salts at a certain adjusted pH and certain temperature with an solvent or a combination of solvents. The solvents can be and not limited to a hydrocarbon solvent such as toluene, xylene, hexanes, heptane, or petroleum ether, alcohol such as methanol, ethanol, n-butanol, n-propanol and propanol, di-isopropyl ether, ethyl-acetate, dichloromethane, acetic acid, acetone, tetrahydrofuran, dichloromethane, and water.
In one embodiment, in order to improve the dehepaticability of the compound disclosed in the present invention for the required physiological effect, a "pro-drug" of the same can be made available. For example, the pro-drug such as an in-vivo hydrolyzable ester can be a obtained by conjugation of the parent drug with a low-molecular weight alcohol or a high molecular weight polyethylene glycol(PEG).
In certain embodiments, the compound disclosed in the invention could contain a nitrate ester group.
In one embodiment, the compounds in the present invention could exist as enantiomers, diastereomers, geometric isomers, racemates, tautomers, rotamers, atropisomers or metabolites.
In one embodiment, some compounds disclosed in the invention can be "neutral antagonists". These agents are said to have no effect on intrinsic receptor activity at least in certain test systems. However, these agents may be able to block receptor binding and activation, usually by a competitive agonist.
In some embodiments, it would be desirable to have antagonists that exhibit essentially no CBI receptor activity and which block or significantly reduce receptor activation by a suitable agonist. It would be further desirable to have neutral antagonists of the CBI receptor that can be used to prevent, treat, or reduce the severity of symptoms of certain medical conditions. It would be especially desirable to have neutral antagonists that exhibit no or minimal side-effects in vivo.
In another embodiment, the compound disclosed in the present invention may act preferentially at the CB1 receptors located in the periphery. In certain embodiments, the compounds do not penetrate the blood-brain-barrier, have restricted penetration or have slow penetration. In certain embodiments, peripherally acting compounds may have advantages over centrally acting compounds, for example, reduced psychotropic adverse effects.
A compound acting on the CB1 receptors located in the periphery could be behave either as a neutral antagonist, an inverse agonists or a partial antagonist.
A compound acting on the CB1 receptors located centrally, could behave as a neutral antagonist, an inverse agonists or a partial antagonist.
In another embodiment, the compounds disclosed in the invention could act either as inverse agonists with no or reduced side effects. In other embodiments, the compounds could act as partial agonists with no or reduced side effects.
The compounds of the present invention can be administered by a variety of known methods, including orally, rectally, or by parenteral routes (e.g., intramuscular, intravenous, subcutaneous, nasal or topical). The form in which the compounds are administered will be determined by the route of administration. Such forms include, but are not limited to, capsular and tablet formulations (for oral and rectal administration), liquid formulations (for oral, intravenous, intramuscular, subcutaneous, ocular, intranasal, inhalation-based and transdermal administration) and slow releasing microcarriers (for rectal, intramuscular or intravenous administration). The formulations can also contain a physiologically acceptable vehicle and optional adjuvants, flavorings, colorants and preservatives.
Suitable physiologically acceptable vehicles include, for example, saline, sterile water, Ringer's solution and isotonic sodium chloride solutions. The specific dosage level of active ingredient will depend upon a number of factors, including, for example, biological activity of the particular preparation, age, body weight, sex and general health of the individual being treated.
In another embodiment, the compounds of the present disclosure can also comprise isotopes at one or more of their atoms. For example, the compounds can be radiolabeled with isotopes, such as 2H (deuterium written as D) 3H (tritium written as T), 11C (carbon-11), 13C (carbon-13), 14C (carbon-14), 150 (oxygen-15), 170 (oxygen-17), 18Q (oxygen-18), 13N (nitrogen-13), 15N (nitrogen-15), 18F
(fluorine-18), 7813r (bromine-75), 76Br (bromine-76), 77Br (bromine-77), 8 _ 2Br (bromine-82), 1231 (iodine-123), 124 (iodine-124), 1281 (iodine-125) or 1311 (iodine-131), 38CI
(chlorine-36) or 35S (sulphur-35), The present disclosure encompasses all isotopic variations of the described compounds, whether natural or unnatural, radioactive or not.
An isotope is one of two or more species of the same element. Each isotope of an element will have the same number of protons in its nucleus, the same atomic number and the same position in the Periodic Table. However each isotope of that element will have a different number of neutrons in its nucleus and therefore a different mass than other isotopes of that species. The term nuclide is sometimes used synonymously with the term isotope. As used herein a natural isotope has an atomic mass corresponding most closely with the atomic mass shown for that element in the Periodic Table. As used herein an unnatural isotope has an atomic mass that is further removed from the atomic mass shown for that element in the Periodic Table than the natural isotope. For example, protium (hydrogen-1 or 1H) is the natural isotope of hydrogen and deuterium (hydrogen-2 or 2H) and tritium (hydrogen-3 or 3H) are all unnatural isotopes of hydrogen.
In a particular embodiment, some of the halogen containing analogs, for example those analogs comprising iodide and fluoride, are potential radioactive probes for imaging in vivo the distribution of cannabinoid receptors. For radio-imaging applications 11C, 18F, 1251, 1231, 1241, 1311 , 75Br, - 75 -Br, or 77Br will generally be most useful.
Some of the radioactive isotope containing analogs have potential as radiopharmaceutical analogs (disclosed analogs that have been labeled with radioactive isotopes). These radiopharmaceuticals can be administered to individuals or animals and the emitted radiation can be measured. The majority of these diagnostic tests involve the formation of an image using a camera suitable to detect the emitted radiation. Positron emission tomography (PET) is one nuclear medicine tomographic imaging technique, which produces a three-dimensional image or map of functional processes in a patient's body. To conduct the PET scan, a short-lived radiopharmaceutical analog that decays by emitting a positron is administered into the subject (usually by injection into the blood stream).
There is a waiting period while the radiopharmaceutical analog becomes concentrated in tissues of interest such as a cannabinoid receptor. After the waiting period the patient is placed in an imaging scanner. The scanner collects multiple images and a computer is used to apply an algorithm to the multiple images and provide a three dimensional image. Single photon emission computed tomography (SPECT) is another nuclear medicine tomographic imaging technique. To conduct the SPECT scan, a short-lived radiopharmaceutical analog that decays to produce a gamma ray is administered into the subject. There is a waiting period while the radiopharmaceutical analog becomes concentrated in tissues of interest such as a cannabinoid receptor. After the waiting period the patient is placed in an imaging scanner and SPECT imaging is performed by using a gamma camera to acquire multiple two dimensional images from multiple angles. A computer is then used to apply an algorithm to the multiple images to provide a three dimensional image.
Table 1 N
r/9 r9 HO ,N-- HO N--/
N. 0 1 N\N ti / N\N. ti i \ H
, HO
0/ arrir CI 01 Ain CI ---- 116 i\
,N \
I
lei CI
0 0 ........., 0 N
, H i N N- (,...11.0 N_ -;
, ,N , N N / N N / N
0 il CI le gib CI
IMPli el is CI
-----=
I I
AcS CI I a 7 CI 8 CI
O o N.0 / \ H / \ H / o so NN ,N
N 110 abiN CI
---;,----;,-- SO ilk CI
IIIV ----;,-IMP
SCN CI
MsS 9 CI 02N0 0 00 =
0 .
N _--)=c .\......0=N--) o N N
----../ / \ H / \ H
N,N
,N
so N / N
0 are% le CI 40 CI
so c, ,...õ
w ....õ
,-;,...
I
NC CI
ri=o rS=0 0 (TO 0 N---/i N--..../
N
N
/ \ H i \ i \
ti ' ,N
,N ,N ,N 01101 101 N ci 0 N ci NH ..õ,õ..
el el 1101 I.
CI
NC CI CI CI
=
, (---9 o 0 N
N
N
=
T comprises a carbocyclic ring having 3 to about 8 ring members, an unsaturated ring having 3 to about 8 carbon atoms as ring members, an aromatic ring having 5 to about 8 carbon atoms as ring members, a heterocyclic ring having 3 to about 8 ring members, a heteroaromatic ring having 5 to about 8 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring.
each n independently comprises an integer from 0 to about 7.
Q comprises CH=CH, Z comprises )¨E or E comprises a Cl to about 04, linear or branched alkyl group, a phenyl group, a substituted phenyl group, a benzyl group or a substituted benzyl group.
In a variation of formula IV, R1 comprises -TACH2)n- Q-(CH2),-Z.
T comprises a carbocyclic ring having 3 to about 8 ring members, an unsaturated ring having 3 to about 8 carbon atoms as ring members, an aromatic ring having 5 to about 8 carbon atoms as ring members, a heterocyclic ring having 3 to about 8 ring members, a heteroaromatic ring having 5 to about 8 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring.
each n independently comprises an integer from 0 to about 7.
Q comprises CH=CH, CC.
Z comprises ______________________________________ 0 H ,A1 0 -NO ¨N1 ____________________ CH2)k <(ICH2 )k ¨Nx or N(CH2)k <(I 2 k is an integer from 1 to about 5. A1 and A2 each independently comprise a Cl to about C4 alkyl group, a phenyl group or a substituted phenyl group.
The inventive compounds in any formula, embodiment or variation include any and all possible isomers and steroisomers. In general, the compositions of the invention may be alternately formulated to comprise, consist of, or consist essentially of, any appropriate components herein disclosed. The compositions of the invention may additionally, or alternatively, be formulated so as to be devoid, or substantially free, of any components, materials, ingredients, adjuvants or species used in the prior art compositions or that are otherwise not necessary to the achievement of the function and/or objectives of the present invention.
Unless otherwise specifically defined, "acyl" refers to the general formula -C(0)alkyl.
Unless otherwise specifically defined, "acyloxy" refers to the general formula -0-acyl.
Unless otherwise specifically defined, "alcohol" refers to the general formula alkyl-OH and includes primary, secondary and tertiary variations.
Unless otherwise specifically defined, "alkyl" or "lower alkyl" refers to a linear, branched or cyclic alkyl group having from 1 to about 10 carbon atoms, and advantageously 1 to about 7 carbon atoms including, for example, methyl, ethyl, propyl, butyl, hexyl, octyl, isopropyl, isobutyl, tert-butyl, cyclopropyl, cyclohexyl, cyclooctyl, vinyl and allyl. The alkyl group can be saturated or unsaturated.
The alkyl group can be unsubstituted, singly substituted or, if possible, multiply substituted, with substituent groups in any possible position. Unless otherwise specifically limited, a cyclic alkyl group includes monocyclic, bicyclic, tricyclic, tetracyclic and polycyclic rings, for example norbornyl, adamantyl and related terpenes.
Unless otherwise specifically defined, "alkoxy" refers to the general formula -0-alkyl.
Unless otherwise specifically defined, "alkylmercapto" refers to the general formula -S-alkyl.
Unless otherwise specifically defined, "alkylamino" refers to the general formula -(NH)-alkyl.
Unless otherwise specifically defined, "di-alkylamino" refers to the general formula -N-(alkyl)2. Unless otherwise specifically limited di-alkylamino includes cyclic amine compounds such as piperidine and morpholine.
Unless otherwise specifically defined, an aromatic ring is an unsaturated ring structure having about 5 to about 7 ring members and including only carbon as ring atoms. The aromatic ring structure can be unsubstituted, singly substituted or, if possible, multiply substituted, with substituent groups in any possible position.
Unless otherwise specifically defined, "aryl" refers to an aromatic ring system that includes only carbon as ring atoms, for example phenyl, biphenyl or naphthyl.
The aryl group can be unsubstituted, singly substituted or, if possible, multiply substituted, with substituent groups in any possible position.
Unless otherwise specifically defined, "aroyl" refers to the general formula -C(=0)-aryl.
Unless otherwise specifically defined, a bicyclic ring structure comprises 2 fused or bridged rings that include only carbon as ring atoms. The bicyclic ring structure can be saturated or unsaturated. The bicyclic ring structure can be unsubstituted, singly substituted or, if possible, multiply substituted, with substituent groups in any possible position. The individual rings may or may not be of the same type. Examples of bicyclic ring structures include naphthalene and bicyclooctane.
Unless otherwise specifically defined, a carbocyclic ring is a non-aromatic ring structure, saturated or unsaturated, having about 3 to about 8 ring members that includes only carbon as ring atoms, for example, cyclohexadiene or cyclohexane.
The carbocyclic ring can be unsubstituted, singly substituted or, if possible, multiply substituted, with substituent groups in any possible position.
Unless otherwise specifically defined, "halogen" refers to an atom selected from fluorine, chlorine, bromine and iodine.
Unless otherwise specifically defined, a heteroaromatic ring is an unsaturated ring structure having about 5 to about 8 ring members independently selected from carbon atoms and one or more heteroatoms, including oxygen, nitrogen and/or sulfur, for example, pyridine, furan, quinoline, and their derivatives. The heteroaromatic ring can be unsubstituted, singly substituted or, if possible, multiply substituted, with substituent groups in any possible position.
Unless otherwise specifically defined, a heterobicyclic ring structure comprises 2 fused or bridged rings having ring members independently selected from carbon and one or more heteroatoms, including oxygen, nitrogen and/or sulfur. The heterobicyclic ring structure can be saturated or unsaturated. The heterobicyclic ring can be unsubstituted, singly substituted or, if possible, multiply substituted, with substituent groups in any possible position. The individual rings may or may not be of the same type. Examples of heterobicyclic ring structures include isobenzofuran and indole.
Unless otherwise specifically defined, a heterocyclic ring is a saturated or unsaturated ring structure having about 3 to about 8 ring members independently selected from carbon atoms and one or more heteroatoms, including oxygen, nitrogen and/or sulfur; for example, piperidine, morpholine, piperazine, pyrrolidine, thiomorpholine, 1,1-dioxothiomorpholine and their derivatives. The heterocyclic ring can be unsubstituted, singly substituted or, if possible, multiply substituted, with substituent groups in any possible position.
Unless otherwise specifically defined, a heterotricyclic ring structure comprises 3 fused, bridged, or both fused and bridged rings having ring members independently selected from carbon and one or more heteroatoms, including oxygen, nitrogen and/or sulfur. The heterotricyclic ring structure may be saturated or unsaturated.
The heterotricyclic ring structure can be unsubstituted, singly substituted or, if possible, multiply substituted, with substituent groups in any possible position. The individual rings may or may not be of the same type. Examples of heterotricyclic ring structures include carbazole, phenanthroline, phenazine, 2,4,10-trioxaadamantane and tetradecahydro-phenanthroline.
Unless otherwise specifically defined, a heteropolycyclic ring structure comprises more than 3 rings that may be fused, bridged or both fused and bridged and that have ring members independently selected from carbon and one or more heteroatoms, including oxygen, nitrogen and/or sulfur. The heteropolycyclic ring structure can be saturated or unsaturated. The heteropolycyclic ring structure can be unsubstituted, singly substituted or, if possible, multiply substituted, with substituent groups in any possible position. The individual rings may or may not be of the same type. Examples of heteropolycyclic ring structures include azaadamantine, tropane, homotropane and 5-norbornene-2,3-dicarboximide.
Unless otherwise specifically defined, the term "phenacyl" refers to the general formula ¨phenyl¨acyl.
Unless otherwise specifically defined, a polycyclic ring structure comprises more than 3 rings that may be fused, bridged or both fused and bridged, and that includes carbon as ring atoms. The polycyclic ring structure can be saturated or unsaturated. The polycyclic ring structure can be unsubstituted, singly substituted or, if possible, multiply substituted, with substituent groups in any possible position. The individual rings may or may not be of the same type. Examples of polycyclic ring structures include adamantine, bicyclooctane, norbornane and bicyclononanes.
Unless otherwise specifically defined, a spirocycle refers to a ring system wherein a single atom is the only common member of two rings. A spirocycle can comprise a saturated carbocyclic ring comprising about 3 to about 8 ring members, a heterocyclic ring comprising about 3 to about 8 ring atoms wherein up to about 3 ring atoms may be N, S, or 0 or a combination thereof.
Unless otherwise specifically defined, a tricyclic ring structure comprises 3 rings that may be fused, bridged or both fused and bridged, and that includes carbon as ring atoms. The tricyclic ring structure can be saturated or unsaturated.
The tricyclic ring structure can be unsubstituted, singly substituted or, if possible, multiply substituted, with substituent groups in any possible position. and may be substituted or unsubstituted. The individual rings may or may not be of the same type.
Examples of tricyclic ring structures include fluorene and anthracene.
Unless otherwise specifically limited the term substituted means substituted by a below-described substituent group in any possible position. Substituent groups for the above moieties useful in the invention are those groups that do not significantly diminish the biological activity of the inventive compound. Substituent groups that do not significantly diminish the biological activity of the inventive compound include, for example, H, halogen, N3, NCS, CN, NO2, NX1X2, OX3, C(X3)3, OAc, 0-acyl, 0-aroyl, NH-acyl, NH-aroyl, NHCOalkyl, CHO, C(halogen)3, COOX3, SO3H, P03H2, SO2NX1X2, CONX1X2, alkyl, alcohol, alkoxy, alkylmercapto, alkylamino, di-alkylamino, sulfonamide, thioalkoxy or methylene dioxy when the substituted structure has two adjacent carbon atoms, wherein X1 and X2 each independently comprise H or alkyl, or X1 and X2 together comprise part of a heterocyclic ring having about 4 to about 7 ring members and optionally one additional heteroatom selected from 0, N or S, or X1 and X2 together comprise part of an imide ring having about 5 to about 6 members and X3 comprises H, alkyl, hydroxyloweralkyl, or alkyl-NX1X2.
Unless otherwise specifically limited a substituent group may be in any possible position.
Some of the inventive compounds show a high affinity for at least one of the cannabinoid receptors. Thus, another aspect of the invention is use of at least one of the inventive compounds to interact with a cannabinoid receptor.
Some of the novel heteropyrrole derivatives show selectivity for the CB1 cannabinoid receptor. These inventive CB1 selective analogs are able to interact with the CB1 cannabinoid receptors present in the CNS as well as the periphery without affecting the CB2 receptors to the same degree. Therefore, still another aspect of the invention is use of at least one of the inventive compounds to preferentially interact with a CBI cannabinoid receptors present either in the CNS or the periphery.
The inventive heteropyrrole analogs described herein, and physiologically acceptable salts thereof, have pharmacological properties when administered in therapeutically effective amounts for providing a physiological response.
Thus, another aspect of the invention is the administration of a therapeutically effective amount of at least one of the inventive compounds, or a physiologically acceptable salt thereof, to an individual or animal to provide a physiological response.
A better understanding of the invention will be obtained from the following detailed description of the article and the desired features, properties, characteristics, and the relation of the elements as well as the process steps, one with respect to each of the others, as set forth and exemplified in the description and illustrative embodiments.
Detailed Description As used herein a "therapeutically effective amount" of a compound, is the quantity of a compound which, when administered to an individual or animal, results in a sufficiently high level of that compound in the individual or animal to cause a physiological response, for example a discernible increase or decrease in stimulation of cannabinoid receptors. The inventive compounds described herein, and physiologically acceptable salts thereof, have pharmacological properties when administered in therapeutically effective amounts individually or in combination for providing a physiological response useful to treat marijuana abuse, obesity, lifestyle choices such as a desire to lose weight, other metabolic disorders including improvement in lipid profiles and insulin related deficiencies, hepatic disease, cardiometabolic diseases, congestive obstructive pulmonary disorders, inflammatory bowel disease, smoking cessation, bone defects, arthritis, inflammation, benign prostatic hypertrophy, asthma, migraine, chronic-intestinal pseudo obstruction, constipation, schizophrenia, epilepsy, stress, memory disorders, migraine, vomiting, thymic disorders, dyskinesia, kinetic disorder, anxiety disorders, psychotic disorders, cognitive disorders, appetite disorders, mood disorders, delirious disorders, neuropathies, Parkinson's disease, Alzheimers disease, depression, psychosomatic-induced disease, diabetes, sexual dysfunctions, as well as for alcohol, opioid, nicotine and cocaine addiction, etc. Additionally, these analogs can be useful in cancer chemotherapy. Typically, a "therapeutically effective amount" of an inventive compound is believed to range from about 0.01 mg/day to about 1,000 mg/day.
As used herein, an "individual" refers to a human. An "animal" refers to, for example nonhuman-primates such as monkeys and baboons, veterinary animals, such as rodents, dogs, cats, horses and the like, and farm animals, such as cows, pigs and the like In a certain embodiments, the compound disclosed in the invention can be used in combination with other acceptable pharmaceutical substances.
In embodiments in which compounds of the disclosure is used in combination with Rimonabant (Accomplia, Sanofi-Aventis) or other CBI antagonists, it will be possible to reduce or even eliminate one or more of these side-effects, particularly nausea. That is, it is possible to reduce the amount of Rimonabant or other antagonists administered to the individual who has had, is receiving or is about to receive a therapeutically effective amount of the compound of the disclosure.
In one embodiment, the amount of Rimonabant administered to the individual is reduced by 1.5 to 5-fold compared to the accepted therapeutic amount. The individual is then dosed with a therapeutically effective amount of at least one of the compounds of the disclosure. Of course, it is also possible to increase the length of time between doses of Rimonabant with the same or similar effect.
Accordingly, one embodiment provides for a method for reducing unwanted side-effects (one or more of nausea, dizziness, diarrhea, and anxiety) typically associated with administration of SR141716A (AccompliaTm/Rimonabant) or other CBI antagonists to certain individuals. A particular method involves administering a therapeutically effective amount of at least one of the compounds of the disclosure so as to reduce the side-effects in that individual. As discussed, the method can involve reducing the amount of SR141716A (AccompliaTm/Rimonabant) or other CB1 antagonists administered to the individual.
As will be apparent, the compounds of the invention can be used alone or in combination with other CBI receptor antagonists or anti-obesity agents known to the field. Examples of such agents include SR141716A or AccompliaTm/rimonabant(Sanofi-Aventis), Xenical (Roche), Meridia (Abbott, Sibutramine), surinabant (Sanofi-Aventis), AVE1625(Sanofi-Aventis), CP-946,598 or otenabant (Pfizer), rosonabant(Esteve), taranabant (Merck), SLV-319 (Solvay Pharmaceuticals/BMS), V24343 (Vernalis), Qnexa(Vivus), Contrave(Orexigen), Empatic(Orexigen), lorcaserin(Arena), Phentermine.
Compounds of the invention can also be used in combination with a a potassium channel opener, opiod antagonist, anticonvulsant agent, contraceptive agent, antipsychotic agent, anticonstipation agent, nicotine receptor agonist or partial agonist, CB2 agonist, melanin-concentrating hormone receptor antagonist, anti-psychotic agents, peroxisome proliferator-activated receptors agonists, ghrelin antagonists, GLP-1 agonist, fatty acid amide hydrolase inhibitor, an intestinal-acting microsomal triglyceride transfer protein inhibitor, a dipeptidyl-peptidase IV
inhibitor, a statin, a sterol absorption inhibitor (f3-lactam), Beta-3 adrenergic agonist, a biguanide, Sodium glucose transport (SGLT2) antagonist, cyclooxygenase-2 inhibitor, renin inhibitor, monoamine oxidase inhibitor, CETP inhibitor, ACAT
inhibitor, DGAT-1 inhibitor, Mitochondrial Transfer Protein inhibitor, noradrenalin-serotonin-dopamine reuptake inhibitor or a lipase inhibitor.
In one embodiment, less than five compounds of the disclosure, preferably one or two of same is used in combination with less than five of the known CB1 antagonists, preferably one or two of same.
In one embodiment, the compound disclosed in the invention could in itself act as a drug with a combination effect. For example compounds disclosed in the invention could dually act as a CBI antagonist as well as 118-hydroxy steroid dehydrogenase-1 inhibitor. In certain embodiments, the compound could act dually as a CBI antagonist as well as a nitric oxide donor.
By "physiologically acceptable salts" is meant, salts typically useful for pharmaceutical applications including acid addition salts and basic salts.
Examples of acid addition salts are hydrochloride salts, hydrobromide salts, methane sulfonate salts etc. Examples of basic salts are salts where the cation is selected from alkali metals, such as sodium and potassium, alkaline earth metals, such as calcium, and ammonium ions. Other examples of physiologically acceptable salts can be found in "Remington's Pharmaceutical Sciences" 17. Ed. Alfonso R. Gennaro (Ed.), Mark Publishing Company, Easton, Pa., U.S.A., 1985 and more recent editions, and in Encyclopedia of Pharmaceutical Technology.
Polymorphic forms show improved physiochemical properties and stability for formulation purposes. In one embodiment, the compounds disclosed in the invention could exist in various solid forms. The solid forms can be crystalline and amorphous forms, but not limited to, solvates, hydrates, hydrolyzable esters and N-oxides of the compounds defined in the specification. These solid forms can be obtained by treating either the free base or their salts at a certain adjusted pH and certain temperature with an solvent or a combination of solvents. The solvents can be and not limited to a hydrocarbon solvent such as toluene, xylene, hexanes, heptane, or petroleum ether, alcohol such as methanol, ethanol, n-butanol, n-propanol and propanol, di-isopropyl ether, ethyl-acetate, dichloromethane, acetic acid, acetone, tetrahydrofuran, dichloromethane, and water.
In one embodiment, in order to improve the dehepaticability of the compound disclosed in the present invention for the required physiological effect, a "pro-drug" of the same can be made available. For example, the pro-drug such as an in-vivo hydrolyzable ester can be a obtained by conjugation of the parent drug with a low-molecular weight alcohol or a high molecular weight polyethylene glycol(PEG).
In certain embodiments, the compound disclosed in the invention could contain a nitrate ester group.
In one embodiment, the compounds in the present invention could exist as enantiomers, diastereomers, geometric isomers, racemates, tautomers, rotamers, atropisomers or metabolites.
In one embodiment, some compounds disclosed in the invention can be "neutral antagonists". These agents are said to have no effect on intrinsic receptor activity at least in certain test systems. However, these agents may be able to block receptor binding and activation, usually by a competitive agonist.
In some embodiments, it would be desirable to have antagonists that exhibit essentially no CBI receptor activity and which block or significantly reduce receptor activation by a suitable agonist. It would be further desirable to have neutral antagonists of the CBI receptor that can be used to prevent, treat, or reduce the severity of symptoms of certain medical conditions. It would be especially desirable to have neutral antagonists that exhibit no or minimal side-effects in vivo.
In another embodiment, the compound disclosed in the present invention may act preferentially at the CB1 receptors located in the periphery. In certain embodiments, the compounds do not penetrate the blood-brain-barrier, have restricted penetration or have slow penetration. In certain embodiments, peripherally acting compounds may have advantages over centrally acting compounds, for example, reduced psychotropic adverse effects.
A compound acting on the CB1 receptors located in the periphery could be behave either as a neutral antagonist, an inverse agonists or a partial antagonist.
A compound acting on the CB1 receptors located centrally, could behave as a neutral antagonist, an inverse agonists or a partial antagonist.
In another embodiment, the compounds disclosed in the invention could act either as inverse agonists with no or reduced side effects. In other embodiments, the compounds could act as partial agonists with no or reduced side effects.
The compounds of the present invention can be administered by a variety of known methods, including orally, rectally, or by parenteral routes (e.g., intramuscular, intravenous, subcutaneous, nasal or topical). The form in which the compounds are administered will be determined by the route of administration. Such forms include, but are not limited to, capsular and tablet formulations (for oral and rectal administration), liquid formulations (for oral, intravenous, intramuscular, subcutaneous, ocular, intranasal, inhalation-based and transdermal administration) and slow releasing microcarriers (for rectal, intramuscular or intravenous administration). The formulations can also contain a physiologically acceptable vehicle and optional adjuvants, flavorings, colorants and preservatives.
Suitable physiologically acceptable vehicles include, for example, saline, sterile water, Ringer's solution and isotonic sodium chloride solutions. The specific dosage level of active ingredient will depend upon a number of factors, including, for example, biological activity of the particular preparation, age, body weight, sex and general health of the individual being treated.
In another embodiment, the compounds of the present disclosure can also comprise isotopes at one or more of their atoms. For example, the compounds can be radiolabeled with isotopes, such as 2H (deuterium written as D) 3H (tritium written as T), 11C (carbon-11), 13C (carbon-13), 14C (carbon-14), 150 (oxygen-15), 170 (oxygen-17), 18Q (oxygen-18), 13N (nitrogen-13), 15N (nitrogen-15), 18F
(fluorine-18), 7813r (bromine-75), 76Br (bromine-76), 77Br (bromine-77), 8 _ 2Br (bromine-82), 1231 (iodine-123), 124 (iodine-124), 1281 (iodine-125) or 1311 (iodine-131), 38CI
(chlorine-36) or 35S (sulphur-35), The present disclosure encompasses all isotopic variations of the described compounds, whether natural or unnatural, radioactive or not.
An isotope is one of two or more species of the same element. Each isotope of an element will have the same number of protons in its nucleus, the same atomic number and the same position in the Periodic Table. However each isotope of that element will have a different number of neutrons in its nucleus and therefore a different mass than other isotopes of that species. The term nuclide is sometimes used synonymously with the term isotope. As used herein a natural isotope has an atomic mass corresponding most closely with the atomic mass shown for that element in the Periodic Table. As used herein an unnatural isotope has an atomic mass that is further removed from the atomic mass shown for that element in the Periodic Table than the natural isotope. For example, protium (hydrogen-1 or 1H) is the natural isotope of hydrogen and deuterium (hydrogen-2 or 2H) and tritium (hydrogen-3 or 3H) are all unnatural isotopes of hydrogen.
In a particular embodiment, some of the halogen containing analogs, for example those analogs comprising iodide and fluoride, are potential radioactive probes for imaging in vivo the distribution of cannabinoid receptors. For radio-imaging applications 11C, 18F, 1251, 1231, 1241, 1311 , 75Br, - 75 -Br, or 77Br will generally be most useful.
Some of the radioactive isotope containing analogs have potential as radiopharmaceutical analogs (disclosed analogs that have been labeled with radioactive isotopes). These radiopharmaceuticals can be administered to individuals or animals and the emitted radiation can be measured. The majority of these diagnostic tests involve the formation of an image using a camera suitable to detect the emitted radiation. Positron emission tomography (PET) is one nuclear medicine tomographic imaging technique, which produces a three-dimensional image or map of functional processes in a patient's body. To conduct the PET scan, a short-lived radiopharmaceutical analog that decays by emitting a positron is administered into the subject (usually by injection into the blood stream).
There is a waiting period while the radiopharmaceutical analog becomes concentrated in tissues of interest such as a cannabinoid receptor. After the waiting period the patient is placed in an imaging scanner. The scanner collects multiple images and a computer is used to apply an algorithm to the multiple images and provide a three dimensional image. Single photon emission computed tomography (SPECT) is another nuclear medicine tomographic imaging technique. To conduct the SPECT scan, a short-lived radiopharmaceutical analog that decays to produce a gamma ray is administered into the subject. There is a waiting period while the radiopharmaceutical analog becomes concentrated in tissues of interest such as a cannabinoid receptor. After the waiting period the patient is placed in an imaging scanner and SPECT imaging is performed by using a gamma camera to acquire multiple two dimensional images from multiple angles. A computer is then used to apply an algorithm to the multiple images to provide a three dimensional image.
Table 1 N
r/9 r9 HO ,N-- HO N--/
N. 0 1 N\N ti / N\N. ti i \ H
, HO
0/ arrir CI 01 Ain CI ---- 116 i\
,N \
I
lei CI
0 0 ........., 0 N
, H i N N- (,...11.0 N_ -;
, ,N , N N / N N / N
0 il CI le gib CI
IMPli el is CI
-----=
I I
AcS CI I a 7 CI 8 CI
O o N.0 / \ H / \ H / o so NN ,N
N 110 abiN CI
---;,----;,-- SO ilk CI
IIIV ----;,-IMP
SCN CI
MsS 9 CI 02N0 0 00 =
0 .
N _--)=c .\......0=N--) o N N
----../ / \ H / \ H
N,N
,N
so N / N
0 are% le CI 40 CI
so c, ,...õ
w ....õ
,-;,...
I
NC CI
ri=o rS=0 0 (TO 0 N---/i N--..../
N
N
/ \ H i \ i \
ti ' ,N
,N ,N ,N 01101 101 N ci 0 N ci NH ..õ,õ..
el el 1101 I.
CI
NC CI CI CI
=
, (---9 o 0 N
N
N
=
7 \ \ H / \ H
, \ \
N ,N
N ,N ,N
Br I 110 N ci le I 0 its% ci CI NC CI
CI CI
9(-0\
rs,=0 N---../ N--/
N NC
N
/ \ H N / \ H N
,N / \ H
,N / \ H
,N ,N
I I I 01 I a N h C I so N ci N
/ ,---- * Abi CI
----"
/ 116 aihN CI
I
WI ISI
I-NC 25 ci 26 IIIV
;I CI NC
24 CI a o 23 NC o /
o .0 0 N .r9 N-....../1 (.
N CN
N
NC/ \ H
N / \ H / \ H
N
/ \ H ,N,N
,N
N.
0 iiihN CI 0 * CI gill CI I
--- ,N c, -"
.õ---, w w w w NC CI NC 29 ci ci a 2 9 , 9 o rs\ NC =0 0 N.N-../) N CN
0 / \ H
NC .N--.Y ,N
N / \ H N
7 \ H ,N
01 itrib CI
,N
1111.
600 N ci 0 AnN CI ../...-I
IIIV illi NC CI
NC CI
, \ \
N ,N
N ,N ,N
Br I 110 N ci le I 0 its% ci CI NC CI
CI CI
9(-0\
rs,=0 N---../ N--/
N NC
N
/ \ H N / \ H N
,N / \ H
,N / \ H
,N ,N
I I I 01 I a N h C I so N ci N
/ ,---- * Abi CI
----"
/ 116 aihN CI
I
WI ISI
I-NC 25 ci 26 IIIV
;I CI NC
24 CI a o 23 NC o /
o .0 0 N .r9 N-....../1 (.
N CN
N
NC/ \ H
N / \ H / \ H
N
/ \ H ,N,N
,N
N.
0 iiihN CI 0 * CI gill CI I
--- ,N c, -"
.õ---, w w w w NC CI NC 29 ci ci a 2 9 , 9 o rs\ NC =0 0 N.N-../) N CN
0 / \ H
NC .N--.Y ,N
N / \ H N
7 \ H ,N
01 itrib CI
,N
1111.
600 N ci 0 AnN CI ../...-I
IIIV illi NC CI
NC CI
8 PCT/US2009/001054 (-9, 0 0 ../
, rs,..
0 .
.
,N r- N
/ _____________________________________________________ ?\---H
N-N
/Y
NN \ ,N
S --,..
N
*
\ S CI CI
\ S, ci CI CI
34 NC , (----,=0 0 0 _________________________________________________ 0 ),õ___ NJ ,N---._/
0 N N' / \(\\---H
N
CI / __ \c H --, ,N
/ __________________ ?--H ,N N
,N N \ S CI
\ S CI
CI
C
CI
CI
, rs,..
0 .
.
,N r- N
/ _____________________________________________________ ?\---H
N-N
/Y
NN \ ,N
S --,..
N
*
\ S CI CI
\ S, ci CI CI
34 NC , (----,=0 0 0 _________________________________________________ 0 ),õ___ NJ ,N---._/
0 N N' / \(\\---H
N
CI / __ \c H --, ,N
/ __________________ ?--H ,N N
,N N \ S CI
\ S CI
CI
C
CI
CI
9 .0 NC 0 ,N--../
,N--..../
NC /
_________________________________________ N N
N ?\'- / __ \c >.\--H
/ _________________ \\)\--H ,N H ,N
,N
N
N
S CI // \ S = ci // . \ S Cl \
// Ig Cl Cl CI
NC NC
0 NCp. 0 9 1=0 0 NC)b, N
N.--) N / __ ?-iti ---, ,N
N
,N / HN
NN N \---,N S 0 ci S Cl --..
=
I
WI I \ S s Cl //
CI
CI
N
Cl C
The invention will be further described in more detail by the following synthetic examples. These examples are offered to illustrate the invention, and are not to be construed in any way as limiting the scope of the invention.
Compound synthesis and formulation Example 1 1-(4-(4-cyanobut-1-ynyl)pheny1)-2-(2,4-dichloropheny1)-N-morpholino-5-(pyrrolidin-1-ylmethyl)-1H-imidazole-4-carboxamide (compound 12) Step A
N-(4-bromopheny1)-2,4-dichlorobenzimidamide To a magnetically stirred solution of EtMgBr (3.3 mL, 3M in diethyl ether, 10 mmol) in THF (30 mL) 4-bromoaniline (1.72 g, 10 mmol) was slowly added portion wise.
After the solution was stirred for 30 min., 2,4-dichlorobenzonitrile (1.72g, 10 mmol) was added. The resulting solution was stirred at room temperature (RT) overnight.
The reaction mixture was quenched with water and extracted with ethyl acetate. The combined extracts were dried over anhydrous MgSO4, filtered and evaporated under reduced pressure to give the benzimidamide as an off-white solid (2.45g, 71.2%).
Step B
Ethyl 1-(4-bromopheny1)-2-(2,4-dichloropheny1)-5-methyl-1H-imidazole-4-carboxylate To a magnetically stirred solution of above imidamide from step A (2.45g, 7 mmol) in 30 mL anhydrous toluene were added ethyl 3-bromo-2-oxobutanoate (1.48g, 7 mmol) and Na2CO3 (0.74g, 7 mmol). The contents were stirred at 100 C for 12 hours.
The reaction was brought to RT. The reaction mixture was quenched with water and extracted with ethyl acetate. The combined extracts were dried over anhydrous MgSO4, filtered and evaporated under reduced pressure. Purification by column chromatography gave the ester as pale white solid (1.5 g, 46.4%).
Step C
2-(2,4-dichloropheny1)-1-(4-iodopheny1)-N-morpholino-5-(pyrrol1din-1-ylmethyl)-imidazole-4-carboxamide (compound 8) To a magnetically stirred solution of ester from step B (1.5 g, 3.3 mmol) in carbon tetrachloride (20 mL) N-bromosuccinimide (0.58g, 3.3 mmol) was added along with a catalytic amount of and 2,2'-azobisisobutyronitrile (AIBN, 15 mg). The resulting mixture was refluxed for 3 h. After cooling to RT, the precipitate was filtered. The filtrate was washed with 2x50 ml water and the organic layer was dried over anhydrous sodium sulfate, filtered, and evaporated. Flash column chromatography on silica gel with petroleum ether/ethyl acetate (1:9) gave bromo derivative (1 mg, 56% yield) as a pale yellow solid. The bromo derivative ( 1g, 1.88 mmol) was taken in acetonitrile (50 ml) and to that Hunnig's base (0.26g, 2 mmol) and pyrrolidine (0.14g, 2 mmol) were added. The reaction mixture was heated at 60-65 C for 1 h hour.
After cooling the reaction mixture was concentrated to give an oily residue which was subsequently dissolved in dichloromethane (50 ml). This was washed with 2x25 ml water and the organic layer was dried over anhydrous sodium sulfate, filtered, and evaporated. Flash column chromatography on silica gel with petroleum ether/ethyl acetate (1:1) gave ester (700 mg, 71.2%) as a white solid. To the suspension of AlC13 (0.53 g, 4 mmol) in dichloroethane (20 mL) was added 4-aminomorpholine (0.41 g, 4 mmol) at 0 C and stirred for 25 min at that temperature. To this was added a solution of ester from step C (700 mg, 1.3 mmol) in dichloroethane (5 mL). The reaction was brought to RT and stirred at that temperature for 8h. The reaction was quenched with dilute HCI and the organic layer was extracted with dichloromethane.
The combined extracts were dried over anhydrous MgSO4, filtered and evaporated under reduced pressure. Purification by column chromatography gave the amide as an off-white solid (500 mg, 60%).
1H NMR (500 MHz, CDCI3-d) 8.39 (s, 1H), 7.65 (d, J = 8.30 Hz, 2H), 7.34 (s, 1H), 7.27 - 7.32 (m, 1H), 7.22 - 7.26 (m, 1H), 7.05 (d, J = 8.30 Hz, 2H), 3.87 (t, J = 4.39 Hz, 4H), 3.83 (s, 2H), 2.94 (br. s., 4H), 2.50 (br. s., 4H), 1.69 (br. s., 4H) Step D
The amide from step C (500 mg, 0.79 mmol) was taken and subjected to the Sonogashira reaction as was performed in example 3F to give compound 12 ( 200 mg, 47.5%).
1H NMR (500 MHz, CDC13-d) 8.19- 8.52 (m, 1H), 7.47 (d, J = 7.81 Hz, 3H), 7.35 (d, J
= 1.95 Hz, 3H), 7.29 - 7.30 (m, 1H), 7.25 - 7.28 (m, 1H), 4.04 - 4.92 (m, 2H), 3.90 (t, J
= 4.39 Hz, 4H), 2.98 (br. s., 4H), 2.73 - 2.88 (m, 2H), 2.63 - 2.74(m, 2H), 2.02 (br. s., 4H), 1.74 (none, 4H) Example 2 4-(4-(1-(2,4-dichloropheny1)-4-methy1-3-(piperidin-1-ylcarbamoy1)-1H-pyrazol-5-yl)phenyl)but-3-ynyl nitrate (compound 10) To a stirred solution of compound 5 [1-(2,4-dichloropheny1)-5-(4-(4-iodobut-1-ynyl)pheny1)-4-methyl-N-(piperidin-1-y1)-1H-pyrazole-3-carboxamideR60 mg, 0.9 mmol) taken in acetonitrile (20 ml) and to that silver nitrate (33.5 mg, 0.19 mmol) was added. The reaction mixture was heated for 2 hours. After cooling to RT, the precipitate was filtered. The filtrate was concentrated to give an oily residue which was subsequently dissolved in dichloromethane (20 ml). This was washed with 2x5 ml water and the organic layer was dried over anhydrous sodium sulfate, filtered, and evaporated. Flash column chromatography on silica gel with petroleum ether/ethyl acetate (1:1) gave compound 2 (40 mg, 74.6% yield) as a white solid.
1H NMR (500 MHz, CDC13-d) 7.65 (s, 1H), 7.43 (s, 1H), 7.36 (d, J = 8.30 Hz, 2H), 7.29 - 7.33 (m, 2H), 7.07 (d, J = 8.30 Hz, 2H), 4.64 (t, J = 6.84 Hz, 2H), 2.74 - 3.02 (m, 6H), 2.39 (s, 3H), 1.69- 1.90 (m, 4H), 1.45 (br. s., 2H) Example 3 5-(4-(4-cyanobut-1-ynyl) pheny1)-1-(2,4-dichloropheny1)-4-methyl-N-(1,1-dioxo-thiomorpholino)-1H-pyrazole-3-carboxamide (compound 15) Step A
4'-iodopropiophenone lodobenzene (100g, 0.49 mol) was taken in a dry 1L3 neck flask equipped with a inlet and to it 200 ml of CS2 was added. The contents were cooled to 0-5 C and then AlC13(80 g, 0.6 moles) and subsequently propionyl chloride (60 g, 0.64 mol) were added while keeping the temperature (internal) at 5-10 C. The contents were stirred for 24 hrs.The reaction mixture was poured into a 5 liter plastic beaker containing 1L
of 10% HCI + 1Kg of crushed ice. The resultant slurry was extracted with 1L of ethyl acetate. The organic layer was separated and washed with 2x500 ml of water and 500 ml of brine. The organic layer was dried over sodium sulphate and concentrated at 40 C to give 4'-iodopropiophenone (48 g, 38%).
1H NMR (500 MHz, CDCI3-d) 7.82 (d, 2H), 7.67 (d, J = 8.30 Hz, 2H), 2.96 (q, J
= 7.00 Hz, 2H), 1.22 (t, J = 7.32 Hz, 3H) Step B
Lithium-4-ethoxy-1-(4-iodopheny1)-2-methy1-3,4-dioxobut-1-en-1-olate 4'-iodopropiophenone obtained from step A was taken in a 2L 3 neck flask equipped with a nitrogen inlet. To that 500 ml of diethyl ether was added and the contents were cooled at -78 C using a dry-ice acetone bath. The reaction mixture was stirred for 15 minutes. Subsequently, a 1 M solution of lithium bis(trimethylsilyl)amide in hexanes (222 ml, 0.22 mol) was added drop wise over 1 hour. The contents were stirred at -78 C an additional 1 hour after diethyl oxalate which (32.3 g, 0.22 mol) taken in diethyl ether was added over 30 minutes. The contents were stirred for 2 hours at -78 C after which the cooling bath was removed. The contents were brought to room temperature over 10 hours. The solids were filtered under a stream of nitrogen and then washed with 200 ml of ether. The solid obtained was air dried for 1 hour and was taken as such to the next reaction directly (52 g, 76.9%).
Step C
ethyl 1-(2,4-dichlorophenyI)-5-(4-iodopheny1)-4-methyl-1H-pyrazole-3-carboxylate The lithium salt obtained from step B was taken in a 1 liter 1 neck flask and to that 2,4-dichlorophenylhydrzine hydrochloride (30.3 g, 0.14 mol) and 1.5 liters of anhydrous ethanol were added in on portion. The resulting mixture was stirred at room temperature for 24 hours. The solids were filtered, washed with ethanol and then dried under vacuum to give a light yellow of ethyl 2-(2-(2,4-dichlorophenyl)hydrazono)-4-(4-iodopheny1)-3-methy1-4-oxobutanoate (27 g). The solids were taken in a 1 L 1 neck flask and to that 1 liter of glacial acetic acid was added. The mixture was refluxed for 4 hours. Acetic acid was distilled out completely and to the residue 500 ml of ethyl acetate was added. The organic layer was separated, washed with 1 liter of water, dried over sodium sulphate and concentrated to give the crude ester. The ester was purified by column chromatography using a
,N--..../
NC /
_________________________________________ N N
N ?\'- / __ \c >.\--H
/ _________________ \\)\--H ,N H ,N
,N
N
N
S CI // \ S = ci // . \ S Cl \
// Ig Cl Cl CI
NC NC
0 NCp. 0 9 1=0 0 NC)b, N
N.--) N / __ ?-iti ---, ,N
N
,N / HN
NN N \---,N S 0 ci S Cl --..
=
I
WI I \ S s Cl //
CI
CI
N
Cl C
The invention will be further described in more detail by the following synthetic examples. These examples are offered to illustrate the invention, and are not to be construed in any way as limiting the scope of the invention.
Compound synthesis and formulation Example 1 1-(4-(4-cyanobut-1-ynyl)pheny1)-2-(2,4-dichloropheny1)-N-morpholino-5-(pyrrolidin-1-ylmethyl)-1H-imidazole-4-carboxamide (compound 12) Step A
N-(4-bromopheny1)-2,4-dichlorobenzimidamide To a magnetically stirred solution of EtMgBr (3.3 mL, 3M in diethyl ether, 10 mmol) in THF (30 mL) 4-bromoaniline (1.72 g, 10 mmol) was slowly added portion wise.
After the solution was stirred for 30 min., 2,4-dichlorobenzonitrile (1.72g, 10 mmol) was added. The resulting solution was stirred at room temperature (RT) overnight.
The reaction mixture was quenched with water and extracted with ethyl acetate. The combined extracts were dried over anhydrous MgSO4, filtered and evaporated under reduced pressure to give the benzimidamide as an off-white solid (2.45g, 71.2%).
Step B
Ethyl 1-(4-bromopheny1)-2-(2,4-dichloropheny1)-5-methyl-1H-imidazole-4-carboxylate To a magnetically stirred solution of above imidamide from step A (2.45g, 7 mmol) in 30 mL anhydrous toluene were added ethyl 3-bromo-2-oxobutanoate (1.48g, 7 mmol) and Na2CO3 (0.74g, 7 mmol). The contents were stirred at 100 C for 12 hours.
The reaction was brought to RT. The reaction mixture was quenched with water and extracted with ethyl acetate. The combined extracts were dried over anhydrous MgSO4, filtered and evaporated under reduced pressure. Purification by column chromatography gave the ester as pale white solid (1.5 g, 46.4%).
Step C
2-(2,4-dichloropheny1)-1-(4-iodopheny1)-N-morpholino-5-(pyrrol1din-1-ylmethyl)-imidazole-4-carboxamide (compound 8) To a magnetically stirred solution of ester from step B (1.5 g, 3.3 mmol) in carbon tetrachloride (20 mL) N-bromosuccinimide (0.58g, 3.3 mmol) was added along with a catalytic amount of and 2,2'-azobisisobutyronitrile (AIBN, 15 mg). The resulting mixture was refluxed for 3 h. After cooling to RT, the precipitate was filtered. The filtrate was washed with 2x50 ml water and the organic layer was dried over anhydrous sodium sulfate, filtered, and evaporated. Flash column chromatography on silica gel with petroleum ether/ethyl acetate (1:9) gave bromo derivative (1 mg, 56% yield) as a pale yellow solid. The bromo derivative ( 1g, 1.88 mmol) was taken in acetonitrile (50 ml) and to that Hunnig's base (0.26g, 2 mmol) and pyrrolidine (0.14g, 2 mmol) were added. The reaction mixture was heated at 60-65 C for 1 h hour.
After cooling the reaction mixture was concentrated to give an oily residue which was subsequently dissolved in dichloromethane (50 ml). This was washed with 2x25 ml water and the organic layer was dried over anhydrous sodium sulfate, filtered, and evaporated. Flash column chromatography on silica gel with petroleum ether/ethyl acetate (1:1) gave ester (700 mg, 71.2%) as a white solid. To the suspension of AlC13 (0.53 g, 4 mmol) in dichloroethane (20 mL) was added 4-aminomorpholine (0.41 g, 4 mmol) at 0 C and stirred for 25 min at that temperature. To this was added a solution of ester from step C (700 mg, 1.3 mmol) in dichloroethane (5 mL). The reaction was brought to RT and stirred at that temperature for 8h. The reaction was quenched with dilute HCI and the organic layer was extracted with dichloromethane.
The combined extracts were dried over anhydrous MgSO4, filtered and evaporated under reduced pressure. Purification by column chromatography gave the amide as an off-white solid (500 mg, 60%).
1H NMR (500 MHz, CDCI3-d) 8.39 (s, 1H), 7.65 (d, J = 8.30 Hz, 2H), 7.34 (s, 1H), 7.27 - 7.32 (m, 1H), 7.22 - 7.26 (m, 1H), 7.05 (d, J = 8.30 Hz, 2H), 3.87 (t, J = 4.39 Hz, 4H), 3.83 (s, 2H), 2.94 (br. s., 4H), 2.50 (br. s., 4H), 1.69 (br. s., 4H) Step D
The amide from step C (500 mg, 0.79 mmol) was taken and subjected to the Sonogashira reaction as was performed in example 3F to give compound 12 ( 200 mg, 47.5%).
1H NMR (500 MHz, CDC13-d) 8.19- 8.52 (m, 1H), 7.47 (d, J = 7.81 Hz, 3H), 7.35 (d, J
= 1.95 Hz, 3H), 7.29 - 7.30 (m, 1H), 7.25 - 7.28 (m, 1H), 4.04 - 4.92 (m, 2H), 3.90 (t, J
= 4.39 Hz, 4H), 2.98 (br. s., 4H), 2.73 - 2.88 (m, 2H), 2.63 - 2.74(m, 2H), 2.02 (br. s., 4H), 1.74 (none, 4H) Example 2 4-(4-(1-(2,4-dichloropheny1)-4-methy1-3-(piperidin-1-ylcarbamoy1)-1H-pyrazol-5-yl)phenyl)but-3-ynyl nitrate (compound 10) To a stirred solution of compound 5 [1-(2,4-dichloropheny1)-5-(4-(4-iodobut-1-ynyl)pheny1)-4-methyl-N-(piperidin-1-y1)-1H-pyrazole-3-carboxamideR60 mg, 0.9 mmol) taken in acetonitrile (20 ml) and to that silver nitrate (33.5 mg, 0.19 mmol) was added. The reaction mixture was heated for 2 hours. After cooling to RT, the precipitate was filtered. The filtrate was concentrated to give an oily residue which was subsequently dissolved in dichloromethane (20 ml). This was washed with 2x5 ml water and the organic layer was dried over anhydrous sodium sulfate, filtered, and evaporated. Flash column chromatography on silica gel with petroleum ether/ethyl acetate (1:1) gave compound 2 (40 mg, 74.6% yield) as a white solid.
1H NMR (500 MHz, CDC13-d) 7.65 (s, 1H), 7.43 (s, 1H), 7.36 (d, J = 8.30 Hz, 2H), 7.29 - 7.33 (m, 2H), 7.07 (d, J = 8.30 Hz, 2H), 4.64 (t, J = 6.84 Hz, 2H), 2.74 - 3.02 (m, 6H), 2.39 (s, 3H), 1.69- 1.90 (m, 4H), 1.45 (br. s., 2H) Example 3 5-(4-(4-cyanobut-1-ynyl) pheny1)-1-(2,4-dichloropheny1)-4-methyl-N-(1,1-dioxo-thiomorpholino)-1H-pyrazole-3-carboxamide (compound 15) Step A
4'-iodopropiophenone lodobenzene (100g, 0.49 mol) was taken in a dry 1L3 neck flask equipped with a inlet and to it 200 ml of CS2 was added. The contents were cooled to 0-5 C and then AlC13(80 g, 0.6 moles) and subsequently propionyl chloride (60 g, 0.64 mol) were added while keeping the temperature (internal) at 5-10 C. The contents were stirred for 24 hrs.The reaction mixture was poured into a 5 liter plastic beaker containing 1L
of 10% HCI + 1Kg of crushed ice. The resultant slurry was extracted with 1L of ethyl acetate. The organic layer was separated and washed with 2x500 ml of water and 500 ml of brine. The organic layer was dried over sodium sulphate and concentrated at 40 C to give 4'-iodopropiophenone (48 g, 38%).
1H NMR (500 MHz, CDCI3-d) 7.82 (d, 2H), 7.67 (d, J = 8.30 Hz, 2H), 2.96 (q, J
= 7.00 Hz, 2H), 1.22 (t, J = 7.32 Hz, 3H) Step B
Lithium-4-ethoxy-1-(4-iodopheny1)-2-methy1-3,4-dioxobut-1-en-1-olate 4'-iodopropiophenone obtained from step A was taken in a 2L 3 neck flask equipped with a nitrogen inlet. To that 500 ml of diethyl ether was added and the contents were cooled at -78 C using a dry-ice acetone bath. The reaction mixture was stirred for 15 minutes. Subsequently, a 1 M solution of lithium bis(trimethylsilyl)amide in hexanes (222 ml, 0.22 mol) was added drop wise over 1 hour. The contents were stirred at -78 C an additional 1 hour after diethyl oxalate which (32.3 g, 0.22 mol) taken in diethyl ether was added over 30 minutes. The contents were stirred for 2 hours at -78 C after which the cooling bath was removed. The contents were brought to room temperature over 10 hours. The solids were filtered under a stream of nitrogen and then washed with 200 ml of ether. The solid obtained was air dried for 1 hour and was taken as such to the next reaction directly (52 g, 76.9%).
Step C
ethyl 1-(2,4-dichlorophenyI)-5-(4-iodopheny1)-4-methyl-1H-pyrazole-3-carboxylate The lithium salt obtained from step B was taken in a 1 liter 1 neck flask and to that 2,4-dichlorophenylhydrzine hydrochloride (30.3 g, 0.14 mol) and 1.5 liters of anhydrous ethanol were added in on portion. The resulting mixture was stirred at room temperature for 24 hours. The solids were filtered, washed with ethanol and then dried under vacuum to give a light yellow of ethyl 2-(2-(2,4-dichlorophenyl)hydrazono)-4-(4-iodopheny1)-3-methy1-4-oxobutanoate (27 g). The solids were taken in a 1 L 1 neck flask and to that 1 liter of glacial acetic acid was added. The mixture was refluxed for 4 hours. Acetic acid was distilled out completely and to the residue 500 ml of ethyl acetate was added. The organic layer was separated, washed with 1 liter of water, dried over sodium sulphate and concentrated to give the crude ester. The ester was purified by column chromatography using a
10% ethyl acetate-hexane mixture to give the pure ester (15 g, 57.6%).
1H NMR (500 MHz, CDCI3-d) 7.69 (d, J = 8.30 Hz, 2H), 7.41 (s, 1H), 7.29 - 7.39 (m, 2H), 6.89 (d, J = 8.30 Hz, 2H), 4.48 (q, J = 7.32 Hz, 2H), 2.35 (s, 3H), 1.37 -1.53 (m, 3H) Step D
1-(2,4-dichlorophenyI)-5-(4-iodopheny1)-4-methyl-1H-pyrazole-3-carboxylic acid The ester (10 g, 19.9 mmoles) obtained from step C was taken in 500 ml 1 neck flask and to it 300 ml of 7:2:1 mixture of THF-methanol-water along with solid lithium hydroxide (2.5 g, 104.6 mol) was added. The mixture was refluxed for 12 hours.
The solvents were removed totally and to the residue 200 ml of DCM was added. To that 100 ml of water was added and the mixture was acidified to pH¨ 2 using concentrated HCI. The organic layer was separated, washed with 100 ml of brine, dried over sodium sulphate and concentrated to give the acid. This was taken directly to the next step (9.4 g, 100%).
1H NMR (500 MHz, CDCI3-d) 7.70 (d, J 7 8.30 Hz, 2H), 7.44 (s, 1H), 7.30 - 7.38 (m, 2H), 6.90 (d, J = 8.30 Hz, 2H), 2.37 (s, 3H) Step E
1-(2,4-dichloropheny1)-4-methy1-5-(4-iodopheny1)-N-(1,1-dioxothiomorpholino)-pyrazole-3-carboxamide (compound 16) The acid (7.5 g, 15.8 mmol) obtained from step D was taken in a 500 ml 1 neck flask equipped with a nitrogen inlet and to it 200 ml of DCM, 4-aminothiomorpholine-1,1-dioxide (2.61 g, 17.4 mmol), TBTU (5.59g, 17.4 mmol) and DIPEA (2.25 g, 17.4 mmol) were added and the contents were stirred for 1 hour. To the reaction mixture, 100 ml of water was added and the contents were acidified to pH-2 using concentrated HC1. The organic layer was separated, washed with brine, dried over sodium sulphate and concentrated to give the amide (3 g, 31.2%).
1H NMR (500 MHz, CDCI3-d) 8.07 (s, 1H), 7.67 (d, J = 8.30 Hz, 2H), 7.45 (d, J
=
1.95 Hz, 1H), 7.29 - 7.34 (m, 1H), 7.25 (s, 1H), 6.85 (d, J = 8.30 Hz, 2H), 3.44 - 3.66 (m, 4H), 3.26 (d, J = 4.88 Hz, 4H), 2.35 (s, 3H) Step F
To a stirred solution of amide obtained from step E (2 g, 3.3 mmol) in pyrrolidine (40 ml), under an argon atmosphere, tetrakis(triphenylphosphine)palladium(0) (0.4 g, 0.3 mmol) was added. The reaction mixture was stirred for 5 min at room temperature, and subsequently 4-cyano-1-butyne (0.78 g, 9.9 mmol) in pyrrolidine (1.5 ml) was added over 5 minutes. The resulting mixture was heated at 80-85 C for 10 h.
The reaction was hydrolyzed with a saturated aqueous solution of ammonium chloride and extracted with ethyl acetate. The organic extract was dried over MgSO4 and the solvent was removed in vacuo. Purification by flash column chromatography on silica gel (eluant ethylacetate) gave compound 15 as a white solid (0.8 g, 43.7%) 1H NMR (500 MHz, CDCI3-d) 8.08 (s, 1H), 7.43 (s, 1H), 7.37 (d, J = 7.81 Hz, 2H), 7.28 - 7.34 (m, 1H), 7.24 (s, 1H), 7.06 (d, J = 7.81 Hz, 2H), 3.56 (d, J =
4.88 Hz, 4H), 3.26 (br. s., 4H), 2.72 - 2.87 (m, 2H), 2.57 - 2.71 (m, 2H), 2.37 (s, 3H) Example 4 5-(5-(4-cyanobut-1-ynyl)thiophen-2-y1)-1-(2,4-dichloropheny1)-4-methyl-N-(piperidin-1-y1)-1H-pyrazole-3-carboxamide (compound 34) Step A
N-Methoxy-N-methylpropionamide:
Pyridine (17 mL, 0.4 mol) at 0 C was added dropwise to a solution of 0,N-dimethyl-hydroxylamine hydrochloride (10 g, 0.1 mol) and propionyl chloride (10 g, 0.1 mol) in anhydrous dichloromethane (250 mL). The solution was stirred at room temperature for 24 h, washed with 2x 50 ml of 5% hydrochloric acid, 100 ml of saturated NaHCO3 and 100 ml brine, dried over MgSO4 and concentrated under reduced pressure to give colorless oil (10 g, 89 %).
Step B
1-(5-iodothiophen-2-yl)propan-1-one 38.4 ml of a 2M solution of lithium diisopropylamide (8.2 g, 76.8 mmol) in THF-heptane-ethylbenzene was added to THE (50 ml) taken in a 500 three neck RB
flask equipped with a nitrogen inlet. The mixture was cooled to -40 C and then 2-iodothiophene (16.1 g, 76.8 mmol) taken in 50 ml of THE was added with vigorous stirring. After 10 minutes the mixture was warmed to -10 C and stirred for 30 min.
The reaction mixture was re-cooled to -40 C and N-methoxy-N-methylpropionamide (9 g, 76.8 mmol) taken in 50 ml of THE was added in one portion. The reaction mixture was allowed to warm slowly to 0 C and then the reaction was quenched with saturated 50 ml of NH4CI solution. The contents were extracted with 3 x 100 ml of DCM, dried over MgSO4 and concentrated to give an oily residue. This was purified by flash chromatography to give the title compound (10 g, 49%).
1H NMR (500 MHz, CDC13-d) 7.32 (d, 1H), 7.27- 7.30 (m, 1H), 2.86 (q, J = 7.32 Hz, 2H), 1.21 (t, J = 7.32 Hz, 3H) Step C
ethy11-(2,4-dichloropheny1)-5-(5-iodothiophen-2-y1)-4-methyl-1H-pyrazole-3-carboxylate The title compound was obtained as in example 3 1H NMR (500 MHz, CDC13-d) 7.46 (d, J = 1.95 Hz, 1H), 7.35 - 7.39 (m, 1H), 7.34 (d, 1H), 7.14 (d, J = 3.91 Hz, 1H), 6.55 (d, J = 3.91 Hz, 1H), 4.45 (q, J = 6.84 Hz, 2H), 2.42 (s, 3H), 1.42 (t, J = 7.08 Hz, 3H) Step D
1-(2,4-dichloropheny1)-5-(5-iodothiophen-2-y1)-4-methyl-N-(piperidin-1-y1)-1H-pyrazole-3-carboxamide The title compound was obtained as in example 3 Step E
The title compound was obtained as in example 3 1H NMR (500 MHz, CDCI3-d) 7.60 (br. s., 1H), 7.50 (d, J = 1.95 Hz, 1H), 7.35 -7.39 (m, 1H), 7.31 - 7.35 (m, 1H), 7.05 (d, J = 3.91 Hz, 1H), 6.72 (d, J = 3.42 Hz, 1H), 2.85 (br. s., 4H), 2.80 (t, J = 7.08 Hz, 2H), 2.56 - 2.70 (m, 2H), 2.47 (s, 3H), 1.75 (quin, J =
5.62 Hz, 4H), 1.43 (br. s., 2H) Example 5 1-(2,4-dichloropheny1)-5-(5-iodothiophen-2-y1)-4-methyl-N-(1,1-dioxothiomorpholino)-1H-pyrazole-3-carboxamide (compound 44) 1H NMR (500 MHz, CDCI3-d) 8.10 (s, 1H), 7.54 (d, J = 1.95 Hz, 1H), 7.36- 7.42 (m, 1H), 7.33 (d, 1H), 7.17 (d, J = 3.91 Hz, 1H), 6.57 (d, J = 3.91 Hz, 1H), 3.57 (br. s., 4H), 3.28 (br. s., 4H), 2.47 (s, 3H) Example 6 N-(1-cyanocyclopropy1)-1-(2 ,4-d ichloropheny1)-5-(5-iodothiophen-2-y1)-4-methy1-1H-pyrazole-3-carboxamide (compound 43) 1H NMR (500 MHz, CDC13-d) 7.53 (s, 1H), 7.41 (none, 1H), 7.30- 7.34 (m, 1H), 7.17 (d, J = 3.91 Hz, 1H), 6.57 (d, J = 3.91 Hz, 1H), 2.46 - 2.57 (m, 3H), 1.63 (br. s., 2H), 1.35 - 1.42 (m, 2H) Example 7 5-(4-(4-cyanobut-1-ynyl)pheny1)-1-(2,4-dichloropheny1)-4-(hydroxymethyl)-N-morpholino-1H-pyrazole-3-carboxamide (compound 2) 1H NMR (500 MHz, CDC13-d) 7.84 (s, 1H), 7.45 (d, J = 2.44 Hz, 1H), 7.37 (d, J
=
8.30 Hz, 2H), 7.29 - 7.33 (m, 1H), 7.25 (s, 1H), 7.07 (d, J = 8.30 Hz, 2H), 5.01 (t, J =
7.08 Hz, 1H), 4.63 (d, J = 7.32 Hz, 2H), 3.89 (t, J = 4.64 Hz, 4H), 2.96 (d, J
= 4.39 Hz, 4H), 2.72 - 2.84 (m, 2H), 2.56 - 2.69 (m, 2H) Example 8 4-(4-(1-(2,4-dichloropheny1)-4-methy1-3-(piperidin-1-ylcarbamoy1)-1H-pyrazol-5-yl)phenyl)but-3-ynyl methanesulfonate (compound 9) 1H NMR (500 MHz, CDC13-d) 7.67 (br. s., 1H), 7.43 (s, 1H), 7.35 (d, J = 7.81 Hz, 2H), 7.29 - 7.33 (m, 2H), 7.07 (d, J = 8.30 Hz, 2H), 4.39 (t, J = 6.59 Hz, 2H), 3.08 (s, 3H), 2.77 - 2.96 (m, 6H), 2.39 (s, 3H), 1.77 (br. s., 4H), 1.45 (br. s., 2H) Example 9 S-4-(4-(1-(2,4-dichloropheny1)-4-methy1-3-(piperidi n-1-ylcarbamoy1)-1H-pyrazol-5-yl)phenyl)but-3-ynyl ethanethioate (compound 5) 1H NMR (500 MHz, CDC13-d) 7.62 (s, 1H), 7.41 (s, 1H), 7.33 (d, J = 8.30 Hz, 2H), 7.27 - 7.30 (m, 2H), 7.04 (d, J = 8.30 Hz, 2H), 3.10 (t, J = 7.08 Hz, 2H), 2.87 (br. s., 4H), 2.69 (t, J = 7.08 Hz, 2H), 2.36 (d, J = 8.79 Hz, 6H), 1.75 (quin, J =
5.62 Hz, 4H), 1.43 (br. s., 2H) Example 10 1-(2,4-dichloropheny1)-5-(4-(4-iodobut-1-ynyl)pheny1)-4-methyl-N-(piperidin-1-y1)-1H-pyrazole-3-carboxamide (compound 6) 1H NMR (500 MHz, CDCI3-d) 7.63 (s, 1H), 7.41 (s, 1H), 7.36 (d, J = 8.30 Hz, 2H), 7.27 - 7.31 (m, 2H), 7.05 (d, J = 8.30 Hz, 2H), 3.30 (t, J = 7.32 Hz, 2H), 3.00 (t, J =
7.32 Hz, 2H), 2.86 (br. s., 4H), 2.37 (s, 3H), 1.67- 1.84 (m, 4H), 1.43 (br.
s., 2H) Example 11 5-(4-(but-3-en-1-ynyl)pheny1)-1-(2,4-dichloropheny1)-4-methyl-N-(piperidin-1-y1)-1H-pyrazole-3-carboxamide (compound 13) 1H NMR (500 MHz, CDCI3-d) 7.63 (s, 1H), 7.41 (s, 1H), 7.37 (d, J = 7.81 Hz, 2H), 7.27 (br. s., 2H), 7.06 (d, J = 7.81 Hz, 2H), 6.00 (dd, J = 11.23, 17.58 Hz, 1H), 5.49 -5.81 (m, 2H), 2.87 (br. s., 4H), 2.38 (s, 3H), 1.64- 1.89 (m, 4H), 1.43 (br.
s., 2H) Example 12 5-(4-(4-azidobut-1-ynyl)phenyI)-1-(2,4-dichloropheny1)-4-methyl-N-(piperidi n-1-yI)-1H-pyrazole-3-carboxam ide (compound 14) 1H NMR (500 MHz, CDCI3-d) D 7.62 (s, 1H), 7.41 (s, 1H), 7.35 (d, J = 7.81 Hz, 2H), 7.27 - 7.29 (m, 2H), 7.04 (d, J = 8.30 Hz, 2H), 3.46 (t, J = 6.59 Hz, 2H), 2.87 (br. s., 4H), 2.71 (t, J = 6.59 Hz, 2H), 2.37 (s, 3H), 1.64 - 1.86 (m, 4H), 1.43 (br.
s., 2H) Example 13 1-(2,4-dichlorophenyI)-5-(4-(4-isothiocyanatobut-1-ynyl)pheny1)-4-methyl-N-(piperidin-1-yI)-1H-pyrazole-3-carboxamide (compound 11) 1H NMR (500 MHz, CDCI3-d) 7.63 (br. s., 1H), 7.42 (s, 1H), 7.38 (d, J = 8.30 Hz, 2H), 7.27 - 7.30 (m, 2H), 7.06 (d, J = 8.30 Hz, 2H), 3.70 (t, J = 6.59 Hz, 2H), 2.87 (br.
s., 4H), 2.82 (t, J= 6.59 Hz, 2H), 2.38 (s, 3H), 1.70 - 1.83 (m, 4H), 1.43 (br. s., 2H) Example 14 5-(4-(4-cyanobut-1-ynyl)pheny1)-1-(2,4-dichloropheny1)-4-ethyl-N-(piperidin-1-y1)-1H-pyrazole-3-carboxamide (compound 22) 1H NMR (500 MHz, CDCI3-d) 7.65 (s, 1H), 7.41 (s, 1H), 7.35 (d, J = 8.30 Hz, 2H), 7.28 - 7.30 (m, 1H), 7.27 (s, 1H), 7.07 (d, J = 7.81 Hz, 2H), 2.87 (br. s., 4H), 2.70 -2.82 (m, 4H), 2.54 - 2.69 (m, 2H), 1.76 (quin, J = 5.62 Hz, 4H), 1.43 (br. s., 2H), 1.21 =
(t, J= 7.32 Hz, 3H) Example 15 5-(4-(4-cyanobut-1-ynyl)phenyI)-1-(2,4-dichloropheny1)-4-ethyl-N-morpholino-1H-pyrazole-3-carboxamide (compound 25) 1H NMR (500 MHz, CDCI3-d) 7.71 (s, 1H), 7.42 (s, 1H), 7.36 (d, J = 8.30 Hz, 2H), 7.30 (none, 1H), 7.26 (s, 1H), 7.08 (d, J = 8.30 Hz, 2H), 3.78 - 3.93 (m, 4H), 2.95 (br.
s., 4H), 2.73 - 2.85 (m, 4H), 2.59 - 2.69 (m, 2H), 1.21 (t, J = 7.32 Hz, 3H) Example 16 3-((4-(1-(2,4-dichloropheny1)-4-methy1-3-(piperidin-1-ylcarbamoy1)-1H-pyrazol-y1)phenypethynyl)pyridine 1-oxide (compound 23) 1H NMR (500 MHz, CDCI3-d) 0 8.31 (s, 1H), 8.17 (d, J = 6.84 Hz, 1H), 7.64 (s, 1H), 7.48 (d, J = 8.30 Hz, 2H), 7.43 (s, 1H), 7.36 (d, J = 8.30 Hz, 1H), 7.31 (s, 2H), 7.28 (s, 1H), 7.14 (d, J = 8.30 Hz, 2H), 2.87 (br. s., 4H), 2.40 (s, 3H), 1.76 (quin, J = 5.62 Hz, 4H), 1.44 (br. s., 2H) Example 17 1-(2,4-dichloropheny1)-4-ethyl-N-morpholino-5-pheny1-1H-pyrazole-3-carboxamide (compound 20) 1H NMR (500 MHz, CDCI3-d) 7.72 (s, 1H), 7.41 (s, 1H), 7.28 -7.37 (m, 3H), 7.27 (s, 2H), 7.08 - 7.19 (m, 2H), 3.63 - 4.07 (m, 4H), 2.86 - 3.15 (m, 4H), 2.78 (q, J
= 7.32 Hz, 2H), 1.22 (t, J = 7.32 Hz, 3H) Example 18 5-(4-(4-cyanobut-1-ynyl)phenyI)-1-(2,4-dichloropheny1)-4-ethyl-N-(1,1-dioxo-thiomorpholino)-1H-pyrazole-3-carboxamide (compound 24) 1H NMR (500 MHz, CDCI3-d) 8.10 (s, 1H), 7.43 (d, J = 1.95 Hz, 1H), 7.37 (d, J
=
8.30 Hz, 2H), 7.28 - 7.32 (m, 1H), 7.24 (s, 1H), 7.07 (d, J = 8.30 Hz, 2H), 3.47 - 3.63 (m, 4H), 3.27 (d, J = 4.88 Hz, 4H), 2.71 - 2.84 (m, 4H), 2.59 - 2.69 (m, 2H), 1.61 (s, 3H), 1.21 (t, J = 7.32 Hz, 3H) Example 19 4-cyano-5-(4-(4-cyanobut-1-ynyl)pheny1)-1-(2,4-dichloropheny1)-N-(piperidin-1-y1)-1H-pyrazole-3-carboxamide (compound 28) 1H NMR (500 MHz, CDCI3-d) 7.54 (br. s., 1H), 7.49 (d, J = 1.95 Hz, 1H), 7.32 -7.44 (m, 4H), 7.25 (d, 2H), 2.91 (br. s., 4H), 2.73 - 2.85 (m, 2H), 2.59 - 2.72 (m, 2H), 1.67 -1.87 (m, 4H), 1.44 (br. s., 2H) Example 20 4-cyano-5-(4-(4-cyanobut-1-ynyl)pheny1)-1-(2,4-dichloropheny1)-N-morpholino-1H-pyrazole-3-carboxamide (compound 29) 1H NMR (500 MHz, CDCI3-d) 7.61 (s, 1H), 7.50 (s, 1H), 7.35- 7.47 (m, 4H), 7.27 (d, 2H), 3.74 - 3.93 (m, 4H), 2.91 - 3.07 (m, 4H), 2.73 - 2.87 (m, 2H), 2.58 -2.71 (m, 2H) Example 21 5-(4-(4-cyanobut-1-ynyl)phenyI)-1-(2,4-dichloropheny1)-4-cyano-N-(1,1-dioxo-thiomorpholino)-1H-pyrazole-3-carboxamide (compound 32) 1H NMR (500 MHz, CDCI3-d) 7.98 (s, 1H), 7.51 (d, J = 1.95 Hz, 1H), 7.38 - 7.45 (m, 3H), 7.33 - 7.38 (m, 1H), 7.25 (d, 2H), 3.50 - 3.68 (m, 4H), 3.17 - 3.34 (m, 4H), 2.72 -2.90 (m, 2H), 2.55 - 2.70 (m, 2H) Forskolin-Stimulated cAMP Assay Intracellular cAMP levels were measured with a competitive protein-binding assay using intact HEK293 cells expressing hCB1 or hCB2 and a cAMP
immunoassay kit from Sigma (St. Louis, MO). In short, forskolin stimulated cells were incubated with various concentrations of compound, cAMP anti-body and cAMP
conjugate for 2 hours at ambient temperature. The reaction was stopped by emptying the wells followed by the addition of p-NPP substrate and incubation for 1 hour. This reaction was stopped and absorbance intensity, detected at 405 nm, was inversely proportional to the concentration of cAMP produced by the cells. The results were expressed as percent inhibition of forskolin-stimulated cAMP
accumulation and EC50 curves were generated with the use of GraphPad Prism software.
For example compound 2 and compound 15 did not change the forskolin-stimulated cAMP accumulation in CB1 transfected HEK cells (Figures 1A and 1B) and are therefore considered to be a CBI neutral antagonists.
The results are from one assay done in triplicate.
Reference herein to a "standard forskolin-stimulated cAMP assay" or like phrase refers to the foregoing assay method.
[3H]CP55,940 Competitive Binding Assay Some of the inventive analogs were tested for CBI receptor binding affinity and for CB2 receptor affinity (to determine selectivity). As used herein, "binding affinity" is represented by the K1 value which is the inhibition constant correlated with the concentration of an analog required to occupy the 50% of the total number (Bmax) of the receptors. The lower the Ki value the higher the binding affinity. As used herein an analog is said to have "binding selectivity" if it has higher binding affinity for one receptor compared to the other receptor; e.g. a cannabinoid analog which has a Ki of 0.1 nM for CB1 and 10 nM for CB2, is 100 times more selective for the CBI receptor.
For the CBI receptor binding studies, membranes were prepared from rat forebrain membranes according to the procedure of P. R. Dodd et at, A Rapid Method for Preparing Synaptosomes: Comparison with Alternative Procedures, Brain Res., 107 - 118 (1981). The binding of the novel analogues to the CB1 cannabinoid receptor was assessed as described in W. A. Devane et al, Determination and Characterization of a Cannabinoid Receptor in a Rat Brain, Mol. Pharmacol., 34, 605 - 613 (1988) and A. Charalambous et at, 5'-azido g THC: A Novel_ Photoaffinity Label for the Cannabinoid Receptor_, J. Med. Chem., 35, 3076 - 3079 (1992) with the following changes.
Membranes, previously frozen at -80 C, were thawed on ice. To the stirred suspension was added three volumes of TME (25 mM Tris-HCI buffer, 5 mM MgC12 and 1 mM EDTA) at a pH 7.4. The suspension was incubated at 4 C for 30 min. At the end of the incubation, the membranes were pelleted and washed three times with TME.
The treated membranes were subsequently used in the binding assay described below. Approximately 30 j.tg of membranes were incubated in silanized 96-well microtiter plate with TME containing 0.1% essentially fatty acid-free bovine serum albumin (BSA), 0.8 nM [3H] CP-55,940, and various concentrations of test materials in a final volume of 200 L. The assays were incubated for 1 hour at and then immediately filtered using Packard Filtermate 196 harvester and Whatman GF/C filterplates and washed with wash buffer (TME) containing 0.5% BSA.
Radioactivity was detected using MicroScint 20 scintillation cocktail added directly to the dried filterplates, and the filterplates were counted using a Packard Instruments Top-Count. Nonspecific binding was assessed using 100 nM CP-55,940. Data collected from three independent experiments performed with duplicate determinations was normalized between 100% and 0% specific binding for CH] CP-55,940, determined using buffer and 100 nM CP-55,940. The normalized data was analyzed using a 4-parameter nonlinear logistic equation to yield IC50 values.
Data from at least two independent experiments performed in duplicate was used to calculate IC50 values which were converted to K1 values using the assumptions of Cheng et at, Relationship Between the Inhibition Constant (KO and the concentration of Inhibitor which causes 50% Inhibition (IC) of an Enzymatic Reaction, Biochem.
Pharmacol., 22, 3099-3102, (1973) For the CB2 receptor binding studies, membranes were prepared from frozen mouse spleen essentially according to the procedure of P. R. Dodd et at, A
Rapid Method for Preparing Synaptosomes: Comparison with Alternative Procedures, Brain Res., 226, 107 - 118 (1981) Silanized centrifuge tubes were used throughout to minimize receptor loss due to adsorption.
The CB2 binding assay was conducted in the same manner as for the CB1 binding assay. The binding affinities (K1) were also expressed in nanomoles (nM).
The CB1 cannabinoid receptor binding affinities (Ki) for some of the compounds disclosed in the invention range between 0.5 nM and less than 100 nM . The CB2 cannabinoid receptor binding affinities (Ki) for the synthesized analogs range between 60 nM and 5000 nM. For example, CB1 cannabinoid receptor binding affinity (Ki) for compound 2 is 7 nM and the CB2 cannabinoid receptor binding affinity (Ki) is 1672 nM. The CB1 selectivity for some of the compounds range from 5 to greater than 5000.
Distribution and the Blood Brain Barrier:
Mice (CD-1, weighing 25-30 g) are dosed intravenously or by oral gavage with 0.1-2 mg/kg of the compound dissolved in appropriate vehicle. Fifteen minutes post-injection or 30 and 60 minutes post-gavage, the animals are sacrificed humanely by decapitation followed by blood collection (-500 pL) and tissue dissection;
samples are flash frozen with liquid nitrogen to prevent post-mortem degradation of the compounds or endogenous ligands. Tissues (plasma or brain) are extracted and analyzed using a Thermo-Finnigan Quantum Ultra triple quadrupole mass spectrometer with an Agilent 1100 HPLC front-end. Chromatographic separation is achieved using a Phenomenex Gemini column (2 x 50 mm, 54 Hardware consists of a Finnigan TSQ Quantum Ultra triple quad mass spectrometer with both an and ESI source and an Agilent 1100 front end. The mass spectrometer with mobile phase consisting of 0.1% formic acid in water (A) and 0.1% formic acid in methanol (B). SR141716 gets into the brain better at 1.8%/g (% of the total dose per gram brain) at 15 minutes post IV as compared to compound 2 which is 0.6%.
1H NMR (500 MHz, CDCI3-d) 7.69 (d, J = 8.30 Hz, 2H), 7.41 (s, 1H), 7.29 - 7.39 (m, 2H), 6.89 (d, J = 8.30 Hz, 2H), 4.48 (q, J = 7.32 Hz, 2H), 2.35 (s, 3H), 1.37 -1.53 (m, 3H) Step D
1-(2,4-dichlorophenyI)-5-(4-iodopheny1)-4-methyl-1H-pyrazole-3-carboxylic acid The ester (10 g, 19.9 mmoles) obtained from step C was taken in 500 ml 1 neck flask and to it 300 ml of 7:2:1 mixture of THF-methanol-water along with solid lithium hydroxide (2.5 g, 104.6 mol) was added. The mixture was refluxed for 12 hours.
The solvents were removed totally and to the residue 200 ml of DCM was added. To that 100 ml of water was added and the mixture was acidified to pH¨ 2 using concentrated HCI. The organic layer was separated, washed with 100 ml of brine, dried over sodium sulphate and concentrated to give the acid. This was taken directly to the next step (9.4 g, 100%).
1H NMR (500 MHz, CDCI3-d) 7.70 (d, J 7 8.30 Hz, 2H), 7.44 (s, 1H), 7.30 - 7.38 (m, 2H), 6.90 (d, J = 8.30 Hz, 2H), 2.37 (s, 3H) Step E
1-(2,4-dichloropheny1)-4-methy1-5-(4-iodopheny1)-N-(1,1-dioxothiomorpholino)-pyrazole-3-carboxamide (compound 16) The acid (7.5 g, 15.8 mmol) obtained from step D was taken in a 500 ml 1 neck flask equipped with a nitrogen inlet and to it 200 ml of DCM, 4-aminothiomorpholine-1,1-dioxide (2.61 g, 17.4 mmol), TBTU (5.59g, 17.4 mmol) and DIPEA (2.25 g, 17.4 mmol) were added and the contents were stirred for 1 hour. To the reaction mixture, 100 ml of water was added and the contents were acidified to pH-2 using concentrated HC1. The organic layer was separated, washed with brine, dried over sodium sulphate and concentrated to give the amide (3 g, 31.2%).
1H NMR (500 MHz, CDCI3-d) 8.07 (s, 1H), 7.67 (d, J = 8.30 Hz, 2H), 7.45 (d, J
=
1.95 Hz, 1H), 7.29 - 7.34 (m, 1H), 7.25 (s, 1H), 6.85 (d, J = 8.30 Hz, 2H), 3.44 - 3.66 (m, 4H), 3.26 (d, J = 4.88 Hz, 4H), 2.35 (s, 3H) Step F
To a stirred solution of amide obtained from step E (2 g, 3.3 mmol) in pyrrolidine (40 ml), under an argon atmosphere, tetrakis(triphenylphosphine)palladium(0) (0.4 g, 0.3 mmol) was added. The reaction mixture was stirred for 5 min at room temperature, and subsequently 4-cyano-1-butyne (0.78 g, 9.9 mmol) in pyrrolidine (1.5 ml) was added over 5 minutes. The resulting mixture was heated at 80-85 C for 10 h.
The reaction was hydrolyzed with a saturated aqueous solution of ammonium chloride and extracted with ethyl acetate. The organic extract was dried over MgSO4 and the solvent was removed in vacuo. Purification by flash column chromatography on silica gel (eluant ethylacetate) gave compound 15 as a white solid (0.8 g, 43.7%) 1H NMR (500 MHz, CDCI3-d) 8.08 (s, 1H), 7.43 (s, 1H), 7.37 (d, J = 7.81 Hz, 2H), 7.28 - 7.34 (m, 1H), 7.24 (s, 1H), 7.06 (d, J = 7.81 Hz, 2H), 3.56 (d, J =
4.88 Hz, 4H), 3.26 (br. s., 4H), 2.72 - 2.87 (m, 2H), 2.57 - 2.71 (m, 2H), 2.37 (s, 3H) Example 4 5-(5-(4-cyanobut-1-ynyl)thiophen-2-y1)-1-(2,4-dichloropheny1)-4-methyl-N-(piperidin-1-y1)-1H-pyrazole-3-carboxamide (compound 34) Step A
N-Methoxy-N-methylpropionamide:
Pyridine (17 mL, 0.4 mol) at 0 C was added dropwise to a solution of 0,N-dimethyl-hydroxylamine hydrochloride (10 g, 0.1 mol) and propionyl chloride (10 g, 0.1 mol) in anhydrous dichloromethane (250 mL). The solution was stirred at room temperature for 24 h, washed with 2x 50 ml of 5% hydrochloric acid, 100 ml of saturated NaHCO3 and 100 ml brine, dried over MgSO4 and concentrated under reduced pressure to give colorless oil (10 g, 89 %).
Step B
1-(5-iodothiophen-2-yl)propan-1-one 38.4 ml of a 2M solution of lithium diisopropylamide (8.2 g, 76.8 mmol) in THF-heptane-ethylbenzene was added to THE (50 ml) taken in a 500 three neck RB
flask equipped with a nitrogen inlet. The mixture was cooled to -40 C and then 2-iodothiophene (16.1 g, 76.8 mmol) taken in 50 ml of THE was added with vigorous stirring. After 10 minutes the mixture was warmed to -10 C and stirred for 30 min.
The reaction mixture was re-cooled to -40 C and N-methoxy-N-methylpropionamide (9 g, 76.8 mmol) taken in 50 ml of THE was added in one portion. The reaction mixture was allowed to warm slowly to 0 C and then the reaction was quenched with saturated 50 ml of NH4CI solution. The contents were extracted with 3 x 100 ml of DCM, dried over MgSO4 and concentrated to give an oily residue. This was purified by flash chromatography to give the title compound (10 g, 49%).
1H NMR (500 MHz, CDC13-d) 7.32 (d, 1H), 7.27- 7.30 (m, 1H), 2.86 (q, J = 7.32 Hz, 2H), 1.21 (t, J = 7.32 Hz, 3H) Step C
ethy11-(2,4-dichloropheny1)-5-(5-iodothiophen-2-y1)-4-methyl-1H-pyrazole-3-carboxylate The title compound was obtained as in example 3 1H NMR (500 MHz, CDC13-d) 7.46 (d, J = 1.95 Hz, 1H), 7.35 - 7.39 (m, 1H), 7.34 (d, 1H), 7.14 (d, J = 3.91 Hz, 1H), 6.55 (d, J = 3.91 Hz, 1H), 4.45 (q, J = 6.84 Hz, 2H), 2.42 (s, 3H), 1.42 (t, J = 7.08 Hz, 3H) Step D
1-(2,4-dichloropheny1)-5-(5-iodothiophen-2-y1)-4-methyl-N-(piperidin-1-y1)-1H-pyrazole-3-carboxamide The title compound was obtained as in example 3 Step E
The title compound was obtained as in example 3 1H NMR (500 MHz, CDCI3-d) 7.60 (br. s., 1H), 7.50 (d, J = 1.95 Hz, 1H), 7.35 -7.39 (m, 1H), 7.31 - 7.35 (m, 1H), 7.05 (d, J = 3.91 Hz, 1H), 6.72 (d, J = 3.42 Hz, 1H), 2.85 (br. s., 4H), 2.80 (t, J = 7.08 Hz, 2H), 2.56 - 2.70 (m, 2H), 2.47 (s, 3H), 1.75 (quin, J =
5.62 Hz, 4H), 1.43 (br. s., 2H) Example 5 1-(2,4-dichloropheny1)-5-(5-iodothiophen-2-y1)-4-methyl-N-(1,1-dioxothiomorpholino)-1H-pyrazole-3-carboxamide (compound 44) 1H NMR (500 MHz, CDCI3-d) 8.10 (s, 1H), 7.54 (d, J = 1.95 Hz, 1H), 7.36- 7.42 (m, 1H), 7.33 (d, 1H), 7.17 (d, J = 3.91 Hz, 1H), 6.57 (d, J = 3.91 Hz, 1H), 3.57 (br. s., 4H), 3.28 (br. s., 4H), 2.47 (s, 3H) Example 6 N-(1-cyanocyclopropy1)-1-(2 ,4-d ichloropheny1)-5-(5-iodothiophen-2-y1)-4-methy1-1H-pyrazole-3-carboxamide (compound 43) 1H NMR (500 MHz, CDC13-d) 7.53 (s, 1H), 7.41 (none, 1H), 7.30- 7.34 (m, 1H), 7.17 (d, J = 3.91 Hz, 1H), 6.57 (d, J = 3.91 Hz, 1H), 2.46 - 2.57 (m, 3H), 1.63 (br. s., 2H), 1.35 - 1.42 (m, 2H) Example 7 5-(4-(4-cyanobut-1-ynyl)pheny1)-1-(2,4-dichloropheny1)-4-(hydroxymethyl)-N-morpholino-1H-pyrazole-3-carboxamide (compound 2) 1H NMR (500 MHz, CDC13-d) 7.84 (s, 1H), 7.45 (d, J = 2.44 Hz, 1H), 7.37 (d, J
=
8.30 Hz, 2H), 7.29 - 7.33 (m, 1H), 7.25 (s, 1H), 7.07 (d, J = 8.30 Hz, 2H), 5.01 (t, J =
7.08 Hz, 1H), 4.63 (d, J = 7.32 Hz, 2H), 3.89 (t, J = 4.64 Hz, 4H), 2.96 (d, J
= 4.39 Hz, 4H), 2.72 - 2.84 (m, 2H), 2.56 - 2.69 (m, 2H) Example 8 4-(4-(1-(2,4-dichloropheny1)-4-methy1-3-(piperidin-1-ylcarbamoy1)-1H-pyrazol-5-yl)phenyl)but-3-ynyl methanesulfonate (compound 9) 1H NMR (500 MHz, CDC13-d) 7.67 (br. s., 1H), 7.43 (s, 1H), 7.35 (d, J = 7.81 Hz, 2H), 7.29 - 7.33 (m, 2H), 7.07 (d, J = 8.30 Hz, 2H), 4.39 (t, J = 6.59 Hz, 2H), 3.08 (s, 3H), 2.77 - 2.96 (m, 6H), 2.39 (s, 3H), 1.77 (br. s., 4H), 1.45 (br. s., 2H) Example 9 S-4-(4-(1-(2,4-dichloropheny1)-4-methy1-3-(piperidi n-1-ylcarbamoy1)-1H-pyrazol-5-yl)phenyl)but-3-ynyl ethanethioate (compound 5) 1H NMR (500 MHz, CDC13-d) 7.62 (s, 1H), 7.41 (s, 1H), 7.33 (d, J = 8.30 Hz, 2H), 7.27 - 7.30 (m, 2H), 7.04 (d, J = 8.30 Hz, 2H), 3.10 (t, J = 7.08 Hz, 2H), 2.87 (br. s., 4H), 2.69 (t, J = 7.08 Hz, 2H), 2.36 (d, J = 8.79 Hz, 6H), 1.75 (quin, J =
5.62 Hz, 4H), 1.43 (br. s., 2H) Example 10 1-(2,4-dichloropheny1)-5-(4-(4-iodobut-1-ynyl)pheny1)-4-methyl-N-(piperidin-1-y1)-1H-pyrazole-3-carboxamide (compound 6) 1H NMR (500 MHz, CDCI3-d) 7.63 (s, 1H), 7.41 (s, 1H), 7.36 (d, J = 8.30 Hz, 2H), 7.27 - 7.31 (m, 2H), 7.05 (d, J = 8.30 Hz, 2H), 3.30 (t, J = 7.32 Hz, 2H), 3.00 (t, J =
7.32 Hz, 2H), 2.86 (br. s., 4H), 2.37 (s, 3H), 1.67- 1.84 (m, 4H), 1.43 (br.
s., 2H) Example 11 5-(4-(but-3-en-1-ynyl)pheny1)-1-(2,4-dichloropheny1)-4-methyl-N-(piperidin-1-y1)-1H-pyrazole-3-carboxamide (compound 13) 1H NMR (500 MHz, CDCI3-d) 7.63 (s, 1H), 7.41 (s, 1H), 7.37 (d, J = 7.81 Hz, 2H), 7.27 (br. s., 2H), 7.06 (d, J = 7.81 Hz, 2H), 6.00 (dd, J = 11.23, 17.58 Hz, 1H), 5.49 -5.81 (m, 2H), 2.87 (br. s., 4H), 2.38 (s, 3H), 1.64- 1.89 (m, 4H), 1.43 (br.
s., 2H) Example 12 5-(4-(4-azidobut-1-ynyl)phenyI)-1-(2,4-dichloropheny1)-4-methyl-N-(piperidi n-1-yI)-1H-pyrazole-3-carboxam ide (compound 14) 1H NMR (500 MHz, CDCI3-d) D 7.62 (s, 1H), 7.41 (s, 1H), 7.35 (d, J = 7.81 Hz, 2H), 7.27 - 7.29 (m, 2H), 7.04 (d, J = 8.30 Hz, 2H), 3.46 (t, J = 6.59 Hz, 2H), 2.87 (br. s., 4H), 2.71 (t, J = 6.59 Hz, 2H), 2.37 (s, 3H), 1.64 - 1.86 (m, 4H), 1.43 (br.
s., 2H) Example 13 1-(2,4-dichlorophenyI)-5-(4-(4-isothiocyanatobut-1-ynyl)pheny1)-4-methyl-N-(piperidin-1-yI)-1H-pyrazole-3-carboxamide (compound 11) 1H NMR (500 MHz, CDCI3-d) 7.63 (br. s., 1H), 7.42 (s, 1H), 7.38 (d, J = 8.30 Hz, 2H), 7.27 - 7.30 (m, 2H), 7.06 (d, J = 8.30 Hz, 2H), 3.70 (t, J = 6.59 Hz, 2H), 2.87 (br.
s., 4H), 2.82 (t, J= 6.59 Hz, 2H), 2.38 (s, 3H), 1.70 - 1.83 (m, 4H), 1.43 (br. s., 2H) Example 14 5-(4-(4-cyanobut-1-ynyl)pheny1)-1-(2,4-dichloropheny1)-4-ethyl-N-(piperidin-1-y1)-1H-pyrazole-3-carboxamide (compound 22) 1H NMR (500 MHz, CDCI3-d) 7.65 (s, 1H), 7.41 (s, 1H), 7.35 (d, J = 8.30 Hz, 2H), 7.28 - 7.30 (m, 1H), 7.27 (s, 1H), 7.07 (d, J = 7.81 Hz, 2H), 2.87 (br. s., 4H), 2.70 -2.82 (m, 4H), 2.54 - 2.69 (m, 2H), 1.76 (quin, J = 5.62 Hz, 4H), 1.43 (br. s., 2H), 1.21 =
(t, J= 7.32 Hz, 3H) Example 15 5-(4-(4-cyanobut-1-ynyl)phenyI)-1-(2,4-dichloropheny1)-4-ethyl-N-morpholino-1H-pyrazole-3-carboxamide (compound 25) 1H NMR (500 MHz, CDCI3-d) 7.71 (s, 1H), 7.42 (s, 1H), 7.36 (d, J = 8.30 Hz, 2H), 7.30 (none, 1H), 7.26 (s, 1H), 7.08 (d, J = 8.30 Hz, 2H), 3.78 - 3.93 (m, 4H), 2.95 (br.
s., 4H), 2.73 - 2.85 (m, 4H), 2.59 - 2.69 (m, 2H), 1.21 (t, J = 7.32 Hz, 3H) Example 16 3-((4-(1-(2,4-dichloropheny1)-4-methy1-3-(piperidin-1-ylcarbamoy1)-1H-pyrazol-y1)phenypethynyl)pyridine 1-oxide (compound 23) 1H NMR (500 MHz, CDCI3-d) 0 8.31 (s, 1H), 8.17 (d, J = 6.84 Hz, 1H), 7.64 (s, 1H), 7.48 (d, J = 8.30 Hz, 2H), 7.43 (s, 1H), 7.36 (d, J = 8.30 Hz, 1H), 7.31 (s, 2H), 7.28 (s, 1H), 7.14 (d, J = 8.30 Hz, 2H), 2.87 (br. s., 4H), 2.40 (s, 3H), 1.76 (quin, J = 5.62 Hz, 4H), 1.44 (br. s., 2H) Example 17 1-(2,4-dichloropheny1)-4-ethyl-N-morpholino-5-pheny1-1H-pyrazole-3-carboxamide (compound 20) 1H NMR (500 MHz, CDCI3-d) 7.72 (s, 1H), 7.41 (s, 1H), 7.28 -7.37 (m, 3H), 7.27 (s, 2H), 7.08 - 7.19 (m, 2H), 3.63 - 4.07 (m, 4H), 2.86 - 3.15 (m, 4H), 2.78 (q, J
= 7.32 Hz, 2H), 1.22 (t, J = 7.32 Hz, 3H) Example 18 5-(4-(4-cyanobut-1-ynyl)phenyI)-1-(2,4-dichloropheny1)-4-ethyl-N-(1,1-dioxo-thiomorpholino)-1H-pyrazole-3-carboxamide (compound 24) 1H NMR (500 MHz, CDCI3-d) 8.10 (s, 1H), 7.43 (d, J = 1.95 Hz, 1H), 7.37 (d, J
=
8.30 Hz, 2H), 7.28 - 7.32 (m, 1H), 7.24 (s, 1H), 7.07 (d, J = 8.30 Hz, 2H), 3.47 - 3.63 (m, 4H), 3.27 (d, J = 4.88 Hz, 4H), 2.71 - 2.84 (m, 4H), 2.59 - 2.69 (m, 2H), 1.61 (s, 3H), 1.21 (t, J = 7.32 Hz, 3H) Example 19 4-cyano-5-(4-(4-cyanobut-1-ynyl)pheny1)-1-(2,4-dichloropheny1)-N-(piperidin-1-y1)-1H-pyrazole-3-carboxamide (compound 28) 1H NMR (500 MHz, CDCI3-d) 7.54 (br. s., 1H), 7.49 (d, J = 1.95 Hz, 1H), 7.32 -7.44 (m, 4H), 7.25 (d, 2H), 2.91 (br. s., 4H), 2.73 - 2.85 (m, 2H), 2.59 - 2.72 (m, 2H), 1.67 -1.87 (m, 4H), 1.44 (br. s., 2H) Example 20 4-cyano-5-(4-(4-cyanobut-1-ynyl)pheny1)-1-(2,4-dichloropheny1)-N-morpholino-1H-pyrazole-3-carboxamide (compound 29) 1H NMR (500 MHz, CDCI3-d) 7.61 (s, 1H), 7.50 (s, 1H), 7.35- 7.47 (m, 4H), 7.27 (d, 2H), 3.74 - 3.93 (m, 4H), 2.91 - 3.07 (m, 4H), 2.73 - 2.87 (m, 2H), 2.58 -2.71 (m, 2H) Example 21 5-(4-(4-cyanobut-1-ynyl)phenyI)-1-(2,4-dichloropheny1)-4-cyano-N-(1,1-dioxo-thiomorpholino)-1H-pyrazole-3-carboxamide (compound 32) 1H NMR (500 MHz, CDCI3-d) 7.98 (s, 1H), 7.51 (d, J = 1.95 Hz, 1H), 7.38 - 7.45 (m, 3H), 7.33 - 7.38 (m, 1H), 7.25 (d, 2H), 3.50 - 3.68 (m, 4H), 3.17 - 3.34 (m, 4H), 2.72 -2.90 (m, 2H), 2.55 - 2.70 (m, 2H) Forskolin-Stimulated cAMP Assay Intracellular cAMP levels were measured with a competitive protein-binding assay using intact HEK293 cells expressing hCB1 or hCB2 and a cAMP
immunoassay kit from Sigma (St. Louis, MO). In short, forskolin stimulated cells were incubated with various concentrations of compound, cAMP anti-body and cAMP
conjugate for 2 hours at ambient temperature. The reaction was stopped by emptying the wells followed by the addition of p-NPP substrate and incubation for 1 hour. This reaction was stopped and absorbance intensity, detected at 405 nm, was inversely proportional to the concentration of cAMP produced by the cells. The results were expressed as percent inhibition of forskolin-stimulated cAMP
accumulation and EC50 curves were generated with the use of GraphPad Prism software.
For example compound 2 and compound 15 did not change the forskolin-stimulated cAMP accumulation in CB1 transfected HEK cells (Figures 1A and 1B) and are therefore considered to be a CBI neutral antagonists.
The results are from one assay done in triplicate.
Reference herein to a "standard forskolin-stimulated cAMP assay" or like phrase refers to the foregoing assay method.
[3H]CP55,940 Competitive Binding Assay Some of the inventive analogs were tested for CBI receptor binding affinity and for CB2 receptor affinity (to determine selectivity). As used herein, "binding affinity" is represented by the K1 value which is the inhibition constant correlated with the concentration of an analog required to occupy the 50% of the total number (Bmax) of the receptors. The lower the Ki value the higher the binding affinity. As used herein an analog is said to have "binding selectivity" if it has higher binding affinity for one receptor compared to the other receptor; e.g. a cannabinoid analog which has a Ki of 0.1 nM for CB1 and 10 nM for CB2, is 100 times more selective for the CBI receptor.
For the CBI receptor binding studies, membranes were prepared from rat forebrain membranes according to the procedure of P. R. Dodd et at, A Rapid Method for Preparing Synaptosomes: Comparison with Alternative Procedures, Brain Res., 107 - 118 (1981). The binding of the novel analogues to the CB1 cannabinoid receptor was assessed as described in W. A. Devane et al, Determination and Characterization of a Cannabinoid Receptor in a Rat Brain, Mol. Pharmacol., 34, 605 - 613 (1988) and A. Charalambous et at, 5'-azido g THC: A Novel_ Photoaffinity Label for the Cannabinoid Receptor_, J. Med. Chem., 35, 3076 - 3079 (1992) with the following changes.
Membranes, previously frozen at -80 C, were thawed on ice. To the stirred suspension was added three volumes of TME (25 mM Tris-HCI buffer, 5 mM MgC12 and 1 mM EDTA) at a pH 7.4. The suspension was incubated at 4 C for 30 min. At the end of the incubation, the membranes were pelleted and washed three times with TME.
The treated membranes were subsequently used in the binding assay described below. Approximately 30 j.tg of membranes were incubated in silanized 96-well microtiter plate with TME containing 0.1% essentially fatty acid-free bovine serum albumin (BSA), 0.8 nM [3H] CP-55,940, and various concentrations of test materials in a final volume of 200 L. The assays were incubated for 1 hour at and then immediately filtered using Packard Filtermate 196 harvester and Whatman GF/C filterplates and washed with wash buffer (TME) containing 0.5% BSA.
Radioactivity was detected using MicroScint 20 scintillation cocktail added directly to the dried filterplates, and the filterplates were counted using a Packard Instruments Top-Count. Nonspecific binding was assessed using 100 nM CP-55,940. Data collected from three independent experiments performed with duplicate determinations was normalized between 100% and 0% specific binding for CH] CP-55,940, determined using buffer and 100 nM CP-55,940. The normalized data was analyzed using a 4-parameter nonlinear logistic equation to yield IC50 values.
Data from at least two independent experiments performed in duplicate was used to calculate IC50 values which were converted to K1 values using the assumptions of Cheng et at, Relationship Between the Inhibition Constant (KO and the concentration of Inhibitor which causes 50% Inhibition (IC) of an Enzymatic Reaction, Biochem.
Pharmacol., 22, 3099-3102, (1973) For the CB2 receptor binding studies, membranes were prepared from frozen mouse spleen essentially according to the procedure of P. R. Dodd et at, A
Rapid Method for Preparing Synaptosomes: Comparison with Alternative Procedures, Brain Res., 226, 107 - 118 (1981) Silanized centrifuge tubes were used throughout to minimize receptor loss due to adsorption.
The CB2 binding assay was conducted in the same manner as for the CB1 binding assay. The binding affinities (K1) were also expressed in nanomoles (nM).
The CB1 cannabinoid receptor binding affinities (Ki) for some of the compounds disclosed in the invention range between 0.5 nM and less than 100 nM . The CB2 cannabinoid receptor binding affinities (Ki) for the synthesized analogs range between 60 nM and 5000 nM. For example, CB1 cannabinoid receptor binding affinity (Ki) for compound 2 is 7 nM and the CB2 cannabinoid receptor binding affinity (Ki) is 1672 nM. The CB1 selectivity for some of the compounds range from 5 to greater than 5000.
Distribution and the Blood Brain Barrier:
Mice (CD-1, weighing 25-30 g) are dosed intravenously or by oral gavage with 0.1-2 mg/kg of the compound dissolved in appropriate vehicle. Fifteen minutes post-injection or 30 and 60 minutes post-gavage, the animals are sacrificed humanely by decapitation followed by blood collection (-500 pL) and tissue dissection;
samples are flash frozen with liquid nitrogen to prevent post-mortem degradation of the compounds or endogenous ligands. Tissues (plasma or brain) are extracted and analyzed using a Thermo-Finnigan Quantum Ultra triple quadrupole mass spectrometer with an Agilent 1100 HPLC front-end. Chromatographic separation is achieved using a Phenomenex Gemini column (2 x 50 mm, 54 Hardware consists of a Finnigan TSQ Quantum Ultra triple quad mass spectrometer with both an and ESI source and an Agilent 1100 front end. The mass spectrometer with mobile phase consisting of 0.1% formic acid in water (A) and 0.1% formic acid in methanol (B). SR141716 gets into the brain better at 1.8%/g (% of the total dose per gram brain) at 15 minutes post IV as compared to compound 2 which is 0.6%.
Claims (20)
1. A compound represented by the following structural formula:
and physiologically acceptable salts thereof, wherein:
A is a direct bond, B is N(R5), R5 is hydrogen, OH, alkyl or substituted alkyl;
R2 comprises -(CH2)n-Z;
n is an integer from 0 to 7;
wherein Z comprises, H, halogen, CF3, CF2H, N3, NCS, CN, NO2, NX1X2, OX3, SX3, OAc, OSO2X3, O-acyl, S-acyl, SO2-alkyl, SO-alkyl, SC(CH3)2COOX8, OC(CH3)2COOX8 , C(CH3)2COOX8, Si(alkyl)3, alkyl-CN, O-aroyl, O(CH2)j OX3, O(CH2)j NX1X2, NH-acyl, NH-aroyl, CHO, C(halogen)3, COOX3, SO3H, SO2NX1X2, CONX1X2, NHC(O)O-alkyl, NHSO2-alkyl, alkoxy, alkyl, alcohol, alkylmercapto, alkylamino, di-alkylamino, alkylsulfinyl or alkylsulfonyl, CX4X5X8, -CH=CHX8 , -C.ident.CX8 ;
X1 and X2 each independently comprise H or alkyl, or X1 and X2 together comprise part of a heterocyclic ring having 4 to 7 ring members and optionally one additional heteroatom selected from O, N or S, or X1 and X2 together comprise part of an imide ring having 5 to 6 members, X3 comprises H, alkyl, aryl, NO2, (CH2)m CN, hydroxyloweralkyl, or alkyl-NX1X2, X4, X5, and X6 each independently comprise H, alkyl, carbocyclic ring, hydroxyloweralkyl, alkyl-OH, halogen, CN, SNO, S(SO2)alkyl, NX1X2, COOX3, CONX3, OX7, or O-alkyl-X7 wherein X7 comprises H, alkyl, NO2, NO, P(O)(OX8)2, PH(O)(OX8), S(O)k N(alkyl)2, S(O)k X8, S(O)k OX8, COOX8, CONX8, SO3H, COX8, wherein X8 comprises H, alkyl, carbocyclic ring, heterocyclic ring, aromatic ring, heteroaromatic ring, or -CX9=CHX10 wherein X9 and X10 each independently comprise H or alkyl Wherein m is an integer from 0 to 7 j is an integer from 0 to 6, or k is an integer from 0 to 2; or R2 comprises -(CH2)n-Z;
n is an integer from 0 to 7; and Z comprises a carbocyclic ring having 4 to 7 ring members, a heterocyclic ring having 4 to 7 ring members, an aromatic ring having 5 to 7 ring members, a heteroaromatic ring having 5 to 7 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring, a heteropolycyclic ring; or any above group substituted on at least one available ring atom by an alkyl group; or any above group substituted on at least one available ring nitrogen atom by a benzyl group, a substituted benzyl group, an alkoxybenzyl group, a substituted alkoxybenzyl group, a benzhydryl group or a substituted benzhydryl group; and wherein the connecting point between the -(CH2)n- group and the Z group can be any available ring carbon atom or any available ring nitrogen atom; or R2 comprises -(CH2)n-Z;
n is an integer from 0 to 7; and Z comprises a 5 member unsaturated ring having 0 to 4 independently selected heteroatoms as ring members, a substituted 5 member unsaturated ring having 0 to 4 independently selected heteroatoms as ring members, a 6 member aromatic ring having 0 to 5 independently selected heteroatoms as ring members or a substituted 6 member aromatic ring having 0 to 5 independently selected heteroatoms; and wherein the connecting point between the -(CH2)n- group and the Z group can be any available ring carbon atom or any available ring nitrogen atom; or R2 comprises -(CH2)n-Z;
n is an integer from 0 to 7; and Z comprises 1-, 2- or 3-pyrrolidinyl, 1-, 2-, 3- or 4-piperidinyl, 2-, 3- or 4-morpholinyl, 2-, 3- or 4-thiomorpholinyl, 1-, 2- or 3-azetidinyl, 1- or 2-piperazinyl, 2- or 3-tetrahydrofuranyl; or any above group substituted on at least one available ring atom by an alkyl group; or any above group substituted on at least one available ring nitrogen atom by a benzyl group, a substituted benzyl group, an alkoxybenzyl group, a substituted alkoxybenzyl group, a benzhydryl group or a substituted benzhydryl group; and wherein the connecting point between the -(CH2)n- group and the Z group can be any available ring carbon atom or any available ring nitrogen atom; or R2 comprises -(CH2)n-Z;
n is an integer from 0 to 7; and Z comprises wherein X and Y each independently comprise, H, halogen, CF3, CF2H, N3, NCS, CN, NO2, NX1X2, OX3, SX3, OAc, OSO2X3, O-acyl, S-acyl, SO2-alkyl, SO-alkyl, SC(CH3)2COOX8, OC(CH3)2COOX8 , C(CH3)2COOX8, Si(alkyl)3, alkyl-CN, O-aroyl, O(CH2)j OX3, O(CH2))j NX1X2, NH-acyl, NH-aroyl, CHO, C(halogen)3, COOX3, SO3H, SO2NX1X2, CONX1X2, NHC(O)O-alkyl, NHSO2-alkyl, alkoxy, alkyl, alcohol, alkylmercapto, alkylamino, di-alkylamino, alkylsulfinyl or alkylsulfonyl, CX4X5X6, -CH=CHX8 , -C.ident.CX8 ;
X1 and X2 each independently comprise H or alkyl, or X1 and X2 together comprise part of a heterocyclic ring having 4 to 7 ring members and optionally one additional heteroatom selected from 0, N or S, or X1 and X2 together comprise part of an imide ring having 5 to 6 members, X3 comprises H, alkyl, aryl, NO2, (CH2)m CN, hydroxyloweralkyl, or alkyl-NX1X2, X4, X6, and X6 each independently comprise H, alkyl, carbocyclic ring, hydroxyloweralkyl, alkyl-OH, halogen, CN, SNO, S(SO2)alkyl, NX1X2, COOX3, CONX3, OX7, or O-alkyl-X7 wherein X7 comprises H, alkyl, NO2, NO, P(O)(OX8)2, PH(O)(OX8), S(O)k N(alkyl)2, S(O)k X8, S(O)k OX8, COOX8, CONX8, SO3H, COX8, wherein X8 comprises H, alkyl, carbocyclic ring, heterocyclic ring, aromatic ring, heteroaromatic ring, or -CX9=CHX10 wherein X9 and X10 each independently comprise H or alkyl Wherein m is an integer from 0 to 7 j is an integer from 0 to 6, or k is an integer from 0 to 2 W comprises H or alkyl; or R2 comprises -(CH2)n-Z;
n is an integer from 0 to 7; and Z comprises a carbocyclic ring having 6 ring atoms fused to a heterocyclic ring having from 5 to 7 ring atoms, a carbocyclic ring having 6 ring atoms fused to a heteroaromatic ring having from 5 to 7 ring atoms, a heterocyclic ring having 6 ring atoms fused to a heterocyclic ring having from 5 to 7 ring atoms, an heterocyclic ring having 6 ring atoms fused to a heteroaromatic ring having from to 7 ring atoms, an aromatic ring having 6 ring atoms fused to a heterocyclic ring having from 5 to 7 ring atoms, an aromatic ring having 6 ring atoms fused to a heteroaromatic ring having from 5 to 7 ring atoms, a heteroaromatic ring having 6 ring atoms fused to a heterocyclic ring having from 5 to 7 ring atoms or a heteroaromatic ring having 6 ring atoms fused to a heteroaromatic ring having from 5 to 7 ring atoms; or R2 comprises --(CH2)n¨Z;
n comprises an integer from 0 to 7; and Z comprises an unsaturated ring having 5 ring atoms and 0 to 2 independently selected heteroatoms as ring members fused to an unsaturated ring having 5 ring atoms and 0 to 4 independently selected heteroatoms as ring members, an unsaturated ring having 5 ring atoms and 0 to 2 independently selected heteroatoms as ring members fused to an unsaturated ring having 6 or 7 ring atoms and 0 to 3 independently selected heteroatoms as ring members or an unsaturated ring having 6 ring atoms and 0 to 4 independently selected heteroatoms as ring members fused to an unsaturated ring having 6 or 7 ring atoms and 0 to 4 independently selected heteroatoms as ring members; or R2 comprises ¨(CH2)m ¨Q1--(CH2)n¨Z;
Q1 comprises NH, O, S,-CH=CH-, -C.ident.C-, -CO, SO2 or OSO2;
m is an integer from 1 to 7;
n is an integer from 0 to 7; and wherein Z comprises, H, halogen, CF3, CF2H, N3, NCS, CN, NO2, NX1X2, OX3, SX3, OAc, OSO2X3, O-acyl, S-acyl, SO2-alkyl, SO-alkyl, SC(CH3)2COOX8, OC(CH3)2COOX8 , C(CH3)2COOX8, Si(alkyl)3, alkyl-CN, O-aroyl, O(CH2)j OX3, O(CH2)j NX1X2, NH-acyl, NH-aroyl, CHO, C(halogen)3, COOX3, SO3H, SO2NX1X2, CONX1X2, NHC(O)O-alkyl, NHSO2-alkyl, alkoxy, alkyl, alcohol, alkylmercapto, alkylamino, di-alkylamino, alkylsulfinyl or alkylsulfonyl, CX4X5X6, -CH=CHX8, --C.ident.CX8;
X1 and X2 each independently comprise H or alkyl, or X1 and X2 together comprise part of a heterocyclic ring having 4 to 7 ring members and optionally one additional heteroatom selected from O, N or S, or X1 and X2 together comprise part of an imide ring having 5 to 6 members, X3 comprises H, alkyl, aryl, NO2, (CH2)m CN, hydroxyloweralkyl, or alkyl-NX1X2, X4, X6, and X6 each independently comprise H, alkyl, carbocyclic ring, hydroxyloweralkyl, alkyl-OH, halogen, CN, SNO, S(SO2)alkyl, NX1X2, COOX3, CONX3, OX7, or O-alkyl-X7 wherein X7 comprises H, alkyl, NO2, NO, P(O)(OX8)2, PH(O)(OX8), S(O)k N(alkyl)2, S(O)k X8, S(O)k OX8, COOX8, CONX8, SO3H, COX8, wherein X3 comprises H, alkyl, carbocyclic ring, heterocyclic ring, aromatic ring, heteroaromatic ring, or -CX9=CHX10 wherein X9 and X10 each independently comprise H or alkyl Wherein m is an integer from 0 to 7 j is an integer from 0 to 6, or k is an integer from 0 to 2; or R2 comprises -Q2-(CH2)n-Z;
Q2 is optionally present and if present comprises -CH2-NH, -CH2-O, -CH2-S, -CH2-SO2 or -CH2-OSO2;
n is an integer from 0 to 7;
wherein Z comprises, H, halogen, CF3, CF2H, N3, NCS, CN, NO2, NX1X2, OX3, SX3, OAc, OSO2X3, O-acyl, S-acyl, SO2-alkyl, SO-alkyl, SC(CH3)2COOX8, OC(CH3)2COOX8 , C(CH3)2COOX8, Si(alkyl)3, alkyl-CN, O-aroyl, O(CH2)j OX3, O(CH2)j NX1X2, NH-acyl, NH-aroyl, CHO, C(halogen)3, COOX3, SO3H, SO2NX1X2, CONX1X2, NHC(O)O-alkyl, NHSO2-alkyl, alkoxy, alkyl, alcohol, alkylmercapto, alkylamino, di-alkylamino, alkylsulfinyl or alkylsulfonyl, CX4X5X8, -CH=CHX8 , -C.ident.CX8 ;
X1 and X2 each independently comprise H or alkyl, or X1 and X2 together comprise part of a heterocyclic ring having 4 to 7 ring members and optionally one additional heteroatom selected from O, N or S, or X1 and X2 together comprise part of an imide ring having 5 to 6 members, X3 comprises H, alkyl, aryl, NO2, (CH2)m CN, hydroxyloweralkyl, or alkyl-NX1X2, X4, X5, and X6 each independently comprise H, alkyl, carbocyclic ring, hydroxyloweralkyl, alkyl-OH, halogen, CN, SNO, S(SO2)alkyl, NX1X2, COOX3, CONX3, OX7, or O-alkyl-X7 wherein X7 comprises H, alkyl, NO2, NO, P(O)(OX8)2, PH(O)(OX8), S(O)k N(alkyl)2, S(O)k X8, S(O)k OX8, COOX8, CONX8, SO3H, COX8, wherein X8 comprises H, alkyl, carbocyclic ring, heterocyclic ring, aromatic ring, heteroaromatic ring, or -CX9=CHX10 wherein X9 and X10 each independently comprise H or alkyl Wherein m is an integer from 0 to 7 j is an integer from 0 to 6, k is an integer from 0 to 2; or R2 comprises -(CH2)m- Q1 -(CH2)n-Z;
Q1 comprises NH, O, S, CH=CH, C.ident.C, CO, SO2 or OSO2;
m is an integer from 1 to 7;
n is an integer from 0 to 7;
Z comprises a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring; or R2 comprises -(CH2)m - Q1 -(CH2)n-Z;
Q1 comprises NH, O, S, CH=CH, C.ident.C, CO, SO2 or OSO2;
m is an integer from 1 to 7;
n is an integer from 0 to 7;
Z comprises a carbocyclic ring having 4 to 7 ring members, a heterocyclic ring having 4 to 7 ring members, an aromatic ring having 5 to 7 ring members, a heteroaromatic ring having 5 to 7 ring members; a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring, a heteropolycyclic ring or any above group substituted on at least one available ring atom by an alkyl group or any above group substituted on at least one available ring nitrogen atom by a benzyl group, a substituted benzyl group, an alkoxybenzyl group, a substituted alkoxybenzyl group, a benzhydryl group or a substituted benzhydryl group; and wherein the connecting point between the -(CH2)n- group and the Z
group can be any available ring carbon atom or any available ring nitrogen atom;
or R2 comprises -(CH2)m- Q1 -(CH2)n-Z;
Q1 comprises NH, O, S, CH=CH, C.ident.C, CO, SO2 or OSO2;
m is an integer from 1 to 7;
n is an integer from 0 to 7; and Z comprises a 5 member unsaturated ring having 0 to 4 independently selected heteroatoms as ring members, a substituted 5 member unsaturated ring having 0 to 4 independently selected heteroatoms as ring members, a 6 member aromatic ring having 0 to 5 independently selected heteroatoms as ring members or a substituted 6 member aromatic ring having 0 to 5 independently selected heteroatoms; and wherein the connecting point between the -(CH2)n- group and the Z group can be any available ring carbon atom or any available ring nitrogen atom; or R2 comprises -(CH2)m - Q1 -(CH2)n-Z;
Q1 comprises NH, O, S, CH=CH, C.ident.C, CO, SO2 or OSO2;
m is an integer from 1 to 7;
n is an integer from 0 to 7;
Z comprises 1-, 2- or 3-pyrrolidinyl, 1-, 2-, 3- or 4-piperidinyl, 2-, 3- or 4-morpholinyl, 2-, 3- or 4-thiomorpholinyl, 1-, 2- or 3-azetidinyl, 1- or 2-piperazinyl, 2- or 3-tetrahydrofuranyl; or any above group substituted on at least one available ring atom by an alkyl group; or any above group substituted on at least one available ring nitrogen atom by a benzyl group, a substituted benzyl group, an alkoxybenzyl group, a substituted alkoxybenzyl group, a benzhydryl group or a substituted benzhydryl group; and wherein the connecting point between the -(CH2)n- group and the Z group can be any available ring carbon atom or any available ring nitrogen atom; or R2 comprises -(CH2)m - Q1 -(CH2)n-Z;
Q1 comprises NH, O, S, CH=CH, C.ident.C, CO, SO2 or OSO2;
m is an integer from 1 to 7;
n is an integer from 0 to 7; and Z comprises wherein X and Y each independently comprise H, halogen, CF3, CF2H, N3, NCS, CN, NO2, NX1X2, OX3, SX3, OAc, OSO2X3, O-acyl, S-acyl, SO2-alkyl, SO-alkyl, SC(CH3)2COOX8, OC(CH3)2COOX8 , C(CH3)2COOX8, Si(alkyl)3, alkyl-CN, O-aroyl, O(CH2)j OX3, O(CH2)NX1X2, NH-acyl, NH-aroyl, CHO, C(halogen)3, COOX3, SO3H, SO2NX1X2, CONX1X2, NHC(O)O-alkyl, NHSO2-alkyl, alkoxy, alkyl, alcohol, alkylmercapto, alkylamino, di-alkylamino, alkylsulfinyl or alkylsulfonyl, CX4X5X6, -CH=CHX8 , -C.ident.CX8 ;
X1 and X2 each independently comprise H or alkyl, or X1 and X2 together comprise part of a heterocyclic ring having 4 to 7 ring members and optionally one additional heteroatom selected from O, N or S, or X1 and X2 together comprise part of an imide ring having 5 to 6 members, X3 comprises H, alkyl, aryl, NO2, (CH2)m CN, hydroxyloweralkyl, or alkyl-NX1X2, X4, X5, and X6 each independently comprise H, alkyl, carbocyclic ring, hydroxyloweralkyl, alkyl-OH, halogen, CN, SNO, S(SO2)alkyl, NX1X2, COOX3, CONX3, OX7, or O-alkyl-X7 wherein X7 comprises H, alkyl, NO2, NO, P(O)(OX8)2, PH(O)(OX8), S(O)k N(alkyl)2, S(O)k X8, S(O)k OX8, COOX8, CONX8, SO3H, COX8, wherein X8 comprises H, alkyl, carbocyclic ring, heterocyclic ring, aromatic ring, heteroaromatic ring, or -CX9=CHX10 wherein X9 and X10 each independently comprise H or alkyl Wherein m is an integer from 0 to 7 j is an integer from 0 to 6, k is an integer from 0 to 2 W comprises H or alkyl; or R2 comprises -(CH2)m - Q1 -(CH2)n-Z;
Q1 comprises NH, O, S, CH=CH, C.ident.C, CO, SO2 or OSO2;
m is an integer from 1 to 7;
n is an integer from 0 to 7; and Z comprises an unsaturated ring having 5 ring atoms and 0 to 2 independently selected heteroatoms as ring members fused to an unsaturated ring having 5 ring atoms and 0 to 4 independently selected heteroatoms as ring members, an unsaturated ring having 5 ring atoms and 0 to 2 independently selected heteroatoms as ring members fused to an unsaturated ring having 6 or 7 ring atoms and 0 to 4 independently selected heteroatoms as ring members or an unsaturated ring having 6 ring atoms and 0 to 4 independently selected heteroatoms as ring members fused to an unsaturated ring having 6 or 7 ring atoms and 0 to 4 independently selected heteroatoms as ring members; or R2 comprises -(CH2)m - Q1 -(CH2)n-Z;
Q1 comprises NH, O, S, CH=CH, C.ident.C, CO, SO2 or OSO2;
m is an integer from 1 to 7;
n is an integer from 0 to 7; and Z comprises R2 comprises -T-(CH2)n-Z;
n comprises an integer from 0 to 7;
T comprises a carbocyclic ring having 3 to 8 ring members, an unsaturated ring having 3 to 8 carbon atoms as ring members, an aromatic ring having 5 to 8 carbon atoms as ring members, a heterocyclic ring having 3 to 8 ring members, a heteroaromatic ring having 5 to 8 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring; and Z comprises, H, halogen, CF3, CF2H, N3, NCS, CN, NO2, NX1X2, OX3, SX3, OAc, OSO2X3, O-acyl, S-acyl, SO2-alkyl, SO-alkyl, SC(CH3)2COOX8, OC(CH3)2COOX8 , C(CH3)2COOX8, Si(alkyl)3, alkyl-CN, O-aroyl, O(CH2)j OX3, O(CH2)j NX1X2, NH-acyl, NH-aroyl, CHO, C(halogen)3, COOX3, SO3H, SO2NX1X2, CONX1X2, NHC(O)O-alkyl, NHSO2-alkyl, alkoxy, alkyl, alcohol, alkylmercapto, alkylamino, di-alkylamino, alkylsulfinyl or alkylsulfonyl, CX4X8X8, -CH=CHX8, --C.ident.CX8;
X1 and X2 each independently comprise H or alkyl, or X1 and X2 together comprise part of a heterocyclic ring having 4 to 7 ring members and optionally one additional heteroatom selected from O, N or S, or X1 and X2 together comprise part of an imide ring having 5 to 6 members, X3 comprises H, alkyl, aryl, NO2, (CH2)m CN, hydroxyloweralkyl, or alkyl-NX1X2, X4, X5, and X6 each independently comprise H, alkyl, carbocyclic ring, hydroxyloweralkyl, alkyl-OH, halogen, CN, SNO, S(SO2)alkyl, NX1X2, COOX3, CONX3, OX7, or O-alkyl-X7 wherein X7 comprises H, alkyl, NO2, NO, P(O)(OX8)2, PH(O)(OX8), S(O)k N(alkyl)2, S(O)k X8, S(O)k OX8, COOX8, CONX8, SO3H, COX8, wherein X8 comprises H, alkyl, carbocyclic ring, heterocyclic ring, aromatic ring, heteroaromatic ring, or -CX9=CHX10 wherein X9 and X10 each independently comprise H or alkyl Wherein m is an integer from 0 to 7 j is an integer from 0 to 6, k is an integer from 0 to 2; or R2 comprises -T-(CH2)n-Z;
n comprises an integer from 0 to 7;
T comprises a carbocyclic ring having 3 to 8 ring members, an unsaturated ring having 3 to 8 carbon atoms as ring members, an aromatic ring having 5 to 8 carbon atoms as ring members, a heterocyclic ring having 3 to 8 ring members, a heteroaromatic ring having 5 to 8 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring; and Z comprises a carbocyclic ring having 4 to 7 ring members, a heterocyclic ring having 4 to 7 ring members, an aromatic ring having 5 to 7 ring members, a heteroaromatic ring having 5 to 7 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring, a heteropolycyclic ring; or any above group substituted on at least one available ring atom by an alkyl group; or any above group substituted on at least one available ring nitrogen atom by a benzyl group, a substituted benzyl group, an alkoxybenzyl group, a substituted alkoxybenzyl group, a benzhydryl group or a substituted benzhydryl group; and wherein the connecting point between the -(CH2)n- group and the Z group can be any available ring carbon atom or any available ring nitrogen atom; or R2 comprises -T-(CH2)n-Z;
n comprises an integer from 0 to 7;
T comprises a carbocyclic ring having 3 to 8 ring members, an unsaturated ring having 3 to 8 carbon atoms as ring members, an aromatic ring having 5 to 8 carbon atoms as ring members, a heterocyclic ring having 3 to 8 ring members, a heteroaromatic ring having 5 to 8 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring; and Z comprises 1-, 2- or 3-pyrrolidinyl, 1-, 2-, 3- or 4-piperidinyl, 2-, 3- or 4-morpholinyl, 2-, 3- or 4-thiomorpholinyl, 1-, 2- or 3-azetidinyl, 1- or 2-piperazinyl, 2- or 3-tetrahydrofuranyl; or any above group substituted on at least one available ring atom by an alkyl group; or any above group substituted on at least one available ring nitrogen atom by a benzyl group, a substituted benzyl group, an alkoxybenzyl group, a substituted alkoxybenzyl group, a benzhydryl group or a substituted benzhydryl group; and wherein the connecting point between the -(CH2)n- group and the Z group can be any available ring carbon atom or any available ring nitrogen atom; or R2 comprises -T-(CH2)n-Z;
n comprises an integer from 0 to 7;
T comprises a carbocyclic ring having 3 to 8 ring members, an unsaturated ring having 3 to 8 carbon atoms as ring members, an aromatic ring having 5 to 8 carbon atoms as ring members, a heterocyclic ring having 3 to 8 ring members, a heteroaromatic ring having 5 to 8 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring; and Z comprises wherein X and Y each independently comprise H, halogen, CF3, CF2H, N3, NCS, CN, NO2, NX1X2, OX3, SX3, OAc, OSO2X3, O-acyl, S-acyl, SO2-alkyl, SO-alkyl, SC(CH3)2COOX8, OC(CH3)2COOX8 , C(CH3)2COOX8, Si(alkyl)3, alkyl-CN, O-aroyl, O(CH2)j OX3, O(CH2)j NX1X2, NH-acyl, NH-aroyl, CHO, C(halogen)3, COOX3, SO3H, SO2NX1X2, CONX1X2, NHC(O)O-alkyl, NHSO2-alkyl, alkoxy, alkyl, alcohol, alkylmercapto, alkylamino, di-alkylamino, alkylsulfinyl or alkylsulfonyl, CX4X5X8, -CH=CHX8 , -C.ident.CX8 ;
X1 and X2 each independently comprise H or alkyl, or X1 and X2 together comprise part of a heterocyclic ring having 4 to 7 ring members and optionally one additional heteroatom selected from O, N or S, or X1 and X2 together comprise part of an imide ring having 5 to 6 members, X3 comprises H, alkyl, aryl, NO2, (CH2)m CN, hydroxyloweralkyl, or alkyl-NX1X2, X4, X5, and X6 each independently comprise H, alkyl, carbocyclic ring, hydroxyloweralkyl, alkyl-OH, halogen, CN, SNO, S(SO2)alkyl, NX1X2, COOX3, CONX3, OX7, or O-alkyl-X7 wherein X7 comprises H, alkyl, NO2, NO, P(O)(OX8)2, PH(O)(OX8), S(O)k N(alkyl)2, S(O)k X8, S(O)k OX8, COOX8, CONX8, SO3H, COX8, wherein X8 comprises H, alkyl, carbocyclic ring, heterocyclic ring, aromatic ring, heteroaromatic ring, or -CX9=CHX10 wherein X9 and X10 each independently comprise H or alkyl Wherein m is an integer from 0 to 7 j is an integer from 0 to 6, k is an integer from 0 to 2 W comprises H or alkyl; or R2 comprises -T-(CH2)n-Z;
n comprises an integer from 0 to 7;
T comprises a carbocyclic ring having 3 to 8 ring members, an unsaturated ring having 3 to 8 carbon atoms as ring members, an aromatic ring having 5 to 8 carbon atoms as ring members, a heterocyclic ring having 3 to 8 ring members, a heteroaromatic ring having 5 to 8 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring; and Z comprises an unsaturated ring having 5 ring atoms and 0 to 2 independently selected heteroatoms as ring members fused to an unsaturated ring having 5 ring atoms and 0 to 4 independently selected heteroatoms as ring members, an unsaturated ring having 5 ring atoms and 0 to 2 independently selected heteroatoms as ring members fused to an unsaturated ring having 6 or 7 ring atoms and 0 to 4 independently selected heteroatoms as ring members or an unsaturated ring having 6 ring atoms and 0 to 3 independently selected heteroatoms as ring members fused to an unsaturated ring having 6 or 7 ring atoms and 0 to 4 independently selected heteroatoms as ring members; or R2 comprises -T-(CH2)m- Q1 -(CH2)n-Z;
m and n independently comprises an integer from 0 to 7;
T comprises a carbocyclic ring having 3 to 8 ring members, an unsaturated ring having 3 to 8 carbon atoms as ring members, an aromatic ring having 5 to 8 carbon atoms as ring members, a heterocyclic ring having 3 to 8 ring members, a heteroaromatic ring having 5 to 8 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring;
Q1 comprises NH, O, S, CH=CH, C.ident.C, CO, SO2 or OSO2; and Z comprises, H, halogen, CF3, CF2H, N3, NCS, CN, NO2, NX1X2, OX3, SX3, OAc, OSO2X3, O-acyl, S-acyl, SO2-alkyl, SO-alkyl, SC(CH3)2COOX8, OC(CH3)2COOX8 , C(CH3)2COOX8, Si(alkyl)3, alkyl-CN, O-aroyl, O(CH2)j OX3, O(CH2)j NX1X2, NH-acyl, NH-aroyl, CHO, C(halogen)3, COOX3, SO3H, SO2NX1X2, CONX1X2, NHC(O)O-alkyl, NHSO2-alkyl, alkoxy, alkyl, alcohol, alkylmercapto, alkylamino, di-alkylamino, alkylsulfinyl or alkylsulfonyl, CX4X8X8, -CH=CHX8 , -C.ident.CX8 ;
X1 and X2 each independently comprise H or alkyl, or X1 and X2 together comprise part of a heterocyclic ring having 4 to 7 ring members and optionally one additional heteroatom selected from O, N or S, or X1 and X2 together comprise part of an imide ring having 5 to 6 members, X3 comprises H, alkyl, aryl, NO2, (CH2)m CN, hydroxyloweralkyl, or alkyl-NX1 X2, X4, X5, and X6 each independently comprise H, alkyl, carbocyclic ring, hydroxyloweralkyl, alkyl-OH, halogen, CN, SNO, S(SO2)alkyl, NX1X2, COOX3, CONX3, OX7, or O-alkyl-X7 wherein X7 comprises H, alkyl, NO2, NO, P(O)(OX8)2, PH(O)(OX8), S(O)k N(alkyl)2, S(O)k X8, S(O)k OX8, COOX8, CONX8, SO3H, COX8, wherein X8 comprises H, alkyl, carbocyclic ring, heterocyclic ring, aromatic ring, heteroaromatic ring, or ¨CX9=CHX10 wherein X9 and X10 each independently comprise H or alkyl Wherein m is an integer from 0 to 7 j is an integer from 0 to 6, k is an integer from 0 to 2; or R2 comprises ¨T¨(CH2)m¨ Q1 ¨(CH2)n¨Z;
m and n independently comprises an integer from 0 to 7;
T comprises a carbocyclic ring having 3 to 8 ring members, an unsaturated ring having 3 to 8 carbon atoms as ring members, an aromatic ring having 5 to 8 carbon atoms as ring members, a heterocyclic ring having 3 to 8 ring members, a heteroaromatic ring having 5 to 8 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring;
Q1 comprises NH, O, S, CH=CH, C.ident.C, CO, SO2 or OSO2; and Z comprises a carbocyclic ring having 4 to 7 ring members, a heterocyclic ring having 4 to 7 ring members, an aromatic ring having 5 to 7 ring members, a heteroaromatic ring having 5 to 7 ring members, a bicyclic ring, a heterobicyclic ring, a polycyclic ring, a heteropolycyclic ring; or any above group substituted on at least one available ring atom by an alkyl group; or any above group substituted on at least one available ring nitrogen atom by a benzyl group, a substituted benzyl group, an alkoxybenzyl group, a substituted alkoxybenzyl group, a benzhydryl group or a substituted benzhydryl group; and wherein the connecting point between the -(CH2)n- group and the Z group can be any available ring carbon atom or any available ring nitrogen atom; or R2 comprises -T-(CH2)m- Q1 -(CH2)n-Z;
m and n independently comprises an integer from 0 to 7;
T comprises a carbocyclic ring having 3 to 8 ring members, an unsaturated ring having 3 to 8 carbon atoms as ring members, an aromatic ring having 5 to 8 carbon atoms as ring members, a heterocyclic ring having 3 to 8 ring members, a heteroaromatic ring having 5 to 8 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring;
Q1 comprises NH, O, S, CH=CH, C.ident.C, CO, SO2 or OSO2; and Z comprises 1-, 2- or 3-pyrrolidinyl, 1-, 2-, 3- or 4-piperidinyl, 2-, 3- or 4-morpholinyl, 2-, 3- or 4-thiomorpholinyl, 1-, 2- or 3-azetidinyl, 1- or 2-piperazinyl, 2- or 3-tetrahydrofuranyl; or any above group substituted on at least one available ring atom by an alkyl group; or any above group substituted on at least one available ring nitrogen atom by a benzyl group, a substituted benzyl group, an alkoxybenzyl group, a substituted alkoxybenzyl group, a benzhydryl group or a substituted benzhydryl group; and wherein the connecting point between the -(CH2)n- group and the Z group can be any available ring carbon atom or any available ring nitrogen atom; or R2 comprises -T-(CH2)m- Q1 -(CH2)n-Z;
m and n independently comprises an integer from 0 to 7;
T comprises a carbocyclic ring having 3 to 8 ring members, an unsaturated ring having 3 to 8 carbon atoms as ring members, an aromatic ring having 5 to 8 carbon atoms as ring members, a heterocyclic ring having 3 to 8 ring members, a heteroaromatic ring having 5 to 8 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring;
Q1 comprises N, O, S, CH=CH, C.ident.C, CO, SO2 or OSO2; and Z comprises wherein X and Y each independently comprise H, halogen, CF3, CF2H, N3, NCS, CN, NO2, NX1X2, OX3, SX3, OAc, OSO2X3, O-acyl, S-acyl, SO2-alkyl, SO-alkyl, SC(CH3)2COOX8, OC(CH3)2COOX8 , C(CH3)2COOX8, Si(alkyl)3, alkyl-CN, O-aroyl, O(CH2)j OX3, O(CH2)j NX1X2, NH-acyl, NH-aroyl, CHO, C(halogen)3, COOX3, SO3H, SO2NX1X2, CONX1X2, NHC(O)O-alkyl, NHSO2-alkyl, alkoxy, alkyl, alcohol, alkylmercapto, alkylamino, di-alkylamino, alkylsulfinyl or alkylsulfonyl, CX4X5X8, -CH=CHX8 , -C.ident.CX8;
X1 and X2 each independently comprise H or alkyl, or X1 and X2 together comprise part of a heterocyclic ring haying 4 to 7 ring members and optionally one additional heteroatom selected from O, N or S, or X1 and X2 together comprise part of an imide ring haying 5 to 6 members, X3 comprises H, alkyl, aryl, NO2, (CH2)m CN, hydroxyloweralkyl, or alkyl-NX1X2, X4, X5, and X6 each independently comprise H, alkyl, carbocyclic ring, hydroxyloweralkyl, alkyl-OH, halogen, CN, SNO, S(SO2)alkyl, NX1X2, COOX3, CONX3, OX7, or O-alkyl-X7 wherein X7 comprises H, alkyl, NO2, NO, P(O)(OX8)2, PH(O)(OX8), S(O)k N(alkyl)2, S(O)k X8, S(O)k OX8, COOX8, CONX8, SO3H, COX8, wherein X8 comprises H, alkyl, carbocyclic ring, heterocyclic ring, aromatic ring, heteroaromatic ring, or -CX9=CHX10 wherein X9 and X10 each independently comprise H or alkyl Wherein m is an integer from 0 to 7 j is an integer from 0 to 6, k is an integer from 0 to 2 W comprises H or alkyl; or R2 comprises -T-(CH2)m- Q1 -(CH2)n-Z;
m and n independently comprises an integer from 0 to 7;
T comprises a carbocyclic ring having 3 to 8 ring members, an unsaturated ring haying 3 to 8 carbon atoms as ring members, an aromatic ring haying 5 to 8 carbon atoms as ring members, a heterocyclic ring having 3 to 8 ring members, a heteroaromatic ring haying 5 to 8 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring;
Q1 comprises NH, O, S, CH=CH, C.ident.C, CO, SO2 or OSO2; and Z comprises an unsaturated ring haying 5 ring atoms and 0 to 2 independently selected heteroatoms as ring members fused to an unsaturated ring having 5 ring atoms and 0 to 2 independently selected heteroatoms as ring members, an unsaturated ring haying 5 ring atoms and 0 to 2 independently selected heteroatoms as ring members fused to an unsaturated ring having 6 or 7 ring atoms and 0 to 4 independently selected heteroatoms as ring members or an unsaturated ring having 6 ring atoms and 0 to 3 independently selected heteroatoms as ring members fused to an unsaturated ring having 6 or 7 ring atoms and 0 to 4 independently selected heteroatoms as ring members, or R2 comprises -T-(CH2)m- Q1 -(CH2)n-Z;
T comprises a carbocyclic ring having 3 to 8 ring members, an unsaturated ring having 3 to 8 carbon atoms as ring members, an aromatic ring having 5 to 8 carbon atoms as ring members, a heterocyclic ring having 3 to 8 ring members, a heteroaromatic ring having 5 to 8 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring;
m and n independently comprises an integer from 0 to 7;
Q1 comprises NH, O, S, CH=CH, C.ident.C, CO, SO2 or OSO2; and Z comprises:
E comprises a C1 to C4, linear or branched alkyl group, a phenyl group, a substituted phenyl group, a benzyl group or a substituted benzyl group; or R2 comprises -T-(CH2)m- Q1 -(CH2)n-Z;
T comprises a carbocyclic ring having 3 to 8 ring members, an unsaturated ring having 3 to 8 carbon atoms as ring members, an aromatic ring having 5 to 8 carbon atoms as ring members, a heterocyclic ring having 3 to 8 ring members, a heteroaromatic ring having 5 to 8 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring;
m and n independently comprises an integer from 0 to 7;
Q1 comprises NH, O, S, CH=CH, C.ident.C, CO, SO2 or OSO2;
Z comprises k is an integer from 1 to 5, A1 and A2 each independently comprise a C1 to C4 alkyl group, a phenyl group or a substituted phenyl group;
R3 comprises wherein G comprises CH, C(CH3), C(CN) or N, L, K and J each independently comprise (CH2)n, (CH3)2, C=O, O, -CHOH, C(CH3)OM1, C(CH2)n(X)Y, NM1, SO2 SO or S, and at least one of L, K or J is SO2, n is an integer from 0 to 7;
M1 is H, alkyl, C(O)M2 where M2 is H, alkyl, NM3M4, OM5 and M3, M4 and M5 are independently H, OH or alkyl and X and Y each independently comprise, H, halogen, CF3, CF2H, N3, NCS, CN, NO2, NX1X2, OX3, SX3, OAc, OSO2X3, O-acyl, S-acyl, SO2-alkyl, SO-alkyl, SC(CH3)2COOX8, OC(CH3)2COOX8 , C(CH3)2COOX8, Si(alkyl)3, alkyl-CN, O-aroyl, O(CH2)j OX3, O(CH2)j NX1X2, NH-acyl, NH-aroyl, CHO, C(halogen)3, COOX3, SO3H, SO2NX1X2, CONX1X2, NHC(O)O-alkyl, NHSO2-alkyl, alkoxy, alkyl, alcohol, alkylmercapto, alkylamino, di-alkylamino, alkylsulfinyl or alkylsulfonyl, CX4X5X8, -CH=CHX8 , -C.ident.CX8;
X1 and X2 each independently comprise H or alkyl, or X1 and X2 together comprise part of a heterocyclic ring having 4 to 7 ring members and optionally one additional heteroatom selected from O, N or S, or X1 and X2 together comprise part of an imide ring having 5 to 6 members, X3 comprises H, alkyl, NO2, (CH2)m CN, hydroxyloweralkyl, or alkyl-NX1X2, X4, X8, and X8 each independently comprise H, alkyl, carbocyclic ring, hydroxyloweralkyl, alkyl-OH, halogen, CN, SNO, S(SO2)alkyl, NX1X2, COOX3, CONX3, OX7, or O-alkyl-X7 wherein X7 comprises H, alkyl, NO2, NO, P(O)OX8)2, PH(O)OX8), S(O)k N(alkyl)2, S(O)k X8, S(O)k OX8, COOX8, CONX8, SO3H, COX8, wherein X8 comprises H, alkyl, carbocyclic ring, heterocyclic ring, aromatic ring, heteroaromatic ring, or -CX9=CHX10 wherein X9 and X10 each independently comprise H or alkyl Wherein m is an integer from 0 to 7 j is an integer from 0 to 6, or k is an integer from 0 to 2 or R1 comprises -T-(CH2)m- Q -(CH2)n-Z, m and n independently comprises an integer from 0 to 7;
T comprises a carbocyclic ring having 3 to 8 ring members, an unsaturated ring having 3 to 8 carbon atoms as ring members, an aromatic ring having 5 to 8 carbon atoms as ring members, a heterocyclic ring having 3 to 8 ring members, a heteroaromatic ring having 5 to 8 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring;
Q comprises CH=CH, C.ident.C;
Z comprises H, halogen, CF3, CF2H, N3, NCS, CN, NO2, NX1X2, OX3, SX3, OAc, OSO2X3, O-acyl, S-acyl, SO2-alkyl, SO-alkyl, SC(CH3)2COOX8, OC(CH3)2COOX8 , C(CH3)2COOX8, Si(alkyl)3, alkyl-CN, O-aroyl, O(CH2)j OX3, O(CH2)j NX1X2, NH-acyl, NH-aroyl, CHO, C(halogen)3, COOX3, SO3H, SO2NX1X2, CONX1X2, NHC(O)O-alkyl, NHSO2-alkyl, alkoxy, alkyl, alcohol, alkylmercapto, alkylamino, di-alkylamino, alkylsulfinyl or alkylsulfonyl, CX4X5X8, -CH=CHX8 , C.ident.CX8;
X1 and X2 each independently comprise H or alkyl, or X1 and X2 together comprise part of a heterocyclic ring having 4 to 7 ring members and optionally one additional heteroatom selected from O, N or S, or X1 and X2 together comprise part of an imide ring having 5 to 6 members, X3 comprises H, alkyl, NO2, (CH2)m CN, hydroxyloweralkyl, or alkyl-NX1X2, X4, X5, and X8 each independently comprise H, alkyl, carbocyclic ring, hydroxyloweralkyl, alkyl-OH, halogen, CN, SNO, S(SO2)alkyl, NX1X2, COOX3, CONX3, OX7, or O-alkyl-X7 wherein X7 comprises H, alkyl, NO2, NO, P(O)(OX8)2, PH(O)(OX8), S(O)k N(alkyl)2, S(O)k X8, S(O)k OX8, COOX8, CONX8, SO3H, COX8, wherein X8 comprises H, alkyl, carbocyclic ring, heterocyclic ring, aromatic ring, heteroaromatic ring, or -CX9=CHX10 wherein X9 and X10 each independently comprise H or alkyl Wherein m is an integer from 0 to 7 j is an integer from 0 to 6, or k is an integer from 0 to 2; or R1 comprises -T-(CH2)m- Q -(CH2)n-Z;
m and n independently comprises an integer from 0 to 7;
T comprises a carbocyclic ring having 3 to 8 ring members, an unsaturated ring having 3 to 8 carbon atoms as ring members, an aromatic ring having 5 to 8 carbon atoms as ring members, a heterocyclic ring having 3 to 8 ring members, a heteroaromatic ring having 5 to 8 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring;
Q comprises CH=CH, C.ident.C; and Z comprises a carbocyclic ring having 4 to 7 ring members, a heterocyclic ring having 4 to 7 ring members, an aromatic ring having 5 to 7 ring members, a heteroaromatic ring having 5 to 7 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring, a heteropolycyclic ring; or any above group substituted on at least one available ring atom by an alkyl group; or any above group substituted on at least one available ring nitrogen atom by a benzyl group, a substituted benzyl group, an alkoxybenzyl group, a substituted alkoxybenzyl group, a benzhydryl group or a substituted benzhydryl group; and wherein the connecting point between the -(CH2)- group and the Z group can be any available ring carbon atom or any available ring nitrogen atom; or R1 comprises -T-(CH2)m - Q -(CH2)n-Z;
m and n independently comprises an integer from 0 to 7;
T comprises a carbocyclic ring having 3 to 8 ring members, an unsaturated ring having 3 to 8 carbon atoms as ring members, an aromatic ring having 5 to 8 carbon atoms as ring members, a heterocyclic ring having 3 to 8 ring members, a heteroaromatic ring having 5 to 8 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring;
Q comprises CH=CH, C.ident.C; and Z comprises 1-, 2- or 3-pyrrolidinyl, 1-, 2-, 3- or 4-piperidinyl, 2-, 3- or 4-morpholinyl, 2-, 3- or 4-thiomorpholinyl, 1-, 2- or 3-azetidinyl, 1- or 2-piperazinyl, 2- or 3-tetrahydrofuranyl; or any above group substituted on at least one available ring atom by an alkyl group; or any above group substituted on at least one available ring nitrogen atom by a benzyl group, a substituted benzyl group, an alkoxybenzyl group, a substituted alkoxybenzyl group, a benzhydryl group or a substituted benzhydryl group; and wherein the connecting point between the -(CH2)n- group and the Z group can be any available ring carbon atom or any available ring nitrogen atom; or R1 comprises -TACH2)m- Q --(CH2)n-Z;
m and n independently comprises an integer from 0 to 7;
T comprises a carbocyclic ring having 3 to 8 ring members, an unsaturated ring having 3 to 8 carbon atoms as ring members, an aromatic ring having 5 to 8 carbon atoms as ring members, a heterocyclic ring having 3 to 8 ring members, a heteroaromatic ring having 5 to 8 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring;
Q comprises CH=CH, C.ident.C; and Z comprises wherein X and Y each independently comprise H, halogen, CF3, CF2H, N3, NCS, CN, NO2, NX1X2, OX3, SX3, OAc, OSO2X3, O-acyl, S-acyl, SO2-alkyl, SO-alkyl, SC(CH3)2COOX8, OC(CH3)2COOX8 , C(CH3)2COOX8, Si(alkyl)3, alkyl-CN, O-aroyl, O(CH2)j OX3, O(CH2)NX1X2, NH-acyl, NH-aroyl, CHO, C(halogen)3, COOX3, SO3H, SO2NX1X2, CONX1X2, NHC(O)O-alkyl, NHSO2-alkyl, alkoxy, alkyl, alcohol, alkylmercapto, alkylamino, di-alkylamino, alkylsulfinyl or alkylsulfonyl, CX4X5X8, -CH=CHX8 , C.ident.CX8;
X1 and X2 each independently comprise H or alkyl, or X1 and X2 together comprise part of a heterocyclic ring having 4 to 7 ring members and optionally one additional heteroatom selected from O, N or S, or X1 and X2 together comprise part of an imide ring having 5 to 6 members, X3 comprises H, alkyl, NO2, (CH2)m CN, hydroxyloweralkyl, or alkyl-NX1X2, X4, X5, and X6 each independently comprise H, alkyl, carbocyclic ring, hydroxyloweralkyl, alkyl-OH, halogen, CN, SNO, S(SO2)alkyl, NX1X2, COOX3, CONX3, OX7, or O-alkyl-X7 wherein X7 comprises H, alkyl, NO2, NO, P(O)(OX8)2, PH(O)(OX8), S(O)k N(alkyl)2, S(O)k X8, S(O)k OX8, COOX8, CONX8, SO3H, COX8, wherein X8 comprises H, alkyl, carbocyclic ring, heterocyclic ring, aromatic ring, heteroaromatic ring, or -CX9=CHX10 wherein X9 and X10 each independently comprise H or alkyl Wherein m is an integer from 0 to 7 j is an integer from 0 to 6, k is an integer from 0 to 2, W comprises H or alkyl; or R1 comprises -T-(CH2)m- Q -(CH2)n-Z;
m and n independently comprises an integer from 0 to 7;
T comprises a carbocyclic ring having 3 to 8 ring members, an unsaturated ring having 3 to 8 carbon atoms as ring members, an aromatic ring having 5 to 8 carbon atoms as ring members, a heterocyclic ring having 3 to 8 ring members, a heteroaromatic ring having 5 to 8 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring;
Q comprises CH=CH, C-.ident.-C; and Z comprises an unsaturated ring having 5 ring atoms and 0 to 2 independently selected heteroatoms as ring members fused to an unsaturated ring having 5 ring atoms and 0 to 4 independently selected heteroatoms as ring members, an unsaturated ring having 5 ring atoms and 0 to 2 independently selected heteroatoms as ring members fused to an unsaturated ring having 6 or 7 ring atoms and 0 to 4 independently selected heteroatoms as ring members or an unsaturated ring having 6 ring atoms and 0 to 3 independently selected heteroatoms as ring members fused to an unsaturated ring having 6 or 7 ring atoms and 0 to 4 independently selected heteroatoms as ring members; or R1 comprises -T-(CH2)m- Q -(CH2)n-Z;
T comprises a carbocyclic ring having 3 to 8 ring members, an unsaturated ring having 3 to 8 carbon atoms as ring members, an aromatic ring having 5 to 8 carbon atoms as ring members, a heterocyclic ring having 3 to 8 ring members, a heteroaromatic ring having 5 to 8 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring;
m and n independently comprises an integer from 0 to 7;
Q comprises CH=CH, C.ident.C;
Z comprises E comprises a C1 to C4, linear or branched alkyl group, a phenyl group, a substituted phenyl group, a benzyl group or a substituted benzyl group; or R1 comprises -T-(CH2)m- Q -(CH2)n-Z;
T comprises a carbocyclic ring having 3 to 8 ring members, an unsaturated ring having 3 to 8 carbon atoms as ring members, an aromatic ring having 5 to 8 carbon atoms as ring members, a heterocyclic ring having 3 to 8 ring members, a heteroaromatic ring having 5 to 8 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring;
m and n independently comprises an integer from 0 to 7;
Q comprises CH=CH, C.ident.C; and Z comprises k is an integer from 1 to 5, and A1 and A2 each independently comprise a C1 to C4 alkyl group, a phenyl group or a substituted phenyl group; or R1 comprises -(CH2)n-Z;
n is an integer from 0 to 7;
wherein Z comprises, H, halogen, CF3, CF2H, N3, NCS, CN, NO2, NX1X2, OX3, SX3, OAc, OSO2X3, O-acyl, S-acyl, SO2-alkyl, SO-alkyl, SC(CH3)2COOX8, OC(CH3)2COOX8 , C(CH3)2COOX8, Si(alkyl)3, alkyl-CN, O-aroyl, O(CH2)j OX3, O(CH2)j NX1X2, NH-acyl, NH-aroyl, CHO, C(halogen)3, COOX3, SO3H, SO2NX1X2, CONX1X2, NHC(O)O-alkyl, NHSO2-alkyl, alkoxy, alkyl, alcohol, alkylmercapto, alkylamino, di-alkylamino, alkylsulfinyl or alkylsulfonyl, CX4X8X8, -CH=CHX8 , -C.ident.CX8 ;
X1 and X2 each independently comprise H or alkyl, or X1 and X2 together comprise part of a heterocyclic ring having 4 to 7 ring members and optionally one additional heteroatom selected from O, N or S, or X1 and X2 together comprise part of an imide ring having 5 to 6 members, X3 comprises H, alkyl, aryl, NO2, (CH2)m CN, hydroxyloweralkyl, or alkyl-NX1X2, X4, X5, and X6 each independently comprise H, alkyl, carbocyclic ring, hydroxyloweralkyl, alkyl-OH, halogen, CN, SNO, S(SO2)alkyl, NX1X2, COOX3, CONX3, OX7, or O-alkyl-X7 wherein X7 comprises H, alkyl, NO2, NO, P(O)(OX8)2, PH(O)(OX8), S(O)k N(alkyl)2, S(O)k X8, S(O)k OX8, COOX8, CONX8, SO3H, COX8, wherein X8 comprises H, alkyl, carbocyclic ring, heterocyclic ring, aromatic ring, heteroaromatic ring, or ¨CX9=CHX10 wherein X9 and X10 each independently comprise H or alkyl Wherein m is an integer from 0 to 7 j is an integer from 0 to 6, or k is an integer from 0 to 2; or R1 comprises ¨(CH2)n¨Z;
n is an integer from 0 to 7; and Z comprises a carbocyclic ring having 4 to 7 ring members, a heterocyclic ring having 4 to 7 ring members, an aromatic ring having 5 to 7 ring members, a heteroaromatic ring having 5 to 7 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring, a heteropolycyclic ring; or any above group substituted on at least one available ring atom by an alkyl group; or any above group substituted on at least one available ring nitrogen atom by a benzyl group, a substituted benzyl group, an alkoxybenzyl group, a substituted alkoxybenzyl group, a benzhydryl group or a substituted benzhydryl group; and wherein the connecting point between the -(CH2)n- group and the Z group can be any available ring carbon atom or any available ring nitrogen atom; or R1 comprises -(CH2)n-Z;
n is an integer from 0 to 7; and Z comprises a 5 member unsaturated ring having 0 to 4 independently selected heteroatoms as ring members, a substituted 5 member unsaturated ring having 0 to 4 independently selected heteroatoms as ring members, a 6 member aromatic ring having 0 to 5 independently selected heteroatoms as ring members or a substituted 6 member aromatic ring having 0 to 5 independently selected heteroatoms; and wherein the connecting point between the -(CH2)n- group and the Z group can be any available ring carbon atom or any available ring nitrogen atom; or R1 comprises -(CH2)n-Z;
n is an integer from 0 to 7; and Z comprises 1-, 2- or 3-pyrrolidinyl, 1-, 2-, 3- or 4-piperidinyl, 2-, 3- or 4-morpholinyl, 2-, 3- or 4-thiomorpholinyl, 1-, 2- or 3-azetidinyl, 1- or 2-piperazinyl, 2- or 3-tetrahydrofuranyl; or any above group substituted on at least one available ring atom by an alkyl group; or any above group substituted on at least one available ring nitrogen atom by a benzyl group, a substituted benzyl group, an alkoxybenzyl group, a substituted alkoxybenzyl group, a benzhydryl group or a substituted benzhydryl group; and wherein the connecting point between the -(CH2)n- group and the Z group can be any available ring carbon atom or any available ring nitrogen atom; or R1 comprises -(CH2)n-Z;
n is an integer from 0 to 7; and Z comprises wherein X and Y each independently comprise, H, halogen, CF3, CF2H, N3, NCS, CN, NO2, NX1X2, OX3, SX3, OAc, OSO2X3, O-acyl, S-acyl, SO2-alkyl, SO-alkyl, SC(CH3)2COOX8, OC(CH3)2COOX8 , C(CH3)2COOX8, Si(alkyl)3, alkyl-CN, O-aroyl, O(CH2)10X3, O(CH2)j NX1X2, NH-acyl, NH-aroyl, CHO, C(halogen)3, COOX3, SO3H, SO2NX1X2, CONX1X2, NHC(0)O-alkyl, NHSO2-alkyl, alkoxy, alkyl, alcohol, alkylmercapto, alkylamino, di-alkylamino, alkylsulfinyl or alkylsulfonyl, CX4X5X6, -CH=CHX8 , -C.ident.CX8;
X1 and X2 each independently comprise H or alkyl, or X1 and X2 together comprise part of a heterocyclic ring having 4 to 7 ring members and optionally one additional heteroatom selected from O, N or S, or X1 and X2 together comprise part of an imide ring having 5 to 6 members, X3 comprises H, alkyl, aryl, NO2, (CH2)m CN, hydroxyloweralkyl, or alkyl-NX1X2, X4, X6, and X6 each independently comprise H, alkyl, carbocyclic ring, hydroxyloweralkyl, alkyl-OH, halogen, CN, SNO, S(SO2)alkyl, NX1X2, COOX3, CONX3, OX7, or O-alkyl-X7 wherein X7 comprises H, alkyl, NO2, NO, P(O)(O)(8)2, PH(O)(OX8), S(O)k N(alkyl)2, S(O)k X8, S(O)k OX8, COOX8, CONX8, SO3H, COX8, wherein X8 comprises H, alkyl, carbocyclic ring, heterocyclic ring, aromatic ring, heteroaromatic ring, or ¨CX9=CHX10 wherein X9 and X10 each independently comprise H or alkyl Wherein m is an integer from 0 to 7 j is an integer from 0 to 6, or k is an integer from 0 to 2 W comprises H or alkyl; or R1 comprises ¨(CH2)n¨Z;
n is an integer from 0 to 7; and Z comprises a carbocyclic ring having 6 ring atoms fused to a heterocyclic ring having from 5 to 7 ring atoms, a carbocyclic ring having 6 ring atoms fused to a heteroaromatic ring having from 5 to 7 ring atoms, a heterocyclic ring having 6 ring atoms fused to a heterocyclic ring having from 5 to 7 ring atoms, an heterocyclic ring having 6 ring atoms fused to a heteroaromatic ring having from to 7 ring atoms, an aromatic ring having 6 ring atoms fused to a heterocyclic ring having from 5 to 7 ring atoms, an aromatic ring having 6 ring atoms fused to a heteroaromatic ring having from 5 to 7 ring atoms, a heteroaromatic ring having 6 ring atoms fused to a heterocyclic ring having from 5 to 7 ring atoms or a heteroaromatic ring having 6 ring atoms fused to a heteroaromatic ring having from 5 to 7 ring atoms; or R1 comprises ¨(CH2),¨Z;
n comprises an integer from 0 to 7; and Z comprises an unsaturated ring having 5 ring atoms and 0 to 2 independently selected heteroatoms as ring members fused to an unsaturated ring having 5 ring atoms and 0 to 4 independently selected heteroatoms as ring members, an unsaturated ring having 5 ring atoms and 0 to 2 independently selected heteroatoms as ring members fused to an unsaturated ring having 6 or 7 ring atoms and 0 to 3 independently selected heteroatoms as ring members or an unsaturated ring having 6 ring atoms and 0 to 4 independently selected heteroatoms as ring members fused to an unsaturated ring having 6 or 7 ring atoms and 0 to 4 independently selected heteroatoms as ring members; or R1 comprises -(CH2)m-Q1-(CH2)n-Z;
Q1 comprises NH, O, S,-CH=CH-,-c.ident.C-, -CO, SO2 or OSO2;
m is an integer from 1 to 7;
n is an integer from 0 to 7; and wherein Z comprises, H, halogen, CF3, CF2H, N3, NCS, CN, NO2, NX1X2, OX3, SX3, OAc, OSO2X3, O-acyl, S-acyl, SO2-alkyl, SO-alkyl, SC(CH3)2COOX8, OC(CH3)2COOX8 , C(CH3)2COOX8, Si(alkyl)3, alkyl-CN, O-aroyl, O(CH2)j OX3, O(CH2)j NX1X2, NH-acyl, NH-aroyl, CHO, C(halogen)3, COOX3, SO3H, SO2NX1X2, CONX1X2, NHC(O)O-alkyl, NHSO2-alkyl, alkoxy, alkyl, alcohol, alkylmercapto, alkylamino, di-alkylamino, alkylsulfinyl or alkylsulfonyl, CX4X8X6, -CH=CHX8 , -C.ident.CX8 ;
X1 and X2 each independently comprise H or alkyl, or X1 and X2 together comprise part of a heterocyclic ring having 4 to 7 ring members and optionally one additional heteroatom selected from O, N or S, or X1 and X2 together comprise part of an imide ring having 5 to 6 members, X3 comprises H, alkyl, aryl, NO2, (CH2)m CN, hydroxyloweralkyl, or alkyl-NX1X2, X4, X5, and X6 each independently comprise H, alkyl, carbocyclic ring, hydroxyloweralkyl, alkyl-OH, halogen, CN, SNO, S(SO2)alkyl, NX1X2, COOX3, CONX3, OX7, or O-alkyl-X7 wherein X7 comprises H, alkyl, NO2, NO, P(O)(OX8)2, PH(O)(OX8), S(O)k N(alkyl)2, S(O)k X8, S(O)k OX8, COOX8, CONX8, SO3H, COX8, wherein X8 comprises H, alkyl, carbocyclic ring, heterocyclic ring, aromatic ring, heteroaromatic ring, or -CX9=CHX10 wherein X9 and X10 each independently comprise H or alkyl Wherein m is an integer from 0 to 7 j is an integer from 0 to 6, or k is an integer from 0 to 2; or R1 comprises -Q2-(CH2)n-Z;
Q2 is optionally present and if present comprises -CH2-NH, -CH2-O, -CH2-S, -CH2-SO2 or -CH2-OSO2;
n is an integer from 0 to 7;
wherein Z comprises, H, halogen, CF3, CF2H, N3, NCS, CN, NO2, NX1X2, OX3, SX3, OAc, OSO2X3, O-acyl, S-acyl, SO2-alkyl, SO-alkyl, SC(CH3)2COOX8, OC(CH3)2COOX8 , C(CH3)2COOX8, Si(alkyl)3, alkyl-CN, O-aroyl, O(CH2)j OX3, O(CH2)j NX1X2, NH-acyl, NH-aroyl, CHO, C(halogen)3, COOX3, SO3H, SO2NX1X2, CONX1X2, NHC(O)O-alkyl, NHSO2-alkyl, alkoxy, alkyl, alcohol, alkylmercapto, alkylamino, di-alkylamino, alkylsulfinyl or alkylsulfonyl, CX4X8X8, -CH=CHX8 , -C.ident.CX8;
X1 and X2 each independently comprise H or alkyl, or X1 and X2 together comprise part of a heterocyclic ring having 4 to 7 ring members and optionally one additional heteroatom selected from O, N or S, or X1 and X2 together comprise part of an imide ring having 5 to 6 members, X3 comprises H, alkyl, aryl, NO2, (CH2)m CN, hydroxyloweralkyl, or alkyl-NX1X2, X4, X5, and X6 each independently comprise H, alkyl, carbocyclic ring, hydroxyloweralkyl, alkyl-OH, halogen, CN, SNO, S(SO2)alkyl, NX1X2, COOX3, CONX3, OX7, or O-alkyl-X7 wherein X7 comprises H, alkyl, NO2, NO, P(O)(OX8)2, PH(O)(OX8), S(O)k N(alkyl)2, S(O)k X8, S(O)k OX8, COOX8, CONX8, SO3H, COX8, wherein X8 comprises H, alkyl, carbocyclic ring, heterocyclic ring, aromatic ring, heteroaromatic ring, or -CX9=CHX10 wherein X9 and X10 each independently comprise H or alkyl Wherein m is an integer from 0 to 7 j is an integer from 0 to 6, k is an integer from 0 to 2; or R1 comprises -(CH2)m - Q1 -(CH2)n-Z;
Q1 comprises NH, O, S, CH=CH, C.ident.C, CO, SO2 or OSO2;
m is an integer from 1 to 7;
n is an integer from 0 to 7;
Z comprises a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring; or R1 comprises -(CH2)m - Q1 --(CH2)n-Z;
Q1 comprises NH, O, S, CH=CH, C.ident.C, CO, SO2 or OSO2;
m is an integer from 1 to 7;
n is an integer from 0 to 7;
Z comprises a carbocyclic ring having 4 to 7 ring members, a heterocyclic ring having 4 to 7 ring members, an aromatic ring having 5 to 7 ring members, a heteroaromatic ring having 5 to 7 ring members; a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring, a heteropolycyclic ring or any above group substituted on at least one available ring atom by an alkyl group or any above group substituted on at least one available ring nitrogen atom by a benzyl group, a substituted benzyl group, an alkoxybenzyl group, a substituted alkoxybenzyl group, a benzhydryl group or a substituted benzhydryl group; and wherein the connecting point between the -(CH2)n- group and the Z
group can be any available ring carbon atom or any available ring nitrogen atom;
or R1 comprises -(CH2)m- Q1 -(CH2)n-Z;
Q1 comprises NH, O, S, CH=CH, C.ident.C, CO, SO2 or OSO2;
m is an integer from 1 to 7;
n is an integer from 0 to 7; and Z comprises a 5 member unsaturated ring having 0 to 4 independently selected heteroatoms as ring members, a substituted 5 member unsaturated ring having 0 to 4 independently selected heteroatoms as ring members, a 6 member aromatic ring having 0 to 5 independently selected heteroatoms as ring members or a substituted 6 member aromatic ring having 0 to 5 independently selected heteroatoms; and wherein the connecting point between the -(CH2)n- group and the Z group can be any available ring carbon atom or any available ring nitrogen atom; or R1 comprises -(CH2)m - Q1 -(CH2)n-Z;
Q1 comprises NH, O, S, CH=CH, C.ident.C, CO, SO2 or OSO2;
m is an integer from 1 to 7;
n is an integer from 0 to 7;
Z comprises 1-, 2- or 3-pyrrolidinyl, 1-, 2-, 3- or 4-piperidinyl, 2-, 3- or 4-morpholinyl, 2-, 3- or 4-thiomorpholinyl, 1-, 2- or 3-azetidinyl, 1- or 2-piperazinyl, 2- or 3-tetrahydrofuranyl; or any above group substituted on at least one available ring atom by an alkyl group; or any above group substituted on at least one available ring nitrogen atom by a benzyl group, a substituted benzyl group, an alkoxybenzyl group, a substituted alkoxybenzyl group, a benzhydryl group or a substituted benzhydryl group; and wherein the connecting point between the -(CH2)n- group and the Z group can be any available ring carbon atom or any available ring nitrogen atom; or R1 comprises -(CH2)m - Q1 -(CH2)n-Z;
Q1 comprises NH, O, S, CH=CH, C.ident.C, CO, SO2 or OSO2;
m is an integer from 1 to 7;
n is an integer from 0 to 7; and Z comprises wherein X and Y each independently comprise H, halogen, CF3, CF2H, N3, NCS, CN, NO2, NX1X2, OX3, SX3, OAc, OSO2X3, O-acyl, S-acyl, SO2-alkyl, SO-alkyl, SC(CH3)2COOX8, OC(CH3)2COOX8 , C(CH3)2COOX8, Si(alkyl)3, alkyl-CN, O-aroyl, O(CH2)j OX3, O(CH2)j NX1X2, NH-acyl, NH-aroyl, CHO, C(halogen)3, COOX3, SO3H, SO2NX1X2, CONX1X2, NHC(O)O-alkyl, NHSO2-alkyl, alkoxy, alkyl, alcohol, alkylmercapto, alkylamino, di-alkylamino, alkylsulfinyl or alkylsulfonyl, CX4X5X6, -CH=CHX8 , -C.ident.CX8 ;
X1 and X2 each independently comprise H or alkyl, or X1 and X2 together comprise part of a heterocyclic ring having 4 to 7 ring members and optionally one additional heteroatom selected from O, N or S, or X1 and X2 together comprise part of an imide ring having 5 to 6 members, X3 comprises H, alkyl, aryl, NO2, (CH2)m CN, hydroxyloweralkyl, or alkyl-NX1X2, X4, X5, and X6 each independently comprise H, alkyl, carbocyclic ring, hydroxyloweralkyl, alkyl-OH, halogen, CN, SNO, S(SO2)alkyl, NX1X2, COOX3, CONX3, OX7, or O-alkyl-X7 wherein X7 comprises H, alkyl, NO2, NO, P(O)(OX8)2, PH(O)(OX8), S(O)k N(alkyl)2, S(O)k X8, S(O)k OX8, COOX8, CONX8, SO3H, COX8, wherein X8 comprises H, alkyl, carbocyclic ring, heterocyclic ring, aromatic ring, heteroaromatic ring, or -CX6=CHX10 wherein X9 and X10 each independently comprise H or alkyl Wherein m is an integer from 0 to 7 j is an integer from 0 to 6, k is an integer from 0 to 2 W comprises H or alkyl; or R1 comprises -(CH2)m - Q1 -(CH2)n-Z;
Q1 comprises NH, O, S, CH=CH, C.ident.C, CO, SO2 or OSO2;
m is an integer from 1 to 7;
n is an integer from 0 to 7; and Z comprises an unsaturated ring having 5 ring atoms and 0 to 2 independently selected heteroatoms as ring members fused to an unsaturated ring having 5 ring atoms and 0 to 4 independently selected heteroatoms as ring members, an unsaturated ring having 5 ring atoms and 0 to 2 independently selected heteroatoms as ring members fused to an unsaturated ring having 6 or 7 ring atoms and 0 to 4 independently selected heteroatoms as ring members or an unsaturated ring having 6 ring atoms and 0 to 4 independently selected heteroatoms as ring members fused to an unsaturated ring having 6 or 7 ring atoms and 0 to 4 independently selected heteroatoms as ring members; or R1 comprises -(CH2)m- Q1 -(CH2)n-Z;
Q1 comprises NH, O, S, CH=CH, C.ident.C, CO, SO2 or OSO2;
m is an integer from 1 to 7;
n is an integer from 0 to 7; and Z comprises R1 comprises -T-(CH2)n-Z;
n comprises an integer from 0 to 7;
T comprises a carbocyclic ring having 3 to 8 ring members, an unsaturated ring having 3 to 8 carbon atoms as ring members, an aromatic ring having 5 to 8 carbon atoms as ring members, a heterocyclic ring having 3 to 8 ring members, a heteroaromatic ring having 5 to 8 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring; and Z comprises, H, halogen, CF3, CF2H, N3, NCS, CN, NO2, NX1X2, OX3, SX3, OAc, OSO2X3, O-acyl, S-acyl, SO2-alkyl, SO-alkyl, SC(CH3)2COOX8, OC(CH3)2COOX8 , C(CH3)2COOX8, Si(alkyl)3, alkyl-CN, O-aroyl, O(CH2)j OX3, O(CH2)j NX1X2, NH-acyl, NH-aroyl, CHO, C(halogen)3, COOX3, SO3H, SO2NX1X2, CONX1X2, NHC(O)O-alkyl, NHSO2-alkyl, alkoxy, alkyl, alcohol, alkylmercapto, alkylamino, di-alkylamino, alkylsulfinyl or alkylsulfonyl, CX4X8X8, -CH=CHX8, --C.ident.CX8;
X1 and X2 each independently comprise H or alkyl, or X1 and X2 together comprise part of a heterocyclic ring having 4 to 7 ring members and optionally one additional heteroatom selected from O, N or S, or X1 and X2 together comprise part of an imide ring having 5 to 6 members, X3 comprises H, alkyl, aryl, NO2, (CH2)m CN, hydroxyloweralkyl, or alkyl-NX1X2, X4, X5, and X6 each independently comprise H, alkyl, carbocyclic ring, hydroxyloweralkyl, alkyl-OH, halogen, CN, SNO, S(SO2)alkyl, NX1X2, COOX3, CONX3, OX7, or O-alkyl-X7 wherein X7 comprises H, alkyl, NO2, NO, P(O)(OX8)2, PH(O)(OX8), S(O)k N(alkyl)2, S(O)k X8, S(O)k OX8, COOX8, CONX8, SO3H, COX8, wherein X8 comprises H, alkyl, carbocyclic ring, heterocyclic ring, aromatic ring, heteroaromatic ring, or -CX9=CHX10 wherein X9 and X10 each independently comprise H or alkyl Wherein m is an integer from 0 to 7 j is an integer from 0 to 6, k is an integer from 0 to 2; or R1 comprises -T-(CH2)n-Z;
n comprises an integer from 0 to 7;
T comprises a carbocyclic ring having 3 to 8 ring members, an unsaturated ring having 3 to 8 carbon atoms as ring members, an aromatic ring having 5 to 8 carbon atoms as ring members, a heterocyclic ring having 3 to 8 ring members, a heteroaromatic ring having 5 to 8 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring; and Z comprises a carbocyclic ring having 4 to 7 ring members, a heterocyclic ring having 4 to 7 ring members, an aromatic ring having 5 to 7 ring members, a heteroaromatic ring having 5 to 7 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring, a heteropolycyclic ring; or any above group substituted on at least one available ring atom by an alkyl group; or any above group substituted on at least one available ring nitrogen atom by a benzyl group, a substituted benzyl group, an alkoxybenzyl group, a substituted alkoxybenzyl group, a benzhydryl group or a substituted benzhydryl group; and wherein the connecting point between the -(CH2)n- group and the Z group can be any available ring carbon atom or any available ring nitrogen atom; or R1 comprises -T--(CH2)n-Z;
n comprises an integer from 0 to 7;
T comprises a carbocyclic ring having 3 to 8 ring members, an unsaturated ring having 3 to 8 carbon atoms as ring members, an aromatic ring having 5 to 8 carbon atoms as ring members, a heterocyclic ring having 3 to 8 ring members, a heteroaromatic ring having 5 to 8 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring; and Z comprises 1-, 2- or 3-pyrrolidinyl, 1-, 2-, 3- or 4-piperidinyl, 2-, 3- or 4-morpholinyl, 2-, 3- or 4-thiomorpholinyl, 1-, 2- or 3-azetidinyl, 1- or 2-piperazinyl, 2- or 3-tetrahydrofuranyl; or any above group substituted on at least one available ring atom by an alkyl group; or any above group substituted on at least one available ring nitrogen atom by a benzyl group, a substituted benzyl group, an alkoxybenzyl group, a substituted alkoxybenzyl group, a benzhydryl group or a substituted benzhydryl group; and wherein the connecting point between the -(CH2)n- group and the Z group can be any available ring carbon atom or any available ring nitrogen atom; or R1 comprises ¨T¨(CH2)n--Z;
n comprises an integer from 0 to 7;
T comprises a carbocyclic ring having 3 to 8 ring members, an unsaturated ring having 3 to 8 carbon atoms as ring members, an aromatic ring having 5 to 8 carbon atoms as ring members, a heterocyclic ring having 3 to 8 ring members, a heteroaromatic ring having 5 to 8 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring; and Z comprises wherein X and Y each independently comprise H, halogen, CF3, CF2H, N3, NCS, CN, NO2, NX1X2, OX3, SX3, OAc, OSO2X3, O-acyl, S-acyl, SO2-alkyl, SO-alkyl, SC(CH3)2COOX5, OC(CH3)2COOX8 , C(CH3)2COOX8, Si(alkyl)3, alkyl-CN, O-aroyl, O(CH2)i OX3, O(CH2)j NX1X2, NH-acyl, NH-aroyl, CHO, C(halogen)3, COOX3, SO3H, SO2NX1X2, CONX1X2, NHC(O)O-alkyl, NHSO2-alkyl, alkoxy, alkyl, alcohol, alkylmercapto, alkylamino, di-alkylamino, alkylsulfinyl or alkylsulfonyl, CX4X5X6, -CH=CHX8 , -C.ident.CX8 ;
X1 and X2 each independently comprise H or alkyl, or X1 and X2 together comprise part of a heterocyclic ring having 4 to 7 ring members and optionally one additional heteroatom selected from O, N or S, or X1 and X2 together comprise part of an imide ring having 5 to 6 members, X3 comprises H, alkyl, aryl, NO2, (CH2)m CN, hydroxyloweralkyl, or alkyl-NX1X2, X4, X5, and X6 each independently comprise H, alkyl, carbocyclic ring, hydroxyloweralkyl, alkyl-OH, halogen, CN, SNO, S(SO2)alkyl, NX1X2, COOX3, CONX3, OX7, or O-alkyl-X7 wherein X7 comprises H, alkyl, NO2, NO, P(O)OX8)2, PH(O)OX8), S(O)k N(alkyl)2, S(O)k X8, S(O)k OX8, COOX8, CONX8, SO3H, COX8, wherein X8 comprises H, alkyl, carbocyclic ring, heterocyclic ring, aromatic ring, heteroaromatic ring, or -CX9=CHX10 wherein X9 and X10 each independently comprise H or alkyl Wherein m is an integer from 0 to 7 j is an integer from 0 to 6, k is an integer from 0 to 2 W comprises H or alkyl; or R1 comprises -T-(CH2)n-Z;
n comprises an integer from 0 to 7;
T comprises a carbocyclic ring having 3 to 8 ring members, an unsaturated ring having 3 to 8 carbon atoms as ring members, an aromatic ring having 5 to 8 carbon atoms as ring members, a heterocyclic ring having 3 to 8 ring members, a heteroaromatic ring having 5 to 8 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring; and Z comprises an unsaturated ring having 5 ring atoms and 0 to 2 independently selected heteroatoms as ring members fused to an unsaturated ring having 5 ring atoms and 0 to 4 independently selected heteroatoms as ring members, an unsaturated ring having 5 ring atoms and 0 to 2 independently selected heteroatoms as ring members fused to an unsaturated ring having 6 or 7 ring atoms and 0 to 4 independently selected heteroatoms as ring members or an unsaturated ring having 6 ring atoms and 0 to 3 independently selected heteroatoms as ring members fused to an unsaturated ring having 6 or 7 ring atoms and 0 to 4 independently selected heteroatoms as ring members; or R1 comprises -T-Q-(CH2)n-Z, each n independently comprises an integer from 0 to 7;
T comprises a carbocyclic ring having 3 to 8 ring members, an unsaturated ring having 3 to 8 carbon atoms as ring members, an aromatic ring having 5 to 8 carbon atoms as ring members, a heterocyclic ring having 3 to 8 ring members, a heteroaromatic ring having 5 to 8 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring;
Q comprises CH.ident.CH, Z comprises H, halogen, CF3, CF2H, N3, NCS, CN, NO2, NX1X2, OX3, SX3, OAc, OSO2X3, O-acyl, S-acyl, SO2-alkyl, SO-alkyl, SC(CH3)2COOX8, OC(CH3)2COOX8 , C(CH3)2COOX8, Si(alkyl)3, alkyl-CN, O-aroyl, O(CH2)j OX3, O(CH2)j NX1X2, NH-acyl, NH-aroyl, CHO, C(halogen)3, COOX3, SO3H, SO2NX1X2, CONX1X2, NHC(O)O-alkyl, NHSO2-alkyl, alkoxy, alkyl, alcohol, alkylmercapto, alkylamino, di-alkylamino, alkylsulfinyl or alkylsulfonyl, CX4X5X6, -CH=CHX8 , -C.ident.CX8;
X1 and X2 each independently comprise H or alkyl, or X1 and X2 together comprise part of a heterocyclic ring having 4 to 7 ring members and optionally one additional heteroatom selected from 0, N or S, or X1 and X2 together comprise part of an imide ring having 5 to 6 members, X3 comprises H, alkyl, NO2, (CH2)m CN, hydroxyloweralkyl, or alkyl-NX1X2, X4, X5, and X6 each independently comprise H, alkyl, carbocyclic ring, hydroxyloweralkyl, alkyl-OH, halogen, CN, SNO, S(SO2)alkyl, NX1X2, COOX3, CONX3, OX7, or O-alkyl-X7 wherein X7 comprises H, alkyl, NO2, NO, P(O)(OX8)2, PH(O)(OX8), S(O)k N(alkyl)2, S(O)k X8, S(O)k OX8, COOX8, CONX8, SO3H, COX8, wherein X8 comprises H, alkyl, carbocyclic ring, heterocyclic ring, aromatic ring, heteroaromatic ring, or -CX9=CHX10 wherein X9 and X10 each independently comprise H or alkyl Wherein m is an integer from 0 to 7 j is an integer from 0 to 6, or k is an integer from 0 to 2; or R1 comprises -T-Q-(CH2)n-Z, each n independently comprises an integer from 0 to 7;
T comprises a carbocyclic ring having 3 to 8 ring members, an unsaturated ring having 3 to 8 carbon atoms as ring members, an aromatic ring having 5 to 8 carbon atoms as ring members, a heterocyclic ring having 3 to 8 ring members, a heteroaromatic ring having 5 to 8 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring;
Q comprises CH=CH, C.ident.C; and Z comprises a carbocyclic ring having 4 to 7 ring members, a heterocyclic ring having 4 to 7 ring members, an aromatic ring having 5 to 7 ring members, a heteroaromatic ring having 5 to 7 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring, a heteropolycyclic ring; or any above group substituted on at least one available ring atom by an alkyl group; or any above group substituted on at least one available ring nitrogen atom by a benzyl group, a substituted benzyl group, an alkoxybenzyl group, a substituted alkoxybenzyl group, a benzhydryl group or a substituted benzhydryl group; and wherein the connecting point between the -(CH2)n- group and the Z group can be any available ring carbon atom or any available ring nitrogen atom; or R1 comprises -T-Q--(CH2)n-Z;
each n independently comprises an integer from 0 to 7;
T comprises a carbocyclic ring having 3 to 8 ring members, an unsaturated ring having 3 to 8 carbon atoms as ring members, an aromatic ring having 5 to 8 carbon atoms as ring members, a heterocyclic ring having 3 to 8 ring members, a heteroaromatic ring having 5 to 8 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring;
Q comprises CH=CH, C.ident.C, and Z comprises 1-, 2- or 3-pyrrolidinyl, 1-, 2-, 3- or 4-piperidinyl, 2-, 3- or 4-morpholinyl, 2-, 3- or 4-thiomorpholinyl, 1-, 2- or 3-azetidinyl, 1- or 2-piperazinyl, 2- or 3-tetrahydrofuranyl; or any above group substituted on at least one available ring atom by an alkyl group; or any above group substituted on at least one available ring nitrogen atom by a benzyl group, a substituted benzyl group, an alkoxybenzyl group, a substituted alkoxybenzyl group, a benzhydryl group or a substituted benzhydryl group; and wherein the connecting point between the -(CH2)n- group and the Z group can be any available ring carbon atom or any available ring nitrogen atom; or R1 comprises -T-Q-(CH2)n-Z;
each n independently comprises an integer from 0 to 7;
T comprises a carbocyclic ring having 3 to 8 ring members, an unsaturated ring having 3 to 8 carbon atoms as ring members, an aromatic ring having 5 to 8 carbon atoms as ring members, a heterocyclic ring having 3 to 8 ring members, a heteroaromatic ring having 5 to 8 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring;
Q comprises CH=CH, C.ident.C; and Z comprises wherein X and Y each independently comprise H, halogen, CF3, CF2H, N3, NCS, CN, NO2, NX1X2, OX3, SX3, OAc, OSO2X3, O-acyl, S-acyl, SO2-alkyl, SO-alkyl, SC(CH3)2COOX8, OC(CH3)2COOX8 , C(CH3)2COOX8, Si(alkyl)3, O-aroyl, O(CH2)j OX3, O(CH2)j NX1X2, NH-acyl, NH-aroyl, CHO, C(halogen)3, COOX3, SO3H, SO2NX1X2, CONX1X2, NHC(O)O-alkyl, NHSO2-alkyl, alkoxy, alkyl, alcohol, alkylmercapto, alkylamino, di-alkylamino, alkylsulfinyl or alkylsulfonyl, CX4X5X6, -CH=CHX8 , -C.ident.CX8;
X1 and X2 each independently comprise H or alkyl, or X1 and X2 together comprise part of a heterocyclic ring having 4 to 7 ring members and optionally one additional heteroatom selected from O, N or S, or X1 and X2 together comprise part of an imide ring having 5 to 6 members, X3 comprises H, alkyl, NO2, (CH2)m CN, hydroxyloweralkyl, or alkyl-NX1X2, X4, X5, and X6 each independently comprise H, alkyl, carbocyclic ring, hydroxyloweralkyl, alkyl-OH, halogen, CN, SNO, S(SO2)alkyl, NX1X2, COOX3, CONX3, OX7, or O-alkyl-X7 wherein X7 comprises H, alkyl, NO2, NO, P(O)(OX8)2, PH(O)(OX8), S(O)k N(alkyl)2, S(O)k X8, S(O)k OX8, COOX8, CONX8, SO3H, COX8, wherein X8 comprises H, alkyl, carbocyclic ring, heterocyclic ring, aromatic ring, heteroaromatic ring, or -CX9=CHX10 wherein X9 and X10 each independently comprise H or alkyl Wherein m is an integer from 0 to 7 j is an integer from 0 to 6, k is an integer from 0 to 2, W comprises H or alkyl; or R1 comprises -T-Q-(CH2)n-Z, each n independently comprises an integer from 0 to 7;
T comprises a carbocyclic ring having 3 to 8 ring members, an unsaturated ring having 3 to 8 carbon atoms as ring members, an aromatic ring having 5 to 8 carbon atoms as ring members, a heterocyclic ring having 3 to 8 ring members, a heteroaromatic ring having 5 to 8 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring;
Q comprises CH=CH, C.ident.C; and Z comprises an unsaturated ring having 5 ring atoms and 0 to 2 independently selected heteroatoms as ring members fused to an unsaturated ring having 5 ring atoms and 0 to 4 independently selected heteroatoms as ring members, an unsaturated ring having 5 ring atoms and 0 to 2 independently selected heteroatoms as ring members fused to an unsaturated ring having 6 or 7 ring atoms and 0 to 4 independently selected heteroatoms as ring members or an unsaturated ring having 6 ring atoms and 0 to 3 independently selected heteroatoms as ring members fused to an unsaturated ring having 6 or 7 ring atoms and 0 to 4 independently selected heteroatoms as ring members; or R1 comprises -T- Q-(CH2)n-Z;
T comprises a carbocyclic ring having 3 to 8 ring members, an unsaturated ring having 3 to 8 carbon atoms as ring members, an aromatic ring having 5 to 8 carbon atoms as ring members, a heterocyclic ring having 3 to 8 ring members, a heteroaromatic ring having 5 to 8 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring;
each n independently comprises an integer from 0 to 7;
Q comprises CH=CH, C.ident.C;
Z comprises E comprises a C1 to C4, linear or branched alkyl group, a phenyl group, a substituted phenyl group, a benzyl group or a substituted benzyl group; or R1 comprises -T- Q-(CH2)n-Z;
T comprises a carbocyclic ring having 3 to 8 ring members, an unsaturated ring having 3 to 8 carbon atoms as ring members, an aromatic ring having 5 to 8 carbon atoms as ring members, a heterocyclic ring having 3 to 8 ring members, a heteroaromatic ring having 5 to 8 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring;
each n independently comprises an integer from 0 to 7;
Q comprises CH=CH, C.ident.C and Z comprises k is an integer from 1 to 5, and A1 and A2 each independently comprise a C1 to C4 alkyl group, a phenyl group or a substituted phenyl group; and R4 comprises H, halogen, CF3, CF2H, N3, NCS, CN, NO2, NX1X2, OH, ONO2, SX3, OAc, OSO2X3, O-acyl, S-acyl, SO2-alkyl, SO-alkyl, SC(CH3)2COOX8, OC(CH3)2COOX8 , C(CH3)2COOX8, Si(alkyl)3, alkyl-CN, O-aroyl, O(CH2)j OX3, O(CH2)j NX1X2, NH-acyl, NH-aroyl, CHO, C(halogen)3, COOX3, SO3H, SO2NX1X2, CONX1X2, NHC(O)O-alkyl, NHSO2-alkyl, alkoxy, alkyl, alcohol, alkylmercapto, alkylamino, di-alkylamino, alkylsulfinyl or alkylsulfonyl, CX4X5X8, -CH=CHX8 , -C.ident.CX8;
X1 and X2 each independently comprise H or alkyl, or X1 and X2 together comprise part of a heterocyclic ring having 4 to 7 ring members and optionally one additional heteroatom selected from O, N or S, or X1 and X2 together comprise part of an imide ring having 5 to 6 members, X3 comprises H, alkyl, NO2, (CH2)m CN, hydroxyloweralkyl, or alkyl-NX1X2, X4, X5, and X6 each independently comprise H, alkyl, carbocyclic ring, hydroxyloweralkyl, alkyl-OH, halogen, CN, SNO, S(SO2)alkyl, NX1X2, COOX3, CONX3, OX7, or O-alkyl-X7 wherein X7 comprises H, alkyl, NO2, NO, P(O)(OX8)2, PH(O)(OX8), S(O)k N(alkyl)2, S(O)k X8, S(O)k OX8, COOX8, CONX8, SO3H, COX8, wherein X8 comprises H, alkyl, carbocyclic ring, heterocyclic ring, aromatic ring, heteroaromatic ring, or -CX9=CHX10 wherein X9 and X10 each independently comprise H or alkyl Wherein m is an integer from 0 to 7 j is an integer from 0 to 6, or k is an integer from 0 to 2; or R4 comprises a carbocyclic ring having 4 to 7 ring members, a heterocyclic ring having 4 to 7 ring members, an aromatic ring having 5 to 7 ring members, a heteroaromatic ring having 5 to 7 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricydic ring, a polycyclic ring or a heteropolycyclic ring; or R4 comprises R4 comprises -(CH2)d-Z;
d is an integer from 1 to 6;
Z comprises H, halogen, CF3, CF2H, N3, NCS, CN, NO2, NX1X2, OX3, SX3, OAc, OSO2X3, O-acyl, S-acyl, SO2-alkyl, SO-alkyl, SC(CH3)2COOX8, OC(CH3)2COOX8 , C(CH3)2COOX8, Si(alkyl)3, alkyl-CN, O-aroyl, O(CH2)10X3, O(CH2)j NX1X2, NH-acyl, NH-aroyl, CHO, C(halogen)3, COOX3, SO3H, SO2NX1X2, CONX1X2, NHC(O)O-alkyl, NHSO2-alkyl, alkoxy, alkyl, alcohol, alkylmercapto, alkylamino, di-alkylamino, alkylsulfinyl or alkylsulfonyl, CX4X5X6, -CH=CHX8 , -C.ident.CX8 ;
X1 and X2 each independently comprise H or alkyl, or X1 and X2 together comprise part of a heterocyclic ring having 4 to 7 ring members and optionally one additional heteroatom selected from O, N or S, or X1 and X2 together comprise part of an imide ring having 5 to 6 members, X3 comprises H, alkyl, NO2, (CH2)m CN, hydroxyloweralkyl, or alkyl-NX1X2, X4, X5, and X6 each independently comprise H, alkyl, carbocyclic ring, hydroxyloweralkyl, alkyl-OH, halogen, CN, SNO, S(SO2)alkyl, NX1X2, COOX3, CONX3, OX7, or O-alkyl-X7 wherein X7 comprises H, alkyl, NO2, NO, P(O)(OX8)2, PH(O)(OX8), S(O) k N(alkyl)2, S(O)k X8, S(O)k OX8, COOX8, CONX8, SO3H, COX8, wherein X8 comprises H, alkyl, carbocyclic ring, heterocyclic ring, aromatic ring, heteroaromatic ring, or -CX9=CHX10wherein X9 and X10 each independently comprise H or alkyl Wherein m is an integer from 0 to 7 j is an integer from 0 to 6, k is an integer from 0 to 2; or R4 comprises -(CH2)d-Z, d is an integer from 1 to 6; and Z comprises a carbocyclic ring having 4 to 7 ring members, a heterocyclic ring having 4 to 7 ring members, an aromatic ring having 5 to 7 ring members, a heteroaromatic ring having 5 to 7 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring, a heteropolycyclic ring; or any above group substituted on at least one available ring atom by an alkyl group; or any above group substituted on at least one available ring nitrogen atom by a benzyl group, a substituted benzyl group, an alkoxybenzyl group, a substituted alkoxybenzyl group, a benzhydryl group or a substituted benzhydryl group; and wherein the_connecting point between the -(CH2)d- group and the Z group can be any available ring carbon atom or any available ring nitrogen atom; or R4 comprises -(CH2)d-Z;
d is an integer from 1 to 6; and Z comprises 1-, 2- or 3-pyrrolidinyl, 1-, 2-, 3- or 4-piperidinyl, 2-, 3- or 4-morpholinyl, 2-, 3- or 4-thiomorpholinyl, 1-, 2- or 3-azetidinyl, 1- or 2-piperazinyl, 2- or 3-tetrahydrofuranyl; or any above group substituted on at least one ring atom by an alkyl group; or any above group substituted on at least one available ring nitrogen atom by a benzyl group, a substituted benzyl group, an alkoxybenzyl group, a substituted alkoxybenzyl group, a benzhydryl group or a substituted benzhydryl group; and wherein the connecting point between the -(CH2)d- group and the Z group can be any available ring carbon atom or any available ring nitrogen atom; or R4 comprises -(CH2 )m - Q1 -(CH2)n-Z;
Q1 comprises NH, O, S, CH=CH, CC, CO, SO2 or OSO2;
m is an integer from 1 to 7;
n is an integer from 0 to 7; and Z comprises H, halogen, CF3, CF2H, N3, NCS, CN, NO2, NX1X2, OX3, SX3, OAc, OSO2X3, O-acyl, S-acyl, SO2-alkyl, SO-alkyl, SC(CH3)2COOX8, OC(CH3)2COOX8 , C(CH3)2COOX8, Si(alkyl)3, alkyl-CN, O-aroyl, O(CH2)j OX3, O(CH2)j NX1X2, NH-acyl, NH-aroyl, CHO, C(halogen)3, COOX3, SO3H, SO2NX1X2, CONX1X2, NHC(O)O-alkyl, NHSO2-alkyl, alkoxy, alkyl, alcohol, alkylmercapto, alkylamino, di-alkylamino, alkylsulfinyl or alkylsulfonyl, CX4X8X8, -CH=CHX8 , -C.ident.CX8 ;
X1 and X2 each independently comprise H or alkyl, or X1 and X2 together comprise part of a heterocyclic ring having 4 to 7 ring members and optionally one additional heteroatom selected from O, N or S, or X1 and X2 together comprise part of an imide ring having 5 to 6 members, X3 comprises H, alkyl, NO2, (CH2)m CN, hydroxyloweralkyl, or alkyl-NX1X2, X4, X5, and X6 each independently comprise H, alkyl, carbocyclic ring, hydroxyloweralkyl, alkyl-OH, halogen, CN, SNO, S(SO2)alkyl, NX1X2, COOX3, CONX3, OX7, or O-alkyl-X7 wherein X7 comprises H, alkyl, NO2, NO, P(O)(OX8)2, PH(O)(OX8), S(O)k N(alkyl)2, S(O)k X8, S(O)k OX8, COOX8, CONX8, SO3H, COX8, wherein X8 comprises H, alkyl, carbocyclic ring, heterocyclic ring, aromatic ring, heteroaromatic ring, or -CX9=CHX10 wherein X9 and X10 each independently comprise H or alkyl Wherein m is an integer from 0 to 7 j is an integer from 0 to 6, or k is an integer from 0 to 2; or R4 comprises -(CH2)m - Q1 -(CH2)n-Z;
Q1 comprises NH, O, S, CH=CH, C.ident.C-C, CO, SO2 or OSO2;
m is an integer from 1 to 7;
n is an integer from 0 to 7; and Z comprises a carbocyclic ring having 4 to 7 ring members, a heterocyclic ring having 4 to 7 ring members, an aromatic ring having 5 to 7 ring members, a heteroaromatic ring having 5 to 7 ring members; a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring, a heteropolycyclic ring; or any above group substituted on at least one available ring atom by an alkyl group; or any above group substituted on at least one available ring nitrogen atom by a benzyl group,a substituted benzyl group, an alkoxybenzyl group, a substituted alkoxybenzyl group, a benzhydryl group or a substituted benzhydryl group; and wherein the connecting point between the -(CH2)n- group and the Z group can be any available ring carbon atom or any available ring nitrogen atom; or R4 comprises -(CH2)m - Q1 -(CH2)n-Z;
Q1 comprises NH, O, S, CH=CH, C.ident.C, CO, SO2 or OSO2;
m is an integer from 1 to 7;
n is an integer from 0 to 7; and Z comprises 1-, 2- or 3-pyrrolidinyl, 1-, 2-, 3- or 4-piperidinyl, 2-, 3- or 4-morpholinyl, 2-, 3- or 4-thiomorpholinyl, 1-, 2- or 3-azetidinyl, 1- or 2-piperazinyl, 2- or 3-tetrahydrofuranyl; or any above group substituted on at least one available ring atom by an alkyl; or any above group substituted on at least one available ring nitrogen atom by a benzyl group, a substituted benzyl group, an alkoxybenzyl group, a substituted alkoxybenzyl group, a benzhydryl group or a substituted benzhydryl group; and wherein the connecting point between the -(CH2)n- group and the Z group can be any available ring carbon atom or any available ring nitrogen atom; or R4 comprises -(CH2)m - Q1 -(CH2)n-Z;
Q1 comprises NH, O, S, CH=CH, C.ident.C, CO, SO2 or OSO2;
m is an integer from 1 to 7;
n is an integer from 0 to 7; and Z comprises wherein X and Y each independently comprise H, halogen, CF3, CF2H, N3, NCS, CN, NO2, NX1X2, OX3, SX3, OAc, OSO2X3, O-acyl, S-acyl, SO2-alkyl, SO-alkyl, SC(CH3)2COOX8, OC(CH3)2COOX8 , C(CH3)2COOX8, Si(alkyl)3, alkyl-CN, O-aroyl, O(CH2)10X3, O(CH2)1NX1X2, NH-acyl, NH-aroyl, CHO, C(halogen)3, COOX3, SO3H, SO2NX1X2, CONX1X2, NHC(O)O-alkyl, NHS02-alkyl, alkoxy, alkyl, alcohol, alkylmercapto, alkylamino, di-alkylamino, alkylsulfinyl or alkylsulfonyl, CX4X5X8, -CH=CHX8 , -C.ident.CX8 ;
X1 and X2 each independently comprise H or alkyl, or X1 and X2 together comprise part of a heterocyclic ring having 4 to 7 ring members and optionally one additional heteroatom selected from O, N or S, or X1 and X2 together comprise part of an imide ring having 5 to 6 members, X3 comprises H, alkyl, NO2, (CH2)m CN, hydroxyloweralkyl, or alkyl-NX1X2, X4, X5, and X6 each independently comprise H, alkyl, carbocyclic ring, hydroxyloweralkyl, alkyl-OH, halogen, CN, SNO, S(SO2)alkyl, NX1X2, COOX3, CONX3, OX7, or O-alkyl-X7 wherein X7 comprises H, alkyl, NO2, NO, P(O)(OX8)2, PH(O)(OX8), S(O)k N(alkyl)2, S(O)k X8, S(O)k OX8, COOX8, CONX8, SO3H, COX8, wherein X8 comprises H, alkyl, carbocyclic ring, heterocyclic ring, aromatic ring, heteroaromatic ring, or -CX9=CHX10 wherein X9 and X10 each independently comprise H or alkyl Wherein m is an integer from 0 to 7 j is an integer from 0 to 6, k is an integer from 0 to 2, W comprises H or alkyl, and Ac is acyl.
and physiologically acceptable salts thereof, wherein:
A is a direct bond, B is N(R5), R5 is hydrogen, OH, alkyl or substituted alkyl;
R2 comprises -(CH2)n-Z;
n is an integer from 0 to 7;
wherein Z comprises, H, halogen, CF3, CF2H, N3, NCS, CN, NO2, NX1X2, OX3, SX3, OAc, OSO2X3, O-acyl, S-acyl, SO2-alkyl, SO-alkyl, SC(CH3)2COOX8, OC(CH3)2COOX8 , C(CH3)2COOX8, Si(alkyl)3, alkyl-CN, O-aroyl, O(CH2)j OX3, O(CH2)j NX1X2, NH-acyl, NH-aroyl, CHO, C(halogen)3, COOX3, SO3H, SO2NX1X2, CONX1X2, NHC(O)O-alkyl, NHSO2-alkyl, alkoxy, alkyl, alcohol, alkylmercapto, alkylamino, di-alkylamino, alkylsulfinyl or alkylsulfonyl, CX4X5X8, -CH=CHX8 , -C.ident.CX8 ;
X1 and X2 each independently comprise H or alkyl, or X1 and X2 together comprise part of a heterocyclic ring having 4 to 7 ring members and optionally one additional heteroatom selected from O, N or S, or X1 and X2 together comprise part of an imide ring having 5 to 6 members, X3 comprises H, alkyl, aryl, NO2, (CH2)m CN, hydroxyloweralkyl, or alkyl-NX1X2, X4, X5, and X6 each independently comprise H, alkyl, carbocyclic ring, hydroxyloweralkyl, alkyl-OH, halogen, CN, SNO, S(SO2)alkyl, NX1X2, COOX3, CONX3, OX7, or O-alkyl-X7 wherein X7 comprises H, alkyl, NO2, NO, P(O)(OX8)2, PH(O)(OX8), S(O)k N(alkyl)2, S(O)k X8, S(O)k OX8, COOX8, CONX8, SO3H, COX8, wherein X8 comprises H, alkyl, carbocyclic ring, heterocyclic ring, aromatic ring, heteroaromatic ring, or -CX9=CHX10 wherein X9 and X10 each independently comprise H or alkyl Wherein m is an integer from 0 to 7 j is an integer from 0 to 6, or k is an integer from 0 to 2; or R2 comprises -(CH2)n-Z;
n is an integer from 0 to 7; and Z comprises a carbocyclic ring having 4 to 7 ring members, a heterocyclic ring having 4 to 7 ring members, an aromatic ring having 5 to 7 ring members, a heteroaromatic ring having 5 to 7 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring, a heteropolycyclic ring; or any above group substituted on at least one available ring atom by an alkyl group; or any above group substituted on at least one available ring nitrogen atom by a benzyl group, a substituted benzyl group, an alkoxybenzyl group, a substituted alkoxybenzyl group, a benzhydryl group or a substituted benzhydryl group; and wherein the connecting point between the -(CH2)n- group and the Z group can be any available ring carbon atom or any available ring nitrogen atom; or R2 comprises -(CH2)n-Z;
n is an integer from 0 to 7; and Z comprises a 5 member unsaturated ring having 0 to 4 independently selected heteroatoms as ring members, a substituted 5 member unsaturated ring having 0 to 4 independently selected heteroatoms as ring members, a 6 member aromatic ring having 0 to 5 independently selected heteroatoms as ring members or a substituted 6 member aromatic ring having 0 to 5 independently selected heteroatoms; and wherein the connecting point between the -(CH2)n- group and the Z group can be any available ring carbon atom or any available ring nitrogen atom; or R2 comprises -(CH2)n-Z;
n is an integer from 0 to 7; and Z comprises 1-, 2- or 3-pyrrolidinyl, 1-, 2-, 3- or 4-piperidinyl, 2-, 3- or 4-morpholinyl, 2-, 3- or 4-thiomorpholinyl, 1-, 2- or 3-azetidinyl, 1- or 2-piperazinyl, 2- or 3-tetrahydrofuranyl; or any above group substituted on at least one available ring atom by an alkyl group; or any above group substituted on at least one available ring nitrogen atom by a benzyl group, a substituted benzyl group, an alkoxybenzyl group, a substituted alkoxybenzyl group, a benzhydryl group or a substituted benzhydryl group; and wherein the connecting point between the -(CH2)n- group and the Z group can be any available ring carbon atom or any available ring nitrogen atom; or R2 comprises -(CH2)n-Z;
n is an integer from 0 to 7; and Z comprises wherein X and Y each independently comprise, H, halogen, CF3, CF2H, N3, NCS, CN, NO2, NX1X2, OX3, SX3, OAc, OSO2X3, O-acyl, S-acyl, SO2-alkyl, SO-alkyl, SC(CH3)2COOX8, OC(CH3)2COOX8 , C(CH3)2COOX8, Si(alkyl)3, alkyl-CN, O-aroyl, O(CH2)j OX3, O(CH2))j NX1X2, NH-acyl, NH-aroyl, CHO, C(halogen)3, COOX3, SO3H, SO2NX1X2, CONX1X2, NHC(O)O-alkyl, NHSO2-alkyl, alkoxy, alkyl, alcohol, alkylmercapto, alkylamino, di-alkylamino, alkylsulfinyl or alkylsulfonyl, CX4X5X6, -CH=CHX8 , -C.ident.CX8 ;
X1 and X2 each independently comprise H or alkyl, or X1 and X2 together comprise part of a heterocyclic ring having 4 to 7 ring members and optionally one additional heteroatom selected from 0, N or S, or X1 and X2 together comprise part of an imide ring having 5 to 6 members, X3 comprises H, alkyl, aryl, NO2, (CH2)m CN, hydroxyloweralkyl, or alkyl-NX1X2, X4, X6, and X6 each independently comprise H, alkyl, carbocyclic ring, hydroxyloweralkyl, alkyl-OH, halogen, CN, SNO, S(SO2)alkyl, NX1X2, COOX3, CONX3, OX7, or O-alkyl-X7 wherein X7 comprises H, alkyl, NO2, NO, P(O)(OX8)2, PH(O)(OX8), S(O)k N(alkyl)2, S(O)k X8, S(O)k OX8, COOX8, CONX8, SO3H, COX8, wherein X8 comprises H, alkyl, carbocyclic ring, heterocyclic ring, aromatic ring, heteroaromatic ring, or -CX9=CHX10 wherein X9 and X10 each independently comprise H or alkyl Wherein m is an integer from 0 to 7 j is an integer from 0 to 6, or k is an integer from 0 to 2 W comprises H or alkyl; or R2 comprises -(CH2)n-Z;
n is an integer from 0 to 7; and Z comprises a carbocyclic ring having 6 ring atoms fused to a heterocyclic ring having from 5 to 7 ring atoms, a carbocyclic ring having 6 ring atoms fused to a heteroaromatic ring having from 5 to 7 ring atoms, a heterocyclic ring having 6 ring atoms fused to a heterocyclic ring having from 5 to 7 ring atoms, an heterocyclic ring having 6 ring atoms fused to a heteroaromatic ring having from to 7 ring atoms, an aromatic ring having 6 ring atoms fused to a heterocyclic ring having from 5 to 7 ring atoms, an aromatic ring having 6 ring atoms fused to a heteroaromatic ring having from 5 to 7 ring atoms, a heteroaromatic ring having 6 ring atoms fused to a heterocyclic ring having from 5 to 7 ring atoms or a heteroaromatic ring having 6 ring atoms fused to a heteroaromatic ring having from 5 to 7 ring atoms; or R2 comprises --(CH2)n¨Z;
n comprises an integer from 0 to 7; and Z comprises an unsaturated ring having 5 ring atoms and 0 to 2 independently selected heteroatoms as ring members fused to an unsaturated ring having 5 ring atoms and 0 to 4 independently selected heteroatoms as ring members, an unsaturated ring having 5 ring atoms and 0 to 2 independently selected heteroatoms as ring members fused to an unsaturated ring having 6 or 7 ring atoms and 0 to 3 independently selected heteroatoms as ring members or an unsaturated ring having 6 ring atoms and 0 to 4 independently selected heteroatoms as ring members fused to an unsaturated ring having 6 or 7 ring atoms and 0 to 4 independently selected heteroatoms as ring members; or R2 comprises ¨(CH2)m ¨Q1--(CH2)n¨Z;
Q1 comprises NH, O, S,-CH=CH-, -C.ident.C-, -CO, SO2 or OSO2;
m is an integer from 1 to 7;
n is an integer from 0 to 7; and wherein Z comprises, H, halogen, CF3, CF2H, N3, NCS, CN, NO2, NX1X2, OX3, SX3, OAc, OSO2X3, O-acyl, S-acyl, SO2-alkyl, SO-alkyl, SC(CH3)2COOX8, OC(CH3)2COOX8 , C(CH3)2COOX8, Si(alkyl)3, alkyl-CN, O-aroyl, O(CH2)j OX3, O(CH2)j NX1X2, NH-acyl, NH-aroyl, CHO, C(halogen)3, COOX3, SO3H, SO2NX1X2, CONX1X2, NHC(O)O-alkyl, NHSO2-alkyl, alkoxy, alkyl, alcohol, alkylmercapto, alkylamino, di-alkylamino, alkylsulfinyl or alkylsulfonyl, CX4X5X6, -CH=CHX8, --C.ident.CX8;
X1 and X2 each independently comprise H or alkyl, or X1 and X2 together comprise part of a heterocyclic ring having 4 to 7 ring members and optionally one additional heteroatom selected from O, N or S, or X1 and X2 together comprise part of an imide ring having 5 to 6 members, X3 comprises H, alkyl, aryl, NO2, (CH2)m CN, hydroxyloweralkyl, or alkyl-NX1X2, X4, X6, and X6 each independently comprise H, alkyl, carbocyclic ring, hydroxyloweralkyl, alkyl-OH, halogen, CN, SNO, S(SO2)alkyl, NX1X2, COOX3, CONX3, OX7, or O-alkyl-X7 wherein X7 comprises H, alkyl, NO2, NO, P(O)(OX8)2, PH(O)(OX8), S(O)k N(alkyl)2, S(O)k X8, S(O)k OX8, COOX8, CONX8, SO3H, COX8, wherein X3 comprises H, alkyl, carbocyclic ring, heterocyclic ring, aromatic ring, heteroaromatic ring, or -CX9=CHX10 wherein X9 and X10 each independently comprise H or alkyl Wherein m is an integer from 0 to 7 j is an integer from 0 to 6, or k is an integer from 0 to 2; or R2 comprises -Q2-(CH2)n-Z;
Q2 is optionally present and if present comprises -CH2-NH, -CH2-O, -CH2-S, -CH2-SO2 or -CH2-OSO2;
n is an integer from 0 to 7;
wherein Z comprises, H, halogen, CF3, CF2H, N3, NCS, CN, NO2, NX1X2, OX3, SX3, OAc, OSO2X3, O-acyl, S-acyl, SO2-alkyl, SO-alkyl, SC(CH3)2COOX8, OC(CH3)2COOX8 , C(CH3)2COOX8, Si(alkyl)3, alkyl-CN, O-aroyl, O(CH2)j OX3, O(CH2)j NX1X2, NH-acyl, NH-aroyl, CHO, C(halogen)3, COOX3, SO3H, SO2NX1X2, CONX1X2, NHC(O)O-alkyl, NHSO2-alkyl, alkoxy, alkyl, alcohol, alkylmercapto, alkylamino, di-alkylamino, alkylsulfinyl or alkylsulfonyl, CX4X5X8, -CH=CHX8 , -C.ident.CX8 ;
X1 and X2 each independently comprise H or alkyl, or X1 and X2 together comprise part of a heterocyclic ring having 4 to 7 ring members and optionally one additional heteroatom selected from O, N or S, or X1 and X2 together comprise part of an imide ring having 5 to 6 members, X3 comprises H, alkyl, aryl, NO2, (CH2)m CN, hydroxyloweralkyl, or alkyl-NX1X2, X4, X5, and X6 each independently comprise H, alkyl, carbocyclic ring, hydroxyloweralkyl, alkyl-OH, halogen, CN, SNO, S(SO2)alkyl, NX1X2, COOX3, CONX3, OX7, or O-alkyl-X7 wherein X7 comprises H, alkyl, NO2, NO, P(O)(OX8)2, PH(O)(OX8), S(O)k N(alkyl)2, S(O)k X8, S(O)k OX8, COOX8, CONX8, SO3H, COX8, wherein X8 comprises H, alkyl, carbocyclic ring, heterocyclic ring, aromatic ring, heteroaromatic ring, or -CX9=CHX10 wherein X9 and X10 each independently comprise H or alkyl Wherein m is an integer from 0 to 7 j is an integer from 0 to 6, k is an integer from 0 to 2; or R2 comprises -(CH2)m- Q1 -(CH2)n-Z;
Q1 comprises NH, O, S, CH=CH, C.ident.C, CO, SO2 or OSO2;
m is an integer from 1 to 7;
n is an integer from 0 to 7;
Z comprises a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring; or R2 comprises -(CH2)m - Q1 -(CH2)n-Z;
Q1 comprises NH, O, S, CH=CH, C.ident.C, CO, SO2 or OSO2;
m is an integer from 1 to 7;
n is an integer from 0 to 7;
Z comprises a carbocyclic ring having 4 to 7 ring members, a heterocyclic ring having 4 to 7 ring members, an aromatic ring having 5 to 7 ring members, a heteroaromatic ring having 5 to 7 ring members; a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring, a heteropolycyclic ring or any above group substituted on at least one available ring atom by an alkyl group or any above group substituted on at least one available ring nitrogen atom by a benzyl group, a substituted benzyl group, an alkoxybenzyl group, a substituted alkoxybenzyl group, a benzhydryl group or a substituted benzhydryl group; and wherein the connecting point between the -(CH2)n- group and the Z
group can be any available ring carbon atom or any available ring nitrogen atom;
or R2 comprises -(CH2)m- Q1 -(CH2)n-Z;
Q1 comprises NH, O, S, CH=CH, C.ident.C, CO, SO2 or OSO2;
m is an integer from 1 to 7;
n is an integer from 0 to 7; and Z comprises a 5 member unsaturated ring having 0 to 4 independently selected heteroatoms as ring members, a substituted 5 member unsaturated ring having 0 to 4 independently selected heteroatoms as ring members, a 6 member aromatic ring having 0 to 5 independently selected heteroatoms as ring members or a substituted 6 member aromatic ring having 0 to 5 independently selected heteroatoms; and wherein the connecting point between the -(CH2)n- group and the Z group can be any available ring carbon atom or any available ring nitrogen atom; or R2 comprises -(CH2)m - Q1 -(CH2)n-Z;
Q1 comprises NH, O, S, CH=CH, C.ident.C, CO, SO2 or OSO2;
m is an integer from 1 to 7;
n is an integer from 0 to 7;
Z comprises 1-, 2- or 3-pyrrolidinyl, 1-, 2-, 3- or 4-piperidinyl, 2-, 3- or 4-morpholinyl, 2-, 3- or 4-thiomorpholinyl, 1-, 2- or 3-azetidinyl, 1- or 2-piperazinyl, 2- or 3-tetrahydrofuranyl; or any above group substituted on at least one available ring atom by an alkyl group; or any above group substituted on at least one available ring nitrogen atom by a benzyl group, a substituted benzyl group, an alkoxybenzyl group, a substituted alkoxybenzyl group, a benzhydryl group or a substituted benzhydryl group; and wherein the connecting point between the -(CH2)n- group and the Z group can be any available ring carbon atom or any available ring nitrogen atom; or R2 comprises -(CH2)m - Q1 -(CH2)n-Z;
Q1 comprises NH, O, S, CH=CH, C.ident.C, CO, SO2 or OSO2;
m is an integer from 1 to 7;
n is an integer from 0 to 7; and Z comprises wherein X and Y each independently comprise H, halogen, CF3, CF2H, N3, NCS, CN, NO2, NX1X2, OX3, SX3, OAc, OSO2X3, O-acyl, S-acyl, SO2-alkyl, SO-alkyl, SC(CH3)2COOX8, OC(CH3)2COOX8 , C(CH3)2COOX8, Si(alkyl)3, alkyl-CN, O-aroyl, O(CH2)j OX3, O(CH2)NX1X2, NH-acyl, NH-aroyl, CHO, C(halogen)3, COOX3, SO3H, SO2NX1X2, CONX1X2, NHC(O)O-alkyl, NHSO2-alkyl, alkoxy, alkyl, alcohol, alkylmercapto, alkylamino, di-alkylamino, alkylsulfinyl or alkylsulfonyl, CX4X5X6, -CH=CHX8 , -C.ident.CX8 ;
X1 and X2 each independently comprise H or alkyl, or X1 and X2 together comprise part of a heterocyclic ring having 4 to 7 ring members and optionally one additional heteroatom selected from O, N or S, or X1 and X2 together comprise part of an imide ring having 5 to 6 members, X3 comprises H, alkyl, aryl, NO2, (CH2)m CN, hydroxyloweralkyl, or alkyl-NX1X2, X4, X5, and X6 each independently comprise H, alkyl, carbocyclic ring, hydroxyloweralkyl, alkyl-OH, halogen, CN, SNO, S(SO2)alkyl, NX1X2, COOX3, CONX3, OX7, or O-alkyl-X7 wherein X7 comprises H, alkyl, NO2, NO, P(O)(OX8)2, PH(O)(OX8), S(O)k N(alkyl)2, S(O)k X8, S(O)k OX8, COOX8, CONX8, SO3H, COX8, wherein X8 comprises H, alkyl, carbocyclic ring, heterocyclic ring, aromatic ring, heteroaromatic ring, or -CX9=CHX10 wherein X9 and X10 each independently comprise H or alkyl Wherein m is an integer from 0 to 7 j is an integer from 0 to 6, k is an integer from 0 to 2 W comprises H or alkyl; or R2 comprises -(CH2)m - Q1 -(CH2)n-Z;
Q1 comprises NH, O, S, CH=CH, C.ident.C, CO, SO2 or OSO2;
m is an integer from 1 to 7;
n is an integer from 0 to 7; and Z comprises an unsaturated ring having 5 ring atoms and 0 to 2 independently selected heteroatoms as ring members fused to an unsaturated ring having 5 ring atoms and 0 to 4 independently selected heteroatoms as ring members, an unsaturated ring having 5 ring atoms and 0 to 2 independently selected heteroatoms as ring members fused to an unsaturated ring having 6 or 7 ring atoms and 0 to 4 independently selected heteroatoms as ring members or an unsaturated ring having 6 ring atoms and 0 to 4 independently selected heteroatoms as ring members fused to an unsaturated ring having 6 or 7 ring atoms and 0 to 4 independently selected heteroatoms as ring members; or R2 comprises -(CH2)m - Q1 -(CH2)n-Z;
Q1 comprises NH, O, S, CH=CH, C.ident.C, CO, SO2 or OSO2;
m is an integer from 1 to 7;
n is an integer from 0 to 7; and Z comprises R2 comprises -T-(CH2)n-Z;
n comprises an integer from 0 to 7;
T comprises a carbocyclic ring having 3 to 8 ring members, an unsaturated ring having 3 to 8 carbon atoms as ring members, an aromatic ring having 5 to 8 carbon atoms as ring members, a heterocyclic ring having 3 to 8 ring members, a heteroaromatic ring having 5 to 8 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring; and Z comprises, H, halogen, CF3, CF2H, N3, NCS, CN, NO2, NX1X2, OX3, SX3, OAc, OSO2X3, O-acyl, S-acyl, SO2-alkyl, SO-alkyl, SC(CH3)2COOX8, OC(CH3)2COOX8 , C(CH3)2COOX8, Si(alkyl)3, alkyl-CN, O-aroyl, O(CH2)j OX3, O(CH2)j NX1X2, NH-acyl, NH-aroyl, CHO, C(halogen)3, COOX3, SO3H, SO2NX1X2, CONX1X2, NHC(O)O-alkyl, NHSO2-alkyl, alkoxy, alkyl, alcohol, alkylmercapto, alkylamino, di-alkylamino, alkylsulfinyl or alkylsulfonyl, CX4X8X8, -CH=CHX8, --C.ident.CX8;
X1 and X2 each independently comprise H or alkyl, or X1 and X2 together comprise part of a heterocyclic ring having 4 to 7 ring members and optionally one additional heteroatom selected from O, N or S, or X1 and X2 together comprise part of an imide ring having 5 to 6 members, X3 comprises H, alkyl, aryl, NO2, (CH2)m CN, hydroxyloweralkyl, or alkyl-NX1X2, X4, X5, and X6 each independently comprise H, alkyl, carbocyclic ring, hydroxyloweralkyl, alkyl-OH, halogen, CN, SNO, S(SO2)alkyl, NX1X2, COOX3, CONX3, OX7, or O-alkyl-X7 wherein X7 comprises H, alkyl, NO2, NO, P(O)(OX8)2, PH(O)(OX8), S(O)k N(alkyl)2, S(O)k X8, S(O)k OX8, COOX8, CONX8, SO3H, COX8, wherein X8 comprises H, alkyl, carbocyclic ring, heterocyclic ring, aromatic ring, heteroaromatic ring, or -CX9=CHX10 wherein X9 and X10 each independently comprise H or alkyl Wherein m is an integer from 0 to 7 j is an integer from 0 to 6, k is an integer from 0 to 2; or R2 comprises -T-(CH2)n-Z;
n comprises an integer from 0 to 7;
T comprises a carbocyclic ring having 3 to 8 ring members, an unsaturated ring having 3 to 8 carbon atoms as ring members, an aromatic ring having 5 to 8 carbon atoms as ring members, a heterocyclic ring having 3 to 8 ring members, a heteroaromatic ring having 5 to 8 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring; and Z comprises a carbocyclic ring having 4 to 7 ring members, a heterocyclic ring having 4 to 7 ring members, an aromatic ring having 5 to 7 ring members, a heteroaromatic ring having 5 to 7 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring, a heteropolycyclic ring; or any above group substituted on at least one available ring atom by an alkyl group; or any above group substituted on at least one available ring nitrogen atom by a benzyl group, a substituted benzyl group, an alkoxybenzyl group, a substituted alkoxybenzyl group, a benzhydryl group or a substituted benzhydryl group; and wherein the connecting point between the -(CH2)n- group and the Z group can be any available ring carbon atom or any available ring nitrogen atom; or R2 comprises -T-(CH2)n-Z;
n comprises an integer from 0 to 7;
T comprises a carbocyclic ring having 3 to 8 ring members, an unsaturated ring having 3 to 8 carbon atoms as ring members, an aromatic ring having 5 to 8 carbon atoms as ring members, a heterocyclic ring having 3 to 8 ring members, a heteroaromatic ring having 5 to 8 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring; and Z comprises 1-, 2- or 3-pyrrolidinyl, 1-, 2-, 3- or 4-piperidinyl, 2-, 3- or 4-morpholinyl, 2-, 3- or 4-thiomorpholinyl, 1-, 2- or 3-azetidinyl, 1- or 2-piperazinyl, 2- or 3-tetrahydrofuranyl; or any above group substituted on at least one available ring atom by an alkyl group; or any above group substituted on at least one available ring nitrogen atom by a benzyl group, a substituted benzyl group, an alkoxybenzyl group, a substituted alkoxybenzyl group, a benzhydryl group or a substituted benzhydryl group; and wherein the connecting point between the -(CH2)n- group and the Z group can be any available ring carbon atom or any available ring nitrogen atom; or R2 comprises -T-(CH2)n-Z;
n comprises an integer from 0 to 7;
T comprises a carbocyclic ring having 3 to 8 ring members, an unsaturated ring having 3 to 8 carbon atoms as ring members, an aromatic ring having 5 to 8 carbon atoms as ring members, a heterocyclic ring having 3 to 8 ring members, a heteroaromatic ring having 5 to 8 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring; and Z comprises wherein X and Y each independently comprise H, halogen, CF3, CF2H, N3, NCS, CN, NO2, NX1X2, OX3, SX3, OAc, OSO2X3, O-acyl, S-acyl, SO2-alkyl, SO-alkyl, SC(CH3)2COOX8, OC(CH3)2COOX8 , C(CH3)2COOX8, Si(alkyl)3, alkyl-CN, O-aroyl, O(CH2)j OX3, O(CH2)j NX1X2, NH-acyl, NH-aroyl, CHO, C(halogen)3, COOX3, SO3H, SO2NX1X2, CONX1X2, NHC(O)O-alkyl, NHSO2-alkyl, alkoxy, alkyl, alcohol, alkylmercapto, alkylamino, di-alkylamino, alkylsulfinyl or alkylsulfonyl, CX4X5X8, -CH=CHX8 , -C.ident.CX8 ;
X1 and X2 each independently comprise H or alkyl, or X1 and X2 together comprise part of a heterocyclic ring having 4 to 7 ring members and optionally one additional heteroatom selected from O, N or S, or X1 and X2 together comprise part of an imide ring having 5 to 6 members, X3 comprises H, alkyl, aryl, NO2, (CH2)m CN, hydroxyloweralkyl, or alkyl-NX1X2, X4, X5, and X6 each independently comprise H, alkyl, carbocyclic ring, hydroxyloweralkyl, alkyl-OH, halogen, CN, SNO, S(SO2)alkyl, NX1X2, COOX3, CONX3, OX7, or O-alkyl-X7 wherein X7 comprises H, alkyl, NO2, NO, P(O)(OX8)2, PH(O)(OX8), S(O)k N(alkyl)2, S(O)k X8, S(O)k OX8, COOX8, CONX8, SO3H, COX8, wherein X8 comprises H, alkyl, carbocyclic ring, heterocyclic ring, aromatic ring, heteroaromatic ring, or -CX9=CHX10 wherein X9 and X10 each independently comprise H or alkyl Wherein m is an integer from 0 to 7 j is an integer from 0 to 6, k is an integer from 0 to 2 W comprises H or alkyl; or R2 comprises -T-(CH2)n-Z;
n comprises an integer from 0 to 7;
T comprises a carbocyclic ring having 3 to 8 ring members, an unsaturated ring having 3 to 8 carbon atoms as ring members, an aromatic ring having 5 to 8 carbon atoms as ring members, a heterocyclic ring having 3 to 8 ring members, a heteroaromatic ring having 5 to 8 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring; and Z comprises an unsaturated ring having 5 ring atoms and 0 to 2 independently selected heteroatoms as ring members fused to an unsaturated ring having 5 ring atoms and 0 to 4 independently selected heteroatoms as ring members, an unsaturated ring having 5 ring atoms and 0 to 2 independently selected heteroatoms as ring members fused to an unsaturated ring having 6 or 7 ring atoms and 0 to 4 independently selected heteroatoms as ring members or an unsaturated ring having 6 ring atoms and 0 to 3 independently selected heteroatoms as ring members fused to an unsaturated ring having 6 or 7 ring atoms and 0 to 4 independently selected heteroatoms as ring members; or R2 comprises -T-(CH2)m- Q1 -(CH2)n-Z;
m and n independently comprises an integer from 0 to 7;
T comprises a carbocyclic ring having 3 to 8 ring members, an unsaturated ring having 3 to 8 carbon atoms as ring members, an aromatic ring having 5 to 8 carbon atoms as ring members, a heterocyclic ring having 3 to 8 ring members, a heteroaromatic ring having 5 to 8 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring;
Q1 comprises NH, O, S, CH=CH, C.ident.C, CO, SO2 or OSO2; and Z comprises, H, halogen, CF3, CF2H, N3, NCS, CN, NO2, NX1X2, OX3, SX3, OAc, OSO2X3, O-acyl, S-acyl, SO2-alkyl, SO-alkyl, SC(CH3)2COOX8, OC(CH3)2COOX8 , C(CH3)2COOX8, Si(alkyl)3, alkyl-CN, O-aroyl, O(CH2)j OX3, O(CH2)j NX1X2, NH-acyl, NH-aroyl, CHO, C(halogen)3, COOX3, SO3H, SO2NX1X2, CONX1X2, NHC(O)O-alkyl, NHSO2-alkyl, alkoxy, alkyl, alcohol, alkylmercapto, alkylamino, di-alkylamino, alkylsulfinyl or alkylsulfonyl, CX4X8X8, -CH=CHX8 , -C.ident.CX8 ;
X1 and X2 each independently comprise H or alkyl, or X1 and X2 together comprise part of a heterocyclic ring having 4 to 7 ring members and optionally one additional heteroatom selected from O, N or S, or X1 and X2 together comprise part of an imide ring having 5 to 6 members, X3 comprises H, alkyl, aryl, NO2, (CH2)m CN, hydroxyloweralkyl, or alkyl-NX1 X2, X4, X5, and X6 each independently comprise H, alkyl, carbocyclic ring, hydroxyloweralkyl, alkyl-OH, halogen, CN, SNO, S(SO2)alkyl, NX1X2, COOX3, CONX3, OX7, or O-alkyl-X7 wherein X7 comprises H, alkyl, NO2, NO, P(O)(OX8)2, PH(O)(OX8), S(O)k N(alkyl)2, S(O)k X8, S(O)k OX8, COOX8, CONX8, SO3H, COX8, wherein X8 comprises H, alkyl, carbocyclic ring, heterocyclic ring, aromatic ring, heteroaromatic ring, or ¨CX9=CHX10 wherein X9 and X10 each independently comprise H or alkyl Wherein m is an integer from 0 to 7 j is an integer from 0 to 6, k is an integer from 0 to 2; or R2 comprises ¨T¨(CH2)m¨ Q1 ¨(CH2)n¨Z;
m and n independently comprises an integer from 0 to 7;
T comprises a carbocyclic ring having 3 to 8 ring members, an unsaturated ring having 3 to 8 carbon atoms as ring members, an aromatic ring having 5 to 8 carbon atoms as ring members, a heterocyclic ring having 3 to 8 ring members, a heteroaromatic ring having 5 to 8 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring;
Q1 comprises NH, O, S, CH=CH, C.ident.C, CO, SO2 or OSO2; and Z comprises a carbocyclic ring having 4 to 7 ring members, a heterocyclic ring having 4 to 7 ring members, an aromatic ring having 5 to 7 ring members, a heteroaromatic ring having 5 to 7 ring members, a bicyclic ring, a heterobicyclic ring, a polycyclic ring, a heteropolycyclic ring; or any above group substituted on at least one available ring atom by an alkyl group; or any above group substituted on at least one available ring nitrogen atom by a benzyl group, a substituted benzyl group, an alkoxybenzyl group, a substituted alkoxybenzyl group, a benzhydryl group or a substituted benzhydryl group; and wherein the connecting point between the -(CH2)n- group and the Z group can be any available ring carbon atom or any available ring nitrogen atom; or R2 comprises -T-(CH2)m- Q1 -(CH2)n-Z;
m and n independently comprises an integer from 0 to 7;
T comprises a carbocyclic ring having 3 to 8 ring members, an unsaturated ring having 3 to 8 carbon atoms as ring members, an aromatic ring having 5 to 8 carbon atoms as ring members, a heterocyclic ring having 3 to 8 ring members, a heteroaromatic ring having 5 to 8 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring;
Q1 comprises NH, O, S, CH=CH, C.ident.C, CO, SO2 or OSO2; and Z comprises 1-, 2- or 3-pyrrolidinyl, 1-, 2-, 3- or 4-piperidinyl, 2-, 3- or 4-morpholinyl, 2-, 3- or 4-thiomorpholinyl, 1-, 2- or 3-azetidinyl, 1- or 2-piperazinyl, 2- or 3-tetrahydrofuranyl; or any above group substituted on at least one available ring atom by an alkyl group; or any above group substituted on at least one available ring nitrogen atom by a benzyl group, a substituted benzyl group, an alkoxybenzyl group, a substituted alkoxybenzyl group, a benzhydryl group or a substituted benzhydryl group; and wherein the connecting point between the -(CH2)n- group and the Z group can be any available ring carbon atom or any available ring nitrogen atom; or R2 comprises -T-(CH2)m- Q1 -(CH2)n-Z;
m and n independently comprises an integer from 0 to 7;
T comprises a carbocyclic ring having 3 to 8 ring members, an unsaturated ring having 3 to 8 carbon atoms as ring members, an aromatic ring having 5 to 8 carbon atoms as ring members, a heterocyclic ring having 3 to 8 ring members, a heteroaromatic ring having 5 to 8 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring;
Q1 comprises N, O, S, CH=CH, C.ident.C, CO, SO2 or OSO2; and Z comprises wherein X and Y each independently comprise H, halogen, CF3, CF2H, N3, NCS, CN, NO2, NX1X2, OX3, SX3, OAc, OSO2X3, O-acyl, S-acyl, SO2-alkyl, SO-alkyl, SC(CH3)2COOX8, OC(CH3)2COOX8 , C(CH3)2COOX8, Si(alkyl)3, alkyl-CN, O-aroyl, O(CH2)j OX3, O(CH2)j NX1X2, NH-acyl, NH-aroyl, CHO, C(halogen)3, COOX3, SO3H, SO2NX1X2, CONX1X2, NHC(O)O-alkyl, NHSO2-alkyl, alkoxy, alkyl, alcohol, alkylmercapto, alkylamino, di-alkylamino, alkylsulfinyl or alkylsulfonyl, CX4X5X8, -CH=CHX8 , -C.ident.CX8;
X1 and X2 each independently comprise H or alkyl, or X1 and X2 together comprise part of a heterocyclic ring haying 4 to 7 ring members and optionally one additional heteroatom selected from O, N or S, or X1 and X2 together comprise part of an imide ring haying 5 to 6 members, X3 comprises H, alkyl, aryl, NO2, (CH2)m CN, hydroxyloweralkyl, or alkyl-NX1X2, X4, X5, and X6 each independently comprise H, alkyl, carbocyclic ring, hydroxyloweralkyl, alkyl-OH, halogen, CN, SNO, S(SO2)alkyl, NX1X2, COOX3, CONX3, OX7, or O-alkyl-X7 wherein X7 comprises H, alkyl, NO2, NO, P(O)(OX8)2, PH(O)(OX8), S(O)k N(alkyl)2, S(O)k X8, S(O)k OX8, COOX8, CONX8, SO3H, COX8, wherein X8 comprises H, alkyl, carbocyclic ring, heterocyclic ring, aromatic ring, heteroaromatic ring, or -CX9=CHX10 wherein X9 and X10 each independently comprise H or alkyl Wherein m is an integer from 0 to 7 j is an integer from 0 to 6, k is an integer from 0 to 2 W comprises H or alkyl; or R2 comprises -T-(CH2)m- Q1 -(CH2)n-Z;
m and n independently comprises an integer from 0 to 7;
T comprises a carbocyclic ring having 3 to 8 ring members, an unsaturated ring haying 3 to 8 carbon atoms as ring members, an aromatic ring haying 5 to 8 carbon atoms as ring members, a heterocyclic ring having 3 to 8 ring members, a heteroaromatic ring haying 5 to 8 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring;
Q1 comprises NH, O, S, CH=CH, C.ident.C, CO, SO2 or OSO2; and Z comprises an unsaturated ring haying 5 ring atoms and 0 to 2 independently selected heteroatoms as ring members fused to an unsaturated ring having 5 ring atoms and 0 to 2 independently selected heteroatoms as ring members, an unsaturated ring haying 5 ring atoms and 0 to 2 independently selected heteroatoms as ring members fused to an unsaturated ring having 6 or 7 ring atoms and 0 to 4 independently selected heteroatoms as ring members or an unsaturated ring having 6 ring atoms and 0 to 3 independently selected heteroatoms as ring members fused to an unsaturated ring having 6 or 7 ring atoms and 0 to 4 independently selected heteroatoms as ring members, or R2 comprises -T-(CH2)m- Q1 -(CH2)n-Z;
T comprises a carbocyclic ring having 3 to 8 ring members, an unsaturated ring having 3 to 8 carbon atoms as ring members, an aromatic ring having 5 to 8 carbon atoms as ring members, a heterocyclic ring having 3 to 8 ring members, a heteroaromatic ring having 5 to 8 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring;
m and n independently comprises an integer from 0 to 7;
Q1 comprises NH, O, S, CH=CH, C.ident.C, CO, SO2 or OSO2; and Z comprises:
E comprises a C1 to C4, linear or branched alkyl group, a phenyl group, a substituted phenyl group, a benzyl group or a substituted benzyl group; or R2 comprises -T-(CH2)m- Q1 -(CH2)n-Z;
T comprises a carbocyclic ring having 3 to 8 ring members, an unsaturated ring having 3 to 8 carbon atoms as ring members, an aromatic ring having 5 to 8 carbon atoms as ring members, a heterocyclic ring having 3 to 8 ring members, a heteroaromatic ring having 5 to 8 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring;
m and n independently comprises an integer from 0 to 7;
Q1 comprises NH, O, S, CH=CH, C.ident.C, CO, SO2 or OSO2;
Z comprises k is an integer from 1 to 5, A1 and A2 each independently comprise a C1 to C4 alkyl group, a phenyl group or a substituted phenyl group;
R3 comprises wherein G comprises CH, C(CH3), C(CN) or N, L, K and J each independently comprise (CH2)n, (CH3)2, C=O, O, -CHOH, C(CH3)OM1, C(CH2)n(X)Y, NM1, SO2 SO or S, and at least one of L, K or J is SO2, n is an integer from 0 to 7;
M1 is H, alkyl, C(O)M2 where M2 is H, alkyl, NM3M4, OM5 and M3, M4 and M5 are independently H, OH or alkyl and X and Y each independently comprise, H, halogen, CF3, CF2H, N3, NCS, CN, NO2, NX1X2, OX3, SX3, OAc, OSO2X3, O-acyl, S-acyl, SO2-alkyl, SO-alkyl, SC(CH3)2COOX8, OC(CH3)2COOX8 , C(CH3)2COOX8, Si(alkyl)3, alkyl-CN, O-aroyl, O(CH2)j OX3, O(CH2)j NX1X2, NH-acyl, NH-aroyl, CHO, C(halogen)3, COOX3, SO3H, SO2NX1X2, CONX1X2, NHC(O)O-alkyl, NHSO2-alkyl, alkoxy, alkyl, alcohol, alkylmercapto, alkylamino, di-alkylamino, alkylsulfinyl or alkylsulfonyl, CX4X5X8, -CH=CHX8 , -C.ident.CX8;
X1 and X2 each independently comprise H or alkyl, or X1 and X2 together comprise part of a heterocyclic ring having 4 to 7 ring members and optionally one additional heteroatom selected from O, N or S, or X1 and X2 together comprise part of an imide ring having 5 to 6 members, X3 comprises H, alkyl, NO2, (CH2)m CN, hydroxyloweralkyl, or alkyl-NX1X2, X4, X8, and X8 each independently comprise H, alkyl, carbocyclic ring, hydroxyloweralkyl, alkyl-OH, halogen, CN, SNO, S(SO2)alkyl, NX1X2, COOX3, CONX3, OX7, or O-alkyl-X7 wherein X7 comprises H, alkyl, NO2, NO, P(O)OX8)2, PH(O)OX8), S(O)k N(alkyl)2, S(O)k X8, S(O)k OX8, COOX8, CONX8, SO3H, COX8, wherein X8 comprises H, alkyl, carbocyclic ring, heterocyclic ring, aromatic ring, heteroaromatic ring, or -CX9=CHX10 wherein X9 and X10 each independently comprise H or alkyl Wherein m is an integer from 0 to 7 j is an integer from 0 to 6, or k is an integer from 0 to 2 or R1 comprises -T-(CH2)m- Q -(CH2)n-Z, m and n independently comprises an integer from 0 to 7;
T comprises a carbocyclic ring having 3 to 8 ring members, an unsaturated ring having 3 to 8 carbon atoms as ring members, an aromatic ring having 5 to 8 carbon atoms as ring members, a heterocyclic ring having 3 to 8 ring members, a heteroaromatic ring having 5 to 8 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring;
Q comprises CH=CH, C.ident.C;
Z comprises H, halogen, CF3, CF2H, N3, NCS, CN, NO2, NX1X2, OX3, SX3, OAc, OSO2X3, O-acyl, S-acyl, SO2-alkyl, SO-alkyl, SC(CH3)2COOX8, OC(CH3)2COOX8 , C(CH3)2COOX8, Si(alkyl)3, alkyl-CN, O-aroyl, O(CH2)j OX3, O(CH2)j NX1X2, NH-acyl, NH-aroyl, CHO, C(halogen)3, COOX3, SO3H, SO2NX1X2, CONX1X2, NHC(O)O-alkyl, NHSO2-alkyl, alkoxy, alkyl, alcohol, alkylmercapto, alkylamino, di-alkylamino, alkylsulfinyl or alkylsulfonyl, CX4X5X8, -CH=CHX8 , C.ident.CX8;
X1 and X2 each independently comprise H or alkyl, or X1 and X2 together comprise part of a heterocyclic ring having 4 to 7 ring members and optionally one additional heteroatom selected from O, N or S, or X1 and X2 together comprise part of an imide ring having 5 to 6 members, X3 comprises H, alkyl, NO2, (CH2)m CN, hydroxyloweralkyl, or alkyl-NX1X2, X4, X5, and X8 each independently comprise H, alkyl, carbocyclic ring, hydroxyloweralkyl, alkyl-OH, halogen, CN, SNO, S(SO2)alkyl, NX1X2, COOX3, CONX3, OX7, or O-alkyl-X7 wherein X7 comprises H, alkyl, NO2, NO, P(O)(OX8)2, PH(O)(OX8), S(O)k N(alkyl)2, S(O)k X8, S(O)k OX8, COOX8, CONX8, SO3H, COX8, wherein X8 comprises H, alkyl, carbocyclic ring, heterocyclic ring, aromatic ring, heteroaromatic ring, or -CX9=CHX10 wherein X9 and X10 each independently comprise H or alkyl Wherein m is an integer from 0 to 7 j is an integer from 0 to 6, or k is an integer from 0 to 2; or R1 comprises -T-(CH2)m- Q -(CH2)n-Z;
m and n independently comprises an integer from 0 to 7;
T comprises a carbocyclic ring having 3 to 8 ring members, an unsaturated ring having 3 to 8 carbon atoms as ring members, an aromatic ring having 5 to 8 carbon atoms as ring members, a heterocyclic ring having 3 to 8 ring members, a heteroaromatic ring having 5 to 8 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring;
Q comprises CH=CH, C.ident.C; and Z comprises a carbocyclic ring having 4 to 7 ring members, a heterocyclic ring having 4 to 7 ring members, an aromatic ring having 5 to 7 ring members, a heteroaromatic ring having 5 to 7 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring, a heteropolycyclic ring; or any above group substituted on at least one available ring atom by an alkyl group; or any above group substituted on at least one available ring nitrogen atom by a benzyl group, a substituted benzyl group, an alkoxybenzyl group, a substituted alkoxybenzyl group, a benzhydryl group or a substituted benzhydryl group; and wherein the connecting point between the -(CH2)- group and the Z group can be any available ring carbon atom or any available ring nitrogen atom; or R1 comprises -T-(CH2)m - Q -(CH2)n-Z;
m and n independently comprises an integer from 0 to 7;
T comprises a carbocyclic ring having 3 to 8 ring members, an unsaturated ring having 3 to 8 carbon atoms as ring members, an aromatic ring having 5 to 8 carbon atoms as ring members, a heterocyclic ring having 3 to 8 ring members, a heteroaromatic ring having 5 to 8 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring;
Q comprises CH=CH, C.ident.C; and Z comprises 1-, 2- or 3-pyrrolidinyl, 1-, 2-, 3- or 4-piperidinyl, 2-, 3- or 4-morpholinyl, 2-, 3- or 4-thiomorpholinyl, 1-, 2- or 3-azetidinyl, 1- or 2-piperazinyl, 2- or 3-tetrahydrofuranyl; or any above group substituted on at least one available ring atom by an alkyl group; or any above group substituted on at least one available ring nitrogen atom by a benzyl group, a substituted benzyl group, an alkoxybenzyl group, a substituted alkoxybenzyl group, a benzhydryl group or a substituted benzhydryl group; and wherein the connecting point between the -(CH2)n- group and the Z group can be any available ring carbon atom or any available ring nitrogen atom; or R1 comprises -TACH2)m- Q --(CH2)n-Z;
m and n independently comprises an integer from 0 to 7;
T comprises a carbocyclic ring having 3 to 8 ring members, an unsaturated ring having 3 to 8 carbon atoms as ring members, an aromatic ring having 5 to 8 carbon atoms as ring members, a heterocyclic ring having 3 to 8 ring members, a heteroaromatic ring having 5 to 8 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring;
Q comprises CH=CH, C.ident.C; and Z comprises wherein X and Y each independently comprise H, halogen, CF3, CF2H, N3, NCS, CN, NO2, NX1X2, OX3, SX3, OAc, OSO2X3, O-acyl, S-acyl, SO2-alkyl, SO-alkyl, SC(CH3)2COOX8, OC(CH3)2COOX8 , C(CH3)2COOX8, Si(alkyl)3, alkyl-CN, O-aroyl, O(CH2)j OX3, O(CH2)NX1X2, NH-acyl, NH-aroyl, CHO, C(halogen)3, COOX3, SO3H, SO2NX1X2, CONX1X2, NHC(O)O-alkyl, NHSO2-alkyl, alkoxy, alkyl, alcohol, alkylmercapto, alkylamino, di-alkylamino, alkylsulfinyl or alkylsulfonyl, CX4X5X8, -CH=CHX8 , C.ident.CX8;
X1 and X2 each independently comprise H or alkyl, or X1 and X2 together comprise part of a heterocyclic ring having 4 to 7 ring members and optionally one additional heteroatom selected from O, N or S, or X1 and X2 together comprise part of an imide ring having 5 to 6 members, X3 comprises H, alkyl, NO2, (CH2)m CN, hydroxyloweralkyl, or alkyl-NX1X2, X4, X5, and X6 each independently comprise H, alkyl, carbocyclic ring, hydroxyloweralkyl, alkyl-OH, halogen, CN, SNO, S(SO2)alkyl, NX1X2, COOX3, CONX3, OX7, or O-alkyl-X7 wherein X7 comprises H, alkyl, NO2, NO, P(O)(OX8)2, PH(O)(OX8), S(O)k N(alkyl)2, S(O)k X8, S(O)k OX8, COOX8, CONX8, SO3H, COX8, wherein X8 comprises H, alkyl, carbocyclic ring, heterocyclic ring, aromatic ring, heteroaromatic ring, or -CX9=CHX10 wherein X9 and X10 each independently comprise H or alkyl Wherein m is an integer from 0 to 7 j is an integer from 0 to 6, k is an integer from 0 to 2, W comprises H or alkyl; or R1 comprises -T-(CH2)m- Q -(CH2)n-Z;
m and n independently comprises an integer from 0 to 7;
T comprises a carbocyclic ring having 3 to 8 ring members, an unsaturated ring having 3 to 8 carbon atoms as ring members, an aromatic ring having 5 to 8 carbon atoms as ring members, a heterocyclic ring having 3 to 8 ring members, a heteroaromatic ring having 5 to 8 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring;
Q comprises CH=CH, C-.ident.-C; and Z comprises an unsaturated ring having 5 ring atoms and 0 to 2 independently selected heteroatoms as ring members fused to an unsaturated ring having 5 ring atoms and 0 to 4 independently selected heteroatoms as ring members, an unsaturated ring having 5 ring atoms and 0 to 2 independently selected heteroatoms as ring members fused to an unsaturated ring having 6 or 7 ring atoms and 0 to 4 independently selected heteroatoms as ring members or an unsaturated ring having 6 ring atoms and 0 to 3 independently selected heteroatoms as ring members fused to an unsaturated ring having 6 or 7 ring atoms and 0 to 4 independently selected heteroatoms as ring members; or R1 comprises -T-(CH2)m- Q -(CH2)n-Z;
T comprises a carbocyclic ring having 3 to 8 ring members, an unsaturated ring having 3 to 8 carbon atoms as ring members, an aromatic ring having 5 to 8 carbon atoms as ring members, a heterocyclic ring having 3 to 8 ring members, a heteroaromatic ring having 5 to 8 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring;
m and n independently comprises an integer from 0 to 7;
Q comprises CH=CH, C.ident.C;
Z comprises E comprises a C1 to C4, linear or branched alkyl group, a phenyl group, a substituted phenyl group, a benzyl group or a substituted benzyl group; or R1 comprises -T-(CH2)m- Q -(CH2)n-Z;
T comprises a carbocyclic ring having 3 to 8 ring members, an unsaturated ring having 3 to 8 carbon atoms as ring members, an aromatic ring having 5 to 8 carbon atoms as ring members, a heterocyclic ring having 3 to 8 ring members, a heteroaromatic ring having 5 to 8 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring;
m and n independently comprises an integer from 0 to 7;
Q comprises CH=CH, C.ident.C; and Z comprises k is an integer from 1 to 5, and A1 and A2 each independently comprise a C1 to C4 alkyl group, a phenyl group or a substituted phenyl group; or R1 comprises -(CH2)n-Z;
n is an integer from 0 to 7;
wherein Z comprises, H, halogen, CF3, CF2H, N3, NCS, CN, NO2, NX1X2, OX3, SX3, OAc, OSO2X3, O-acyl, S-acyl, SO2-alkyl, SO-alkyl, SC(CH3)2COOX8, OC(CH3)2COOX8 , C(CH3)2COOX8, Si(alkyl)3, alkyl-CN, O-aroyl, O(CH2)j OX3, O(CH2)j NX1X2, NH-acyl, NH-aroyl, CHO, C(halogen)3, COOX3, SO3H, SO2NX1X2, CONX1X2, NHC(O)O-alkyl, NHSO2-alkyl, alkoxy, alkyl, alcohol, alkylmercapto, alkylamino, di-alkylamino, alkylsulfinyl or alkylsulfonyl, CX4X8X8, -CH=CHX8 , -C.ident.CX8 ;
X1 and X2 each independently comprise H or alkyl, or X1 and X2 together comprise part of a heterocyclic ring having 4 to 7 ring members and optionally one additional heteroatom selected from O, N or S, or X1 and X2 together comprise part of an imide ring having 5 to 6 members, X3 comprises H, alkyl, aryl, NO2, (CH2)m CN, hydroxyloweralkyl, or alkyl-NX1X2, X4, X5, and X6 each independently comprise H, alkyl, carbocyclic ring, hydroxyloweralkyl, alkyl-OH, halogen, CN, SNO, S(SO2)alkyl, NX1X2, COOX3, CONX3, OX7, or O-alkyl-X7 wherein X7 comprises H, alkyl, NO2, NO, P(O)(OX8)2, PH(O)(OX8), S(O)k N(alkyl)2, S(O)k X8, S(O)k OX8, COOX8, CONX8, SO3H, COX8, wherein X8 comprises H, alkyl, carbocyclic ring, heterocyclic ring, aromatic ring, heteroaromatic ring, or ¨CX9=CHX10 wherein X9 and X10 each independently comprise H or alkyl Wherein m is an integer from 0 to 7 j is an integer from 0 to 6, or k is an integer from 0 to 2; or R1 comprises ¨(CH2)n¨Z;
n is an integer from 0 to 7; and Z comprises a carbocyclic ring having 4 to 7 ring members, a heterocyclic ring having 4 to 7 ring members, an aromatic ring having 5 to 7 ring members, a heteroaromatic ring having 5 to 7 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring, a heteropolycyclic ring; or any above group substituted on at least one available ring atom by an alkyl group; or any above group substituted on at least one available ring nitrogen atom by a benzyl group, a substituted benzyl group, an alkoxybenzyl group, a substituted alkoxybenzyl group, a benzhydryl group or a substituted benzhydryl group; and wherein the connecting point between the -(CH2)n- group and the Z group can be any available ring carbon atom or any available ring nitrogen atom; or R1 comprises -(CH2)n-Z;
n is an integer from 0 to 7; and Z comprises a 5 member unsaturated ring having 0 to 4 independently selected heteroatoms as ring members, a substituted 5 member unsaturated ring having 0 to 4 independently selected heteroatoms as ring members, a 6 member aromatic ring having 0 to 5 independently selected heteroatoms as ring members or a substituted 6 member aromatic ring having 0 to 5 independently selected heteroatoms; and wherein the connecting point between the -(CH2)n- group and the Z group can be any available ring carbon atom or any available ring nitrogen atom; or R1 comprises -(CH2)n-Z;
n is an integer from 0 to 7; and Z comprises 1-, 2- or 3-pyrrolidinyl, 1-, 2-, 3- or 4-piperidinyl, 2-, 3- or 4-morpholinyl, 2-, 3- or 4-thiomorpholinyl, 1-, 2- or 3-azetidinyl, 1- or 2-piperazinyl, 2- or 3-tetrahydrofuranyl; or any above group substituted on at least one available ring atom by an alkyl group; or any above group substituted on at least one available ring nitrogen atom by a benzyl group, a substituted benzyl group, an alkoxybenzyl group, a substituted alkoxybenzyl group, a benzhydryl group or a substituted benzhydryl group; and wherein the connecting point between the -(CH2)n- group and the Z group can be any available ring carbon atom or any available ring nitrogen atom; or R1 comprises -(CH2)n-Z;
n is an integer from 0 to 7; and Z comprises wherein X and Y each independently comprise, H, halogen, CF3, CF2H, N3, NCS, CN, NO2, NX1X2, OX3, SX3, OAc, OSO2X3, O-acyl, S-acyl, SO2-alkyl, SO-alkyl, SC(CH3)2COOX8, OC(CH3)2COOX8 , C(CH3)2COOX8, Si(alkyl)3, alkyl-CN, O-aroyl, O(CH2)10X3, O(CH2)j NX1X2, NH-acyl, NH-aroyl, CHO, C(halogen)3, COOX3, SO3H, SO2NX1X2, CONX1X2, NHC(0)O-alkyl, NHSO2-alkyl, alkoxy, alkyl, alcohol, alkylmercapto, alkylamino, di-alkylamino, alkylsulfinyl or alkylsulfonyl, CX4X5X6, -CH=CHX8 , -C.ident.CX8;
X1 and X2 each independently comprise H or alkyl, or X1 and X2 together comprise part of a heterocyclic ring having 4 to 7 ring members and optionally one additional heteroatom selected from O, N or S, or X1 and X2 together comprise part of an imide ring having 5 to 6 members, X3 comprises H, alkyl, aryl, NO2, (CH2)m CN, hydroxyloweralkyl, or alkyl-NX1X2, X4, X6, and X6 each independently comprise H, alkyl, carbocyclic ring, hydroxyloweralkyl, alkyl-OH, halogen, CN, SNO, S(SO2)alkyl, NX1X2, COOX3, CONX3, OX7, or O-alkyl-X7 wherein X7 comprises H, alkyl, NO2, NO, P(O)(O)(8)2, PH(O)(OX8), S(O)k N(alkyl)2, S(O)k X8, S(O)k OX8, COOX8, CONX8, SO3H, COX8, wherein X8 comprises H, alkyl, carbocyclic ring, heterocyclic ring, aromatic ring, heteroaromatic ring, or ¨CX9=CHX10 wherein X9 and X10 each independently comprise H or alkyl Wherein m is an integer from 0 to 7 j is an integer from 0 to 6, or k is an integer from 0 to 2 W comprises H or alkyl; or R1 comprises ¨(CH2)n¨Z;
n is an integer from 0 to 7; and Z comprises a carbocyclic ring having 6 ring atoms fused to a heterocyclic ring having from 5 to 7 ring atoms, a carbocyclic ring having 6 ring atoms fused to a heteroaromatic ring having from 5 to 7 ring atoms, a heterocyclic ring having 6 ring atoms fused to a heterocyclic ring having from 5 to 7 ring atoms, an heterocyclic ring having 6 ring atoms fused to a heteroaromatic ring having from to 7 ring atoms, an aromatic ring having 6 ring atoms fused to a heterocyclic ring having from 5 to 7 ring atoms, an aromatic ring having 6 ring atoms fused to a heteroaromatic ring having from 5 to 7 ring atoms, a heteroaromatic ring having 6 ring atoms fused to a heterocyclic ring having from 5 to 7 ring atoms or a heteroaromatic ring having 6 ring atoms fused to a heteroaromatic ring having from 5 to 7 ring atoms; or R1 comprises ¨(CH2),¨Z;
n comprises an integer from 0 to 7; and Z comprises an unsaturated ring having 5 ring atoms and 0 to 2 independently selected heteroatoms as ring members fused to an unsaturated ring having 5 ring atoms and 0 to 4 independently selected heteroatoms as ring members, an unsaturated ring having 5 ring atoms and 0 to 2 independently selected heteroatoms as ring members fused to an unsaturated ring having 6 or 7 ring atoms and 0 to 3 independently selected heteroatoms as ring members or an unsaturated ring having 6 ring atoms and 0 to 4 independently selected heteroatoms as ring members fused to an unsaturated ring having 6 or 7 ring atoms and 0 to 4 independently selected heteroatoms as ring members; or R1 comprises -(CH2)m-Q1-(CH2)n-Z;
Q1 comprises NH, O, S,-CH=CH-,-c.ident.C-, -CO, SO2 or OSO2;
m is an integer from 1 to 7;
n is an integer from 0 to 7; and wherein Z comprises, H, halogen, CF3, CF2H, N3, NCS, CN, NO2, NX1X2, OX3, SX3, OAc, OSO2X3, O-acyl, S-acyl, SO2-alkyl, SO-alkyl, SC(CH3)2COOX8, OC(CH3)2COOX8 , C(CH3)2COOX8, Si(alkyl)3, alkyl-CN, O-aroyl, O(CH2)j OX3, O(CH2)j NX1X2, NH-acyl, NH-aroyl, CHO, C(halogen)3, COOX3, SO3H, SO2NX1X2, CONX1X2, NHC(O)O-alkyl, NHSO2-alkyl, alkoxy, alkyl, alcohol, alkylmercapto, alkylamino, di-alkylamino, alkylsulfinyl or alkylsulfonyl, CX4X8X6, -CH=CHX8 , -C.ident.CX8 ;
X1 and X2 each independently comprise H or alkyl, or X1 and X2 together comprise part of a heterocyclic ring having 4 to 7 ring members and optionally one additional heteroatom selected from O, N or S, or X1 and X2 together comprise part of an imide ring having 5 to 6 members, X3 comprises H, alkyl, aryl, NO2, (CH2)m CN, hydroxyloweralkyl, or alkyl-NX1X2, X4, X5, and X6 each independently comprise H, alkyl, carbocyclic ring, hydroxyloweralkyl, alkyl-OH, halogen, CN, SNO, S(SO2)alkyl, NX1X2, COOX3, CONX3, OX7, or O-alkyl-X7 wherein X7 comprises H, alkyl, NO2, NO, P(O)(OX8)2, PH(O)(OX8), S(O)k N(alkyl)2, S(O)k X8, S(O)k OX8, COOX8, CONX8, SO3H, COX8, wherein X8 comprises H, alkyl, carbocyclic ring, heterocyclic ring, aromatic ring, heteroaromatic ring, or -CX9=CHX10 wherein X9 and X10 each independently comprise H or alkyl Wherein m is an integer from 0 to 7 j is an integer from 0 to 6, or k is an integer from 0 to 2; or R1 comprises -Q2-(CH2)n-Z;
Q2 is optionally present and if present comprises -CH2-NH, -CH2-O, -CH2-S, -CH2-SO2 or -CH2-OSO2;
n is an integer from 0 to 7;
wherein Z comprises, H, halogen, CF3, CF2H, N3, NCS, CN, NO2, NX1X2, OX3, SX3, OAc, OSO2X3, O-acyl, S-acyl, SO2-alkyl, SO-alkyl, SC(CH3)2COOX8, OC(CH3)2COOX8 , C(CH3)2COOX8, Si(alkyl)3, alkyl-CN, O-aroyl, O(CH2)j OX3, O(CH2)j NX1X2, NH-acyl, NH-aroyl, CHO, C(halogen)3, COOX3, SO3H, SO2NX1X2, CONX1X2, NHC(O)O-alkyl, NHSO2-alkyl, alkoxy, alkyl, alcohol, alkylmercapto, alkylamino, di-alkylamino, alkylsulfinyl or alkylsulfonyl, CX4X8X8, -CH=CHX8 , -C.ident.CX8;
X1 and X2 each independently comprise H or alkyl, or X1 and X2 together comprise part of a heterocyclic ring having 4 to 7 ring members and optionally one additional heteroatom selected from O, N or S, or X1 and X2 together comprise part of an imide ring having 5 to 6 members, X3 comprises H, alkyl, aryl, NO2, (CH2)m CN, hydroxyloweralkyl, or alkyl-NX1X2, X4, X5, and X6 each independently comprise H, alkyl, carbocyclic ring, hydroxyloweralkyl, alkyl-OH, halogen, CN, SNO, S(SO2)alkyl, NX1X2, COOX3, CONX3, OX7, or O-alkyl-X7 wherein X7 comprises H, alkyl, NO2, NO, P(O)(OX8)2, PH(O)(OX8), S(O)k N(alkyl)2, S(O)k X8, S(O)k OX8, COOX8, CONX8, SO3H, COX8, wherein X8 comprises H, alkyl, carbocyclic ring, heterocyclic ring, aromatic ring, heteroaromatic ring, or -CX9=CHX10 wherein X9 and X10 each independently comprise H or alkyl Wherein m is an integer from 0 to 7 j is an integer from 0 to 6, k is an integer from 0 to 2; or R1 comprises -(CH2)m - Q1 -(CH2)n-Z;
Q1 comprises NH, O, S, CH=CH, C.ident.C, CO, SO2 or OSO2;
m is an integer from 1 to 7;
n is an integer from 0 to 7;
Z comprises a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring; or R1 comprises -(CH2)m - Q1 --(CH2)n-Z;
Q1 comprises NH, O, S, CH=CH, C.ident.C, CO, SO2 or OSO2;
m is an integer from 1 to 7;
n is an integer from 0 to 7;
Z comprises a carbocyclic ring having 4 to 7 ring members, a heterocyclic ring having 4 to 7 ring members, an aromatic ring having 5 to 7 ring members, a heteroaromatic ring having 5 to 7 ring members; a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring, a heteropolycyclic ring or any above group substituted on at least one available ring atom by an alkyl group or any above group substituted on at least one available ring nitrogen atom by a benzyl group, a substituted benzyl group, an alkoxybenzyl group, a substituted alkoxybenzyl group, a benzhydryl group or a substituted benzhydryl group; and wherein the connecting point between the -(CH2)n- group and the Z
group can be any available ring carbon atom or any available ring nitrogen atom;
or R1 comprises -(CH2)m- Q1 -(CH2)n-Z;
Q1 comprises NH, O, S, CH=CH, C.ident.C, CO, SO2 or OSO2;
m is an integer from 1 to 7;
n is an integer from 0 to 7; and Z comprises a 5 member unsaturated ring having 0 to 4 independently selected heteroatoms as ring members, a substituted 5 member unsaturated ring having 0 to 4 independently selected heteroatoms as ring members, a 6 member aromatic ring having 0 to 5 independently selected heteroatoms as ring members or a substituted 6 member aromatic ring having 0 to 5 independently selected heteroatoms; and wherein the connecting point between the -(CH2)n- group and the Z group can be any available ring carbon atom or any available ring nitrogen atom; or R1 comprises -(CH2)m - Q1 -(CH2)n-Z;
Q1 comprises NH, O, S, CH=CH, C.ident.C, CO, SO2 or OSO2;
m is an integer from 1 to 7;
n is an integer from 0 to 7;
Z comprises 1-, 2- or 3-pyrrolidinyl, 1-, 2-, 3- or 4-piperidinyl, 2-, 3- or 4-morpholinyl, 2-, 3- or 4-thiomorpholinyl, 1-, 2- or 3-azetidinyl, 1- or 2-piperazinyl, 2- or 3-tetrahydrofuranyl; or any above group substituted on at least one available ring atom by an alkyl group; or any above group substituted on at least one available ring nitrogen atom by a benzyl group, a substituted benzyl group, an alkoxybenzyl group, a substituted alkoxybenzyl group, a benzhydryl group or a substituted benzhydryl group; and wherein the connecting point between the -(CH2)n- group and the Z group can be any available ring carbon atom or any available ring nitrogen atom; or R1 comprises -(CH2)m - Q1 -(CH2)n-Z;
Q1 comprises NH, O, S, CH=CH, C.ident.C, CO, SO2 or OSO2;
m is an integer from 1 to 7;
n is an integer from 0 to 7; and Z comprises wherein X and Y each independently comprise H, halogen, CF3, CF2H, N3, NCS, CN, NO2, NX1X2, OX3, SX3, OAc, OSO2X3, O-acyl, S-acyl, SO2-alkyl, SO-alkyl, SC(CH3)2COOX8, OC(CH3)2COOX8 , C(CH3)2COOX8, Si(alkyl)3, alkyl-CN, O-aroyl, O(CH2)j OX3, O(CH2)j NX1X2, NH-acyl, NH-aroyl, CHO, C(halogen)3, COOX3, SO3H, SO2NX1X2, CONX1X2, NHC(O)O-alkyl, NHSO2-alkyl, alkoxy, alkyl, alcohol, alkylmercapto, alkylamino, di-alkylamino, alkylsulfinyl or alkylsulfonyl, CX4X5X6, -CH=CHX8 , -C.ident.CX8 ;
X1 and X2 each independently comprise H or alkyl, or X1 and X2 together comprise part of a heterocyclic ring having 4 to 7 ring members and optionally one additional heteroatom selected from O, N or S, or X1 and X2 together comprise part of an imide ring having 5 to 6 members, X3 comprises H, alkyl, aryl, NO2, (CH2)m CN, hydroxyloweralkyl, or alkyl-NX1X2, X4, X5, and X6 each independently comprise H, alkyl, carbocyclic ring, hydroxyloweralkyl, alkyl-OH, halogen, CN, SNO, S(SO2)alkyl, NX1X2, COOX3, CONX3, OX7, or O-alkyl-X7 wherein X7 comprises H, alkyl, NO2, NO, P(O)(OX8)2, PH(O)(OX8), S(O)k N(alkyl)2, S(O)k X8, S(O)k OX8, COOX8, CONX8, SO3H, COX8, wherein X8 comprises H, alkyl, carbocyclic ring, heterocyclic ring, aromatic ring, heteroaromatic ring, or -CX6=CHX10 wherein X9 and X10 each independently comprise H or alkyl Wherein m is an integer from 0 to 7 j is an integer from 0 to 6, k is an integer from 0 to 2 W comprises H or alkyl; or R1 comprises -(CH2)m - Q1 -(CH2)n-Z;
Q1 comprises NH, O, S, CH=CH, C.ident.C, CO, SO2 or OSO2;
m is an integer from 1 to 7;
n is an integer from 0 to 7; and Z comprises an unsaturated ring having 5 ring atoms and 0 to 2 independently selected heteroatoms as ring members fused to an unsaturated ring having 5 ring atoms and 0 to 4 independently selected heteroatoms as ring members, an unsaturated ring having 5 ring atoms and 0 to 2 independently selected heteroatoms as ring members fused to an unsaturated ring having 6 or 7 ring atoms and 0 to 4 independently selected heteroatoms as ring members or an unsaturated ring having 6 ring atoms and 0 to 4 independently selected heteroatoms as ring members fused to an unsaturated ring having 6 or 7 ring atoms and 0 to 4 independently selected heteroatoms as ring members; or R1 comprises -(CH2)m- Q1 -(CH2)n-Z;
Q1 comprises NH, O, S, CH=CH, C.ident.C, CO, SO2 or OSO2;
m is an integer from 1 to 7;
n is an integer from 0 to 7; and Z comprises R1 comprises -T-(CH2)n-Z;
n comprises an integer from 0 to 7;
T comprises a carbocyclic ring having 3 to 8 ring members, an unsaturated ring having 3 to 8 carbon atoms as ring members, an aromatic ring having 5 to 8 carbon atoms as ring members, a heterocyclic ring having 3 to 8 ring members, a heteroaromatic ring having 5 to 8 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring; and Z comprises, H, halogen, CF3, CF2H, N3, NCS, CN, NO2, NX1X2, OX3, SX3, OAc, OSO2X3, O-acyl, S-acyl, SO2-alkyl, SO-alkyl, SC(CH3)2COOX8, OC(CH3)2COOX8 , C(CH3)2COOX8, Si(alkyl)3, alkyl-CN, O-aroyl, O(CH2)j OX3, O(CH2)j NX1X2, NH-acyl, NH-aroyl, CHO, C(halogen)3, COOX3, SO3H, SO2NX1X2, CONX1X2, NHC(O)O-alkyl, NHSO2-alkyl, alkoxy, alkyl, alcohol, alkylmercapto, alkylamino, di-alkylamino, alkylsulfinyl or alkylsulfonyl, CX4X8X8, -CH=CHX8, --C.ident.CX8;
X1 and X2 each independently comprise H or alkyl, or X1 and X2 together comprise part of a heterocyclic ring having 4 to 7 ring members and optionally one additional heteroatom selected from O, N or S, or X1 and X2 together comprise part of an imide ring having 5 to 6 members, X3 comprises H, alkyl, aryl, NO2, (CH2)m CN, hydroxyloweralkyl, or alkyl-NX1X2, X4, X5, and X6 each independently comprise H, alkyl, carbocyclic ring, hydroxyloweralkyl, alkyl-OH, halogen, CN, SNO, S(SO2)alkyl, NX1X2, COOX3, CONX3, OX7, or O-alkyl-X7 wherein X7 comprises H, alkyl, NO2, NO, P(O)(OX8)2, PH(O)(OX8), S(O)k N(alkyl)2, S(O)k X8, S(O)k OX8, COOX8, CONX8, SO3H, COX8, wherein X8 comprises H, alkyl, carbocyclic ring, heterocyclic ring, aromatic ring, heteroaromatic ring, or -CX9=CHX10 wherein X9 and X10 each independently comprise H or alkyl Wherein m is an integer from 0 to 7 j is an integer from 0 to 6, k is an integer from 0 to 2; or R1 comprises -T-(CH2)n-Z;
n comprises an integer from 0 to 7;
T comprises a carbocyclic ring having 3 to 8 ring members, an unsaturated ring having 3 to 8 carbon atoms as ring members, an aromatic ring having 5 to 8 carbon atoms as ring members, a heterocyclic ring having 3 to 8 ring members, a heteroaromatic ring having 5 to 8 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring; and Z comprises a carbocyclic ring having 4 to 7 ring members, a heterocyclic ring having 4 to 7 ring members, an aromatic ring having 5 to 7 ring members, a heteroaromatic ring having 5 to 7 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring, a heteropolycyclic ring; or any above group substituted on at least one available ring atom by an alkyl group; or any above group substituted on at least one available ring nitrogen atom by a benzyl group, a substituted benzyl group, an alkoxybenzyl group, a substituted alkoxybenzyl group, a benzhydryl group or a substituted benzhydryl group; and wherein the connecting point between the -(CH2)n- group and the Z group can be any available ring carbon atom or any available ring nitrogen atom; or R1 comprises -T--(CH2)n-Z;
n comprises an integer from 0 to 7;
T comprises a carbocyclic ring having 3 to 8 ring members, an unsaturated ring having 3 to 8 carbon atoms as ring members, an aromatic ring having 5 to 8 carbon atoms as ring members, a heterocyclic ring having 3 to 8 ring members, a heteroaromatic ring having 5 to 8 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring; and Z comprises 1-, 2- or 3-pyrrolidinyl, 1-, 2-, 3- or 4-piperidinyl, 2-, 3- or 4-morpholinyl, 2-, 3- or 4-thiomorpholinyl, 1-, 2- or 3-azetidinyl, 1- or 2-piperazinyl, 2- or 3-tetrahydrofuranyl; or any above group substituted on at least one available ring atom by an alkyl group; or any above group substituted on at least one available ring nitrogen atom by a benzyl group, a substituted benzyl group, an alkoxybenzyl group, a substituted alkoxybenzyl group, a benzhydryl group or a substituted benzhydryl group; and wherein the connecting point between the -(CH2)n- group and the Z group can be any available ring carbon atom or any available ring nitrogen atom; or R1 comprises ¨T¨(CH2)n--Z;
n comprises an integer from 0 to 7;
T comprises a carbocyclic ring having 3 to 8 ring members, an unsaturated ring having 3 to 8 carbon atoms as ring members, an aromatic ring having 5 to 8 carbon atoms as ring members, a heterocyclic ring having 3 to 8 ring members, a heteroaromatic ring having 5 to 8 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring; and Z comprises wherein X and Y each independently comprise H, halogen, CF3, CF2H, N3, NCS, CN, NO2, NX1X2, OX3, SX3, OAc, OSO2X3, O-acyl, S-acyl, SO2-alkyl, SO-alkyl, SC(CH3)2COOX5, OC(CH3)2COOX8 , C(CH3)2COOX8, Si(alkyl)3, alkyl-CN, O-aroyl, O(CH2)i OX3, O(CH2)j NX1X2, NH-acyl, NH-aroyl, CHO, C(halogen)3, COOX3, SO3H, SO2NX1X2, CONX1X2, NHC(O)O-alkyl, NHSO2-alkyl, alkoxy, alkyl, alcohol, alkylmercapto, alkylamino, di-alkylamino, alkylsulfinyl or alkylsulfonyl, CX4X5X6, -CH=CHX8 , -C.ident.CX8 ;
X1 and X2 each independently comprise H or alkyl, or X1 and X2 together comprise part of a heterocyclic ring having 4 to 7 ring members and optionally one additional heteroatom selected from O, N or S, or X1 and X2 together comprise part of an imide ring having 5 to 6 members, X3 comprises H, alkyl, aryl, NO2, (CH2)m CN, hydroxyloweralkyl, or alkyl-NX1X2, X4, X5, and X6 each independently comprise H, alkyl, carbocyclic ring, hydroxyloweralkyl, alkyl-OH, halogen, CN, SNO, S(SO2)alkyl, NX1X2, COOX3, CONX3, OX7, or O-alkyl-X7 wherein X7 comprises H, alkyl, NO2, NO, P(O)OX8)2, PH(O)OX8), S(O)k N(alkyl)2, S(O)k X8, S(O)k OX8, COOX8, CONX8, SO3H, COX8, wherein X8 comprises H, alkyl, carbocyclic ring, heterocyclic ring, aromatic ring, heteroaromatic ring, or -CX9=CHX10 wherein X9 and X10 each independently comprise H or alkyl Wherein m is an integer from 0 to 7 j is an integer from 0 to 6, k is an integer from 0 to 2 W comprises H or alkyl; or R1 comprises -T-(CH2)n-Z;
n comprises an integer from 0 to 7;
T comprises a carbocyclic ring having 3 to 8 ring members, an unsaturated ring having 3 to 8 carbon atoms as ring members, an aromatic ring having 5 to 8 carbon atoms as ring members, a heterocyclic ring having 3 to 8 ring members, a heteroaromatic ring having 5 to 8 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring; and Z comprises an unsaturated ring having 5 ring atoms and 0 to 2 independently selected heteroatoms as ring members fused to an unsaturated ring having 5 ring atoms and 0 to 4 independently selected heteroatoms as ring members, an unsaturated ring having 5 ring atoms and 0 to 2 independently selected heteroatoms as ring members fused to an unsaturated ring having 6 or 7 ring atoms and 0 to 4 independently selected heteroatoms as ring members or an unsaturated ring having 6 ring atoms and 0 to 3 independently selected heteroatoms as ring members fused to an unsaturated ring having 6 or 7 ring atoms and 0 to 4 independently selected heteroatoms as ring members; or R1 comprises -T-Q-(CH2)n-Z, each n independently comprises an integer from 0 to 7;
T comprises a carbocyclic ring having 3 to 8 ring members, an unsaturated ring having 3 to 8 carbon atoms as ring members, an aromatic ring having 5 to 8 carbon atoms as ring members, a heterocyclic ring having 3 to 8 ring members, a heteroaromatic ring having 5 to 8 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring;
Q comprises CH.ident.CH, Z comprises H, halogen, CF3, CF2H, N3, NCS, CN, NO2, NX1X2, OX3, SX3, OAc, OSO2X3, O-acyl, S-acyl, SO2-alkyl, SO-alkyl, SC(CH3)2COOX8, OC(CH3)2COOX8 , C(CH3)2COOX8, Si(alkyl)3, alkyl-CN, O-aroyl, O(CH2)j OX3, O(CH2)j NX1X2, NH-acyl, NH-aroyl, CHO, C(halogen)3, COOX3, SO3H, SO2NX1X2, CONX1X2, NHC(O)O-alkyl, NHSO2-alkyl, alkoxy, alkyl, alcohol, alkylmercapto, alkylamino, di-alkylamino, alkylsulfinyl or alkylsulfonyl, CX4X5X6, -CH=CHX8 , -C.ident.CX8;
X1 and X2 each independently comprise H or alkyl, or X1 and X2 together comprise part of a heterocyclic ring having 4 to 7 ring members and optionally one additional heteroatom selected from 0, N or S, or X1 and X2 together comprise part of an imide ring having 5 to 6 members, X3 comprises H, alkyl, NO2, (CH2)m CN, hydroxyloweralkyl, or alkyl-NX1X2, X4, X5, and X6 each independently comprise H, alkyl, carbocyclic ring, hydroxyloweralkyl, alkyl-OH, halogen, CN, SNO, S(SO2)alkyl, NX1X2, COOX3, CONX3, OX7, or O-alkyl-X7 wherein X7 comprises H, alkyl, NO2, NO, P(O)(OX8)2, PH(O)(OX8), S(O)k N(alkyl)2, S(O)k X8, S(O)k OX8, COOX8, CONX8, SO3H, COX8, wherein X8 comprises H, alkyl, carbocyclic ring, heterocyclic ring, aromatic ring, heteroaromatic ring, or -CX9=CHX10 wherein X9 and X10 each independently comprise H or alkyl Wherein m is an integer from 0 to 7 j is an integer from 0 to 6, or k is an integer from 0 to 2; or R1 comprises -T-Q-(CH2)n-Z, each n independently comprises an integer from 0 to 7;
T comprises a carbocyclic ring having 3 to 8 ring members, an unsaturated ring having 3 to 8 carbon atoms as ring members, an aromatic ring having 5 to 8 carbon atoms as ring members, a heterocyclic ring having 3 to 8 ring members, a heteroaromatic ring having 5 to 8 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring;
Q comprises CH=CH, C.ident.C; and Z comprises a carbocyclic ring having 4 to 7 ring members, a heterocyclic ring having 4 to 7 ring members, an aromatic ring having 5 to 7 ring members, a heteroaromatic ring having 5 to 7 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring, a heteropolycyclic ring; or any above group substituted on at least one available ring atom by an alkyl group; or any above group substituted on at least one available ring nitrogen atom by a benzyl group, a substituted benzyl group, an alkoxybenzyl group, a substituted alkoxybenzyl group, a benzhydryl group or a substituted benzhydryl group; and wherein the connecting point between the -(CH2)n- group and the Z group can be any available ring carbon atom or any available ring nitrogen atom; or R1 comprises -T-Q--(CH2)n-Z;
each n independently comprises an integer from 0 to 7;
T comprises a carbocyclic ring having 3 to 8 ring members, an unsaturated ring having 3 to 8 carbon atoms as ring members, an aromatic ring having 5 to 8 carbon atoms as ring members, a heterocyclic ring having 3 to 8 ring members, a heteroaromatic ring having 5 to 8 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring;
Q comprises CH=CH, C.ident.C, and Z comprises 1-, 2- or 3-pyrrolidinyl, 1-, 2-, 3- or 4-piperidinyl, 2-, 3- or 4-morpholinyl, 2-, 3- or 4-thiomorpholinyl, 1-, 2- or 3-azetidinyl, 1- or 2-piperazinyl, 2- or 3-tetrahydrofuranyl; or any above group substituted on at least one available ring atom by an alkyl group; or any above group substituted on at least one available ring nitrogen atom by a benzyl group, a substituted benzyl group, an alkoxybenzyl group, a substituted alkoxybenzyl group, a benzhydryl group or a substituted benzhydryl group; and wherein the connecting point between the -(CH2)n- group and the Z group can be any available ring carbon atom or any available ring nitrogen atom; or R1 comprises -T-Q-(CH2)n-Z;
each n independently comprises an integer from 0 to 7;
T comprises a carbocyclic ring having 3 to 8 ring members, an unsaturated ring having 3 to 8 carbon atoms as ring members, an aromatic ring having 5 to 8 carbon atoms as ring members, a heterocyclic ring having 3 to 8 ring members, a heteroaromatic ring having 5 to 8 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring;
Q comprises CH=CH, C.ident.C; and Z comprises wherein X and Y each independently comprise H, halogen, CF3, CF2H, N3, NCS, CN, NO2, NX1X2, OX3, SX3, OAc, OSO2X3, O-acyl, S-acyl, SO2-alkyl, SO-alkyl, SC(CH3)2COOX8, OC(CH3)2COOX8 , C(CH3)2COOX8, Si(alkyl)3, O-aroyl, O(CH2)j OX3, O(CH2)j NX1X2, NH-acyl, NH-aroyl, CHO, C(halogen)3, COOX3, SO3H, SO2NX1X2, CONX1X2, NHC(O)O-alkyl, NHSO2-alkyl, alkoxy, alkyl, alcohol, alkylmercapto, alkylamino, di-alkylamino, alkylsulfinyl or alkylsulfonyl, CX4X5X6, -CH=CHX8 , -C.ident.CX8;
X1 and X2 each independently comprise H or alkyl, or X1 and X2 together comprise part of a heterocyclic ring having 4 to 7 ring members and optionally one additional heteroatom selected from O, N or S, or X1 and X2 together comprise part of an imide ring having 5 to 6 members, X3 comprises H, alkyl, NO2, (CH2)m CN, hydroxyloweralkyl, or alkyl-NX1X2, X4, X5, and X6 each independently comprise H, alkyl, carbocyclic ring, hydroxyloweralkyl, alkyl-OH, halogen, CN, SNO, S(SO2)alkyl, NX1X2, COOX3, CONX3, OX7, or O-alkyl-X7 wherein X7 comprises H, alkyl, NO2, NO, P(O)(OX8)2, PH(O)(OX8), S(O)k N(alkyl)2, S(O)k X8, S(O)k OX8, COOX8, CONX8, SO3H, COX8, wherein X8 comprises H, alkyl, carbocyclic ring, heterocyclic ring, aromatic ring, heteroaromatic ring, or -CX9=CHX10 wherein X9 and X10 each independently comprise H or alkyl Wherein m is an integer from 0 to 7 j is an integer from 0 to 6, k is an integer from 0 to 2, W comprises H or alkyl; or R1 comprises -T-Q-(CH2)n-Z, each n independently comprises an integer from 0 to 7;
T comprises a carbocyclic ring having 3 to 8 ring members, an unsaturated ring having 3 to 8 carbon atoms as ring members, an aromatic ring having 5 to 8 carbon atoms as ring members, a heterocyclic ring having 3 to 8 ring members, a heteroaromatic ring having 5 to 8 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring;
Q comprises CH=CH, C.ident.C; and Z comprises an unsaturated ring having 5 ring atoms and 0 to 2 independently selected heteroatoms as ring members fused to an unsaturated ring having 5 ring atoms and 0 to 4 independently selected heteroatoms as ring members, an unsaturated ring having 5 ring atoms and 0 to 2 independently selected heteroatoms as ring members fused to an unsaturated ring having 6 or 7 ring atoms and 0 to 4 independently selected heteroatoms as ring members or an unsaturated ring having 6 ring atoms and 0 to 3 independently selected heteroatoms as ring members fused to an unsaturated ring having 6 or 7 ring atoms and 0 to 4 independently selected heteroatoms as ring members; or R1 comprises -T- Q-(CH2)n-Z;
T comprises a carbocyclic ring having 3 to 8 ring members, an unsaturated ring having 3 to 8 carbon atoms as ring members, an aromatic ring having 5 to 8 carbon atoms as ring members, a heterocyclic ring having 3 to 8 ring members, a heteroaromatic ring having 5 to 8 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring;
each n independently comprises an integer from 0 to 7;
Q comprises CH=CH, C.ident.C;
Z comprises E comprises a C1 to C4, linear or branched alkyl group, a phenyl group, a substituted phenyl group, a benzyl group or a substituted benzyl group; or R1 comprises -T- Q-(CH2)n-Z;
T comprises a carbocyclic ring having 3 to 8 ring members, an unsaturated ring having 3 to 8 carbon atoms as ring members, an aromatic ring having 5 to 8 carbon atoms as ring members, a heterocyclic ring having 3 to 8 ring members, a heteroaromatic ring having 5 to 8 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring;
each n independently comprises an integer from 0 to 7;
Q comprises CH=CH, C.ident.C and Z comprises k is an integer from 1 to 5, and A1 and A2 each independently comprise a C1 to C4 alkyl group, a phenyl group or a substituted phenyl group; and R4 comprises H, halogen, CF3, CF2H, N3, NCS, CN, NO2, NX1X2, OH, ONO2, SX3, OAc, OSO2X3, O-acyl, S-acyl, SO2-alkyl, SO-alkyl, SC(CH3)2COOX8, OC(CH3)2COOX8 , C(CH3)2COOX8, Si(alkyl)3, alkyl-CN, O-aroyl, O(CH2)j OX3, O(CH2)j NX1X2, NH-acyl, NH-aroyl, CHO, C(halogen)3, COOX3, SO3H, SO2NX1X2, CONX1X2, NHC(O)O-alkyl, NHSO2-alkyl, alkoxy, alkyl, alcohol, alkylmercapto, alkylamino, di-alkylamino, alkylsulfinyl or alkylsulfonyl, CX4X5X8, -CH=CHX8 , -C.ident.CX8;
X1 and X2 each independently comprise H or alkyl, or X1 and X2 together comprise part of a heterocyclic ring having 4 to 7 ring members and optionally one additional heteroatom selected from O, N or S, or X1 and X2 together comprise part of an imide ring having 5 to 6 members, X3 comprises H, alkyl, NO2, (CH2)m CN, hydroxyloweralkyl, or alkyl-NX1X2, X4, X5, and X6 each independently comprise H, alkyl, carbocyclic ring, hydroxyloweralkyl, alkyl-OH, halogen, CN, SNO, S(SO2)alkyl, NX1X2, COOX3, CONX3, OX7, or O-alkyl-X7 wherein X7 comprises H, alkyl, NO2, NO, P(O)(OX8)2, PH(O)(OX8), S(O)k N(alkyl)2, S(O)k X8, S(O)k OX8, COOX8, CONX8, SO3H, COX8, wherein X8 comprises H, alkyl, carbocyclic ring, heterocyclic ring, aromatic ring, heteroaromatic ring, or -CX9=CHX10 wherein X9 and X10 each independently comprise H or alkyl Wherein m is an integer from 0 to 7 j is an integer from 0 to 6, or k is an integer from 0 to 2; or R4 comprises a carbocyclic ring having 4 to 7 ring members, a heterocyclic ring having 4 to 7 ring members, an aromatic ring having 5 to 7 ring members, a heteroaromatic ring having 5 to 7 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricydic ring, a polycyclic ring or a heteropolycyclic ring; or R4 comprises R4 comprises -(CH2)d-Z;
d is an integer from 1 to 6;
Z comprises H, halogen, CF3, CF2H, N3, NCS, CN, NO2, NX1X2, OX3, SX3, OAc, OSO2X3, O-acyl, S-acyl, SO2-alkyl, SO-alkyl, SC(CH3)2COOX8, OC(CH3)2COOX8 , C(CH3)2COOX8, Si(alkyl)3, alkyl-CN, O-aroyl, O(CH2)10X3, O(CH2)j NX1X2, NH-acyl, NH-aroyl, CHO, C(halogen)3, COOX3, SO3H, SO2NX1X2, CONX1X2, NHC(O)O-alkyl, NHSO2-alkyl, alkoxy, alkyl, alcohol, alkylmercapto, alkylamino, di-alkylamino, alkylsulfinyl or alkylsulfonyl, CX4X5X6, -CH=CHX8 , -C.ident.CX8 ;
X1 and X2 each independently comprise H or alkyl, or X1 and X2 together comprise part of a heterocyclic ring having 4 to 7 ring members and optionally one additional heteroatom selected from O, N or S, or X1 and X2 together comprise part of an imide ring having 5 to 6 members, X3 comprises H, alkyl, NO2, (CH2)m CN, hydroxyloweralkyl, or alkyl-NX1X2, X4, X5, and X6 each independently comprise H, alkyl, carbocyclic ring, hydroxyloweralkyl, alkyl-OH, halogen, CN, SNO, S(SO2)alkyl, NX1X2, COOX3, CONX3, OX7, or O-alkyl-X7 wherein X7 comprises H, alkyl, NO2, NO, P(O)(OX8)2, PH(O)(OX8), S(O) k N(alkyl)2, S(O)k X8, S(O)k OX8, COOX8, CONX8, SO3H, COX8, wherein X8 comprises H, alkyl, carbocyclic ring, heterocyclic ring, aromatic ring, heteroaromatic ring, or -CX9=CHX10wherein X9 and X10 each independently comprise H or alkyl Wherein m is an integer from 0 to 7 j is an integer from 0 to 6, k is an integer from 0 to 2; or R4 comprises -(CH2)d-Z, d is an integer from 1 to 6; and Z comprises a carbocyclic ring having 4 to 7 ring members, a heterocyclic ring having 4 to 7 ring members, an aromatic ring having 5 to 7 ring members, a heteroaromatic ring having 5 to 7 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring, a heteropolycyclic ring; or any above group substituted on at least one available ring atom by an alkyl group; or any above group substituted on at least one available ring nitrogen atom by a benzyl group, a substituted benzyl group, an alkoxybenzyl group, a substituted alkoxybenzyl group, a benzhydryl group or a substituted benzhydryl group; and wherein the_connecting point between the -(CH2)d- group and the Z group can be any available ring carbon atom or any available ring nitrogen atom; or R4 comprises -(CH2)d-Z;
d is an integer from 1 to 6; and Z comprises 1-, 2- or 3-pyrrolidinyl, 1-, 2-, 3- or 4-piperidinyl, 2-, 3- or 4-morpholinyl, 2-, 3- or 4-thiomorpholinyl, 1-, 2- or 3-azetidinyl, 1- or 2-piperazinyl, 2- or 3-tetrahydrofuranyl; or any above group substituted on at least one ring atom by an alkyl group; or any above group substituted on at least one available ring nitrogen atom by a benzyl group, a substituted benzyl group, an alkoxybenzyl group, a substituted alkoxybenzyl group, a benzhydryl group or a substituted benzhydryl group; and wherein the connecting point between the -(CH2)d- group and the Z group can be any available ring carbon atom or any available ring nitrogen atom; or R4 comprises -(CH2 )m - Q1 -(CH2)n-Z;
Q1 comprises NH, O, S, CH=CH, CC, CO, SO2 or OSO2;
m is an integer from 1 to 7;
n is an integer from 0 to 7; and Z comprises H, halogen, CF3, CF2H, N3, NCS, CN, NO2, NX1X2, OX3, SX3, OAc, OSO2X3, O-acyl, S-acyl, SO2-alkyl, SO-alkyl, SC(CH3)2COOX8, OC(CH3)2COOX8 , C(CH3)2COOX8, Si(alkyl)3, alkyl-CN, O-aroyl, O(CH2)j OX3, O(CH2)j NX1X2, NH-acyl, NH-aroyl, CHO, C(halogen)3, COOX3, SO3H, SO2NX1X2, CONX1X2, NHC(O)O-alkyl, NHSO2-alkyl, alkoxy, alkyl, alcohol, alkylmercapto, alkylamino, di-alkylamino, alkylsulfinyl or alkylsulfonyl, CX4X8X8, -CH=CHX8 , -C.ident.CX8 ;
X1 and X2 each independently comprise H or alkyl, or X1 and X2 together comprise part of a heterocyclic ring having 4 to 7 ring members and optionally one additional heteroatom selected from O, N or S, or X1 and X2 together comprise part of an imide ring having 5 to 6 members, X3 comprises H, alkyl, NO2, (CH2)m CN, hydroxyloweralkyl, or alkyl-NX1X2, X4, X5, and X6 each independently comprise H, alkyl, carbocyclic ring, hydroxyloweralkyl, alkyl-OH, halogen, CN, SNO, S(SO2)alkyl, NX1X2, COOX3, CONX3, OX7, or O-alkyl-X7 wherein X7 comprises H, alkyl, NO2, NO, P(O)(OX8)2, PH(O)(OX8), S(O)k N(alkyl)2, S(O)k X8, S(O)k OX8, COOX8, CONX8, SO3H, COX8, wherein X8 comprises H, alkyl, carbocyclic ring, heterocyclic ring, aromatic ring, heteroaromatic ring, or -CX9=CHX10 wherein X9 and X10 each independently comprise H or alkyl Wherein m is an integer from 0 to 7 j is an integer from 0 to 6, or k is an integer from 0 to 2; or R4 comprises -(CH2)m - Q1 -(CH2)n-Z;
Q1 comprises NH, O, S, CH=CH, C.ident.C-C, CO, SO2 or OSO2;
m is an integer from 1 to 7;
n is an integer from 0 to 7; and Z comprises a carbocyclic ring having 4 to 7 ring members, a heterocyclic ring having 4 to 7 ring members, an aromatic ring having 5 to 7 ring members, a heteroaromatic ring having 5 to 7 ring members; a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring, a heteropolycyclic ring; or any above group substituted on at least one available ring atom by an alkyl group; or any above group substituted on at least one available ring nitrogen atom by a benzyl group,a substituted benzyl group, an alkoxybenzyl group, a substituted alkoxybenzyl group, a benzhydryl group or a substituted benzhydryl group; and wherein the connecting point between the -(CH2)n- group and the Z group can be any available ring carbon atom or any available ring nitrogen atom; or R4 comprises -(CH2)m - Q1 -(CH2)n-Z;
Q1 comprises NH, O, S, CH=CH, C.ident.C, CO, SO2 or OSO2;
m is an integer from 1 to 7;
n is an integer from 0 to 7; and Z comprises 1-, 2- or 3-pyrrolidinyl, 1-, 2-, 3- or 4-piperidinyl, 2-, 3- or 4-morpholinyl, 2-, 3- or 4-thiomorpholinyl, 1-, 2- or 3-azetidinyl, 1- or 2-piperazinyl, 2- or 3-tetrahydrofuranyl; or any above group substituted on at least one available ring atom by an alkyl; or any above group substituted on at least one available ring nitrogen atom by a benzyl group, a substituted benzyl group, an alkoxybenzyl group, a substituted alkoxybenzyl group, a benzhydryl group or a substituted benzhydryl group; and wherein the connecting point between the -(CH2)n- group and the Z group can be any available ring carbon atom or any available ring nitrogen atom; or R4 comprises -(CH2)m - Q1 -(CH2)n-Z;
Q1 comprises NH, O, S, CH=CH, C.ident.C, CO, SO2 or OSO2;
m is an integer from 1 to 7;
n is an integer from 0 to 7; and Z comprises wherein X and Y each independently comprise H, halogen, CF3, CF2H, N3, NCS, CN, NO2, NX1X2, OX3, SX3, OAc, OSO2X3, O-acyl, S-acyl, SO2-alkyl, SO-alkyl, SC(CH3)2COOX8, OC(CH3)2COOX8 , C(CH3)2COOX8, Si(alkyl)3, alkyl-CN, O-aroyl, O(CH2)10X3, O(CH2)1NX1X2, NH-acyl, NH-aroyl, CHO, C(halogen)3, COOX3, SO3H, SO2NX1X2, CONX1X2, NHC(O)O-alkyl, NHS02-alkyl, alkoxy, alkyl, alcohol, alkylmercapto, alkylamino, di-alkylamino, alkylsulfinyl or alkylsulfonyl, CX4X5X8, -CH=CHX8 , -C.ident.CX8 ;
X1 and X2 each independently comprise H or alkyl, or X1 and X2 together comprise part of a heterocyclic ring having 4 to 7 ring members and optionally one additional heteroatom selected from O, N or S, or X1 and X2 together comprise part of an imide ring having 5 to 6 members, X3 comprises H, alkyl, NO2, (CH2)m CN, hydroxyloweralkyl, or alkyl-NX1X2, X4, X5, and X6 each independently comprise H, alkyl, carbocyclic ring, hydroxyloweralkyl, alkyl-OH, halogen, CN, SNO, S(SO2)alkyl, NX1X2, COOX3, CONX3, OX7, or O-alkyl-X7 wherein X7 comprises H, alkyl, NO2, NO, P(O)(OX8)2, PH(O)(OX8), S(O)k N(alkyl)2, S(O)k X8, S(O)k OX8, COOX8, CONX8, SO3H, COX8, wherein X8 comprises H, alkyl, carbocyclic ring, heterocyclic ring, aromatic ring, heteroaromatic ring, or -CX9=CHX10 wherein X9 and X10 each independently comprise H or alkyl Wherein m is an integer from 0 to 7 j is an integer from 0 to 6, k is an integer from 0 to 2, W comprises H or alkyl, and Ac is acyl.
2. A pharmaceutical composition comprising at least one compound as defined in claim 1, and a pharmaceutically acceptable carrier.
3. Use of the compound of claim 1 for the production of a medicament for modulating the function of cannabinoid receptors in an individual or animal.
4. The use of claim 3 wherein the compound is for selectively stimulating a CB1 cannabinoid receptor in said individual or animal.
5. Use of the compound of claim 1, for the production of a medicament for treating or reducing the severity of a condition selected from the group consisting of obesity; metabolic disorders consisting of insulin related deficiencies and lipid profiles, hepatic diseases, cardiometabolic diseases, diabetes and appetite disorders; cancer chemotherapy; benign prostatic hypertrophy; schizophrenia;
Parkinson's disease; marijuana abuse; and alcohol, opioid, nicotine or cocaine addiction in an individual or animal having that condition.
Parkinson's disease; marijuana abuse; and alcohol, opioid, nicotine or cocaine addiction in an individual or animal having that condition.
6. A compound of claim 1 wherein at least one atom in the compound is an unnatural isotope.
7. A compound of claim 1, and physiologically accepted salts thereof, selected from one of the following structures:
8. A compound of claim 1, and physiologically accepted salts thereof, consisting of the following structure:
9. A compound of claim 1, wherein R2 comprises -(CH2)n-Z;
n is an integer from 0 to 7; and Z comprises a carbocyclic ring having 4 to 7 ring members, a heterocyclic ring having 4 to 7 ring members, an aromatic ring having 5 to 7 ring members, a heteroaromatic ring having 5 to 7 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring, a heteropolycyclic ring; or any above group substituted on at least one available ring atom by an alkyl group; or any above group substituted on at least one available ring nitrogen atom by a benzyl group, a substituted benzyl group, an alkoxybenzyl group, a substituted alkoxybenzyl group, a benzhydryl group or a substituted benzhydryl group; and wherein the connecting point between the -(CH2)n- group and the Z group can be any available ring carbon atom or any available ring nitrogen atom; or R2 comprises -(CH2)n-Z;
n is an integer from 0 to 7; and Z comprises wherein X and Y each independently comprise, H, halogen, CF3, CF2H, N3, NCS, CN, NO2, NX1X2, OX3, SX3, OAc, OSO2X3, O-acyl, S-acyl, SO2-alkyl, SO-alkyl, SC(CH3)2COOX8, OC(CH3)2COOX8 , C(CH3)2COOX8, Si(alkyl)3, alkyl-CN, O-aroyl, O(CH2)j OX3, O(CH2)j NX1X2, NH-acyl, NH-aroyl, CHO, C(halogen)3, COOX3, SO3H, SO2NX1X2, CONX1X2, NHC(O)O-alkyl, NHSO2-alkyl, alkoxy, alkyl, alcohol, alkylmercapto, alkylamino, di-alkylamino, alkylsulfinyl or alkylsulfonyl, CX4X5X6, -CH=CHX8 , -C.ident.CX8 ;
X1 and X2 each independently comprise H or alkyl, or X1 and X2 together comprise part of a heterocyclic ring having 4 to 7 ring members and optionally one additional heteroatom selected from O, N or S, or X1 and X2 together comprise part of an imide ring having 5 to 6 members, X3 comprises H, alkyl, aryl, NO2, (CH2)m CN, hydroxyloweralkyl, or alkyl-NX1X2, X4, X5, and X6 each independently comprise H, alkyl, carbocyclic ring, hydroxyloweralkyl, alkyl-OH, halogen, CN, SNO, S(SO2)alkyl, NX1X2, COOX3, CONX3, OX7, or O-alkyl-X7 wherein X7 comprises H, alkyl, NO2, NO, P(O)(OX8)2, PH(O)(OX8), S(O)k N(alkyl)2, S(O)k X8, S(O)k OX8, COOX8, CONX8, SO3H, COX8, wherein X8 comprises H, alkyl, carbocyclic ring, heterocyclic ring, aromatic ring, heteroaromatic ring, or -CX9=CHX10 wherein X9 and X10 each independently comprise H or alkyl Wherein m is an integer from 0 to 7 j is an integer from 0 to 6, or k is an integer from 0 to 2 W comprises H or alkyl; or R2 comprises -(CH2)n--Z;
n is an integer from 0 to 7; and Z comprises a carbocyclic ring having 6 ring atoms fused to a heterocyclic ring having from 5 to 7 ring atoms, a carbocyclic ring having 6 ring atoms fused to a heteroaromatic ring having from 5 to 7 ring atoms, a heterocyclic ring having 6 ring atoms fused to a heterocyclic ring having from 5 to 7 ring atoms, an heterocyclic ring having 6 ring atoms fused to a heteroaromatic ring having from to 7 ring atoms, an aromatic ring having 6 ring atoms fused to a heterocyclic ring having from 5 to 7 ring atoms, an aromatic ring having 6 ring atoms fused to a heteroaromatic ring having from 5 to 7 ring atoms, a heteroaromatic ring having 6 ring atoms fused to a heterocyclic ring having from 5 to 7 ring atoms or a heteroaromatic ring having 6 ring atoms fused to a heteroaromatic ring having from 5 to 7 ring atoms;
R1 comprises ¨T¨Q¨(CH2)n¨Z;
n is an integer from 0 to 7;
T comprises a carbocyclic ring having 3 to 8 ring members, an unsaturated ring having 3 to 8 carbon atoms as ring members, an aromatic ring having 5 to 8 carbon atoms as ring members, a heterocyclic ring having 3 to 8 ring members, a heteroaromatic ring having 5 to 8 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring;
Q comprises C.ident.C.
n is an integer from 0 to 7; and Z comprises a carbocyclic ring having 4 to 7 ring members, a heterocyclic ring having 4 to 7 ring members, an aromatic ring having 5 to 7 ring members, a heteroaromatic ring having 5 to 7 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring, a heteropolycyclic ring; or any above group substituted on at least one available ring atom by an alkyl group; or any above group substituted on at least one available ring nitrogen atom by a benzyl group, a substituted benzyl group, an alkoxybenzyl group, a substituted alkoxybenzyl group, a benzhydryl group or a substituted benzhydryl group; and wherein the connecting point between the -(CH2)n- group and the Z group can be any available ring carbon atom or any available ring nitrogen atom; or R2 comprises -(CH2)n-Z;
n is an integer from 0 to 7; and Z comprises wherein X and Y each independently comprise, H, halogen, CF3, CF2H, N3, NCS, CN, NO2, NX1X2, OX3, SX3, OAc, OSO2X3, O-acyl, S-acyl, SO2-alkyl, SO-alkyl, SC(CH3)2COOX8, OC(CH3)2COOX8 , C(CH3)2COOX8, Si(alkyl)3, alkyl-CN, O-aroyl, O(CH2)j OX3, O(CH2)j NX1X2, NH-acyl, NH-aroyl, CHO, C(halogen)3, COOX3, SO3H, SO2NX1X2, CONX1X2, NHC(O)O-alkyl, NHSO2-alkyl, alkoxy, alkyl, alcohol, alkylmercapto, alkylamino, di-alkylamino, alkylsulfinyl or alkylsulfonyl, CX4X5X6, -CH=CHX8 , -C.ident.CX8 ;
X1 and X2 each independently comprise H or alkyl, or X1 and X2 together comprise part of a heterocyclic ring having 4 to 7 ring members and optionally one additional heteroatom selected from O, N or S, or X1 and X2 together comprise part of an imide ring having 5 to 6 members, X3 comprises H, alkyl, aryl, NO2, (CH2)m CN, hydroxyloweralkyl, or alkyl-NX1X2, X4, X5, and X6 each independently comprise H, alkyl, carbocyclic ring, hydroxyloweralkyl, alkyl-OH, halogen, CN, SNO, S(SO2)alkyl, NX1X2, COOX3, CONX3, OX7, or O-alkyl-X7 wherein X7 comprises H, alkyl, NO2, NO, P(O)(OX8)2, PH(O)(OX8), S(O)k N(alkyl)2, S(O)k X8, S(O)k OX8, COOX8, CONX8, SO3H, COX8, wherein X8 comprises H, alkyl, carbocyclic ring, heterocyclic ring, aromatic ring, heteroaromatic ring, or -CX9=CHX10 wherein X9 and X10 each independently comprise H or alkyl Wherein m is an integer from 0 to 7 j is an integer from 0 to 6, or k is an integer from 0 to 2 W comprises H or alkyl; or R2 comprises -(CH2)n--Z;
n is an integer from 0 to 7; and Z comprises a carbocyclic ring having 6 ring atoms fused to a heterocyclic ring having from 5 to 7 ring atoms, a carbocyclic ring having 6 ring atoms fused to a heteroaromatic ring having from 5 to 7 ring atoms, a heterocyclic ring having 6 ring atoms fused to a heterocyclic ring having from 5 to 7 ring atoms, an heterocyclic ring having 6 ring atoms fused to a heteroaromatic ring having from to 7 ring atoms, an aromatic ring having 6 ring atoms fused to a heterocyclic ring having from 5 to 7 ring atoms, an aromatic ring having 6 ring atoms fused to a heteroaromatic ring having from 5 to 7 ring atoms, a heteroaromatic ring having 6 ring atoms fused to a heterocyclic ring having from 5 to 7 ring atoms or a heteroaromatic ring having 6 ring atoms fused to a heteroaromatic ring having from 5 to 7 ring atoms;
R1 comprises ¨T¨Q¨(CH2)n¨Z;
n is an integer from 0 to 7;
T comprises a carbocyclic ring having 3 to 8 ring members, an unsaturated ring having 3 to 8 carbon atoms as ring members, an aromatic ring having 5 to 8 carbon atoms as ring members, a heterocyclic ring having 3 to 8 ring members, a heteroaromatic ring having 5 to 8 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring;
Q comprises C.ident.C.
10. A compound of claim 1, wherein R2 comprises ¨(CH2)n¨Z;
n is 0; and Z comprises an aromatic ring having 5 to 7 ring members, a heteroaromatic ring having 5 to 7 ring members; or R2 comprises ¨(CH2)n¨Z;
n is an integer from 0 to 7; and Z comprises wherein X and Y each independently comprise, H, halogen, CF3, CF2H, N3, NCS, CN, NO2, NX1X2, OX3, SX3, OAc, OSO2X3, O-acyl, S-acyl, SO2-alkyl, SO-alkyl, SC(CH3)2COOX8, OC(CH3)2COOX8 , C(CH3)2COOX8, Si(alkyl)3, alkyl-CN, O-aroyl, O(CH2)j OX3, Q(CH2)j NX1X2, NH-acyl, NH-aroyl, CHO, C(halogen)3, COOX3, SO3H, SO2NX1X2, CONX1X2, NHC(O)O-alkyl, NHSO2-alkyl, alkoxy, alkyl, alcohol, alkylmercapto, alkylamino, di-alkylamino, alkylsulfinyl or alkylsulfonyl, CX4X5X8, -CH=CHX8 , -C.ident.CX8 ;
X1 and X2 each independently comprise H or alkyl, or X1 and X2 together comprise part of a heterocyclic ring having 4 to 7 ring members and optionally one additional heteroatom selected from O, N or S, or X1 and X2 together comprise part of an imide ring having 5 to 6 members, X3 comprises H, alkyl, aryl, NO2, (CH2)m CN, hydroxyloweralkyl, or alkyl-NX1X2, X4, X5, and X6 each independently comprise H, alkyl, carbocyclic ring, hydroxyloweralkyl, alkyl-OH, halogen, CN, SNO, S(SO2)alkyl, NX1X2, COOX3, CONX3, OX7, or O-alkyl-X7 wherein X7 comprises H, alkyl, NO2, NO, P(O)(OX8)2, PH(O)(OX8), S(O)k N(alkyl)2, S(O)k X8, S(O)k OX8, COOX8, CONX8, SO3H, COX8, wherein X8 comprises H, alkyl, carbocyclic ring, heterocyclic ring, aromatic ring, heteroaromatic ring, or -CX9=CHX10 wherein X9 and X10 each independently comprise H or alkyl Wherein m is an integer from 0 to 7 j is an integer from 0 to 6, or k is an integer from 0 to 2 W comprises H or alkyl; or R1 comprises -T-Q-(CH2)n-Z;
n is an integer from 0 to 7;
T comprises an aromatic ring having 5 to 8 carbon atoms as ring members, a heteroaromatic ring having 5 to 8 ring members;
Q comprises C.ident.C.
n is 0; and Z comprises an aromatic ring having 5 to 7 ring members, a heteroaromatic ring having 5 to 7 ring members; or R2 comprises ¨(CH2)n¨Z;
n is an integer from 0 to 7; and Z comprises wherein X and Y each independently comprise, H, halogen, CF3, CF2H, N3, NCS, CN, NO2, NX1X2, OX3, SX3, OAc, OSO2X3, O-acyl, S-acyl, SO2-alkyl, SO-alkyl, SC(CH3)2COOX8, OC(CH3)2COOX8 , C(CH3)2COOX8, Si(alkyl)3, alkyl-CN, O-aroyl, O(CH2)j OX3, Q(CH2)j NX1X2, NH-acyl, NH-aroyl, CHO, C(halogen)3, COOX3, SO3H, SO2NX1X2, CONX1X2, NHC(O)O-alkyl, NHSO2-alkyl, alkoxy, alkyl, alcohol, alkylmercapto, alkylamino, di-alkylamino, alkylsulfinyl or alkylsulfonyl, CX4X5X8, -CH=CHX8 , -C.ident.CX8 ;
X1 and X2 each independently comprise H or alkyl, or X1 and X2 together comprise part of a heterocyclic ring having 4 to 7 ring members and optionally one additional heteroatom selected from O, N or S, or X1 and X2 together comprise part of an imide ring having 5 to 6 members, X3 comprises H, alkyl, aryl, NO2, (CH2)m CN, hydroxyloweralkyl, or alkyl-NX1X2, X4, X5, and X6 each independently comprise H, alkyl, carbocyclic ring, hydroxyloweralkyl, alkyl-OH, halogen, CN, SNO, S(SO2)alkyl, NX1X2, COOX3, CONX3, OX7, or O-alkyl-X7 wherein X7 comprises H, alkyl, NO2, NO, P(O)(OX8)2, PH(O)(OX8), S(O)k N(alkyl)2, S(O)k X8, S(O)k OX8, COOX8, CONX8, SO3H, COX8, wherein X8 comprises H, alkyl, carbocyclic ring, heterocyclic ring, aromatic ring, heteroaromatic ring, or -CX9=CHX10 wherein X9 and X10 each independently comprise H or alkyl Wherein m is an integer from 0 to 7 j is an integer from 0 to 6, or k is an integer from 0 to 2 W comprises H or alkyl; or R1 comprises -T-Q-(CH2)n-Z;
n is an integer from 0 to 7;
T comprises an aromatic ring having 5 to 8 carbon atoms as ring members, a heteroaromatic ring having 5 to 8 ring members;
Q comprises C.ident.C.
11. A compound of claim 1, wherein R2 comprises -(CH2)n-Z;
n is an integer from 0 to 7; and Z comprises a carbocyclic ring having 4 to 7 ring members, a heterocyclic ring having 4 to 7 ring members, an aromatic ring having 5 to 7 ring members, a heteroaromatic ring having 5 to 7 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring, a heteropolycyclic ring; or any above group substituted on at least one available ring atom by an alkyl group; or any above group substituted on at least one available ring nitrogen atom by a benzyl group, a substituted benzyl group, an alkoxybenzyl group, a substituted alkoxybenzyl group, a benzhydryl group or a substituted benzhydryl group; and wherein the connecting point between the -(CH2)n- group and the Z group can be any available ring carbon atom or any available ring nitrogen atom; or R2 comprises -(CH2)n-Z;
n is an integer from 0 to 7; and Z comprises wherein X and Y each independently comprise, H, halogen, CF3, CF2H, N3, NCS, CN, NO2, NX1X2, OX3, SX3, OAc, OSO2X3, O-acyl, S-acyl, SO2-alkyl, SO-alkyl, SC(CH3)2COOX8, OC(CH3)2COOX8 , C(CH3)2COOX8, Si(alkyl)3, alkyl-CN, O-aroyl, O(CH2)j OX3, O(CH2)j NX1X2, NH-acyl, NH-aroyl, CHO, C(halogen)3, COOX3, SO3H, SO2NX1X2, CONX1X2, NHC(O)O-alkyl, NHSO2-alkyl, alkoxy, alkyl, alcohol, alkylmercapto, alkylamino, di-alkylamino, alkylsulfinyl or alkylsulfonyl, CX4X5X8, -CH=CHX8 , -C.ident.CX8;
X1 and X2 each independently comprise H or alkyl, or X1 and X2 together comprise part of a heterocyclic ring having 4 to 7 ring members and optionally one additional heteroatom selected from O, N or S, or X1 and X2 together comprise part of an imide ring having 5 to 6 members, X3 comprises H, alkyl, aryl, NO2, (CH2)m CN, hydroxyloweralkyl, or alkyl-NX1X2, X4, X5, and X6 each independently comprise H, alkyl, carbocyclic ring, hydroxyloweralkyl, alkyl-OH, halogen, CN, SNO, S(SO2)alkyl, NX1X2, COOX3, CONX3, OX7, or O-alkyl-X7 wherein X7 comprises H, alkyl, NO2, NO, P(O)(OX8)2, PH(O)(OX8), S(O)k N(alkyl)2, S(O)k X8, S(O)k OX8, COOX8, CONX8, SO3H, COX8, wherein X8 comprises H, alkyl, carbocyclic ring, heterocyclic ring, aromatic ring, heteroaromatic ring, or -CX9=CHX10 wherein X9 and X10 each independently comprise H or alkyl Wherein m is an integer from 0 to 7 j is an integer from 0 to 6, or k is an integer from 0 to 2 W comprises H or alkyl; or R2 comprises -(CH2)n-Z;
n is an integer from 0 to 7; and Z comprises a carbocyclic ring having 6 ring atoms fused to a heterocyclic ring having from 5 to 7 ring atoms, a carbocyclic ring having 6 ring atoms fused to a heteroaromatic ring having from 5 to 7 ring atoms, a heterocyclic ring having 6 ring atoms fused to a heterocyclic ring having from 5 to 7 ring atoms, an heterocyclic ring having 6 ring atoms fused to a heteroaromatic ring having from to 7 ring atoms, an aromatic ring having 6 ring atoms fused to a heterocyclic ring having from 5 to 7 ring atoms, an aromatic ring having 6 ring atoms fused to a heteroaromatic ring having from 5 to 7 ring atoms, a heteroaromatic ring having 6 ring atoms fused to a heterocyclic ring having from 5 to 7 ring atoms or a heteroaromatic ring having 6 ring atoms fused to a heteroaromatic ring having from 5 to 7 ring atoms;
R1 comprises -T-Q-(CH2)n-Z, n is an integer from 0 to 7;
T comprises an aromatic ring having 5 to 8 carbon atoms as ring members or a heteroaromatic ring having 5 to 8 ring members;
Q comprises C.ident.C; and Z comprises CN, alkyl-CN, or ONO2.
n is an integer from 0 to 7; and Z comprises a carbocyclic ring having 4 to 7 ring members, a heterocyclic ring having 4 to 7 ring members, an aromatic ring having 5 to 7 ring members, a heteroaromatic ring having 5 to 7 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring, a heteropolycyclic ring; or any above group substituted on at least one available ring atom by an alkyl group; or any above group substituted on at least one available ring nitrogen atom by a benzyl group, a substituted benzyl group, an alkoxybenzyl group, a substituted alkoxybenzyl group, a benzhydryl group or a substituted benzhydryl group; and wherein the connecting point between the -(CH2)n- group and the Z group can be any available ring carbon atom or any available ring nitrogen atom; or R2 comprises -(CH2)n-Z;
n is an integer from 0 to 7; and Z comprises wherein X and Y each independently comprise, H, halogen, CF3, CF2H, N3, NCS, CN, NO2, NX1X2, OX3, SX3, OAc, OSO2X3, O-acyl, S-acyl, SO2-alkyl, SO-alkyl, SC(CH3)2COOX8, OC(CH3)2COOX8 , C(CH3)2COOX8, Si(alkyl)3, alkyl-CN, O-aroyl, O(CH2)j OX3, O(CH2)j NX1X2, NH-acyl, NH-aroyl, CHO, C(halogen)3, COOX3, SO3H, SO2NX1X2, CONX1X2, NHC(O)O-alkyl, NHSO2-alkyl, alkoxy, alkyl, alcohol, alkylmercapto, alkylamino, di-alkylamino, alkylsulfinyl or alkylsulfonyl, CX4X5X8, -CH=CHX8 , -C.ident.CX8;
X1 and X2 each independently comprise H or alkyl, or X1 and X2 together comprise part of a heterocyclic ring having 4 to 7 ring members and optionally one additional heteroatom selected from O, N or S, or X1 and X2 together comprise part of an imide ring having 5 to 6 members, X3 comprises H, alkyl, aryl, NO2, (CH2)m CN, hydroxyloweralkyl, or alkyl-NX1X2, X4, X5, and X6 each independently comprise H, alkyl, carbocyclic ring, hydroxyloweralkyl, alkyl-OH, halogen, CN, SNO, S(SO2)alkyl, NX1X2, COOX3, CONX3, OX7, or O-alkyl-X7 wherein X7 comprises H, alkyl, NO2, NO, P(O)(OX8)2, PH(O)(OX8), S(O)k N(alkyl)2, S(O)k X8, S(O)k OX8, COOX8, CONX8, SO3H, COX8, wherein X8 comprises H, alkyl, carbocyclic ring, heterocyclic ring, aromatic ring, heteroaromatic ring, or -CX9=CHX10 wherein X9 and X10 each independently comprise H or alkyl Wherein m is an integer from 0 to 7 j is an integer from 0 to 6, or k is an integer from 0 to 2 W comprises H or alkyl; or R2 comprises -(CH2)n-Z;
n is an integer from 0 to 7; and Z comprises a carbocyclic ring having 6 ring atoms fused to a heterocyclic ring having from 5 to 7 ring atoms, a carbocyclic ring having 6 ring atoms fused to a heteroaromatic ring having from 5 to 7 ring atoms, a heterocyclic ring having 6 ring atoms fused to a heterocyclic ring having from 5 to 7 ring atoms, an heterocyclic ring having 6 ring atoms fused to a heteroaromatic ring having from to 7 ring atoms, an aromatic ring having 6 ring atoms fused to a heterocyclic ring having from 5 to 7 ring atoms, an aromatic ring having 6 ring atoms fused to a heteroaromatic ring having from 5 to 7 ring atoms, a heteroaromatic ring having 6 ring atoms fused to a heterocyclic ring having from 5 to 7 ring atoms or a heteroaromatic ring having 6 ring atoms fused to a heteroaromatic ring having from 5 to 7 ring atoms;
R1 comprises -T-Q-(CH2)n-Z, n is an integer from 0 to 7;
T comprises an aromatic ring having 5 to 8 carbon atoms as ring members or a heteroaromatic ring having 5 to 8 ring members;
Q comprises C.ident.C; and Z comprises CN, alkyl-CN, or ONO2.
12. A compound of claim 1, wherein R2 comprises -(CH2)n-Z;
n is an integer from 0 to 7;
Z is OX3; and X3 is NO2.
n is an integer from 0 to 7;
Z is OX3; and X3 is NO2.
13. A compound of claim 1, wherein R1 comprises -T-Q-(CH2)n-Z;
n is an integer from 0 to 7;
T comprises a carbocyclic ring having 3 to 8 ring members, an unsaturated ring having 3 to 8 carbon atoms as ring members, an aromatic ring having 5 to 8 carbon atoms as ring members, a heterocyclic ring having 3 to 8 ring members, a heteroaromatic ring having 5 to 8 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring;
Z is OX3; and X3 is NO2.
n is an integer from 0 to 7;
T comprises a carbocyclic ring having 3 to 8 ring members, an unsaturated ring having 3 to 8 carbon atoms as ring members, an aromatic ring having 5 to 8 carbon atoms as ring members, a heterocyclic ring having 3 to 8 ring members, a heteroaromatic ring having 5 to 8 ring members, a bicyclic ring, a heterobicyclic ring, a tricyclic ring, a heterotricyclic ring, a polycyclic ring or a heteropolycyclic ring;
Z is OX3; and X3 is NO2.
14. A compound of claim 1, wherein R4 comprises -(CH2)d-Z, or -(CH2 )m - Q1 -(CH2)n-Z.
15. A compound of claim 1, wherein R1 comprises -T-(CH2)m- Q1 -(CH2)n-Z;
-(CH2)n-Z;
-(CH2)m -Q1-(CH2)n-Z;
-T-(CH2)n-Z; or -T-Q-(CH2)n-Z; and R2 comprises -(CH2)m -Q1-(CH2)n-Z;
-T-(CH2)n-Z; or -T-(CH2)m- Q1 -(CH2)n-Z.
-(CH2)n-Z;
-(CH2)m -Q1-(CH2)n-Z;
-T-(CH2)n-Z; or -T-Q-(CH2)n-Z; and R2 comprises -(CH2)m -Q1-(CH2)n-Z;
-T-(CH2)n-Z; or -T-(CH2)m- Q1 -(CH2)n-Z.
16. A compound of claim 1, wherein R3 is and R2 is selected from
17. A compound of claim 1, and physiologically accepted salts thereof, comprising a structure selected from the group consisting of:
5-(4-[4-cyanobut-1-ynyl]phenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-(1,1-dioxo-thiomorpholino)-1H-pyrazole-3-carboxamide 1-(2-chloro-4-fluorophenyl)-5-(4-(4-cyanobut-l-yn-1-yl)phenyl)-N-(1,1-dioxidothiomorpholino)-4-ethyl-1H-pyrazole-3-carboxamide;
5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-N-(1,1-dioxidothiomorpholino)-4-methyl-1H-pyrazole-3-carboxamide;
5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-N-(1,1-dioxidothiomorpholino)-4-methyl-1H-pyrazole-3-carboxamide;
1-(2,4-dichlorophenyl)-N-(1,1-dioxidothiomorpholino)-5-(4-iodophenyl)-4-methyl-1H-pyrazole-3-carboxamide;
5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-N-(1,1-dioxidothiomorpholino)-4-ethyl-1H-pyrazole-3-carboxamide;
5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-N-(1,1-dioxidothiomorpholino)-4-ethyl-1H-pyrazole-3-carboxamide;
1-(2,4-dichlorophenyl)-N-(1,1-dioxidothiomorpholino)-4-ethyl-5-(4-iodophenyl)-1H-pyrazole-3-carboxamide;
1-(2-chloro-4-fluorophenyl)-5-(4-chlorophenyl)-N-(1,1-dioxidothiomorpholino)-4-ethyl-1H-pyrazole-3-carboxamide;
5-(4-bromophenyl)-1-(2-chloro-4-fluorophenyl)-N-(1,1-dioxidothiomorpholino)-4-ethyl-1H-pyrazole-3-carboxamide;
1-(2-chloro-4-fluorophenyl)-N-(1,1-dioxidothiomorpholino)-4-ethyl-5-(4-iodophenyl)-1H-pyrazole-3-carboxamide; and 4-(4-(1-(2,4-dichlorophenyl)-3-((1,1-dioxidothiomorpholino)carbamoyl)-4-methyl-1H-pyrazol-5-yl)phenyl)but-3-yn-1-yl nitrate.
5-(4-[4-cyanobut-1-ynyl]phenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-(1,1-dioxo-thiomorpholino)-1H-pyrazole-3-carboxamide 1-(2-chloro-4-fluorophenyl)-5-(4-(4-cyanobut-l-yn-1-yl)phenyl)-N-(1,1-dioxidothiomorpholino)-4-ethyl-1H-pyrazole-3-carboxamide;
5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-N-(1,1-dioxidothiomorpholino)-4-methyl-1H-pyrazole-3-carboxamide;
5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-N-(1,1-dioxidothiomorpholino)-4-methyl-1H-pyrazole-3-carboxamide;
1-(2,4-dichlorophenyl)-N-(1,1-dioxidothiomorpholino)-5-(4-iodophenyl)-4-methyl-1H-pyrazole-3-carboxamide;
5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-N-(1,1-dioxidothiomorpholino)-4-ethyl-1H-pyrazole-3-carboxamide;
5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-N-(1,1-dioxidothiomorpholino)-4-ethyl-1H-pyrazole-3-carboxamide;
1-(2,4-dichlorophenyl)-N-(1,1-dioxidothiomorpholino)-4-ethyl-5-(4-iodophenyl)-1H-pyrazole-3-carboxamide;
1-(2-chloro-4-fluorophenyl)-5-(4-chlorophenyl)-N-(1,1-dioxidothiomorpholino)-4-ethyl-1H-pyrazole-3-carboxamide;
5-(4-bromophenyl)-1-(2-chloro-4-fluorophenyl)-N-(1,1-dioxidothiomorpholino)-4-ethyl-1H-pyrazole-3-carboxamide;
1-(2-chloro-4-fluorophenyl)-N-(1,1-dioxidothiomorpholino)-4-ethyl-5-(4-iodophenyl)-1H-pyrazole-3-carboxamide; and 4-(4-(1-(2,4-dichlorophenyl)-3-((1,1-dioxidothiomorpholino)carbamoyl)-4-methyl-1H-pyrazol-5-yl)phenyl)but-3-yn-1-yl nitrate.
18. A compound of claim 1, wherein R3 comprises wherein G comprises CH or N, L, K and J each independently comprise (CH2)n, and at least one of L, K or J is SO2, n is an integer from 0 to 7.
19. A compound of claim 1, wherein R3 is and R4 is alkyl or CN.
20. A compound of claim 1, wherein R3 is and Q is C.ident.C.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2009/001054 WO2010104488A1 (en) | 2009-02-19 | 2009-02-19 | Novel hetero pyrrole analogs acting on cannapinoid receptors |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2753061A1 CA2753061A1 (en) | 2010-09-16 |
CA2753061C true CA2753061C (en) | 2016-08-09 |
Family
ID=42728589
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2753061A Active CA2753061C (en) | 2009-02-19 | 2009-02-19 | Novel hetero pyrrole analogs acting on cannabinoid receptors |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP2398323A4 (en) |
CA (1) | CA2753061C (en) |
WO (1) | WO2010104488A1 (en) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10053444B2 (en) * | 2009-02-19 | 2018-08-21 | University Of Connecticut | Cannabinergic nitrate esters and related analogs |
CN105130967B (en) | 2011-05-13 | 2018-04-17 | 阵列生物制药公司 | Pyrrolidinyl urea and pyrrolidinyl thiourea compound as TRKA kinase inhibitors |
UA117573C2 (en) | 2012-11-13 | 2018-08-27 | Ерей Біофарма Інк. | Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain |
US9822118B2 (en) | 2012-11-13 | 2017-11-21 | Array Biopharma Inc. | Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
RS57001B1 (en) | 2012-11-13 | 2018-05-31 | Array Biopharma Inc | N-pyrrolidinyl, n'-pyrazolyl- urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
WO2014078378A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
WO2014078325A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | N-(monocyclic aryl),n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
US9809578B2 (en) | 2012-11-13 | 2017-11-07 | Array Biopharma Inc. | Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trkA kinase inhibitors |
WO2014078331A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | N-(arylalkyl)-n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
WO2014078322A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
WO2014078372A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
WO2014078328A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | N-bicyclic aryl,n'-pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
ES2746530T3 (en) | 2014-05-15 | 2020-03-06 | Array Biopharma Inc | 1 - ((3S, 4R) -4- (3-fluorophenyl) -1- (2-methoxyethyl) pyrrolidin-3-yl) -3- (4-methyl-3- (2-methylpyrimidin-5-yl) - 1-phenyl-1H-pyrazol-5-yl) urea as a TrkA kinase inhibitor |
CA3125847A1 (en) | 2020-07-27 | 2022-01-27 | Makscientific, Llc | Process for making biologically active compounds and intermediates thereof |
WO2022026478A1 (en) * | 2020-07-27 | 2022-02-03 | Makscientific, Llc | Novel compounds for treating fibrosis and inflammatory conditions |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4256727A (en) * | 1978-09-18 | 1981-03-17 | The University Of Kentucky Research Foundation | Synthesis and use of diagnostic radio-pharmaceuticals comprising radioactive isotopes of bromine with dyes |
AU2003209388A1 (en) * | 2002-01-29 | 2003-09-02 | Merck And Co., Inc. | Substituted imidazoles as cannabinoid receptor modulators |
EP1845972A4 (en) * | 2005-01-10 | 2010-12-22 | Univ Connecticut | Novel heteropyrrole analogs acting on cannabiniod receptors |
US20070117858A1 (en) * | 2005-11-23 | 2007-05-24 | Mingde Xia | Substituted 5-heteroaryl-1-phenyl-pyrazole cannabinoid modulators |
-
2009
- 2009-02-19 CA CA2753061A patent/CA2753061C/en active Active
- 2009-02-19 EP EP09841603A patent/EP2398323A4/en not_active Withdrawn
- 2009-02-19 WO PCT/US2009/001054 patent/WO2010104488A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2010104488A1 (en) | 2010-09-16 |
EP2398323A1 (en) | 2011-12-28 |
CA2753061A1 (en) | 2010-09-16 |
EP2398323A4 (en) | 2012-08-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2753061C (en) | Novel hetero pyrrole analogs acting on cannabinoid receptors | |
EP1363632B1 (en) | Receptor selective cannabimimetic aminoalkylindoles | |
US8410097B2 (en) | Heteropyrrole analogs acting on cannabinoid receptors | |
US7666867B2 (en) | Heteroindanes: a new class of potent cannabimimetic ligands | |
AU2009247262B2 (en) | Amide compound | |
CA2498966A1 (en) | Novel pyrazole analogs acting on cannabinoid receptors | |
EP1421077A2 (en) | Novel pyrazole analogs acting on cannabinoid receptors | |
US8853205B2 (en) | Heteropyrrole analogs acting on cannabinoid receptors | |
EA027882B1 (en) | Ethynyl derivatives as metabotropic glutamate receptor antagonists | |
CA2520281A1 (en) | Benzimidazole derivatives and their use for modulating the gabaa recept or complex | |
JP2002522423A (en) | Imidazole and related compounds as α1A agonists | |
AU2006309576B2 (en) | Ortho-substituted aniline derivative and antioxidant drug | |
JP4943826B2 (en) | Pharmaceutical composition | |
TW202412782A (en) | Indazole derivatives for treating trpm3-mediated disorders | |
TW202412770A (en) | Indolizine derivatives for treating trpm3-mediated disorders | |
AU2002353895A1 (en) | Heteroindanes: a new class of potent cannabimimetic ligands | |
AU2002235482A1 (en) | Receptor selective cannabimimetic aminoalkylindoles | |
AU2004201292A1 (en) | Novel pyrazole analogs acting on cannabinoid receptors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |
Effective date: 20140210 |